{
  "$schema": "folio-library-document/v1",
  "id": "10665-360948",
  "title": "Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact",
  "variant": "pdf",
  "pages": 424,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Acknowledgements",
      "number": null,
      "page": 8,
      "pageLabel": "vi",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-acknowledgements"
    },
    {
      "level": 1,
      "title": "Abbreviations and acronyms",
      "number": null,
      "page": 12,
      "pageLabel": "x",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-abbreviations-and-acronyms"
    },
    {
      "level": 1,
      "title": "Glossary",
      "number": null,
      "page": 15,
      "pageLabel": "xiii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-glossary"
    },
    {
      "level": 1,
      "title": "Executive summary",
      "number": null,
      "page": 19,
      "pageLabel": "xvii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-executive-summary"
    },
    {
      "level": 1,
      "title": "Summary recommendations",
      "number": null,
      "page": 22,
      "pageLabel": "xx",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-summary-recommendations"
    },
    {
      "level": 1,
      "title": "Summary list of priority indicators",
      "number": null,
      "page": 25,
      "pageLabel": "xxiii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-summary-list-of-priority-indicators"
    },
    {
      "level": 1,
      "title": "Chapter 1 – Introduction",
      "number": null,
      "page": 31,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-chapter-1-introduction"
    },
    {
      "level": 2,
      "title": "Background and rationale",
      "number": "1.1",
      "page": 32,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-11-background-and-rationale"
    },
    {
      "level": 2,
      "title": "What’s new in this consolidation of WHO strategic information guidelines",
      "number": "1.2",
      "page": 40,
      "pageLabel": "10",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-12-whats-new-in-this-consolidation-of-who-strate"
    },
    {
      "level": 2,
      "title": "Objectives and guiding principles",
      "number": "1.3",
      "page": 42,
      "pageLabel": "12",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-13-objectives-and-guiding-principles"
    },
    {
      "level": 2,
      "title": "Process of development",
      "number": "1.4",
      "page": 43,
      "pageLabel": "13",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-14-process-of-development"
    },
    {
      "level": 2,
      "title": "Organization of the guidelines",
      "number": "1.5",
      "page": 44,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-15-organization-of-the-guidelines"
    },
    {
      "level": 2,
      "title": "Intended audiences",
      "number": "1.6",
      "page": 44,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-16-intended-audiences"
    },
    {
      "level": 2,
      "title": "References",
      "number": null,
      "page": 45,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-019-references"
    },
    {
      "level": 1,
      "title": "Chapter 2 – Person-centred HIV prevention monitoring",
      "number": null,
      "page": 49,
      "pageLabel": "19",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-020-chapter-2-person-centred-hiv-prevention-monitori"
    },
    {
      "level": 2,
      "title": "Key recommendations",
      "number": null,
      "page": 50,
      "pageLabel": "20",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-021-key-recommendations"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "2.1",
      "page": 51,
      "pageLabel": "21",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-022-21-introduction"
    },
    {
      "level": 2,
      "title": "Individual-level HIV prevention data",
      "number": "2.2",
      "page": 56,
      "pageLabel": "26",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-026-22-individual-level-hiv-prevention-data"
    },
    {
      "level": 2,
      "title": "Use of individual-level data on HIV prevention",
      "number": "2.3",
      "page": 66,
      "pageLabel": "36",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-035-23-use-of-individual-level-data-on-hiv-preventio"
    },
    {
      "level": 2,
      "title": "HIV prevention indicators",
      "number": "2.4",
      "page": 69,
      "pageLabel": "39",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-040-24-hiv-prevention-indicators"
    },
    {
      "level": 2,
      "title": "References",
      "number": null,
      "page": 74,
      "pageLabel": "44",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-041-references"
    },
    {
      "level": 1,
      "title": "Chapter 3 – Person-centred HIV patient monitoring for testing, early diagnosis and treatment",
      "number": null,
      "page": 79,
      "pageLabel": "49",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-042-chapter-3-person-centred-hiv-patient-monitoring"
    },
    {
      "level": 2,
      "title": "Key recommendations",
      "number": null,
      "page": 82,
      "pageLabel": "52",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-043-key-recommendations"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "3.1",
      "page": 83,
      "pageLabel": "53",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-044-31-introduction"
    },
    {
      "level": 2,
      "title": "HIV testing services, early diagnosis and linkage to treatment",
      "number": "3.2",
      "page": 89,
      "pageLabel": "59",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-048-32-hiv-testing-services-early-diagnosis-and-link"
    },
    {
      "level": 2,
      "title": "Key considerations for monitoring HTS and linkage",
      "number": "3.3",
      "page": 93,
      "pageLabel": "63",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-050-33-key-considerations-for-monitoring-hts-and-lin"
    },
    {
      "level": 2,
      "title": "ART initiation, retention and viral suppression",
      "number": "3.4",
      "page": 97,
      "pageLabel": "67",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-056-34-art-initiation-retention-and-viral-suppressio"
    },
    {
      "level": 2,
      "title": "Monitoring vertical transmission",
      "number": "3.5",
      "page": 118,
      "pageLabel": "88",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-066-35-monitoring-vertical-transmission"
    },
    {
      "level": 2,
      "title": "Monitoring TB/HIV",
      "number": "3.6",
      "page": 129,
      "pageLabel": "99",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-071-36-monitoring-tbhiv"
    },
    {
      "level": 2,
      "title": "Monitoring service delivery for HIV treatment and care",
      "number": "3.7",
      "page": 134,
      "pageLabel": "104",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-075-37-monitoring-service-delivery-for-hiv-treatment"
    },
    {
      "level": 2,
      "title": "Key populations",
      "number": "3.8",
      "page": 150,
      "pageLabel": "120",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-085-38-key-populations"
    },
    {
      "level": 2,
      "title": "Minimum dataset and key definitions for HIV patient monitoring",
      "number": "3.9",
      "page": 153,
      "pageLabel": "123",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-090-39-minimum-dataset-and-key-definitions-for-hiv-p"
    },
    {
      "level": 2,
      "title": "Standardized data collection and reporting tools for HIV patient testing, treatment and care",
      "number": "3.10",
      "page": 158,
      "pageLabel": "128",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-091-310-standardized-data-collection-and-reporting-t"
    },
    {
      "level": 2,
      "title": "Improving the quality and use of individual-level data to strengthen HIV patient monitoring and care",
      "number": "3.11",
      "page": 168,
      "pageLabel": "138",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-098-311-improving-the-quality-and-use-of-individual"
    },
    {
      "level": 2,
      "title": "Adaption and implementation of the HIV patient monitoring system",
      "number": "3.12",
      "page": 178,
      "pageLabel": "148",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-101-312-adaption-and-implementation-of-the-hiv-patie"
    },
    {
      "level": 2,
      "title": "References",
      "number": null,
      "page": 187,
      "pageLabel": "157",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-106-references"
    },
    {
      "level": 1,
      "title": "Chapter 4 – Integrating related infections into HIV surveillance systems",
      "number": null,
      "page": 191,
      "pageLabel": "161",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-107-chapter-4-integrating-related-infections-into-hi"
    },
    {
      "level": 2,
      "title": "Key recommendations",
      "number": null,
      "page": 192,
      "pageLabel": "162",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-108-key-recommendations"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "4.1",
      "page": 193,
      "pageLabel": "163",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-109-41-introduction"
    },
    {
      "level": 2,
      "title": "Sexually transmitted infections",
      "number": "4.2",
      "page": 194,
      "pageLabel": "164",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-110-42-sexually-transmitted-infections"
    },
    {
      "level": 2,
      "title": "Viral hepatitis",
      "number": "4.3",
      "page": 201,
      "pageLabel": "171",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-114-43-viral-hepatitis"
    },
    {
      "level": 2,
      "title": "Cervical cancer",
      "number": "4.4",
      "page": 206,
      "pageLabel": "176",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-118-44-cervical-cancer"
    },
    {
      "level": 2,
      "title": "References",
      "number": null,
      "page": 212,
      "pageLabel": "182",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-122-references"
    },
    {
      "level": 1,
      "title": "Chapter 5 – Harnessing the strength of routine data for HIV surveillance",
      "number": null,
      "page": 217,
      "pageLabel": "187",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-123-chapter-5-harnessing-the-strength-of-routine-dat"
    },
    {
      "level": 2,
      "title": "Key recommendations",
      "number": null,
      "page": 218,
      "pageLabel": "188",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-124-key-recommendations"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "5.1",
      "page": 219,
      "pageLabel": "189",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-125-51-introduction"
    },
    {
      "level": 2,
      "title": "Methods for estimating HIV incidence and prevalence using routine data",
      "number": "5.2",
      "page": 224,
      "pageLabel": "194",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-128-52-methods-for-estimating-hiv-incidence-and-prev"
    },
    {
      "level": 2,
      "title": "Minimum dataset required for estimating HIV incidence and prevalence",
      "number": "5.3",
      "page": 243,
      "pageLabel": "213",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-136-53-minimum-dataset-required-for-estimating-hiv-i"
    },
    {
      "level": 2,
      "title": "Data quality needs for the use of routine data",
      "number": "5.4",
      "page": 246,
      "pageLabel": "216",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-137-54-data-quality-needs-for-the-use-of-routine-dat"
    },
    {
      "level": 2,
      "title": "References",
      "number": null,
      "page": 247,
      "pageLabel": "217",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-138-references"
    },
    {
      "level": 1,
      "title": "Chapter 6 – Digital health data",
      "number": null,
      "page": 255,
      "pageLabel": "225",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-139-chapter-6-digital-health-data"
    },
    {
      "level": 2,
      "title": "Key recommendations",
      "number": null,
      "page": 256,
      "pageLabel": "226",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-140-key-recommendations"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "6.1",
      "page": 257,
      "pageLabel": "227",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-141-61-introduction"
    },
    {
      "level": 2,
      "title": "Interoperability",
      "number": "6.2",
      "page": 262,
      "pageLabel": "232",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-143-62-interoperability"
    },
    {
      "level": 2,
      "title": "Unique identifiers",
      "number": "6.3",
      "page": 269,
      "pageLabel": "239",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-149-63-unique-identifiers"
    },
    {
      "level": 2,
      "title": "Privacy, security, data access and control",
      "number": "6.4",
      "page": 282,
      "pageLabel": "252",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-153-64-privacy-security-data-access-and-control"
    },
    {
      "level": 2,
      "title": "References",
      "number": null,
      "page": 289,
      "pageLabel": "259",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-158-references"
    },
    {
      "level": 1,
      "title": "Chapter 7 – Strengthening data use from all sources",
      "number": null,
      "page": 295,
      "pageLabel": "265",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-159-chapter-7-strengthening-data-use-from-all-source"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "7.1",
      "page": 296,
      "pageLabel": "266",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-160-71-introduction"
    },
    {
      "level": 2,
      "title": "Measuring and improving the quality of person-centred care",
      "number": "7.2",
      "page": 298,
      "pageLabel": "268",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-163-72-measuring-and-improving-the-quality-of-person"
    },
    {
      "level": 2,
      "title": "Community-led monitoring",
      "number": "7.3",
      "page": 305,
      "pageLabel": "275",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-169-73-community-led-monitoring"
    },
    {
      "level": 2,
      "title": "Logistics management information systems",
      "number": "7.4",
      "page": 307,
      "pageLabel": "277",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-170-74-logistics-management-information-systems"
    },
    {
      "level": 2,
      "title": "Health facility assessments",
      "number": "7.5",
      "page": 309,
      "pageLabel": "279",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-171-75-health-facility-assessments"
    },
    {
      "level": 2,
      "title": "Civil registration and vital statistics",
      "number": "7.6",
      "page": 310,
      "pageLabel": "280",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-172-76-civil-registration-and-vital-statistics"
    },
    {
      "level": 2,
      "title": "Population-based survey data",
      "number": "7.7",
      "page": 310,
      "pageLabel": "280",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-173-77-population-based-survey-data"
    },
    {
      "level": 2,
      "title": "Mathematical modelling",
      "number": "7.8",
      "page": 311,
      "pageLabel": "281",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-174-78-mathematical-modelling"
    },
    {
      "level": 2,
      "title": "Data quality review, triangulation and use",
      "number": "7.9",
      "page": 312,
      "pageLabel": "282",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-175-79-data-quality-review-triangulation-and-use"
    },
    {
      "level": 2,
      "title": "Evaluation and operational research",
      "number": "7.10",
      "page": 313,
      "pageLabel": "283",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-176-710-evaluation-and-operational-research"
    },
    {
      "level": 2,
      "title": "References",
      "number": null,
      "page": 314,
      "pageLabel": "284",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-177-references"
    },
    {
      "level": 1,
      "title": "Chapter 8 – Priority indicators",
      "number": null,
      "page": 317,
      "pageLabel": "287",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-178-chapter-8-priority-indicators"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "8.1",
      "page": 318,
      "pageLabel": "288",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-179-81-introduction"
    },
    {
      "level": 2,
      "title": "Priority indicators by programme area",
      "number": "8.2",
      "page": 321,
      "pageLabel": "291",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-183-82-priority-indicators-by-programme-area"
    },
    {
      "level": 1,
      "title": "Background and rationale",
      "number": "1.1",
      "page": 32,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-11-background-and-rationale"
    },
    {
      "level": 2,
      "title": "Evolving data needs for a new phase of the HIV response",
      "number": "1.1.1",
      "page": 32,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-111-evolving-data-needs-for-a-new-phase-of-the-h"
    },
    {
      "level": 2,
      "title": "Advancing from aggregate to individual-level data use",
      "number": "1.1.2",
      "page": 33,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-112-advancing-from-aggregate-to-individual-level"
    },
    {
      "level": 2,
      "title": "Integration of sexually transmitted infections, viral hepatitis, tuberculosis and cervical cancer into HIV reporting systems",
      "number": "1.1.3",
      "page": 36,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-113-integration-of-sexually-transmitted-infectio"
    },
    {
      "level": 2,
      "title": "Data considerations for key populations",
      "number": "1.1.4",
      "page": 36,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-114-data-considerations-for-key-populations"
    },
    {
      "level": 2,
      "title": "Strengthening the use of data from other sources",
      "number": "1.1.5",
      "page": 38,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-115-strengthening-the-use-of-data-from-other-sou"
    },
    {
      "level": 1,
      "title": "What’s new in this consolidation of WHO strategic information guidelines",
      "number": "1.2",
      "page": 40,
      "pageLabel": "10",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-12-whats-new-in-this-consolidation-of-who-strate"
    },
    {
      "level": 2,
      "title": "Data system maturity for use of person-centred data",
      "number": "1.2.1",
      "page": 41,
      "pageLabel": "11",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-121-data-system-maturity-for-use-of-person-centr"
    },
    {
      "level": 1,
      "title": "Objectives and guiding principles",
      "number": "1.3",
      "page": 42,
      "pageLabel": "12",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-13-objectives-and-guiding-principles"
    },
    {
      "level": 1,
      "title": "Process of development",
      "number": "1.4",
      "page": 43,
      "pageLabel": "13",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-14-process-of-development"
    },
    {
      "level": 1,
      "title": "Organization of the guidelines",
      "number": "1.5",
      "page": 44,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-15-organization-of-the-guidelines"
    },
    {
      "level": 1,
      "title": "Intended audiences",
      "number": "1.6",
      "page": 44,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-16-intended-audiences"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 45,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-019-references"
    },
    {
      "level": 1,
      "title": "Key recommendations",
      "number": null,
      "page": 50,
      "pageLabel": "20",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-021-key-recommendations"
    },
    {
      "level": 1,
      "title": "Introduction",
      "number": "2.1",
      "page": 51,
      "pageLabel": "21",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-022-21-introduction"
    },
    {
      "level": 2,
      "title": "Epidemiology of HIV and prevention need",
      "number": "2.1.1",
      "page": 51,
      "pageLabel": "21",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-023-211-epidemiology-of-hiv-and-prevention-need"
    },
    {
      "level": 2,
      "title": "Strategic information for HIV prevention",
      "number": "2.1.2",
      "page": 52,
      "pageLabel": "22",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-024-212-strategic-information-for-hiv-prevention"
    },
    {
      "level": 2,
      "title": "HIV prevention interventions",
      "number": "2.1.3",
      "page": 54,
      "pageLabel": "24",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-025-213-hiv-prevention-interventions"
    },
    {
      "level": 1,
      "title": "Individual-level HIV prevention data",
      "number": "2.2",
      "page": 56,
      "pageLabel": "26",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-026-22-individual-level-hiv-prevention-data"
    },
    {
      "level": 2,
      "title": "Using routine programme data to measure HIV prevention interventions",
      "number": "2.2.1",
      "page": 56,
      "pageLabel": "26",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-027-221-using-routine-programme-data-to-measure-hiv"
    },
    {
      "level": 2,
      "title": "Anonymity, confidentiality and the use of unique identification (UID) codes",
      "number": "2.2.2",
      "page": 57,
      "pageLabel": "27",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-028-222-anonymity-confidentiality-and-the-use-of-uni"
    },
    {
      "level": 2,
      "title": "Prioritizing HIV prevention services",
      "number": "2.2.3",
      "page": 58,
      "pageLabel": "28",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-029-223-prioritizing-hiv-prevention-services"
    },
    {
      "level": 2,
      "title": "Understanding person-centred HIV prevention need",
      "number": "2.2.4",
      "page": 59,
      "pageLabel": "29",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-030-224-understanding-person-centred-hiv-prevention"
    },
    {
      "level": 2,
      "title": "Capturing information on HIV prevention demand in a health data system",
      "number": "2.2.5",
      "page": 62,
      "pageLabel": "32",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-031-225-capturing-information-on-hiv-prevention-dema"
    },
    {
      "level": 2,
      "title": "Entry points to the data system for the collection of individual-level prevention data",
      "number": "2.2.6",
      "page": 64,
      "pageLabel": "34",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-032-226-entry-points-to-the-data-system-for-the-coll"
    },
    {
      "level": 2,
      "title": "Registration process",
      "number": "2.2.7",
      "page": 64,
      "pageLabel": "34",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-033-227-registration-process"
    },
    {
      "level": 2,
      "title": "A minimum dataset for HIV prevention",
      "number": "2.2.8",
      "page": 65,
      "pageLabel": "35",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-034-228-a-minimum-dataset-for-hiv-prevention"
    },
    {
      "level": 1,
      "title": "Use of individual-level data on HIV prevention",
      "number": "2.3",
      "page": 66,
      "pageLabel": "36",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-035-23-use-of-individual-level-data-on-hiv-preventio"
    },
    {
      "level": 2,
      "title": "Use of individual-level HIV prevention data for client management",
      "number": "2.3.1",
      "page": 66,
      "pageLabel": "36",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-036-231-use-of-individual-level-hiv-prevention-data"
    },
    {
      "level": 2,
      "title": "Use of individual-level data for programme management",
      "number": "2.3.2",
      "page": 67,
      "pageLabel": "37",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-037-232-use-of-individual-level-data-for-programme-m"
    },
    {
      "level": 2,
      "title": "Longitudinal individual-level data as the basis for routine aggregated reporting",
      "number": "2.3.3",
      "page": 67,
      "pageLabel": "37",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-038-233-longitudinal-individual-level-data-as-the-ba"
    },
    {
      "level": 2,
      "title": "Use of individual-level data to construct HIV prevention cascades",
      "number": "2.3.4",
      "page": 68,
      "pageLabel": "38",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-039-234-use-of-individual-level-data-to-construct-hi"
    },
    {
      "level": 1,
      "title": "HIV prevention indicators",
      "number": "2.4",
      "page": 69,
      "pageLabel": "39",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-040-24-hiv-prevention-indicators"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 74,
      "pageLabel": "44",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-041-references"
    },
    {
      "level": 1,
      "title": "Key recommendations",
      "number": null,
      "page": 82,
      "pageLabel": "52",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-043-key-recommendations"
    },
    {
      "level": 1,
      "title": "Introduction",
      "number": "3.1",
      "page": 83,
      "pageLabel": "53",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-044-31-introduction"
    },
    {
      "level": 2,
      "title": "Purpose of person-centred monitoring of HIV testing, treatment and care",
      "number": "3.1.1",
      "page": 83,
      "pageLabel": "53",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-045-311-purpose-of-person-centred-monitoring-of-hiv"
    },
    {
      "level": 2,
      "title": "Evolution of person-centred HIV patient monitoring",
      "number": "3.1.2",
      "page": 84,
      "pageLabel": "54",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-046-312-evolution-of-person-centred-hiv-patient-moni"
    },
    {
      "level": 2,
      "title": "Application of this guidance",
      "number": "3.1.3",
      "page": 88,
      "pageLabel": "58",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-047-313-application-of-this-guidance"
    },
    {
      "level": 1,
      "title": "HIV testing services, early diagnosis and linkage to treatment",
      "number": "3.2",
      "page": 89,
      "pageLabel": "59",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-048-32-hiv-testing-services-early-diagnosis-and-link"
    },
    {
      "level": 2,
      "title": "Purposes of monitoring testing",
      "number": "3.2.1",
      "page": 91,
      "pageLabel": "61",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-049-321-purposes-of-monitoring-testing"
    },
    {
      "level": 1,
      "title": "Key considerations for monitoring HTS and linkage",
      "number": "3.3",
      "page": 93,
      "pageLabel": "63",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-050-33-key-considerations-for-monitoring-hts-and-lin"
    },
    {
      "level": 2,
      "title": "Increasing number of people living with HIV who know their status",
      "number": "3.3.1",
      "page": 93,
      "pageLabel": "63",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-051-331-increasing-number-of-people-living-with-hiv"
    },
    {
      "level": 2,
      "title": "Early HIV diagnosis",
      "number": "3.3.2",
      "page": 93,
      "pageLabel": "63",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-052-332-early-hiv-diagnosis"
    },
    {
      "level": 2,
      "title": "Linkage to treatment and care",
      "number": "3.3.3",
      "page": 94,
      "pageLabel": "64",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-053-333-linkage-to-treatment-and-care"
    },
    {
      "level": 2,
      "title": "Standardized data collection tools for HTS",
      "number": "3.3.4",
      "page": 96,
      "pageLabel": "66",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-054-334-standardized-data-collection-tools-for-hts"
    },
    {
      "level": 2,
      "title": "Minimum dataset",
      "number": "3.3.5",
      "page": 97,
      "pageLabel": "67",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-055-335-minimum-dataset"
    },
    {
      "level": 1,
      "title": "ART initiation, retention and viral suppression",
      "number": "3.4",
      "page": 97,
      "pageLabel": "67",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-056-34-art-initiation-retention-and-viral-suppressio"
    },
    {
      "level": 2,
      "title": "What to monitor and relevant treatment indicators",
      "number": "3.4.1",
      "page": 98,
      "pageLabel": "68",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-057-341-what-to-monitor-and-relevant-treatment-indic"
    },
    {
      "level": 2,
      "title": "Monitoring ART initiation, late initiation and clinical management",
      "number": "3.4.2",
      "page": 102,
      "pageLabel": "72",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-058-342-monitoring-art-initiation-late-initiation-an"
    },
    {
      "level": 2,
      "title": "Monitoring treatment outcomes",
      "number": "3.4.3",
      "page": 104,
      "pageLabel": "74",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-059-343-monitoring-treatment-outcomes"
    },
    {
      "level": 2,
      "title": "ART retention/attrition",
      "number": "3.4.4",
      "page": 105,
      "pageLabel": "75",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-060-344-art-retentionattrition"
    },
    {
      "level": 2,
      "title": "Loss to follow-up",
      "number": "3.4.5",
      "page": 106,
      "pageLabel": "76",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-061-345-loss-to-follow-up"
    },
    {
      "level": 2,
      "title": "Advanced HIV disease",
      "number": "3.4.6",
      "page": 108,
      "pageLabel": "78",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-062-346-advanced-hiv-disease"
    },
    {
      "level": 2,
      "title": "ARV toxicity monitoring",
      "number": "3.4.7",
      "page": 111,
      "pageLabel": "81",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-063-347-arv-toxicity-monitoring"
    },
    {
      "level": 2,
      "title": "Early warning indicators of HIV drug resistance",
      "number": "3.4.8",
      "page": 113,
      "pageLabel": "83",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-064-348-early-warning-indicators-of-hiv-drug-resista"
    },
    {
      "level": 2,
      "title": "Monitoring considerations for paediatric populations",
      "number": "3.4.9",
      "page": 116,
      "pageLabel": "86",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-065-349-monitoring-considerations-for-paediatric-pop"
    },
    {
      "level": 1,
      "title": "Monitoring vertical transmission",
      "number": "3.5",
      "page": 118,
      "pageLabel": "88",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-066-35-monitoring-vertical-transmission"
    },
    {
      "level": 2,
      "title": "Conceptual framework for preventing vertical transmission",
      "number": "3.5.1",
      "page": 122,
      "pageLabel": "92",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-067-351-conceptual-framework-for-preventing-vertical"
    },
    {
      "level": 2,
      "title": "Following the cascade across multiple service delivery points and over prolonged periods",
      "number": "3.5.2",
      "page": 123,
      "pageLabel": "93",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-068-352-following-the-cascade-across-multiple-servic"
    },
    {
      "level": 2,
      "title": "Monitoring key outcomes towards elimination of vertical transmission",
      "number": "3.5.3",
      "page": 123,
      "pageLabel": "93",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-069-353-monitoring-key-outcomes-towards-elimination"
    },
    {
      "level": 2,
      "title": "Follow-up of the mother–infant pair",
      "number": "3.5.4",
      "page": 125,
      "pageLabel": "95",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-070-354-follow-up-of-the-motherinfant-pair"
    },
    {
      "level": 1,
      "title": "Monitoring TB/HIV",
      "number": "3.6",
      "page": 129,
      "pageLabel": "99",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-071-36-monitoring-tbhiv"
    },
    {
      "level": 2,
      "title": "TB in people living with HIV captured in the HIV patient monitoring system",
      "number": "3.6.1",
      "page": 130,
      "pageLabel": "100",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-072-361-tb-in-people-living-with-hiv-captured-in-the"
    },
    {
      "level": 2,
      "title": "HIV in presumptive and diagnosed TB patients captured in the TB patient monitoring system",
      "number": "3.6.2",
      "page": 131,
      "pageLabel": "101",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-073-362-hiv-in-presumptive-and-diagnosed-tb-patients"
    },
    {
      "level": 2,
      "title": "Coordination of care, treatment and patient monitoring",
      "number": "3.6.3",
      "page": 131,
      "pageLabel": "101",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-074-363-coordination-of-care-treatment-and-patient-m"
    },
    {
      "level": 1,
      "title": "Monitoring service delivery for HIV treatment and care",
      "number": "3.7",
      "page": 134,
      "pageLabel": "104",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-075-37-monitoring-service-delivery-for-hiv-treatment"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "3.7.1",
      "page": 134,
      "pageLabel": "104",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-076-371-introduction"
    },
    {
      "level": 2,
      "title": "Overview of DSD",
      "number": "3.7.2",
      "page": 135,
      "pageLabel": "105",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-077-372-overview-of-dsd"
    },
    {
      "level": 2,
      "title": "Monitoring DSD",
      "number": "3.7.3",
      "page": 137,
      "pageLabel": "107",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-078-373-monitoring-dsd"
    },
    {
      "level": 2,
      "title": "Key DSD indicators",
      "number": "3.7.4",
      "page": 138,
      "pageLabel": "108",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-079-374-key-dsd-indicators"
    },
    {
      "level": 2,
      "title": "Multi-month ARV dispensing",
      "number": "3.7.5",
      "page": 138,
      "pageLabel": "108",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-080-375-multi-month-arv-dispensing"
    },
    {
      "level": 2,
      "title": "Clinical outcomes among people living with HIV enrolled in DSD ART models",
      "number": "3.7.6",
      "page": 140,
      "pageLabel": "110",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-081-376-clinical-outcomes-among-people-living-with-h"
    },
    {
      "level": 2,
      "title": "Tracing interventions to identify people who interrupt treatment and support re-engagement in care",
      "number": "3.7.7",
      "page": 141,
      "pageLabel": "111",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-082-377-tracing-interventions-to-identify-people-who"
    },
    {
      "level": 2,
      "title": "Key data elements to monitor for DSD ART",
      "number": "3.7.8",
      "page": 143,
      "pageLabel": "113",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-083-378-key-data-elements-to-monitor-for-dsd-art"
    },
    {
      "level": 2,
      "title": "Monitoring considerations for community ART services",
      "number": "3.7.9",
      "page": 145,
      "pageLabel": "115",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-084-379-monitoring-considerations-for-community-art"
    },
    {
      "level": 1,
      "title": "Key populations",
      "number": "3.8",
      "page": 150,
      "pageLabel": "120",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-085-38-key-populations"
    },
    {
      "level": 2,
      "title": "Background",
      "number": "3.8.1",
      "page": 150,
      "pageLabel": "120",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-086-381-background"
    },
    {
      "level": 2,
      "title": "Considerations for patient management",
      "number": "3.8.2",
      "page": 151,
      "pageLabel": "121",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-087-382-considerations-for-patient-management"
    },
    {
      "level": 2,
      "title": "Considerations for programme monitoring",
      "number": "3.8.3",
      "page": 151,
      "pageLabel": "121",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-088-383-considerations-for-programme-monitoring"
    },
    {
      "level": 2,
      "title": "Considerations when collecting data about gender",
      "number": "3.8.4",
      "page": 153,
      "pageLabel": "123",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-089-384-considerations-when-collecting-data-about-ge"
    },
    {
      "level": 1,
      "title": "Minimum dataset and key definitions for HIV patient monitoring",
      "number": "3.9",
      "page": 153,
      "pageLabel": "123",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-090-39-minimum-dataset-and-key-definitions-for-hiv-p"
    },
    {
      "level": 2,
      "title": "Minimum dataset",
      "number": "3.9.1",
      "page": 153,
      "pageLabel": "123",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-055-335-minimum-dataset"
    },
    {
      "level": 1,
      "title": "Standardized data collection and reporting tools for HIV patient testing, treatment and care",
      "number": "3.10",
      "page": 158,
      "pageLabel": "128",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-091-310-standardized-data-collection-and-reporting-t"
    },
    {
      "level": 2,
      "title": "Tools for facility-based monitoring of HIV treatment and care",
      "number": "3.10.1",
      "page": 159,
      "pageLabel": "129",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-092-3101-tools-for-facility-based-monitoring-of-hiv"
    },
    {
      "level": 2,
      "title": "HIV transfer or referral form",
      "number": "3.10.2",
      "page": 161,
      "pageLabel": "131",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-093-3102-hiv-transfer-or-referral-form"
    },
    {
      "level": 2,
      "title": "ART register",
      "number": "3.10.3",
      "page": 161,
      "pageLabel": "131",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-094-3103-art-register"
    },
    {
      "level": 2,
      "title": "Cross-sectional and cohort reports",
      "number": "3.10.4",
      "page": 163,
      "pageLabel": "133",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-095-3104-cross-sectional-and-cohort-reports"
    },
    {
      "level": 2,
      "title": "Other recommended tools to facilitate HIV patient monitoring",
      "number": "3.10.5",
      "page": 165,
      "pageLabel": "135",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-096-3105-other-recommended-tools-to-facilitate-hiv-p"
    },
    {
      "level": 2,
      "title": "Tools for community - delivered treatment and care services",
      "number": "3.10.6",
      "page": 166,
      "pageLabel": "136",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-097-3106-tools-for-community---delivered-treatment-a"
    },
    {
      "level": 1,
      "title": "Improving the quality and use of individual-level data to strengthen HIV patient monitoring and care",
      "number": "3.11",
      "page": 168,
      "pageLabel": "138",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-098-311-improving-the-quality-and-use-of-individual"
    },
    {
      "level": 2,
      "title": "Importance of strengthening the quality of individual-level HIV patient monitoring data",
      "number": "3.11.1",
      "page": 168,
      "pageLabel": "138",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-099-3111-importance-of-strengthening-the-quality-of"
    },
    {
      "level": 2,
      "title": "Data use for improved service delivery",
      "number": "3.11.2",
      "page": 173,
      "pageLabel": "143",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-100-3112-data-use-for-improved-service-delivery"
    },
    {
      "level": 1,
      "title": "Adaption and implementation of the HIV patient monitoring system",
      "number": "3.12",
      "page": 178,
      "pageLabel": "148",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-101-312-adaption-and-implementation-of-the-hiv-patie"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "3.12.1",
      "page": 178,
      "pageLabel": "148",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-102-3121-introduction"
    },
    {
      "level": 2,
      "title": "Steps for country adaptation of the guidance",
      "number": "3.12.2",
      "page": 178,
      "pageLabel": "148",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-103-3122-steps-for-country-adaptation-of-the-guidanc"
    },
    {
      "level": 2,
      "title": "Human resources and capacity-building",
      "number": "3.12.3",
      "page": 182,
      "pageLabel": "152",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-104-3123-human-resources-and-capacity-building"
    },
    {
      "level": 2,
      "title": "Transitioning to digital health systems",
      "number": "3.12.4",
      "page": 186,
      "pageLabel": "156",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-105-3124-transitioning-to-digital-health-systems"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 187,
      "pageLabel": "157",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-106-references"
    },
    {
      "level": 1,
      "title": "Key recommendations",
      "number": null,
      "page": 192,
      "pageLabel": "162",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-108-key-recommendations"
    },
    {
      "level": 1,
      "title": "Introduction",
      "number": "4.1",
      "page": 193,
      "pageLabel": "163",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-109-41-introduction"
    },
    {
      "level": 1,
      "title": "Sexually transmitted infections",
      "number": "4.2",
      "page": 194,
      "pageLabel": "164",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-110-42-sexually-transmitted-infections"
    },
    {
      "level": 2,
      "title": "Background and rationale",
      "number": "4.2.1",
      "page": 194,
      "pageLabel": "164",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-111-421-background-and-rationale"
    },
    {
      "level": 2,
      "title": "Minimum dataset for STIs",
      "number": "4.2.2",
      "page": 198,
      "pageLabel": "168",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-112-422-minimum-dataset-for-stis"
    },
    {
      "level": 2,
      "title": "Priority indicators for STIs",
      "number": "4.2.3",
      "page": 199,
      "pageLabel": "169",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-113-423-priority-indicators-for-stis"
    },
    {
      "level": 1,
      "title": "Viral hepatitis",
      "number": "4.3",
      "page": 201,
      "pageLabel": "171",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-114-43-viral-hepatitis"
    },
    {
      "level": 2,
      "title": "Background and rationale",
      "number": "4.3.1",
      "page": 201,
      "pageLabel": "171",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-115-431-background-and-rationale"
    },
    {
      "level": 2,
      "title": "Minimum dataset for viral hepatitis",
      "number": "4.3.2",
      "page": 203,
      "pageLabel": "173",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-116-432-minimum-dataset-for-viral-hepatitis"
    },
    {
      "level": 2,
      "title": "Priority indicators for viral hepatitis",
      "number": "4.3.3",
      "page": 204,
      "pageLabel": "174",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-117-433-priority-indicators-for-viral-hepatitis"
    },
    {
      "level": 1,
      "title": "Cervical cancer",
      "number": "4.4",
      "page": 206,
      "pageLabel": "176",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-118-44-cervical-cancer"
    },
    {
      "level": 2,
      "title": "Background and rationale",
      "number": "4.4.1",
      "page": 206,
      "pageLabel": "176",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-119-441-background-and-rationale"
    },
    {
      "level": 2,
      "title": "Minimum dataset for cervical cancer",
      "number": "4.4.2",
      "page": 208,
      "pageLabel": "178",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-120-442-minimum-dataset-for-cervical-cancer"
    },
    {
      "level": 2,
      "title": "Priority indicators for cervical cancer",
      "number": "4.4.3",
      "page": 210,
      "pageLabel": "180",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-121-443-priority-indicators-for-cervical-cancer"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 212,
      "pageLabel": "182",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-122-references"
    },
    {
      "level": 1,
      "title": "Key recommendations",
      "number": null,
      "page": 218,
      "pageLabel": "188",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-124-key-recommendations"
    },
    {
      "level": 1,
      "title": "Introduction",
      "number": "5.1",
      "page": 219,
      "pageLabel": "189",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-125-51-introduction"
    },
    {
      "level": 2,
      "title": "Harnessing routine data to track the epidemic and guide the response",
      "number": "5.1.1",
      "page": 219,
      "pageLabel": "189",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-126-511-harnessing-routine-data-to-track-the-epidemi"
    },
    {
      "level": 2,
      "title": "Using data from routine HIV surveillance systems",
      "number": "5.1.2",
      "page": 223,
      "pageLabel": "193",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-127-512-using-data-from-routine-hiv-surveillance-sys"
    },
    {
      "level": 1,
      "title": "Methods for estimating HIV incidence and prevalence using routine data",
      "number": "5.2",
      "page": 224,
      "pageLabel": "194",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-128-52-methods-for-estimating-hiv-incidence-and-prev"
    },
    {
      "level": 2,
      "title": "CD4/AIDS back-calculation",
      "number": "5.2.1",
      "page": 224,
      "pageLabel": "194",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-129-521-cd4aids-back-calculation"
    },
    {
      "level": 2,
      "title": "Retesting",
      "number": "5.2.2",
      "page": 228,
      "pageLabel": "198",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-130-522-retesting"
    },
    {
      "level": 2,
      "title": "Recency assays",
      "number": "5.2.3",
      "page": 231,
      "pageLabel": "201",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-131-523-recency-assays"
    },
    {
      "level": 2,
      "title": "Routine antenatal HIV testing",
      "number": "5.2.4",
      "page": 234,
      "pageLabel": "204",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-132-524-routine-antenatal-hiv-testing"
    },
    {
      "level": 2,
      "title": "Age-specific HIV prevalence",
      "number": "5.2.5",
      "page": 238,
      "pageLabel": "208",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-133-525-age-specific-hiv-prevalence"
    },
    {
      "level": 2,
      "title": "Phylogenetics",
      "number": "5.2.6",
      "page": 239,
      "pageLabel": "209",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-134-526-phylogenetics"
    },
    {
      "level": 2,
      "title": "Inclusion of routine data in modelling",
      "number": "5.2.7",
      "page": 241,
      "pageLabel": "211",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-135-527-inclusion-of-routine-data-in-modelling"
    },
    {
      "level": 1,
      "title": "Minimum dataset required for estimating HIV incidence and prevalence",
      "number": "5.3",
      "page": 243,
      "pageLabel": "213",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-136-53-minimum-dataset-required-for-estimating-hiv-i"
    },
    {
      "level": 1,
      "title": "Data quality needs for the use of routine data",
      "number": "5.4",
      "page": 246,
      "pageLabel": "216",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-137-54-data-quality-needs-for-the-use-of-routine-dat"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 247,
      "pageLabel": "217",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-138-references"
    },
    {
      "level": 1,
      "title": "Key recommendations",
      "number": null,
      "page": 256,
      "pageLabel": "226",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-140-key-recommendations"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "6.1",
      "page": 257,
      "pageLabel": "227",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-141-61-introduction"
    },
    {
      "level": 3,
      "title": "Overview",
      "number": "6.1.1",
      "page": 257,
      "pageLabel": "227",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-142-611-overview"
    },
    {
      "level": 2,
      "title": "Interoperability",
      "number": "6.2",
      "page": 262,
      "pageLabel": "232",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-143-62-interoperability"
    },
    {
      "level": 3,
      "title": "Overview",
      "number": "6.2.1",
      "page": 262,
      "pageLabel": "232",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-144-621-overview"
    },
    {
      "level": 3,
      "title": "Organizational interoperability (governance)",
      "number": "6.2.2",
      "page": 264,
      "pageLabel": "234",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-145-622-organizational-interoperability-governance"
    },
    {
      "level": 3,
      "title": "Legal interoperability",
      "number": "6.2.3",
      "page": 266,
      "pageLabel": "236",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-146-623-legal-interoperability"
    },
    {
      "level": 3,
      "title": "Technical interoperability",
      "number": "6.2.4",
      "page": 267,
      "pageLabel": "237",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-147-624-technical-interoperability"
    },
    {
      "level": 3,
      "title": "Data use and exchange",
      "number": "6.2.5",
      "page": 268,
      "pageLabel": "238",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-148-625-data-use-and-exchange"
    },
    {
      "level": 2,
      "title": "Unique identifiers",
      "number": "6.3",
      "page": 269,
      "pageLabel": "239",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-149-63-unique-identifiers"
    },
    {
      "level": 3,
      "title": "Overview",
      "number": "6.3.1",
      "page": 269,
      "pageLabel": "239",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-150-631-overview"
    },
    {
      "level": 3,
      "title": "Development path for UIDs",
      "number": "6.3.2",
      "page": 271,
      "pageLabel": "241",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-151-632-development-path-for-uids"
    },
    {
      "level": 1,
      "title": "System architecture and methods of UID",
      "number": "6.3.3",
      "page": 277,
      "pageLabel": "247",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-152-633-system-architecture-and-methods-of-uid"
    },
    {
      "level": 1,
      "title": "Privacy, security, data access and control",
      "number": "6.4",
      "page": 282,
      "pageLabel": "252",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-153-64-privacy-security-data-access-and-control"
    },
    {
      "level": 2,
      "title": "Overview",
      "number": "6.4.1",
      "page": 282,
      "pageLabel": "252",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-154-641-overview"
    },
    {
      "level": 1,
      "title": "Situation analysis to assess privacy, confidentiality and security of a digital system",
      "number": "6.4.2",
      "page": 284,
      "pageLabel": "254",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-155-642-situation-analysis-to-assess-privacy-confide"
    },
    {
      "level": 1,
      "title": "Data access and control",
      "number": "6.4.3",
      "page": 285,
      "pageLabel": "255",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-156-643-data-access-and-control"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 289,
      "pageLabel": "259",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-158-references"
    },
    {
      "level": 1,
      "title": "Indirect benefits",
      "number": "6.4.4",
      "page": 288,
      "pageLabel": "258",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-157-644-indirect-benefits"
    },
    {
      "level": 1,
      "title": "Introduction",
      "number": "7.1",
      "page": 296,
      "pageLabel": "266",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-160-71-introduction"
    },
    {
      "level": 2,
      "title": "A comprehensive data use framework",
      "number": "7.1.1",
      "page": 296,
      "pageLabel": "266",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-161-711-a-comprehensive-data-use-framework"
    },
    {
      "level": 3,
      "title": "Sources of data on HIV and their use",
      "number": "7.1.2",
      "page": 297,
      "pageLabel": "267",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-162-712-sources-of-data-on-hiv-and-their-use"
    },
    {
      "level": 2,
      "title": "Measuring and improving the quality of person-centred care",
      "number": "7.2",
      "page": 298,
      "pageLabel": "268",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-163-72-measuring-and-improving-the-quality-of-person"
    },
    {
      "level": 3,
      "title": "Background and rationale",
      "number": "7.2.1",
      "page": 298,
      "pageLabel": "268",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-164-721-background-and-rationale"
    },
    {
      "level": 3,
      "title": "Measuring QOC",
      "number": "7.2.2",
      "page": 299,
      "pageLabel": "269",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-165-722-measuring-qoc"
    },
    {
      "level": 1,
      "title": "Community engagement in measuring QOC",
      "number": "7.2.3",
      "page": 301,
      "pageLabel": "271",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-166-723-community-engagement-in-measuring-qoc"
    },
    {
      "level": 2,
      "title": "A QOC framework for selecting indicators",
      "number": "7.2.4",
      "page": 301,
      "pageLabel": "271",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-167-724-a-qoc-framework-for-selecting-indicators"
    },
    {
      "level": 1,
      "title": "Priority indicators",
      "number": "7.2.5",
      "page": 303,
      "pageLabel": "273",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-168-725-priority-indicators"
    },
    {
      "level": 1,
      "title": "Community-led monitoring",
      "number": "7.3",
      "page": 305,
      "pageLabel": "275",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-169-73-community-led-monitoring"
    },
    {
      "level": 1,
      "title": "References",
      "number": null,
      "page": 314,
      "pageLabel": "284",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-177-references"
    },
    {
      "level": 1,
      "title": "Evaluation and operational research",
      "number": "7.10",
      "page": 313,
      "pageLabel": "283",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-176-710-evaluation-and-operational-research"
    },
    {
      "level": 1,
      "title": "Data quality review, triangulation and use",
      "number": "7.9",
      "page": 312,
      "pageLabel": "282",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-175-79-data-quality-review-triangulation-and-use"
    },
    {
      "level": 1,
      "title": "Mathematical modelling",
      "number": "7.8",
      "page": 311,
      "pageLabel": "281",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-174-78-mathematical-modelling"
    },
    {
      "level": 1,
      "title": "Population-based survey data",
      "number": "7.7",
      "page": 310,
      "pageLabel": "280",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-173-77-population-based-survey-data"
    },
    {
      "level": 1,
      "title": "Civil registration and vital statistics",
      "number": "7.6",
      "page": 310,
      "pageLabel": "280",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-172-76-civil-registration-and-vital-statistics"
    },
    {
      "level": 1,
      "title": "Health facility assessments",
      "number": "7.5",
      "page": 309,
      "pageLabel": "279",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-171-75-health-facility-assessments"
    },
    {
      "level": 1,
      "title": "Logistics management information systems",
      "number": "7.4",
      "page": 307,
      "pageLabel": "277",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-170-74-logistics-management-information-systems"
    },
    {
      "level": 1,
      "title": "Introduction",
      "number": "8.1",
      "page": 318,
      "pageLabel": "288",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-179-81-introduction"
    },
    {
      "level": 2,
      "title": "Disaggregation",
      "number": "8.1.1",
      "page": 318,
      "pageLabel": "288",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-180-811-disaggregation"
    },
    {
      "level": 3,
      "title": "Time periods",
      "number": "8.1.2",
      "page": 319,
      "pageLabel": "289",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-181-812-time-periods"
    },
    {
      "level": 3,
      "title": "Inclusion of community-based service data",
      "number": "8.1.3",
      "page": 320,
      "pageLabel": "290",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-182-813-inclusion-of-community-based-service-data"
    },
    {
      "level": 2,
      "title": "Priority indicators by programme area",
      "number": "8.2",
      "page": 321,
      "pageLabel": "291",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-183-82-priority-indicators-by-programme-area"
    },
    {
      "level": 3,
      "title": "HIV prevention",
      "number": "8.2.1",
      "page": 321,
      "pageLabel": "291",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-184-821-hiv-prevention"
    },
    {
      "level": 3,
      "title": "HIV testing services",
      "number": "8.2.2",
      "page": 343,
      "pageLabel": "313",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-185-822-hiv-testing-services"
    },
    {
      "level": 3,
      "title": "HIV treatment",
      "number": "8.2.3",
      "page": 355,
      "pageLabel": "325",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-186-823-hiv-treatment"
    },
    {
      "level": 3,
      "title": "TB/HIV",
      "number": "8.2.4",
      "page": 374,
      "pageLabel": "344",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-187-824-tbhiv"
    },
    {
      "level": 3,
      "title": "Differentiated service delivery",
      "number": "8.2.5",
      "page": 383,
      "pageLabel": "353",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-188-825-differentiated-service-delivery"
    },
    {
      "level": 3,
      "title": "Sexually transmitted infections",
      "number": "8.2.6",
      "page": 389,
      "pageLabel": "359",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-189-826-sexually-transmitted-infections"
    },
    {
      "level": 3,
      "title": "Viral hepatitis",
      "number": "8.2.7",
      "page": 403,
      "pageLabel": "373",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-190-827-viral-hepatitis"
    },
    {
      "level": 3,
      "title": "Cervical cancer",
      "number": "8.2.8",
      "page": 412,
      "pageLabel": "382",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-191-828-cervical-cancer"
    },
    {
      "level": 3,
      "title": "HIV incidence",
      "number": "8.2.9",
      "page": 416,
      "pageLabel": "386",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-192-829-hiv-incidence"
    },
    {
      "level": 3,
      "title": "AIDS-related mortality",
      "number": "8.2.10",
      "page": 417,
      "pageLabel": "387",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-193-8210-aids-related-mortality"
    },
    {
      "level": 3,
      "title": "Stigma and discrimination",
      "number": "8.2.11",
      "page": 418,
      "pageLabel": "388",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-194-8211-stigma-and-discrimination"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 8,
      "labelStart": "C1",
      "labelEnd": "vi",
      "words": 1079,
      "summary": {
        "text": "The front matter of WHO's 2022 consolidated guidelines on person-centred HIV strategic information, with ISBNs and Creative Commons licence terms. It also contains a detailed table of contents running through chapters on prevention, testing, treatment, data systems and priority indicators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "web annex",
          "heading": false
        },
        {
          "term": "person-centred hiv",
          "heading": false
        },
        {
          "term": "chapter person-centred",
          "heading": false
        },
        {
          "term": "hiv strategic",
          "heading": false
        },
        {
          "term": "estimating hiv",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": false
        },
        {
          "term": "individual-level data",
          "heading": false
        },
        {
          "term": "routine data",
          "heading": false
        }
      ],
      "extract": "CONSOLIDATED GUIDELINES ON PERSON-CENTRED HIV STRATEGIC INFORMATION STRENGTHENING ROUTINE DATA FOR IMPACT CONSOLIDATED GUIDELINES ON PERSON-CENTRED HIV STRATEGIC INFORMATION STRENGTHENING ROUTINE DATA FOR IMPACT Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact ISBN 978-92-4-005531-5 (electronic version) ISBN 978-92-4-005532-2 (print version) © World Health",
      "extractCut": true,
      "blocks": [
        "library/10665-360948/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 1,
      "pageStart": 8,
      "pageEnd": 12,
      "labelStart": "vi",
      "labelEnd": "x",
      "words": 1772,
      "summary": {
        "text": "The acknowledgements of the consolidated HIV strategic information guidelines, naming WHO staff, external reviewers and contributing organizations. It also notes funding from the US government through USAID and CDC.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "united kingdom",
          "heading": false
        },
        {
          "term": "mpact global",
          "heading": false
        },
        {
          "term": "gay men",
          "heading": false
        },
        {
          "term": "neil mcculloch",
          "heading": false
        },
        {
          "term": "andrew spieldenner",
          "heading": false
        },
        {
          "term": "ruth morgan",
          "heading": false
        },
        {
          "term": "andrew leigh",
          "heading": false
        },
        {
          "term": "andrew boulle",
          "heading": false
        }
      ],
      "extract": "The World Health Organization (WHO) gratefully acknowledges the contributions of many individuals and organizations to these consolidated guidelines. WHO STAFF AND CONSULTANTS Shona Dalal coordinated the overall guideline process with Diana Faini, Annette Gerritsen, Hiwot Haille-Selassie, Bradley Mathers, William Probert, Francoise Renaud and Jane Rowley under the leadership of Daniel Low-Beer, Unit Head, and Meg",
      "extractCut": true
    },
    {
      "id": "sec-001-abbreviations-and-acronyms",
      "number": null,
      "title": "Abbreviations and acronyms",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 15,
      "labelStart": "x",
      "labelEnd": "xiii",
      "words": 448,
      "summary": {
        "text": "A list of abbreviations and acronyms used in the HIV strategic information guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hepatitis virus",
          "heading": false
        },
        {
          "term": "bio-behavioural survey",
          "heading": false
        },
        {
          "term": "recent infection",
          "heading": false
        },
        {
          "term": "false recent",
          "heading": false
        },
        {
          "term": "united states",
          "heading": false
        },
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "quality improvement",
          "heading": false
        }
      ],
      "extract": "AEM AIDS Epidemic Model AIM Spectrum AIDS Impact Model AIS AIDS Indicator Surveys ANC antenatal care ART antiretroviral therapy ARV antiretroviral BBS bio-behavioural survey (also called IBBS – integrated bio-behavioural survey) CAB-LA long-acting injectable cabotegravir CAG community ART group CDC United States Centers for Disease Control and Prevention CHW community health worker CLM community-led monitoring CPT",
      "extractCut": true
    },
    {
      "id": "sec-002-glossary",
      "number": null,
      "title": "Glossary",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 19,
      "labelStart": "xiii",
      "labelEnd": "xvii",
      "words": 2292,
      "summary": {
        "text": "A glossary of terms used in the HIV strategic information guidelines, from active TB disease and advanced HIV disease through aggregate data to key and vulnerable populations. It defines clinical, programme and data system concepts relevant to person-centred HIV monitoring. Definitions are generally given for both clinical and data-management purposes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv viral",
          "heading": false
        },
        {
          "term": "gender nonconforming",
          "heading": false
        },
        {
          "term": "hiv services",
          "heading": false
        },
        {
          "term": "sentinel event",
          "heading": false
        },
        {
          "term": "hiv testing",
          "heading": false
        },
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "people tested",
          "heading": false
        },
        {
          "term": "individual-level data",
          "heading": false
        }
      ],
      "extract": "Active TB disease case A person who exhibits signs or symptoms of active disease and tests positive for Mycobacterium tuberculosis on smear examination, culture or a molecular WHO- recommended rapid diagnostic test such as Xpert MTB/RIF, or who is clinically diagnosed as a TB case by a clinician or other medical practitioner with a decision to treat with a full course of TB treatment. This is synonymous with",
      "extractCut": true
    },
    {
      "id": "sec-003-executive-summary",
      "number": null,
      "title": "Executive summary",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 22,
      "labelStart": "xvii",
      "labelEnd": "xx",
      "words": 1423,
      "summary": {
        "text": "The executive summary of the consolidated HIV strategic information guidelines notes that despite abundant data, new infections remain above targets and retention and late diagnosis are problems. It explains that the guidelines focus on individual-level routine data to strengthen person-centred services and linkage to prevention and treatment. It also notes the inclusion of data on STIs, TB, viral hepatitis and cervical cancer in HIV data systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "person-centred data",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        },
        {
          "term": "person-centred hiv",
          "heading": false
        },
        {
          "term": "person-centred services",
          "heading": false
        },
        {
          "term": "digital data",
          "heading": false
        },
        {
          "term": "data systems",
          "heading": false
        },
        {
          "term": "priority indicators",
          "heading": false
        },
        {
          "term": "hiv-related infections",
          "heading": false
        }
      ],
      "extract": "Person-centred data for improved health outcomes and impact Now into the fourth decade of the global response to HIV, a wealth of data exists on where and among whom new infections occur, methods of prevention and treatment, viral suppression and programme coverage and performance. Yet, substantial gaps in the response remain. New infections are occurring at a rate far above global targets, and, while treatment",
      "extractCut": true
    },
    {
      "id": "sec-004-summary-recommendations",
      "number": null,
      "title": "Summary recommendations",
      "level": 1,
      "pageStart": 22,
      "pageEnd": 25,
      "labelStart": "xx",
      "labelEnd": "xxiii",
      "words": 1423,
      "summary": {
        "text": "Summarizes the guidelines' recommendations by chapter, starting with new recommendations on collecting individual-level HIV prevention data to measure coverage and impact. Further recommendations cover testing, treatment, data systems and use of digital tools. It closes by stressing confidentiality and security of personal data, given elevated risks for key populations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "person-centred hiv",
          "heading": false
        },
        {
          "term": "person-centred data",
          "heading": false
        },
        {
          "term": "data security",
          "heading": false
        },
        {
          "term": "unique identifiers",
          "heading": false
        },
        {
          "term": "strengthen data",
          "heading": false
        },
        {
          "term": "hiv treatment",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "personal data",
          "heading": false
        }
      ],
      "extract": "Chapter 2 – Person-centred HIV prevention monitoring NEW 1. \u0007The collection of a minimum dataset of individual-level data elements on HIV prevention interventions is recommended to measure interventions received and health outcomes among individuals seeking HIV prevention. NEW 2. \u0007Individual-level data on HIV prevention should be used, alongside other available data sources, to strengthen the measurement of: a) \u0007the",
      "extractCut": true
    },
    {
      "id": "sec-005-summary-list-of-priority-indicators",
      "number": null,
      "title": "Summary list of priority indicators",
      "level": 1,
      "pageStart": 25,
      "pageEnd": 31,
      "labelStart": "xxiii",
      "labelEnd": "1",
      "words": 1982,
      "summary": {
        "text": "A summary table of priority indicators from WHO's 2022 consolidated guidelines on person-centred HIV strategic information, giving each indicator's reference number, short name and definition, with new and updated indicators flagged. It spans HIV prevention (condoms, PrEP, PEP, needle–syringe programmes and more), testing, treatment and viral load, vertical transmission, and differentiated service delivery. It also covers TB–HIV, related infections such as cervical cancer, incidence and mortality, and ends with indicators on avoidance of health care due to stigma and discrimination.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dsd art",
          "heading": false
        },
        {
          "term": "oamt recipients",
          "heading": false
        },
        {
          "term": "art coverage",
          "heading": false
        },
        {
          "term": "art during",
          "heading": false
        },
        {
          "term": "pep recipients",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "art models",
          "heading": false
        },
        {
          "term": "hcv treatment",
          "heading": false
        }
      ],
      "extract": "Programme indicators Ref.no Short name Indicator definition Condom programming PRV.1 Condoms distributed Total number of condoms distributed during the reporting period Pre-exposure prophylaxis (PrEP) PRV.2 Total PrEP recipients Number of people who received PrEP at least once during the reporting period PRV.3 (NEW) PrEP coverage % of people prescribed PrEP among those identified as being at elevated risk for HIV",
      "extractCut": true
    },
    {
      "id": "sec-006-chapter-1-introduction",
      "number": null,
      "title": "Chapter 1 – Introduction",
      "level": 1,
      "pageStart": 31,
      "pageEnd": 32,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 114,
      "summary": {
        "text": "The contents listing for Chapter 1, the introduction, covering background, evolving data needs, individual-level data, integration of related infections, key populations, new features, objectives, development process and intended audiences.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "introduction",
          "heading": true
        },
        {
          "term": "chapter",
          "heading": true
        },
        {
          "term": "consolidation",
          "heading": false
        }
      ],
      "extract": "INTRODUCTION 1 1.1 Background and rationale\b 2 1.1.1 Evolving data needs for a new phase of the HIV response\b 2 1.1.2 Advancing from aggregate to individual-level data use\b 3 1.1.3 Integration of sexually transmitted infections, viral hepatitis, tuberculosis and cervical cancer into HIV reporting systems\b 6 1.1.4 Data considerations for key populations\b 6 1.1.5 Strengthening the use of data from other sources \b 8",
      "extractCut": true
    },
    {
      "id": "sec-007-11-background-and-rationale",
      "number": "1.1",
      "title": "Background and rationale",
      "level": 2,
      "pageStart": 32,
      "pageEnd": 32,
      "labelStart": "2",
      "labelEnd": "2",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-008-111-evolving-data-needs-for-a-new-phase-of-the-h",
      "number": "1.1.1",
      "title": "Evolving data needs for a new phase of the HIV response",
      "level": 2,
      "pageStart": 32,
      "pageEnd": 33,
      "labelStart": "2",
      "labelEnd": "3",
      "words": 817,
      "summary": {
        "text": "Describes progress in the HIV response, with about 28 million of 38 million people living with HIV on treatment in 2021, and new challenges such as loss to follow-up and slow declines in new infections. It argues that routine data systems must evolve to identify gaps faster, alongside surveys, studies and models, while keeping the people whose data are gathered safe and their data secure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv response",
          "heading": true
        },
        {
          "term": "epidemiologic patterns",
          "heading": false
        },
        {
          "term": "data",
          "heading": true
        },
        {
          "term": "data systems",
          "heading": false
        },
        {
          "term": "routine data",
          "heading": false
        },
        {
          "term": "identify epidemiologic",
          "heading": false
        },
        {
          "term": "million people",
          "heading": false
        },
        {
          "term": "health data",
          "heading": false
        }
      ],
      "extract": "Enormous gains have been made in the HIV response over the four decades since the first identification of the virus. Treatment has expanded to an estimated 28 million people of the 38 million people living with HIV in 2021, and eight countries have achieved the UNAIDS 90–90–90 targets (1). These gains have increased life expectancy and enabled people living with HIV to lead healthier lives. As large numbers of",
      "extractCut": true
    },
    {
      "id": "sec-009-112-advancing-from-aggregate-to-individual-level",
      "number": "1.1.2",
      "title": "Advancing from aggregate to individual-level data use",
      "level": 2,
      "pageStart": 33,
      "pageEnd": 36,
      "labelStart": "3",
      "labelEnd": "6",
      "words": 1350,
      "summary": {
        "text": "Contrasts aggregate facility data with individual-level data, explaining that person-level records linked by unique identifiers improve continuity of care, reduce duplicate counts and allow more accurate automated reporting. It describes how paper-based and electronic reporting may run in parallel while systems mature and be combined at subnational or national level. It stresses checking completeness and quality and the principle of collecting data once and using it many times.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "individual-level data",
          "heading": true
        },
        {
          "term": "aggregate",
          "heading": true
        },
        {
          "term": "person-centred data",
          "heading": false
        },
        {
          "term": "person-centred monitoring",
          "heading": false
        },
        {
          "term": "aggregate reporting",
          "heading": false
        },
        {
          "term": "improve person-centred",
          "heading": false
        },
        {
          "term": "data systems",
          "heading": false
        },
        {
          "term": "routine data",
          "heading": false
        }
      ],
      "extract": "The major source of strategic information used to monitor the HIV response in the health sector is aggregate routine facility data. Understanding the strengths and limitations of this type of data is critical to their proper use and interpretation. Individual-level data, as reflected in primary data collection tools such as patient records, have always been viewed as critical to patient care, supporting the",
      "extractCut": true
    },
    {
      "id": "sec-010-113-integration-of-sexually-transmitted-infectio",
      "number": "1.1.3",
      "title": "Integration of sexually transmitted infections, viral hepatitis, tuberculosis and cervical cancer into HIV reporting systems",
      "level": 2,
      "pageStart": 36,
      "pageEnd": 36,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 495,
      "summary": {
        "text": "Notes the large global burden of STIs, HPV, herpes and hepatitis B and C among people with HIV, and the overlap in transmission routes and services. It explains that the guidelines integrate these infections, along with TB and cervical cancer, into person-centred HIV monitoring through suggested minimum datasets and indicators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "viral hepatitis",
          "heading": true
        },
        {
          "term": "cervical cancer",
          "heading": true
        },
        {
          "term": "infections",
          "heading": true
        },
        {
          "term": "hiv",
          "heading": true
        },
        {
          "term": "person-centred hiv",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "elevated risk",
          "heading": false
        }
      ],
      "extract": "tuberculosis and cervical cancer into HIV reporting systems Every day, worldwide, people acquire more than 1 million curable sexually transmitted infections (STIs). More than one in every seven women is estimated to be infected with human papillomavirus (HPV), and more than 500 million people are estimated to have genital herpes simplex virus (HSV) infection (13, 14). An estimated 5–25% of people living with HIV",
      "extractCut": true
    },
    {
      "id": "sec-011-114-data-considerations-for-key-populations",
      "number": "1.1.4",
      "title": "Data considerations for key populations",
      "level": 2,
      "pageStart": 36,
      "pageEnd": 38,
      "labelStart": "6",
      "labelEnd": "8",
      "words": 691,
      "summary": {
        "text": "Identifies five key populations disproportionately affected by HIV, viral hepatitis and STIs and the social, legal and structural barriers they face. It discusses the risks of recording key population status in routine data and advises against collecting such information where it could harm individuals or deter them from services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "key populations",
          "heading": true
        },
        {
          "term": "population members",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        },
        {
          "term": "routine data",
          "heading": false
        },
        {
          "term": "population group",
          "heading": false
        },
        {
          "term": "population status",
          "heading": false
        },
        {
          "term": "general population",
          "heading": false
        },
        {
          "term": "information systems",
          "heading": false
        }
      ],
      "extract": "Five key populations are disproportionately affected by HIV and in almost every setting have a higher prevalence and incidence than people outside of these groups (1). These key populations are men who have sex with men, sex workers, people who inject drugs, trans and gender diverse people, and people in prisons and other closed settings. Members of these populations are also disproportionally affected by viral",
      "extractCut": true
    },
    {
      "id": "sec-012-115-strengthening-the-use-of-data-from-other-sou",
      "number": "1.1.5",
      "title": "Strengthening the use of data from other sources",
      "level": 2,
      "pageStart": 38,
      "pageEnd": 40,
      "labelStart": "8",
      "labelEnd": "10",
      "words": 561,
      "summary": {
        "text": "Explains that HIV strategic information should fit within the wider health information system, illustrated by an integrated data architecture figure. It notes that routine data cover only people reached by services and should be triangulated with surveys, models and studies, and highlights community-based services and community-led monitoring.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "community-led monitoring",
          "heading": false
        },
        {
          "term": "through community-led",
          "heading": false
        },
        {
          "term": "hiv services",
          "heading": false
        },
        {
          "term": "data",
          "heading": true
        },
        {
          "term": "routine data",
          "heading": false
        },
        {
          "term": "community engagement",
          "heading": false
        },
        {
          "term": "health services",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        }
      ],
      "extract": "For sustainability, the strategic information system of the health sector response to HIV must align with the broader health information system (HIS) as part of an integrated architecture (Fig. 1.2). Guidance for national HIS standards and tools are available to support development of appropriate HIS and digital health policies, guidelines, strategic plans and roadmaps, including for system interoperability (see",
      "extractCut": true
    },
    {
      "id": "sec-013-12-whats-new-in-this-consolidation-of-who-strate",
      "number": "1.2",
      "title": "What’s new in this consolidation of WHO strategic information guidelines",
      "level": 2,
      "pageStart": 40,
      "pageEnd": 41,
      "labelStart": "10",
      "labelEnd": "11",
      "words": 695,
      "summary": {
        "text": "Explains that the consolidated guidelines bring together data elements, indicators and data-system guidance across all HIV services, replacing two earlier WHO strategic information guidelines from 2017 and 2020. It describes implementation gaps in patient monitoring and case surveillance and the aim of linking individual-level and aggregate data under the collect-once-use-many principle. A box lists new areas, including the first minimum datasets for HIV prevention, STIs, viral hepatitis and cervical cancer.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "strategic information",
          "heading": true
        },
        {
          "term": "information guidelines",
          "heading": true
        },
        {
          "term": "hiv strategic",
          "heading": false
        },
        {
          "term": "individual-level data",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "person-centred hiv",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "hiv acquisition",
          "heading": false
        }
      ],
      "extract": "information guidelines The aim of this consolidation of strategic information guidelines is to provide in one place the recommended data elements, indicators and guidance on data systems and use across the spectrum of health sector HIV services and to reference technical guidelines published by WHO and its partners that detail recommended interventions and how to operationalize the collection and use of related",
      "extractCut": true
    },
    {
      "id": "sec-014-121-data-system-maturity-for-use-of-person-centr",
      "number": "1.2.1",
      "title": "Data system maturity for use of person-centred data",
      "level": 2,
      "pageStart": 41,
      "pageEnd": 42,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 510,
      "summary": {
        "text": "Notes that while the guidelines focus on person-centred data, many settings lack mature integrated systems, so priority indicators can still be calculated with existing reporting. It explains how data from digital and paper systems can be combined during transition, with limits on deduplication, and the role of the guidance in common understanding among managers and developers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "person-centred data",
          "heading": true
        },
        {
          "term": "person-centred digital",
          "heading": false
        },
        {
          "term": "digital systems",
          "heading": false
        },
        {
          "term": "digital tracking",
          "heading": false
        },
        {
          "term": "support systems",
          "heading": false
        },
        {
          "term": "health information",
          "heading": false
        },
        {
          "term": "decision support",
          "heading": false
        },
        {
          "term": "health workers",
          "heading": false
        }
      ],
      "extract": "While these 2022 guidelines focus on the collection, analysis and use of person-centred data at the facility, subnational or national level, in many places fully integrated systems are not yet operational. These guidelines contain information pertinent to all contexts. In settings where person-centred electronic data systems are not yet mature or at scale, priority indicators that are proportions can still be",
      "extractCut": true
    },
    {
      "id": "sec-015-13-objectives-and-guiding-principles",
      "number": "1.3",
      "title": "Objectives and guiding principles",
      "level": 2,
      "pageStart": 42,
      "pageEnd": 43,
      "labelStart": "12",
      "labelEnd": "13",
      "words": 551,
      "summary": {
        "text": "Sets out the goal of helping countries generate person-centred data from routine health information systems and use it across the HIV cascade. It lists objectives, such as greater use of individual-level data linked by unique identifiers, and guiding principles including privacy, security, ethics, equity and governance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "health data",
          "heading": false
        },
        {
          "term": "digital health",
          "heading": false
        },
        {
          "term": "health systems",
          "heading": false
        },
        {
          "term": "health initiatives",
          "heading": false
        },
        {
          "term": "health priorities",
          "heading": false
        },
        {
          "term": "unique identifiers",
          "heading": false
        },
        {
          "term": "health services",
          "heading": false
        },
        {
          "term": "health information",
          "heading": false
        }
      ],
      "extract": "The overarching goal of these guidelines is to support countries in generating responsive person-centred data from routine national health information management systems. Keeping the person at the centre and understanding how people access services can improve health decision-making and health outcomes. These guidelines aim to strengthen the analysis and use of data at each stage of the cascade and to emphasize",
      "extractCut": true
    },
    {
      "id": "sec-016-14-process-of-development",
      "number": "1.4",
      "title": "Process of development",
      "level": 2,
      "pageStart": 43,
      "pageEnd": 44,
      "labelStart": "13",
      "labelEnd": "14",
      "words": 245,
      "summary": {
        "text": "Describes how WHO developed the guidelines through review of existing guidance, expert consultation, a Core Advisory Group and technical working groups for each programme area. It notes that external contributors completed declarations of interests.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "global fund",
          "heading": false
        },
        {
          "term": "minimum datasets",
          "heading": false
        },
        {
          "term": "technical experts",
          "heading": false
        },
        {
          "term": "civil society",
          "heading": false
        },
        {
          "term": "advisory group",
          "heading": false
        },
        {
          "term": "technical working",
          "heading": false
        },
        {
          "term": "co-chairs",
          "heading": false
        },
        {
          "term": "health ministries",
          "heading": false
        }
      ],
      "extract": "WHO staff and consultants developed these guidelines based on review of recent global and regional guidance documents, consultative meetings and inputs of technical experts. The minimum datasets and priority indicators included in these guidelines were identified through consultation with technical experts with country-level, regional and global perspectives. The Core Advisory Group, which had responsibility for",
      "extractCut": true
    },
    {
      "id": "sec-017-15-organization-of-the-guidelines",
      "number": "1.5",
      "title": "Organization of the guidelines",
      "level": 2,
      "pageStart": 44,
      "pageEnd": 44,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 189,
      "summary": {
        "text": "Outlines the six technical chapters of the guidelines, the indicator metadata in Chapter 8, and web annexes containing the full minimum dataset and additional indicators and tools.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "web annexes",
          "heading": false
        },
        {
          "term": "person-centred hiv",
          "heading": false
        },
        {
          "term": "minimum dataset",
          "heading": false
        },
        {
          "term": "web annex",
          "heading": false
        },
        {
          "term": "hiv surveillance",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": false
        },
        {
          "term": "patient monitoring",
          "heading": false
        }
      ],
      "extract": "These guidelines are organized into six technical chapters on person-centred HIV prevention monitoring; person-centred HIV patient monitoring for testing, early diagnosis, and treatment; integrating related infections into HIV surveillance systems; harnessing the strength of routine data for HIV surveillance; digital health data; and strengthening data use. Each chapter includes a brief description of critical",
      "extractCut": true
    },
    {
      "id": "sec-018-16-intended-audiences",
      "number": "1.6",
      "title": "Intended audiences",
      "level": 2,
      "pageStart": 44,
      "pageEnd": 45,
      "labelStart": "14",
      "labelEnd": "15",
      "words": 141,
      "summary": {
        "text": "Identifies the intended users of the guidelines, chiefly national and subnational HIV programme managers, surveillance officers and partners, as well as NGOs, private providers and academics.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "strategic information",
          "heading": false
        },
        {
          "term": "health sector",
          "heading": false
        },
        {
          "term": "hiv health",
          "heading": false
        },
        {
          "term": "intended",
          "heading": true
        },
        {
          "term": "subnational",
          "heading": false
        }
      ],
      "extract": "This guideline is intended primarily for national and subnational HIV programme managers, surveillance officers, partners and other stakeholders involved in the design and use of M&E systems, surveillance and tools for the collection, analysis and use of HIV health sector data. These include national-level staff establishing strategic information policy, guidelines, frameworks, tools and HIS as well as staff",
      "extractCut": true
    },
    {
      "id": "sec-019-references",
      "number": null,
      "title": "References",
      "level": 2,
      "pageStart": 45,
      "pageEnd": 49,
      "labelStart": "15",
      "labelEnd": "19",
      "words": 1008,
      "summary": {
        "text": "The reference list for the introduction chapter, citing UNAIDS global AIDS updates, population survey and incidence studies, and WHO guidance on strategic information and digital health.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "sex transm",
          "heading": false
        },
        {
          "term": "transm dis",
          "heading": false
        },
        {
          "term": "transm infect",
          "heading": false
        },
        {
          "term": "publications item",
          "heading": false
        },
        {
          "term": "int publications",
          "heading": false
        },
        {
          "term": "hiv incidence",
          "heading": false
        },
        {
          "term": "adaptation kit",
          "heading": false
        }
      ],
      "extract": "1. Global AIDS Update 2021. Confronting inequalities: lessons for pandemic responses from 40 years of AIDS. Geneva: United Nations Joint Programme on HIV/AIDS (UNAIDS); 2021 (https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update, accessed 23 June 2022). 2. Justman JE, Mugurungi O, El-Sadr WM. HIV population surveys - bringing precision to the global response. N Engl J Med. 2018;378:1859-61. doi:",
      "extractCut": true
    },
    {
      "id": "sec-020-chapter-2-person-centred-hiv-prevention-monitori",
      "number": null,
      "title": "Chapter 2 – Person-centred HIV prevention monitoring",
      "level": 1,
      "pageStart": 49,
      "pageEnd": 50,
      "labelStart": "19",
      "labelEnd": "20",
      "words": 181,
      "summary": {
        "text": "The contents listing for Chapter 2 on person-centred HIV prevention monitoring, covering prevention epidemiology, individual-level prevention data, confidentiality and unique identifiers, minimum datasets, data use and indicators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": true
        },
        {
          "term": "person-centred hiv",
          "heading": true
        },
        {
          "term": "individual-level hiv",
          "heading": false
        },
        {
          "term": "individual-level data",
          "heading": false
        },
        {
          "term": "prevention interventions",
          "heading": false
        },
        {
          "term": "data system",
          "heading": false
        }
      ],
      "extract": "PERSON-CENTRED HIV PREVENTION MONITORING 2 Key recommendations\b 20 2.1 Introduction\b 21 2.1.1 Epidemiology of HIV and prevention need \b 21 2.1.2 Strategic information for HIV prevention \b 22 2.1.3 HIV prevention interventions\b 24 2.2 Individual-level HIV prevention data\b 26 2.2.1 Using routine programme data to measure HIV prevention interventions\b 26 2.2.2 Anonymity, confidentiality and the use of unique",
      "extractCut": true
    },
    {
      "id": "sec-021-key-recommendations",
      "number": null,
      "title": "Key recommendations",
      "level": 2,
      "pageStart": 50,
      "pageEnd": 51,
      "labelStart": "20",
      "labelEnd": "21",
      "words": 239,
      "summary": {
        "text": "Sets out new key recommendations for HIV prevention monitoring: collecting a minimum individual-level dataset, using it to measure people reached and prevention impact, and recording clinical and behavioural risk factors to target services. It stresses safeguarding confidentiality when linking prevention data to other clinical datasets.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "prevention interventions",
          "heading": false
        },
        {
          "term": "behavioural information",
          "heading": false
        },
        {
          "term": "individual-level data",
          "heading": false
        },
        {
          "term": "identifying information",
          "heading": false
        },
        {
          "term": "data systems",
          "heading": false
        },
        {
          "term": "individual",
          "heading": false
        },
        {
          "term": "sensitive",
          "heading": false
        }
      ],
      "extract": "NEW \u00071. \u0007The collection of a minimum dataset of individual-level data elements on HIV prevention interventions is recommended to measure interventions received and health outcomes among individuals seeking HIV prevention. NEW \u00072. \u0007Individual-level data on HIV prevention should be used, alongside other available data sources, to strengthen the measurement of: a) the coverage of interventions provided to populations",
      "extractCut": true
    },
    {
      "id": "sec-022-21-introduction",
      "number": "2.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 51,
      "pageEnd": 51,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-023-211-epidemiology-of-hiv-and-prevention-need",
      "number": "2.1.1",
      "title": "Epidemiology of HIV and prevention need",
      "level": 2,
      "pageStart": 51,
      "pageEnd": 52,
      "labelStart": "21",
      "labelEnd": "22",
      "words": 618,
      "summary": {
        "text": "Describes slow declines in HIV incidence, with 1.5 million new infections in 2020, and the rising share among key populations and their partners. It notes that criminalization, stigma and discrimination create barriers that must be addressed for equitable access to prevention.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": true
        },
        {
          "term": "hiv infections",
          "heading": false
        },
        {
          "term": "sub-saharan africa",
          "heading": false
        },
        {
          "term": "hiv incidence",
          "heading": false
        },
        {
          "term": "adolescent girls",
          "heading": false
        },
        {
          "term": "hiv acquisition",
          "heading": false
        },
        {
          "term": "key populations",
          "heading": false
        },
        {
          "term": "sex workers",
          "heading": false
        }
      ],
      "extract": "The prevention of new HIV infections remains critical to achieving the goal to end the HIV epidemic by 2030, as set out in the 2016 United Nations Political Declaration (1). Yet, declines in HIV incidence have been slow, far short of the global target of reducing annual new HIV infections to under 370 000 by 2025 (2-4). In 2020, 1.5 million (1.0 million–2.0 million) people became newly infected with HIV, with women",
      "extractCut": true
    },
    {
      "id": "sec-024-212-strategic-information-for-hiv-prevention",
      "number": "2.1.2",
      "title": "Strategic information for HIV prevention",
      "level": 2,
      "pageStart": 52,
      "pageEnd": 54,
      "labelStart": "22",
      "labelEnd": "24",
      "words": 633,
      "summary": {
        "text": "Explains why HIV prevention outcomes are hard to measure, since people start and stop prevention as needs change, and why multiple data sources are needed. The guidelines focus on routine programmatic data, which can also identify people at elevated risk and track whether interventions are received and used.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": true
        },
        {
          "term": "bio-behavioural surveys",
          "heading": false
        },
        {
          "term": "population-based surveys",
          "heading": false
        },
        {
          "term": "prevention service",
          "heading": false
        },
        {
          "term": "individual-level programme",
          "heading": false
        },
        {
          "term": "programmatic data",
          "heading": false
        },
        {
          "term": "routine programmatic",
          "heading": false
        },
        {
          "term": "monitoring hiv",
          "heading": false
        }
      ],
      "extract": "Measuring HIV prevention programmes against health outcomes (such as individuals remaining HIV-negative or new HIV infections) can be challenging. This is because, by its very nature, HIV prevention can be started and stopped at will according to an individual’s need. Therefore, as with all other areas of the HIV response, data from multiple sources are necessary to obtain a full picture of HIV prevention service",
      "extractCut": true
    },
    {
      "id": "sec-025-213-hiv-prevention-interventions",
      "number": "2.1.3",
      "title": "HIV prevention interventions",
      "level": 2,
      "pageStart": 54,
      "pageEnd": 56,
      "labelStart": "24",
      "labelEnd": "26",
      "words": 957,
      "summary": {
        "text": "Advocates a person-centred, context-specific approach to HIV prevention delivered through varied settings, including community-led services, in line with the Global AIDS Strategy. It lists evidence-based biomedical and health-sector prevention interventions, from ART and PrEP to needle–syringe programmes and male circumcision, and notes that counselling alone has not shown an effect on incidence. It points to tools for setting prevention targets for key populations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": true
        },
        {
          "term": "prevention interventions",
          "heading": true
        },
        {
          "term": "structural interventions",
          "heading": false
        },
        {
          "term": "hiv transmission",
          "heading": false
        },
        {
          "term": "prevention services",
          "heading": false
        },
        {
          "term": "prevention programmes",
          "heading": false
        },
        {
          "term": "sector interventions",
          "heading": false
        },
        {
          "term": "monitor hiv",
          "heading": false
        }
      ],
      "extract": "A person-centred approach should address the range of HIV prevention and other health needs that individuals might have and make appropriate interventions available in a manner acceptable to them. The design of HIV prevention programmes should be informed by the local context and the nature of the local HIV epidemic and tailored to meet the HIV prevention needs of the individuals and communities they serve. To meet",
      "extractCut": true
    },
    {
      "id": "sec-026-22-individual-level-hiv-prevention-data",
      "number": "2.2",
      "title": "Individual-level HIV prevention data",
      "level": 2,
      "pageStart": 56,
      "pageEnd": 56,
      "labelStart": "26",
      "labelEnd": "26",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-027-221-using-routine-programme-data-to-measure-hiv",
      "number": "2.2.1",
      "title": "Using routine programme data to measure HIV prevention interventions",
      "level": 2,
      "pageStart": 56,
      "pageEnd": 57,
      "labelStart": "26",
      "labelEnd": "27",
      "words": 343,
      "summary": {
        "text": "Notes that individual-level data have been central to HIV treatment cascades but little used for prevention, and lists prevention outcomes worth monitoring. It sets out the prerequisites for such data, including confidentiality, standardized tools and a minimum dataset.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": true
        },
        {
          "term": "prevention interventions",
          "heading": true
        },
        {
          "term": "individual-level data",
          "heading": false
        },
        {
          "term": "monitor hiv",
          "heading": false
        },
        {
          "term": "across hiv",
          "heading": false
        },
        {
          "term": "hiv treatment",
          "heading": false
        },
        {
          "term": "level data",
          "heading": false
        },
        {
          "term": "individual level",
          "heading": false
        }
      ],
      "extract": "interventions Individual-level data on people living with HIV across HIV treatment and care has proved critical to understanding the effectiveness of HIV treatment at the individual and population levels and has enabled the construction of HIV treatment cascades (24). By comparison, collection and use of individual-level data on HIV-negative people to monitor HIV prevention services and to develop “HIV prevention",
      "extractCut": true
    },
    {
      "id": "sec-028-222-anonymity-confidentiality-and-the-use-of-uni",
      "number": "2.2.2",
      "title": "Anonymity, confidentiality and the use of unique identification (UID) codes",
      "level": 2,
      "pageStart": 57,
      "pageEnd": 58,
      "labelStart": "27",
      "labelEnd": "28",
      "words": 626,
      "summary": {
        "text": "Explains why confidentiality of individual-level data matters for key populations and adolescents whose behaviours may be criminalized, listing harms such as law enforcement use and underreporting of risk. It discusses the use of unique identification codes to link records while protecting anonymity, with further guidance in Chapter 6.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "uid codes",
          "heading": true
        },
        {
          "term": "criminalized behaviours",
          "heading": false
        },
        {
          "term": "confidentiality",
          "heading": true
        },
        {
          "term": "personal identifiers",
          "heading": false
        },
        {
          "term": "identifying information",
          "heading": false
        },
        {
          "term": "data systems",
          "heading": false
        },
        {
          "term": "behavioural information",
          "heading": false
        },
        {
          "term": "prevention data",
          "heading": false
        }
      ],
      "extract": "(UID) codes Maintaining the confidentiality of individual-level health information is important for all people and particularly for populations who may experience criminalization, stigma and discrimination, such as key populations and adolescents. In many settings same-gender sexual activity, sex work, or drug use or possession are stigmatized and, in some settings, criminalized. Health services collecting",
      "extractCut": true
    },
    {
      "id": "sec-029-223-prioritizing-hiv-prevention-services",
      "number": "2.2.3",
      "title": "Prioritizing HIV prevention services",
      "level": 2,
      "pageStart": 58,
      "pageEnd": 59,
      "labelStart": "28",
      "labelEnd": "29",
      "words": 533,
      "summary": {
        "text": "Discusses how intersecting factors such as age, gender and criminalization shape HIV risk and access to prevention, and how individual risk changes over time. It suggests building a process into health information systems to identify people most likely to benefit from prevention services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": true
        },
        {
          "term": "prevention services",
          "heading": true
        },
        {
          "term": "hiv acquisition",
          "heading": false
        },
        {
          "term": "hiv prevalence",
          "heading": false
        },
        {
          "term": "hiv incidence",
          "heading": false
        },
        {
          "term": "substantial risk",
          "heading": false
        },
        {
          "term": "differentiating individuals",
          "heading": false
        },
        {
          "term": "diverse people",
          "heading": false
        }
      ],
      "extract": "It is important that HIV prevention programmes and service providers understand the different vulnerabilities and risks of HIV acquisition of the individuals and communities they serve as well as their values and preferences. It is critical to consider how the intersection of society’s attitudes toward people based on factors such as their age, gender, ethnicity, disability and the criminalization of key populations",
      "extractCut": true
    },
    {
      "id": "sec-030-224-understanding-person-centred-hiv-prevention",
      "number": "2.2.4",
      "title": "Understanding person-centred HIV prevention need",
      "level": 2,
      "pageStart": 59,
      "pageEnd": 62,
      "labelStart": "29",
      "labelEnd": "32",
      "words": 1291,
      "summary": {
        "text": "Describes how client–provider conversations, held with privacy and often with peer support, help identify an individual's HIV prevention needs, and stresses offering prevention to anyone who asks without requiring explanation. It covers the use of prevention prioritization or risk assessment tools when people underestimate their risk, especially adolescents. It advises reassessing need regularly and gives example screening questions to adapt locally.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": true
        },
        {
          "term": "person-centred hiv",
          "heading": true
        },
        {
          "term": "prevention prioritization",
          "heading": false
        },
        {
          "term": "prioritization questions",
          "heading": false
        },
        {
          "term": "prioritization tools",
          "heading": false
        },
        {
          "term": "sexual partner",
          "heading": false
        },
        {
          "term": "hiv acquisition",
          "heading": false
        },
        {
          "term": "risk differentiation",
          "heading": false
        }
      ],
      "extract": "Conversations between service providers and clients during a consultation are key to understanding an individual’s HIV prevention needs. Such conversations may take place before or after HIV testing, during a sexual health consultation, or when providing HIV prevention services. It should be noted that discussing issues such as sexual behaviours, sexual identity and expression, and drug use can be uncomfortable for",
      "extractCut": true
    },
    {
      "id": "sec-031-225-capturing-information-on-hiv-prevention-dema",
      "number": "2.2.5",
      "title": "Capturing information on HIV prevention demand in a health data system",
      "level": 2,
      "pageStart": 62,
      "pageEnd": 64,
      "labelStart": "32",
      "labelEnd": "34",
      "words": 642,
      "summary": {
        "text": "Explains in WHO's consolidated guidelines on person-centred HIV strategic information how health data systems can capture HIV prevention need, through prioritization questions recorded during services and through records showing an individual has received services for key populations or other at-risk groups. It warns that people may not answer behavioural questions, so recorded need may be underestimated. It notes that trans and gender diverse people can be identified from data on sex assigned at birth and current gender identity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": true
        },
        {
          "term": "individual-level data",
          "heading": false
        },
        {
          "term": "prevention prioritization",
          "heading": false
        },
        {
          "term": "gender diverse",
          "heading": false
        },
        {
          "term": "data indicating",
          "heading": false
        },
        {
          "term": "prevention services",
          "heading": false
        },
        {
          "term": "prep received",
          "heading": false
        },
        {
          "term": "injects drugs",
          "heading": false
        }
      ],
      "extract": "data system The collection of individual-level data on HIV prevention need allows for the monitoring of how well HIV prevention services are meeting this demand. There are two main sources of data indicating HIV prevention need captured by health data systems: 1. Data from HIV prevention prioritization questions or information gathered in the course of providing services can be recorded directly in HIV prevention",
      "extractCut": true
    },
    {
      "id": "sec-032-226-entry-points-to-the-data-system-for-the-coll",
      "number": "2.2.6",
      "title": "Entry points to the data system for the collection of individual-level prevention data",
      "level": 2,
      "pageStart": 64,
      "pageEnd": 64,
      "labelStart": "34",
      "labelEnd": "34",
      "words": 171,
      "summary": {
        "text": "Lists the many entry points where individual-level HIV prevention data can be recorded, such as HIV testing, STI, PrEP and PEP services, harm reduction, gender-based violence, family planning, antenatal care and youth programmes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "entry points",
          "heading": true
        },
        {
          "term": "prevention",
          "heading": true
        },
        {
          "term": "potential entry",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "prevention interventions",
          "heading": false
        },
        {
          "term": "pep",
          "heading": false
        }
      ],
      "extract": "level prevention data Entry or referral to HIV prevention interventions can come from a number of prevention and allied programmes in whatever setting the intervention is provided, such as a facility, outpatient clinics, community settings and outreach. Individual-level data may be recorded at the referral or entry point where the HIV prevention intervention is provided. Various potential entry points are listed in",
      "extractCut": true
    },
    {
      "id": "sec-033-227-registration-process",
      "number": "2.2.7",
      "title": "Registration process",
      "level": 2,
      "pageStart": 64,
      "pageEnd": 65,
      "labelStart": "34",
      "labelEnd": "35",
      "words": 393,
      "summary": {
        "text": "Describes registration in HIV prevention data systems, recommending an anonymous unique identifier rather than personal details, with contact information recorded only with informed consent and strong confidentiality safeguards. It lists the registration data to collect and suggests recording both current gender and sex assigned at birth where appropriate.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "male female",
          "heading": false
        },
        {
          "term": "gender identity",
          "heading": false
        },
        {
          "term": "gender diverse",
          "heading": false
        },
        {
          "term": "registration",
          "heading": true
        },
        {
          "term": "sex assigned",
          "heading": false
        },
        {
          "term": "diverse people",
          "heading": false
        },
        {
          "term": "ensure anonymity",
          "heading": false
        },
        {
          "term": "trans",
          "heading": false
        }
      ],
      "extract": "Data systems collecting individual-level data on HIV prevention will need to collect basic demographic information on each individual and to assign some form of unique identification so that individuals can be followed longitudinally. Since collecting personally identifying information is not advisable when providing HIV prevention interventions, an anonymous UID code can be issued at the time of registration (see",
      "extractCut": true
    },
    {
      "id": "sec-034-228-a-minimum-dataset-for-hiv-prevention",
      "number": "2.2.8",
      "title": "A minimum dataset for HIV prevention",
      "level": 2,
      "pageStart": 65,
      "pageEnd": 66,
      "labelStart": "35",
      "labelEnd": "36",
      "words": 341,
      "summary": {
        "text": "Recommends collecting a minimum set of individual-level data for each HIV prevention intervention, using event dates to show what happened and when, on paper or electronic tools. A table sets out the minimum dataset for interventions such as HIV testing, condoms, PrEP, needle–syringe programmes, opioid agonist maintenance treatment and voluntary medical male circumcision.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minimum dataset",
          "heading": true
        },
        {
          "term": "date oamt",
          "heading": false
        },
        {
          "term": "date prep",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": true
        },
        {
          "term": "prep prescribed",
          "heading": false
        },
        {
          "term": "received date",
          "heading": false
        },
        {
          "term": "date individual",
          "heading": false
        },
        {
          "term": "product prescribed",
          "heading": false
        }
      ],
      "extract": "In the course of delivering each HIV prevention intervention, collection of a minimum set of individual-level data is suggested (Table 2.2). In this minimum dataset, the date that an event occurs (for example, date of HIV test, date PrEP prescribed, etc.) serves to indicate that the event occurred as well as when it occurred. These data can be collected at the point where an HIV prevention intervention is provided.",
      "extractCut": true
    },
    {
      "id": "sec-035-23-use-of-individual-level-data-on-hiv-preventio",
      "number": "2.3",
      "title": "Use of individual-level data on HIV prevention",
      "level": 2,
      "pageStart": 66,
      "pageEnd": 66,
      "labelStart": "36",
      "labelEnd": "36",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-036-231-use-of-individual-level-hiv-prevention-data",
      "number": "2.3.1",
      "title": "Use of individual-level HIV prevention data for client management",
      "level": 2,
      "pageStart": 66,
      "pageEnd": 67,
      "labelStart": "36",
      "labelEnd": "37",
      "words": 205,
      "summary": {
        "text": "Describes how providers can use individual prevention records and automated alerts to follow up people who miss appointments or services, with reminders sent only with consent. It stresses protecting privacy when contacting people and referring them to other needed services such as STI or hepatitis care.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "contacting",
          "heading": false
        },
        {
          "term": "individual-level",
          "heading": true
        },
        {
          "term": "prevention",
          "heading": true
        },
        {
          "term": "phone",
          "heading": false
        },
        {
          "term": "person",
          "heading": false
        },
        {
          "term": "management",
          "heading": true
        }
      ],
      "extract": "management Health care providers can use individual-level HIV prevention data to improve the personalized management of a person’s prevention needs. Follow-up actions relevant to different interventions can be flagged by regularly reviewing data records or through alerts generated by an automated system. If an individual has not attained a relevant outcome (for example, they have missed an appointment or not",
      "extractCut": true
    },
    {
      "id": "sec-037-232-use-of-individual-level-data-for-programme-m",
      "number": "2.3.2",
      "title": "Use of individual-level data for programme management",
      "level": 2,
      "pageStart": 67,
      "pageEnd": 67,
      "labelStart": "37",
      "labelEnd": "37",
      "words": 153,
      "summary": {
        "text": "Explains how site-level aggregation of individual data can help monitor service use, outcomes, stock levels, follow-up and referrals, with automatic reporting through tools such as DHIS2 and dashboards.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "service delivery",
          "heading": false
        },
        {
          "term": "service utilization",
          "heading": false
        },
        {
          "term": "individual-level",
          "heading": true
        },
        {
          "term": "stocked",
          "heading": false
        },
        {
          "term": "displayed",
          "heading": false
        }
      ],
      "extract": "Providers can use individual-level data aggregated at the level of the site or facility to monitor service utilization and outcomes among the clients accessing the service. This information can be used to improve service delivery by: a) monitoring service utilization and delivery b) evaluating service delivery by monitoring intervention outcomes c) ensuring that commodities are appropriately stocked d) identifying",
      "extractCut": true
    },
    {
      "id": "sec-038-233-longitudinal-individual-level-data-as-the-ba",
      "number": "2.3.3",
      "title": "Longitudinal individual-level data as the basis for routine aggregated reporting",
      "level": 2,
      "pageStart": 67,
      "pageEnd": 68,
      "labelStart": "37",
      "labelEnd": "38",
      "words": 499,
      "summary": {
        "text": "Explains that indicators derived from routine individual-level data can reveal trends and programme gaps that once needed surveys, such as ongoing risk, prevention choices and whether people stay HIV-negative. It describes tracking unique individuals and commodity volumes and cohort-style analysis, and notes the importance of monitoring community-led services against Global AIDS Strategy targets.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "individual-level data",
          "heading": true
        },
        {
          "term": "aggregated",
          "heading": true
        },
        {
          "term": "community-led services",
          "heading": false
        },
        {
          "term": "some indicators",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "reporting",
          "heading": true
        },
        {
          "term": "reporting period",
          "heading": false
        },
        {
          "term": "service delivery",
          "heading": false
        }
      ],
      "extract": "aggregated reporting Indicators derived from aggregated routinely collected individual-level data can provide important information on trends, programmatic gaps and various other aspects of HIV prevention programme delivery, which previously required research or surveys to obtain – for example, whether individuals continue to face elevated risk, which prevention methods they choose, the presence of related",
      "extractCut": true
    },
    {
      "id": "sec-039-234-use-of-individual-level-data-to-construct-hi",
      "number": "2.3.4",
      "title": "Use of individual-level data to construct HIV prevention cascades",
      "level": 2,
      "pageStart": 68,
      "pageEnd": 69,
      "labelStart": "38",
      "labelEnd": "39",
      "words": 266,
      "summary": {
        "text": "Explains why HIV prevention cascades are harder to build than treatment cascades, since interventions are delivered in varied ways, risk changes over time, outcomes are non-linear and commodities come from many sources. It points to existing frameworks, including a PAHO approach for key populations, and advises reading prevention cascades alongside testing and treatment cascades.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prevention cascades",
          "heading": true
        },
        {
          "term": "hiv prevention",
          "heading": true
        },
        {
          "term": "treatment cascades",
          "heading": false
        },
        {
          "term": "prevention interventions",
          "heading": false
        },
        {
          "term": "construct",
          "heading": true
        },
        {
          "term": "individual-level",
          "heading": true
        },
        {
          "term": "key populations",
          "heading": false
        },
        {
          "term": "condoms",
          "heading": false
        }
      ],
      "extract": "cascades While HIV treatment cascades can be derived across the continuum of care from initial HIV diagnosis to receiving ART and achieving viral suppression, construction of HIV prevention cascades is more complicated due to a number of factors: a) HIV prevention interventions are delivered in a variety of ways (at a single point in time, episodically or continuously) (9, 10). b) An individual’s level of HIV risk",
      "extractCut": true
    },
    {
      "id": "sec-040-24-hiv-prevention-indicators",
      "number": "2.4",
      "title": "HIV prevention indicators",
      "level": 2,
      "pageStart": 69,
      "pageEnd": 74,
      "labelStart": "39",
      "labelEnd": "44",
      "words": 1674,
      "summary": {
        "text": "Introduces the priority indicators for HIV prevention, drawing on individual-level programme data, aggregate data and surveys, with disaggregation by key population and other factors. A table defines each indicator with numerators and denominators, covering condom distribution and use, PrEP recipients, coverage and volume, and other prevention services. It ends with indicators on retesting among people at elevated risk who previously tested negative.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": true
        },
        {
          "term": "oamt recipients",
          "heading": false
        },
        {
          "term": "pep recipients",
          "heading": false
        },
        {
          "term": "oamt during",
          "heading": false
        },
        {
          "term": "people prescribed",
          "heading": false
        },
        {
          "term": "reporting period",
          "heading": false
        },
        {
          "term": "oamt minimum",
          "heading": false
        },
        {
          "term": "pep course",
          "heading": false
        }
      ],
      "extract": "Priority indicators for HIV prevention are listed in Table 2.3; additional indicators are listed in Web Annex B. These indicators use data from a range of sources, including individual-level programme data, programme data that are not linked to individuals using some form of unique identification but are reported in aggregate form, and survey data. The recommended priority and additional indicators that utilize",
      "extractCut": true
    },
    {
      "id": "sec-041-references",
      "number": null,
      "title": "References",
      "level": 2,
      "pageStart": 74,
      "pageEnd": 79,
      "labelStart": "44",
      "labelEnd": "49",
      "words": 1432,
      "summary": {
        "text": "The reference list for the HIV prevention chapter of the strategic information guidelines, citing UN political declarations, UNAIDS strategies and data, WHO guidance and studies on prevention and community-led responses.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "joint united",
          "heading": false
        },
        {
          "term": "defic syndr",
          "heading": false
        },
        {
          "term": "hiv aids",
          "heading": false
        },
        {
          "term": "aids soc",
          "heading": false
        },
        {
          "term": "nations programme",
          "heading": false
        },
        {
          "term": "acquir immune",
          "heading": false
        }
      ],
      "extract": "1. United Nations General Assembly. Political declaration on HIV and AIDS. On the fast track to accelerating the fight against HIV and to ending the AIDS epidemic by 2030. New York: United Nations; 2016 (https://digitallibrary.un.org/record/833243?ln=es, accessed 24 June 2022). 2. Global AIDS Strategy 2021–2026. End inequalities. End AIDS. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2021",
      "extractCut": true
    },
    {
      "id": "sec-042-chapter-3-person-centred-hiv-patient-monitoring",
      "number": null,
      "title": "Chapter 3 – Person-centred HIV patient monitoring for testing, early diagnosis and treatment",
      "level": 1,
      "pageStart": 79,
      "pageEnd": 82,
      "labelStart": "49",
      "labelEnd": "52",
      "words": 552,
      "summary": {
        "text": "The table of contents for Chapter 3 on person-centred HIV patient monitoring for testing, early diagnosis and treatment, listing sections on HIV testing and linkage, ART initiation, retention and viral suppression, data quality and use, and country adaptation and digital transition.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "patient monitoring",
          "heading": true
        },
        {
          "term": "hiv patient",
          "heading": true
        },
        {
          "term": "hiv treatment",
          "heading": true
        },
        {
          "term": "person-centred hiv",
          "heading": true
        },
        {
          "term": "hiv testing",
          "heading": true
        },
        {
          "term": "dsd art",
          "heading": false
        },
        {
          "term": "monitoring considerations",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        }
      ],
      "extract": "PERSON-CENTRED HIV PATIENT MONITORING FOR TESTING, EARLY DIAGNOSIS AND TREATMENT 3 Key recommendations\b 52 3.1 Introduction\b 53 3.1.1 Purpose of person-centred monitoring of HIV testing, treatment and care \b 53 3.1.2 Evolution of person-centred HIV patient monitoring \b 54 3.1.3 Application of this guidance \b 58 3.2 HIV testing services, early diagnosis and linkage to treatment\b 59 3.2.1 Purposes of monitoring",
      "extractCut": true
    },
    {
      "id": "sec-043-key-recommendations",
      "number": null,
      "title": "Key recommendations",
      "level": 2,
      "pageStart": 82,
      "pageEnd": 83,
      "labelStart": "52",
      "labelEnd": "53",
      "words": 263,
      "summary": {
        "text": "Lists the chapter's key recommendations on HIV patient monitoring, marked as new or updated, including using routine testing data to reach undiagnosed people and support early diagnosis. They also cover using person-centred data to detect treatment interruption and support re-engagement, standardized digital tools, and monitoring differentiated service delivery and its outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "community-delivered services",
          "heading": false
        },
        {
          "term": "differentiated service",
          "heading": false
        },
        {
          "term": "strengthen data",
          "heading": false
        },
        {
          "term": "patient monitoring",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": false
        },
        {
          "term": "hiv diagnosis",
          "heading": false
        },
        {
          "term": "data collection",
          "heading": false
        },
        {
          "term": "service delivery",
          "heading": false
        }
      ],
      "extract": "NEW \u00071. \u0007Promote the analysis and use of routinely collected testing data to optimize HIV testing services, reaching populations and settings with the largest proportion of people living with HIV who do not know their status and supporting early HIV diagnosis. a) \u0007Improve the monitoring of time to HIV diagnosis to support rapid ART initiation and engagement in care, thus reducing morbidity and mortality. UPDATE \u00072.",
      "extractCut": true
    },
    {
      "id": "sec-044-31-introduction",
      "number": "3.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 83,
      "pageEnd": 83,
      "labelStart": "53",
      "labelEnd": "53",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-045-311-purpose-of-person-centred-monitoring-of-hiv",
      "number": "3.1.1",
      "title": "Purpose of person-centred monitoring of HIV testing, treatment and care",
      "level": 2,
      "pageStart": 83,
      "pageEnd": 84,
      "labelStart": "53",
      "labelEnd": "54",
      "words": 415,
      "summary": {
        "text": "Defines HIV patient monitoring as routinely gathering, analysing and using data about people with HIV across services and over time, mainly to guide clinical care and ensure continuity of testing and treatment. It lists further uses of the data, such as tracking epidemic trends, measuring programme performance and informing drug stock management to reduce wastage and stock-outs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "person-centred hiv",
          "heading": true
        },
        {
          "term": "hiv treatment",
          "heading": true
        },
        {
          "term": "hiv testing",
          "heading": true
        },
        {
          "term": "hiv strategic",
          "heading": false
        },
        {
          "term": "data quality",
          "heading": false
        },
        {
          "term": "monitoring",
          "heading": true
        },
        {
          "term": "hiv patient",
          "heading": false
        },
        {
          "term": "long-term data",
          "heading": false
        }
      ],
      "extract": "treatment and care HIV patient monitoring encompasses the routine collection, compilation, analysis and use of data on people living with HIV over time and across service delivery points. Its primary purposes are to guide the clinical management of people living with HIV and to ensure the quality and continuity of HIV testing, early diagnosis and access to treatment and care services. Person-centred monitoring",
      "extractCut": true
    },
    {
      "id": "sec-046-312-evolution-of-person-centred-hiv-patient-moni",
      "number": "3.1.2",
      "title": "Evolution of person-centred HIV patient monitoring",
      "level": 2,
      "pageStart": 84,
      "pageEnd": 88,
      "labelStart": "54",
      "labelEnd": "58",
      "words": 2061,
      "summary": {
        "text": "Describes how investments in digital health information systems, electronic medical records and unique identifiers have strengthened person-centred monitoring and led to a prioritized minimum dataset. It explains that the chapter updates WHO's 2017 patient monitoring guidance to cover the full care cascade and support differentiated service delivery. It also notes the expansion from 40 to 80 priority indicators, of which 36 come from patient monitoring and 25 are core, plus optional additional indicators for countries with stronger systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "patient monitoring",
          "heading": true
        },
        {
          "term": "hiv patient",
          "heading": true
        },
        {
          "term": "person-centred hiv",
          "heading": true
        },
        {
          "term": "dsd art",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "art coverage",
          "heading": false
        },
        {
          "term": "art models",
          "heading": false
        },
        {
          "term": "rapid art",
          "heading": false
        }
      ],
      "extract": "The investments that countries have made in digital HIS, including electronic medical records (EMRs) and the adoption of UIDs, has strengthened person-centred patient monitoring and service delivery. The quality of individual-level data has also improved over time, not only for patient monitoring but also as the underlying data source for aggregate reporting for programme management, case surveillance and global",
      "extractCut": true
    },
    {
      "id": "sec-047-313-application-of-this-guidance",
      "number": "3.1.3",
      "title": "Application of this guidance",
      "level": 2,
      "pageStart": 88,
      "pageEnd": 89,
      "labelStart": "58",
      "labelEnd": "59",
      "words": 509,
      "summary": {
        "text": "Explains that the updated guidance supports monitoring people as they move between facilities, recommending facility-held patient cards, ART registers or electronic records with data flowing in from community services, as well as new tools for differentiated service delivery. It describes the intended audiences and notes that pharmacy services and non-HIV TB and maternal and child health data elements are outside its scope.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "patient monitoring",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": false
        },
        {
          "term": "guidance",
          "heading": true
        },
        {
          "term": "facility level",
          "heading": false
        },
        {
          "term": "improve hiv",
          "heading": false
        },
        {
          "term": "hiv testing",
          "heading": false
        },
        {
          "term": "health facility",
          "heading": false
        },
        {
          "term": "data elements",
          "heading": false
        }
      ],
      "extract": "The updated guidance in this chapter seeks particularly to support monitoring of people living with HIV as they move between health facilities over time. WHO recommends the use of an HIV patient card and ART register or electronic versions of these, which remain at the health facility so that the facility retains overall responsibility for patient management and follow-up, with prompt and efficient data flow from",
      "extractCut": true
    },
    {
      "id": "sec-048-32-hiv-testing-services-early-diagnosis-and-link",
      "number": "3.2",
      "title": "HIV testing services, early diagnosis and linkage to treatment",
      "level": 2,
      "pageStart": 89,
      "pageEnd": 91,
      "labelStart": "59",
      "labelEnd": "61",
      "words": 640,
      "summary": {
        "text": "A box summarizing new WHO HIV testing recommendations relevant to patient monitoring, including testing all pregnant women for HIV, syphilis and hepatitis B, dual HIV/syphilis rapid tests in antenatal care and differing approaches for high- and low-burden settings. It also covers self-testing, index and network-based testing and the need to update tools and records to track linkage between facilities and community services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv testing",
          "heading": true
        },
        {
          "term": "testing services",
          "heading": true
        },
        {
          "term": "key populations",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        },
        {
          "term": "hiv self-testing",
          "heading": false
        },
        {
          "term": "community-based hiv",
          "heading": false
        },
        {
          "term": "hiv burden",
          "heading": false
        },
        {
          "term": "facility-based testing",
          "heading": false
        }
      ],
      "extract": "to treatment Box 3.2 What’s new in HTS relevant to HIV patient monitoring Facility-based testing • Pregnant women and key populations: All pregnant women should be tested for HIV, syphilis and hepatitis B surface antigen (HBsAg) at least once and as early as possible. In the 2022 WHO Consolidated guidelines for HIV, viral hepatitis and STI prevention, diagnosis and treatment and care for key populations, this",
      "extractCut": true
    },
    {
      "id": "sec-049-321-purposes-of-monitoring-testing",
      "number": "3.2.1",
      "title": "Purposes of monitoring testing",
      "level": 2,
      "pageStart": 91,
      "pageEnd": 93,
      "labelStart": "61",
      "labelEnd": "63",
      "words": 986,
      "summary": {
        "text": "Explains that understanding people's HIV testing history and results guides their care and that monitoring should cover all prevention, testing and treatment service points. It outlines the purposes of testing data, such as optimizing case finding and linkage to ART and prevention, and presents a table of six priority HIV testing indicators. It ends with guidance on which partners and family members of index clients should be offered testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hts indicators",
          "heading": false
        },
        {
          "term": "received hts",
          "heading": false
        },
        {
          "term": "hiv testing",
          "heading": false
        },
        {
          "term": "people diagnosed",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "reporting period",
          "heading": false
        },
        {
          "term": "person-centred hiv",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": false
        }
      ],
      "extract": "Understanding HIV testing history, patterns of testing, retesting and test results is necessary to guide the provision of support and clinical care to clients. Patient monitoring systems, whether paper-based or electronic, can facilitate effective clinical management and also generate data for programme monitoring. To support collection of comprehensive client data and support linkage, HIV programmes should promote",
      "extractCut": true
    },
    {
      "id": "sec-050-33-key-considerations-for-monitoring-hts-and-lin",
      "number": "3.3",
      "title": "Key considerations for monitoring HTS and linkage",
      "level": 2,
      "pageStart": 93,
      "pageEnd": 93,
      "labelStart": "63",
      "labelEnd": "63",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-051-331-increasing-number-of-people-living-with-hiv",
      "number": "3.3.1",
      "title": "Increasing number of people living with HIV who know their status",
      "level": 2,
      "pageStart": 93,
      "pageEnd": 93,
      "labelStart": "63",
      "labelEnd": "63",
      "words": 301,
      "summary": {
        "text": "Notes that as more people living with HIV know their status, test positivity falls and reaching undiagnosed people becomes harder, making analysis of routine testing data essential. It explains how unique identifiers enable tracking along the care continuum and introduces indicators on test volume and positivity and on individuals testing positive.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "people living",
          "heading": true
        },
        {
          "term": "indicator hts",
          "heading": false
        },
        {
          "term": "hiv",
          "heading": true
        },
        {
          "term": "status",
          "heading": true
        },
        {
          "term": "treatment services",
          "heading": false
        },
        {
          "term": "number",
          "heading": true
        },
        {
          "term": "testing",
          "heading": false
        },
        {
          "term": "know",
          "heading": true
        }
      ],
      "extract": "status As HIV testing and treatment expands, there is a greater need to focus testing services so as to reach individuals most at risk of acquiring HIV and to support access to HIV prevention and treatment services, in the process achieving the first 95 (testing) target. However, as the proportion of people living with HIV who are aware of their HIV serologic status increases, the testing yield (the percentage",
      "extractCut": true
    },
    {
      "id": "sec-052-332-early-hiv-diagnosis",
      "number": "3.3.2",
      "title": "Early HIV diagnosis",
      "level": 2,
      "pageStart": 93,
      "pageEnd": 94,
      "labelStart": "63",
      "labelEnd": "64",
      "words": 255,
      "summary": {
        "text": "Highlights early diagnosis as key to treatment success and reduced transmission, recommending monitoring of CD4 count and disease stage at diagnosis to detect late presenters. It stresses self-testing and community and network-based testing with timely linkage, supported by interoperable data systems and community-led monitoring.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv",
          "heading": true
        },
        {
          "term": "hiv treatment",
          "heading": false
        },
        {
          "term": "testing services",
          "heading": false
        },
        {
          "term": "community-based testing",
          "heading": false
        },
        {
          "term": "diagnosis",
          "heading": true
        },
        {
          "term": "care services",
          "heading": false
        },
        {
          "term": "linkage",
          "heading": false
        },
        {
          "term": "diagnoses",
          "heading": false
        }
      ],
      "extract": "Early diagnosis is key to treatment success, improved patient outcomes and reduced onward HIV transmission. New diagnoses likely reflect a mix of those newly identified with HIV infection, those previously diagnosed but not linked to care and those previously diagnosed but disengaged from HIV treatment and care services. Monitoring CD4 count and disease stage at diagnosis is important to identify late diagnoses, as",
      "extractCut": true
    },
    {
      "id": "sec-053-333-linkage-to-treatment-and-care",
      "number": "3.3.3",
      "title": "Linkage to treatment and care",
      "level": 2,
      "pageStart": 94,
      "pageEnd": 96,
      "labelStart": "64",
      "labelEnd": "66",
      "words": 1630,
      "summary": {
        "text": "Explains that prompt linkage to treatment improves viral suppression and reduces resistance, illness, death and transmission, and that it includes re-engaging people who have dropped out of care. It describes the core linkage indicator measuring the share of newly diagnosed people who start ART, disaggregated by time since diagnosis. It also covers partner and contact testing services with consent and confidentiality, their cascade data, and a survey-based indicator on key populations who know their status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "indicator hts",
          "heading": false
        },
        {
          "term": "hivst kits",
          "heading": false
        },
        {
          "term": "hivst kit",
          "heading": false
        },
        {
          "term": "receiving hivst",
          "heading": false
        },
        {
          "term": "community-based hts",
          "heading": false
        },
        {
          "term": "linkage",
          "heading": true
        },
        {
          "term": "hts register",
          "heading": false
        },
        {
          "term": "network-based partner",
          "heading": false
        }
      ],
      "extract": "Linkage to treatment and care is the first step toward onward services, including timely initiation of ART as well as access to interventions to prevent the further transmission of HIV, to prevent other infections and to manage co-morbidities. Linkage to treatment and care is essential to achieve programmatic impact and effective patient management and care. Delays in ART linkage are associated with lower levels of",
      "extractCut": true
    },
    {
      "id": "sec-054-334-standardized-data-collection-tools-for-hts",
      "number": "3.3.4",
      "title": "Standardized data collection tools for HTS",
      "level": 2,
      "pageStart": 96,
      "pageEnd": 97,
      "labelStart": "66",
      "labelEnd": "67",
      "words": 49,
      "summary": {
        "text": "Notes that the annexes include examples of standardized HIV testing data collection tools from Malawi, such as testing, screening, confirmatory and self-test distribution registers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hts",
          "heading": true
        },
        {
          "term": "web annex",
          "heading": false
        },
        {
          "term": "register",
          "heading": false
        }
      ],
      "extract": "Annexes provide examples of countries’ standardized data collection tools for HTS. These include an HTS register (Web Annex C), digital scan forms that include an HTS initial screening register (Web Annex F), an HTS confirmatory register (Web Annex E) and an HIVST distribution register (Web Annex D) from Malawi.",
      "extractCut": false
    },
    {
      "id": "sec-055-335-minimum-dataset",
      "number": "3.3.5",
      "title": "Minimum dataset",
      "level": 2,
      "pageStart": 97,
      "pageEnd": 97,
      "labelStart": "67",
      "labelEnd": "67",
      "words": 92,
      "summary": {
        "text": "Lists the minimum HIV testing data to record consistently across facility and community sites: test date, result, date of diagnosis, date the result was received and linkage to care where feasible.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "minimum",
          "heading": true
        },
        {
          "term": "hiv testing",
          "heading": false
        },
        {
          "term": "dataset",
          "heading": true
        }
      ],
      "extract": "Data collection practices and completeness of records may vary across settings and testing approaches. Where possible, HIV testing information should be collected in a standardized manner across all service sites, including at the facility and community levels. At a minimum the following information should be recorded: • HIV test date • HIV test result • date of diagnosis • date that client received the result •",
      "extractCut": true
    },
    {
      "id": "sec-056-34-art-initiation-retention-and-viral-suppressio",
      "number": "3.4",
      "title": "ART initiation, retention and viral suppression",
      "level": 2,
      "pageStart": 97,
      "pageEnd": 98,
      "labelStart": "67",
      "labelEnd": "68",
      "words": 538,
      "summary": {
        "text": "A box summarizing new WHO HIV treatment recommendations relevant to patient monitoring, such as rapid and same-day ART initiation, updated first-, second- and third-line regimens and a revised viral load monitoring algorithm. It notes that patient tools, electronic records and the minimum dataset must be updated accordingly, including for revised antiretroviral toxicity indicators covering weight gain, cardiometabolic effects and adverse pregnancy outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "art initiation",
          "heading": true
        },
        {
          "term": "patient monitoring",
          "heading": false
        },
        {
          "term": "monitoring tools",
          "heading": false
        },
        {
          "term": "emr systems",
          "heading": false
        },
        {
          "term": "arv dispensing",
          "heading": false
        },
        {
          "term": "arv toxicity",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": false
        },
        {
          "term": "treatment initiation",
          "heading": false
        }
      ],
      "extract": "Box 3.3 What’s new in HIV treatment relevant to HIV patient monitoring • Rapid initiation and same-day start of ART: Since 2017 WHO has recommended that ART should be offered to all people living with HIV following a confirmed HIV diagnosis and clinical assessment within seven days of diagnosis and preferably on the same day as confirmed HIV diagnosis, for people who are ready to start ART (11). Patient monitoring",
      "extractCut": true
    },
    {
      "id": "sec-057-341-what-to-monitor-and-relevant-treatment-indic",
      "number": "3.4.1",
      "title": "What to monitor and relevant treatment indicators",
      "level": 2,
      "pageStart": 98,
      "pageEnd": 102,
      "labelStart": "68",
      "labelEnd": "72",
      "words": 1560,
      "summary": {
        "text": "Explains that under WHO's treat-all policy, people on ART must be monitored over time as they move between facilities, with priority treatment indicators tracking the cascade from initiation or re-entry to retention, viral suppression, discontinuation, toxicity, loss to follow-up and death. It presents a table of these indicators, starting with ART coverage towards the second 95 target and total attrition. It describes updates to the attrition indicator and invites country feedback on its feasibility.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "indicator art",
          "heading": false
        },
        {
          "term": "total attrition",
          "heading": false
        },
        {
          "term": "reporting period",
          "heading": false
        },
        {
          "term": "art during",
          "heading": false
        },
        {
          "term": "attrition rate",
          "heading": false
        },
        {
          "term": "art coverage",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "numerator calculation",
          "heading": false
        }
      ],
      "extract": "In the context of current WHO “treat all” recommendations, it remains critical to monitor people living with HIV who receive ART over time as they move between health facilities and access care at different service delivery points. Priority indicators for HIV treatment focus on monitoring the treatment cascade from ART initiation and/or re-entry into treatment through to treatment outcomes that include retention, VL",
      "extractCut": true
    },
    {
      "id": "sec-058-342-monitoring-art-initiation-late-initiation-an",
      "number": "3.4.2",
      "title": "Monitoring ART initiation, late initiation and clinical management",
      "level": 2,
      "pageStart": 102,
      "pageEnd": 104,
      "labelStart": "72",
      "labelEnd": "74",
      "words": 832,
      "summary": {
        "text": "Stresses person-centred ART initiation and introduces the indicators on new ART patients and late initiation, with a table of WHO recommendations on when to start ART, including rapid and same-day initiation and exceptions. It covers monitoring of clinical management and lists paediatric monitoring priorities such as early infant diagnosis coverage and age at diagnosis and treatment start. It also notes the need for fine age disaggregation of testing and treatment indicators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "art initiation",
          "heading": true
        },
        {
          "term": "late initiation",
          "heading": true
        },
        {
          "term": "rapid art",
          "heading": false
        },
        {
          "term": "initiation among",
          "heading": false
        },
        {
          "term": "children living",
          "heading": false
        },
        {
          "term": "late diagnosis",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "cryptococcal meningitis",
          "heading": false
        }
      ],
      "extract": "management ART initiation should follow the overarching principles of providing person-centred care. Person-centred care should be focused and organized around the health needs, preferences and expectations of people and communities. Likewise, patient monitoring should also be person-centred and enable longitudinal monitoring of people living with HIV as they access HIV treatment and care services and, where",
      "extractCut": true
    },
    {
      "id": "sec-059-343-monitoring-treatment-outcomes",
      "number": "3.4.3",
      "title": "Monitoring treatment outcomes",
      "level": 2,
      "pageStart": 104,
      "pageEnd": 105,
      "labelStart": "74",
      "labelEnd": "75",
      "words": 593,
      "summary": {
        "text": "Describes updates to viral load monitoring, with the first test reviewed by six months after starting ART and a repeat test three months after an unsuppressed result following enhanced adherence counselling. It distinguishes treatment failure above 1,000 copies/mL from lower detectable levels and presents WHO's 2021 viral load testing algorithm with actions for each result.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "viral load",
          "heading": false
        },
        {
          "term": "treatment monitoring",
          "heading": true
        },
        {
          "term": "viral suppression",
          "heading": false
        },
        {
          "term": "load test",
          "heading": false
        },
        {
          "term": "repeat viral",
          "heading": false
        },
        {
          "term": "adherence counselling",
          "heading": false
        },
        {
          "term": "enhanced adherence",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        }
      ],
      "extract": "Viral suppression A number of updates have been made to the treatment monitoring algorithm. First, the initial VL test should be collected and tested, and the result should be reviewed, by the time of the six-month visit after ART initiation. The timing of subsequent VL monitoring tests remains the same (12 months after ART initiation and yearly thereafter). Second, for patients with an unsuppressed VL, a second VL",
      "extractCut": true
    },
    {
      "id": "sec-060-344-art-retentionattrition",
      "number": "3.4.4",
      "title": "ART retention/attrition",
      "level": 2,
      "pageStart": 105,
      "pageEnd": 106,
      "labelStart": "75",
      "labelEnd": "76",
      "words": 290,
      "summary": {
        "text": "Explains that retention on ART is key to viral suppression and lower mortality, citing sub-Saharan African data showing nearly one fifth stopped ART and 15–20% died within five years. It describes monitoring attrition and the role of unique identifiers in tracking people between facilities and avoiding miscounting of silent transfers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "art attrition",
          "heading": true
        },
        {
          "term": "indicator art",
          "heading": false
        },
        {
          "term": "retention",
          "heading": true
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "ltfu",
          "heading": false
        },
        {
          "term": "hiv",
          "heading": false
        },
        {
          "term": "facility",
          "heading": false
        },
        {
          "term": "person-centred",
          "heading": false
        }
      ],
      "extract": "The main function of an ART programme, after initiation, is to support retention in treatment and adherence in order to achieve viral suppression and so reduce mortality. Long-term retention in care is a key challenge, with impacts on patient health, the emergence of HIV drug resistance and onward transmission of HIV. Programmatic data from sub-Saharan Africa indicate that, five years after initiating ART, nearly",
      "extractCut": true
    },
    {
      "id": "sec-061-345-loss-to-follow-up",
      "number": "3.4.5",
      "title": "Loss to follow-up",
      "level": 2,
      "pageStart": 106,
      "pageEnd": 108,
      "labelStart": "76",
      "labelEnd": "78",
      "words": 761,
      "summary": {
        "text": "Calls for analysis of attrition data to find facilities needing support and the causes of poor retention, from waiting times to drug toxicity. It explains that people counted as lost to follow-up are often silent transfers, deaths or discontinuations, and describes data-driven tracing and re-engagement, criteria for tracing and an updated patient card recording prior ARV exposure and restarts. It also mentions monitoring ART initiation alongside treatment interruption as people return to care.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "art re-initiation",
          "heading": false
        },
        {
          "term": "treatment interruption",
          "heading": false
        },
        {
          "term": "support re-engagement",
          "heading": false
        },
        {
          "term": "art register",
          "heading": false
        },
        {
          "term": "hiv care",
          "heading": false
        },
        {
          "term": "ltfu",
          "heading": false
        },
        {
          "term": "patient card",
          "heading": false
        },
        {
          "term": "care cascade",
          "heading": false
        }
      ],
      "extract": "ART clients moving into out of and among health facilities. In addition, these data should be analysed to identify facilities that need support and the reasons for retention problems, including health system issues (long waiting times, quality of service), sociodemographic issues and client- and treatment-related factors (for example, ARV toxicity). These should be assessed and observations used to inform",
      "extractCut": true
    },
    {
      "id": "sec-062-346-advanced-hiv-disease",
      "number": "3.4.6",
      "title": "Advanced HIV disease",
      "level": 2,
      "pageStart": 108,
      "pageEnd": 111,
      "labelStart": "78",
      "labelEnd": "81",
      "words": 928,
      "summary": {
        "text": "Defines advanced HIV disease as a CD4 count below 200 cells/mm³ or WHO clinical stage 3 or 4 in adults and adolescents, and all children under five living with HIV, noting these people need closer follow-up. It describes the package of screening, prophylaxis and rapid ART recommended for advanced disease and the data elements to monitor it. It also stresses resource planning and monitoring for immune reconstitution inflammatory syndrome and adverse drug reactions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "advanced hiv",
          "heading": true
        },
        {
          "term": "hiv disease",
          "heading": true
        },
        {
          "term": "cryptococcal disease",
          "heading": false
        },
        {
          "term": "who-recommended rdt",
          "heading": false
        },
        {
          "term": "cell count",
          "heading": false
        },
        {
          "term": "who-recommended package",
          "heading": false
        },
        {
          "term": "cryptococcal antigen",
          "heading": false
        },
        {
          "term": "molecular who-recommended",
          "heading": false
        }
      ],
      "extract": "Advanced HIV disease in adults and adolescents is defined by a CD4 cell count of less than 200 cells/mm3 and/or WHO clinical stage 3 or 4 disease (2). All children younger than five years of age living with HIV are considered to have advanced HIV disease. People with advanced HIV disease are at greater risk of mortality and require closer follow-up during the initial period of ART to monitor the response to",
      "extractCut": true
    },
    {
      "id": "sec-063-347-arv-toxicity-monitoring",
      "number": "3.4.7",
      "title": "ARV toxicity monitoring",
      "level": 2,
      "pageStart": 111,
      "pageEnd": 113,
      "labelStart": "81",
      "labelEnd": "83",
      "words": 786,
      "summary": {
        "text": "Explains why monitoring ARV drug safety is increasingly important as treatment scales up and newer drugs are introduced, including for pregnant and breastfeeding women. It describes WHO's recommended combination of approaches, such as pregnancy safety surveillance and active and routine toxicity monitoring. A table lists data elements for monitoring weight gain and cardiometabolic toxicity, including risk factors and drug exposure.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "arv toxicity",
          "heading": true
        },
        {
          "term": "toxicity monitoring",
          "heading": true
        },
        {
          "term": "arv drug",
          "heading": false
        },
        {
          "term": "adverse pregnancy",
          "heading": false
        },
        {
          "term": "date drug",
          "heading": false
        },
        {
          "term": "longitudinal monitoring",
          "heading": false
        },
        {
          "term": "stop date",
          "heading": false
        },
        {
          "term": "weight gain",
          "heading": false
        }
      ],
      "extract": "As ART scale-up continues, with earlier and more prolonged exposure to treatment, and with the transition to new ARVs among all age groups including pregnant and breastfeeding women, monitoring the safety of ARV drugs has become a critical component of HIV treatment and prevention programmes. Newer ARVs have more favourable toxicity profiles and provide an opportunity to standardize and optimize HIV treatment.",
      "extractCut": true
    },
    {
      "id": "sec-064-348-early-warning-indicators-of-hiv-drug-resista",
      "number": "3.4.8",
      "title": "Early warning indicators of HIV drug resistance",
      "level": 2,
      "pageStart": 113,
      "pageEnd": 116,
      "labelStart": "83",
      "labelEnd": "86",
      "words": 1474,
      "summary": {
        "text": "Describes early warning indicators of HIV drug resistance, a set of quality-of-care measures used to identify clinics where service gaps could foster resistance. It reviews viral, drug, patient and programme factors linked to resistance and presents a table of the current indicators and targets. It also describes a WHO tool for collecting and reporting the indicators and urges countries to use routine patient monitoring rather than parallel systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "drug resistance",
          "heading": true
        },
        {
          "term": "hiv drug",
          "heading": true
        },
        {
          "term": "ewi data",
          "heading": false
        },
        {
          "term": "ewi monitoring",
          "heading": false
        },
        {
          "term": "art sites",
          "heading": false
        },
        {
          "term": "art adherence",
          "heading": false
        },
        {
          "term": "second-line art",
          "heading": false
        },
        {
          "term": "art programmes",
          "heading": false
        }
      ],
      "extract": "The early warning indicators (EWIs) are a set of standard quality-of-care indicators used to assess whether ART programmes deliver services of sufficient quality to minimize the emergence of HIV drug resistance. The EWIs use standardized definitions that have evolved over time as programmes mature and public health actions are refined (Table 3.5). Monitoring EWIs is useful to identify gaps in service delivery that",
      "extractCut": true
    },
    {
      "id": "sec-065-349-monitoring-considerations-for-paediatric-pop",
      "number": "3.4.9",
      "title": "Monitoring considerations for paediatric populations",
      "level": 2,
      "pageStart": 116,
      "pageEnd": 118,
      "labelStart": "86",
      "labelEnd": "88",
      "words": 802,
      "summary": {
        "text": "Sets out general child health monitoring for children living with HIV, such as growth, development, immunization and infant feeding, noting WHO guidance that mothers on ART with suppressed viral loads can breastfeed up to two years. It lists additional paediatric indicators, including viral suppression by age, psychosocial support and optimized second-line regimens, and stresses continuity of records as children move into adolescent and adult care.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "postnatal prophylaxis",
          "heading": false
        },
        {
          "term": "hiv-exposed infants",
          "heading": false
        },
        {
          "term": "prophylaxis coverage",
          "heading": false
        },
        {
          "term": "children receiving",
          "heading": false
        },
        {
          "term": "exclusive breastfeeding",
          "heading": false
        },
        {
          "term": "dtg-based regimens",
          "heading": false
        },
        {
          "term": "infants identified",
          "heading": false
        },
        {
          "term": "six weeks",
          "heading": false
        }
      ],
      "extract": "Monitoring for children includes general and HIV-specific monitoring. Age disaggregation (five-year intervals) is important, as interventions may depend on age. Key general child health monitoring includes: • growth monitoring (weight, height and mid-upper arm circumference measurements) • developmental assessments to determine achievement of motor, sensory, cognition, communication, behaviour, social and adaptive",
      "extractCut": true
    },
    {
      "id": "sec-066-35-monitoring-vertical-transmission",
      "number": "3.5",
      "title": "Monitoring vertical transmission",
      "level": 2,
      "pageStart": 118,
      "pageEnd": 122,
      "labelStart": "88",
      "labelEnd": "92",
      "words": 1336,
      "summary": {
        "text": "Summarizes what is new in monitoring vertical transmission of HIV, including stronger tracking of the PMTCT cascade across services and over the full exposure period and an emphasis on elimination. It describes the priority indicator on viral suppression at labour and delivery and recent WHO recommendations relevant to pregnant and breastfeeding women. It explains that these changes require updates to patient monitoring tools and indicators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vertical transmission",
          "heading": true
        },
        {
          "term": "monitoring vertical",
          "heading": true
        },
        {
          "term": "hiv-exposed infants",
          "heading": false
        },
        {
          "term": "breastfeeding infants",
          "heading": false
        },
        {
          "term": "anc attendees",
          "heading": false
        },
        {
          "term": "breastfeeding women",
          "heading": false
        },
        {
          "term": "infants born",
          "heading": false
        },
        {
          "term": "pregnant women",
          "heading": false
        }
      ],
      "extract": "Box 3.8 What’s new in monitoring vertical transmission? • A focus on strengthening monitoring of the PMTCT cascade for prevention of mother-to-child transmission (PMTCT) across multiple service delivery points and extended follow-up to improve tracking throughout the entire exposure period; • Increased emphasis on elimination of vertical transmission of HIV to reduce new infections in infants/young children as well",
      "extractCut": true
    },
    {
      "id": "sec-067-351-conceptual-framework-for-preventing-vertical",
      "number": "3.5.1",
      "title": "Conceptual framework for preventing vertical transmission",
      "level": 2,
      "pageStart": 122,
      "pageEnd": 123,
      "labelStart": "92",
      "labelEnd": "93",
      "words": 78,
      "summary": {
        "text": "Outlines the conceptual framework for monitoring PMTCT across multiple services and over a long period, from primary prevention and reproductive health services to treating mothers and following exposed infants to final diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "retaining",
          "heading": false
        },
        {
          "term": "period",
          "heading": false
        },
        {
          "term": "pmtct",
          "heading": false
        }
      ],
      "extract": "Monitoring of PMTCT services needs to follow the cascade across multiple service delivery points and over a prolonged period, for both mother and child' from primary prevention and access to comprehensive sexual and reproductive health services to diagnosing and treating HIV-positive mothers and retaining them on ART, ensuring safe delivery and optimizing infant feeding practices to, finally, tracking exposed",
      "extractCut": true
    },
    {
      "id": "sec-068-352-following-the-cascade-across-multiple-servic",
      "number": "3.5.2",
      "title": "Following the cascade across multiple service delivery points and over prolonged periods",
      "level": 2,
      "pageStart": 123,
      "pageEnd": 123,
      "labelStart": "93",
      "labelEnd": "93",
      "words": 167,
      "summary": {
        "text": "Explains that data tools must follow mother–baby pairs between service points and facilities, relying on unique identifiers, integration of HIV information into maternal and child health cards or electronic systems. It recommends integrating PMTCT and paediatric HIV services and their monitoring with maternal, newborn and child health care.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "mnch care",
          "heading": false
        },
        {
          "term": "mother baby",
          "heading": false
        },
        {
          "term": "patient monitoring",
          "heading": false
        },
        {
          "term": "pmtct",
          "heading": false
        },
        {
          "term": "prolonged",
          "heading": true
        },
        {
          "term": "monitoring system",
          "heading": false
        }
      ],
      "extract": "and over prolonged periods Tools to collect data must reflect the patient care workflows of these different service delivery points and possibly different health facilities and be able to track mother–baby pairs from one such point to another. The patient monitoring system for vertical transmission relies on robust systems for assigning UIDs to link records of the mother or the mother–baby pair, integrating HIV",
      "extractCut": true
    },
    {
      "id": "sec-069-353-monitoring-key-outcomes-towards-elimination",
      "number": "3.5.3",
      "title": "Monitoring key outcomes towards elimination of vertical transmission",
      "level": 2,
      "pageStart": 123,
      "pageEnd": 125,
      "labelStart": "93",
      "labelEnd": "95",
      "words": 730,
      "summary": {
        "text": "Describes the updated vertical transmission indicators, which since 2020 emphasize results like maternal viral suppression and early diagnosis of infants, with seven designated national priority indicators tied to key points in the risk period. A figure maps maternal and child health service points to the patient monitoring tools used at each, such as registers and cards for antenatal care, delivery and postnatal care.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "vertical transmission",
          "heading": true
        },
        {
          "term": "txt card",
          "heading": false
        },
        {
          "term": "mip register",
          "heading": false
        },
        {
          "term": "mnch pmtct",
          "heading": false
        },
        {
          "term": "patient card",
          "heading": false
        },
        {
          "term": "care txt",
          "heading": false
        },
        {
          "term": "art register",
          "heading": false
        },
        {
          "term": "card maternal",
          "heading": false
        }
      ],
      "extract": "transmission The vertical transmission indicators recommended in this guidance reflect important updates to definitions and disaggregation for tracking progress and managing PMTCT programmes across the array of services offered (Table 3.6). The indicators for monitoring vertical transmission were updated in 2020 to focus on outcomes such as viral suppression and early infant diagnosis in addition to intermediate",
      "extractCut": true
    },
    {
      "id": "sec-070-354-follow-up-of-the-motherinfant-pair",
      "number": "3.5.4",
      "title": "Follow-up of the mother–infant pair",
      "level": 2,
      "pageStart": 125,
      "pageEnd": 129,
      "labelStart": "95",
      "labelEnd": "99",
      "words": 1194,
      "summary": {
        "text": "Stresses following mother–infant pairs from antenatal and delivery care to child health and ART services, using a mother–infant pair register and recording the mother's identifier on the infant's record. It lists the care HIV-exposed infants should receive and be monitored for, such as prophylaxis, timely nucleic acid testing, feeding practices and final outcome testing. It sets out the minimum dataset for exposed infants, highlighting updates since 2017.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "infant pair",
          "heading": true
        },
        {
          "term": "mother infant",
          "heading": true
        },
        {
          "term": "date infant",
          "heading": false
        },
        {
          "term": "infant uid",
          "heading": false
        },
        {
          "term": "hiv-exposed infant",
          "heading": false
        },
        {
          "term": "date started",
          "heading": false
        },
        {
          "term": "test date",
          "heading": false
        },
        {
          "term": "infant arv",
          "heading": false
        }
      ],
      "extract": "Strengthening follow-up of mother–infant pairs, from ANC, labour and delivery (maternity) and postpartum maternal visits to child health clinics and ART services, remains critical for elimination of vertical transmission and improved maternal and child health outcomes. A mother–infant pair register can be used for this (see Box 3.9). Monitoring tools should capture the full spectrum of care that HIV-exposed infants",
      "extractCut": true
    },
    {
      "id": "sec-071-36-monitoring-tbhiv",
      "number": "3.6",
      "title": "Monitoring TB/HIV",
      "level": 2,
      "pageStart": 129,
      "pageEnd": 130,
      "labelStart": "99",
      "labelEnd": "100",
      "words": 253,
      "summary": {
        "text": "Summarizes 2020 updates to TB–HIV patient monitoring, including revised indicators on TB preventive treatment and rapid molecular TB testing and new shorter preventive regimens. It recalls WHO's collaborative TB/HIV activities and lists recent recommendations relevant to recording and reporting, such as new screening tools and starting ART within two weeks of TB treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "rifamycin-based regimens",
          "heading": false
        },
        {
          "term": "shorter rifamycin-based",
          "heading": false
        },
        {
          "term": "molecular who-approved",
          "heading": false
        },
        {
          "term": "who-approved rapid",
          "heading": false
        },
        {
          "term": "hiv",
          "heading": true
        },
        {
          "term": "hiv activities",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": false
        },
        {
          "term": "monitoring",
          "heading": true
        }
      ],
      "extract": "Box 3.11 What is new in TB–HIV patient monitoring in 2020 • Updates to the TB–HIV indicators on TB preventive treatment (TPT) initiation and completion; TB diagnostic testing with molecular WHO-approved rapid diagnostics among people living with HIV; and TB burden among new ART patients • Updated TPT regimens, including 6H and shorter rifamycin-based regimens • Five additional indicators reflecting the TB screening",
      "extractCut": true
    },
    {
      "id": "sec-072-361-tb-in-people-living-with-hiv-captured-in-the",
      "number": "3.6.1",
      "title": "TB in people living with HIV captured in the HIV patient monitoring system",
      "level": 2,
      "pageStart": 130,
      "pageEnd": 131,
      "labelStart": "100",
      "labelEnd": "101",
      "words": 320,
      "summary": {
        "text": "Describes TB-related services for people living with HIV that are measured through the HIV patient monitoring system, such as ART, case-finding, preventive treatment and infection control. A box lists the TB–HIV indicators, including national core indicators on preventive treatment initiation and completion and priority indicators on diagnostic testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "people living",
          "heading": true
        },
        {
          "term": "initiated tpt",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": true
        },
        {
          "term": "tpt completion",
          "heading": false
        },
        {
          "term": "patients dft",
          "heading": false
        },
        {
          "term": "monitoring system",
          "heading": true
        },
        {
          "term": "molecular who-recommended",
          "heading": false
        },
        {
          "term": "tbh",
          "heading": false
        }
      ],
      "extract": "monitoring system Services to reduce the burden of TB among people living with HIV, which are measured and reported from the HIV patient monitoring system, include initiation of ART, intensified case- finding, TPT and infection control (28). The 2020 Consolidated HIV strategic information guidelines include TPT completion as a national core indicator as well as key indicators to capture the TB diagnostic and care",
      "extractCut": true
    },
    {
      "id": "sec-073-362-hiv-in-presumptive-and-diagnosed-tb-patients",
      "number": "3.6.2",
      "title": "HIV in presumptive and diagnosed TB patients captured in the TB patient monitoring system",
      "level": 2,
      "pageStart": 131,
      "pageEnd": 131,
      "labelStart": "101",
      "labelEnd": "101",
      "words": 304,
      "summary": {
        "text": "Explains how HIV among TB patients is monitored through standardized TB treatment cards, registers and quarterly reports, increasingly in electronic systems such as DHIS2. It notes the need to reconcile ART and TB registers for indicators on ART among TB patients and that other TB–HIV indicators come from TB programme records.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "patients",
          "heading": true
        },
        {
          "term": "hiv",
          "heading": true
        },
        {
          "term": "relapse",
          "heading": false
        },
        {
          "term": "monitoring",
          "heading": true
        },
        {
          "term": "captured",
          "heading": true
        },
        {
          "term": "registers",
          "heading": false
        },
        {
          "term": "presumptive",
          "heading": true
        },
        {
          "term": "hiv-positive",
          "heading": false
        }
      ],
      "extract": "TB patient monitoring system The TB definitions and reporting framework with integrated HIV recording and reporting requirements have been developed and updated previously by WHO (4). These guidelines provide, in addition, a list of supplementary recommended HIV data elements to be included in programme-specific TB monitoring tools. Monitoring of HIV among TB patients is based on a standardized TB patient treatment",
      "extractCut": true
    },
    {
      "id": "sec-074-363-coordination-of-care-treatment-and-patient-m",
      "number": "3.6.3",
      "title": "Coordination of care, treatment and patient monitoring",
      "level": 2,
      "pageStart": 131,
      "pageEnd": 134,
      "labelStart": "101",
      "labelEnd": "104",
      "words": 890,
      "summary": {
        "text": "Calls for strong coordination, referral and communication between TB and HIV services, supported by electronic systems and co-located clinics, to ensure joint care and reconciled records. It tabulates TB–HIV data elements for HIV patient cards and registers. It also lists additional HIV data elements recommended for TB treatment cards, such as unique identifier, CD4 count, viral load and ARV regimen.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "patient monitoring",
          "heading": true
        },
        {
          "term": "cpt start",
          "heading": false
        },
        {
          "term": "art register",
          "heading": false
        },
        {
          "term": "treatment card",
          "heading": false
        },
        {
          "term": "rifamycin-based regimen",
          "heading": false
        },
        {
          "term": "tpt regimen",
          "heading": false
        },
        {
          "term": "mdr-tb treatment",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": false
        }
      ],
      "extract": "Robust mechanisms for effective coordination, referral and communication between TB and HIV services should be established to ensure effective care and treatment of both diseases. Electronic data systems can facilitate integrated patient monitoring, which captures information on how well HIV prevention, diagnosis and care or referral for HIV care take place within TB programmes, and how well TB screening, prevention",
      "extractCut": true
    },
    {
      "id": "sec-075-37-monitoring-service-delivery-for-hiv-treatment",
      "number": "3.7",
      "title": "Monitoring service delivery for HIV treatment and care",
      "level": 2,
      "pageStart": 134,
      "pageEnd": 134,
      "labelStart": "104",
      "labelEnd": "104",
      "words": 2,
      "summary": {
        "text": "A heading fragment reading 'and care', from the section title on monitoring service delivery for HIV treatment and care.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "and care",
      "extractCut": false
    },
    {
      "id": "sec-076-371-introduction",
      "number": "3.7.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 134,
      "pageEnd": 135,
      "labelStart": "104",
      "labelEnd": "105",
      "words": 140,
      "summary": {
        "text": "Introduces WHO's 2021 service delivery recommendations for HIV treatment and care, aimed at improving access, simplifying care and supporting return to care. It notes that the section presents eight key recommendations supporting differentiated service delivery and its monitoring.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dsd",
          "heading": false
        },
        {
          "term": "hiv treatment",
          "heading": false
        },
        {
          "term": "service delivery",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "focusses",
          "heading": false
        }
      ],
      "extract": "In 2021 WHO released updated recommendations on treatment and care service delivery for people living with HIV (3) with a series of recommendations and good practice statements intended to promote continued improvements in access to ART, to simplify care delivery for providers and end users and to support return to care for those who have disengaged (Box 3.15). These recommendations include approaches for DSD of HIV",
      "extractCut": true
    },
    {
      "id": "sec-077-372-overview-of-dsd",
      "number": "3.7.2",
      "title": "Overview of DSD",
      "level": 2,
      "pageStart": 135,
      "pageEnd": 137,
      "labelStart": "105",
      "labelEnd": "107",
      "words": 780,
      "summary": {
        "text": "Defines differentiated service delivery as a person-centred approach that adapts HIV services to people's needs while using resources efficiently, built on four elements: what, where, who and when. It describes four categories of differentiated ART models, from health worker-managed groups to individual facility and community models. It summarizes WHO recommendations on less frequent visits and refills, community delivery and task sharing with nurses, community health workers and lay providers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dsd",
          "heading": true
        },
        {
          "term": "low-certainty evidence",
          "heading": false
        },
        {
          "term": "maintaining art",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "psychosocial support",
          "heading": false
        },
        {
          "term": "moderate-certainty evidence",
          "heading": false
        },
        {
          "term": "task sharing",
          "heading": false
        },
        {
          "term": "six months",
          "heading": false
        }
      ],
      "extract": "DSD is a person-centred approach that simplifies and adapts HIV services across the care and treatment cascade to reflect the needs and preferences of people living with HIV or vulnerable to infection. At the same time, it optimizes the use of available health system resources. “DSD seeks to create efficiencies in HIV service delivery to achieve programme expansion, while ensuring that care meets the diversity of",
      "extractCut": true
    },
    {
      "id": "sec-078-373-monitoring-dsd",
      "number": "3.7.3",
      "title": "Monitoring DSD",
      "level": 2,
      "pageStart": 137,
      "pageEnd": 138,
      "labelStart": "107",
      "labelEnd": "108",
      "words": 383,
      "summary": {
        "text": "Explains that patient monitoring systems and tools must be adapted to capture data from differentiated service delivery models, with updated patient cards, registers and reports. It stresses that the linked facility keeps clinical responsibility and that community site data should be entered promptly into facility systems to avoid parallel reporting and support tracking of missed pick-ups.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dsd",
          "heading": true
        },
        {
          "term": "community art",
          "heading": false
        },
        {
          "term": "missed appointments",
          "heading": false
        },
        {
          "term": "patient monitoring",
          "heading": false
        },
        {
          "term": "facility-based patient",
          "heading": false
        },
        {
          "term": "monitoring systems",
          "heading": false
        },
        {
          "term": "web annex",
          "heading": false
        },
        {
          "term": "delivery models",
          "heading": false
        }
      ],
      "extract": "Patient monitoring systems must provide accurate and timely data on the diverse services and delivery models for DSD. Doing this requires adaptation of patient monitoring systems and tools and the introduction of indicators to monitor the unique aspects of DSD (36, 37). Updates have been made to the HIV treatment and care patient card (see Web Annex H), ART register (Web Annex K), HIV cross sectional report (Web",
      "extractCut": true
    },
    {
      "id": "sec-079-374-key-dsd-indicators",
      "number": "3.7.4",
      "title": "Key DSD indicators",
      "level": 2,
      "pageStart": 138,
      "pageEnd": 138,
      "labelStart": "108",
      "labelEnd": "108",
      "words": 141,
      "summary": {
        "text": "Notes that the key indicators for differentiated service delivery cover coverage, uptake and clinical outcomes, but that programme management also needs measures of client and worker experience, costs, efficiency and workload. It points to forthcoming WHO guidance and an existing ICAP framework for monitoring and evaluation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dsd",
          "heading": true
        },
        {
          "term": "indicators",
          "heading": true
        },
        {
          "term": "icap",
          "heading": false
        },
        {
          "term": "clients",
          "heading": false
        },
        {
          "term": "cquin",
          "heading": false
        }
      ],
      "extract": "Table 3.8 summarizes key indicators, drawn from the HIV patient monitoring system, recommended to monitor the coverage, uptake and clinical outcomes of DSD. These indicators do not, however, represent the entire range of DSD indicators required for programme monitoring and management. For this, countries should consider a wider range of indicators including the experience or satisfaction of clients and health care",
      "extractCut": true
    },
    {
      "id": "sec-080-375-multi-month-arv-dispensing",
      "number": "3.7.5",
      "title": "Multi-month ARV dispensing",
      "level": 2,
      "pageStart": 138,
      "pageEnd": 140,
      "labelStart": "108",
      "labelEnd": "110",
      "words": 795,
      "summary": {
        "text": "Presents multi-month ARV dispensing (indicator DSD.1) as the minimum indicator when rolling out differentiated service delivery (DSD) for HIV treatment, noting it is also a Global AIDS Monitoring indicator. It suggests aligning drug pick-ups, clinical visits and dispensing for co-infections, and Table 3.8 defines five priority DSD indicators, including enrolment, retention and viral suppression in DSD models. Programmes are also advised to monitor whether eligibility criteria for DSD are applied correctly.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "multi-month arv",
          "heading": true
        },
        {
          "term": "multi-month dispensing",
          "heading": true
        },
        {
          "term": "dsd art",
          "heading": false
        },
        {
          "term": "receiving dsd",
          "heading": false
        },
        {
          "term": "art models",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "people enrolled",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        }
      ],
      "extract": "This key indicator, DSD.1, multi-month ARV dispensing is recommended by WHO, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and UNAIDS and is now included as a Global AIDS Monitoring (GAM) indicator. This is recommended as the minimum indicator for monitoring when DSD ART is rolled out in countries. As DSD implementation is expanded, five core indicators are recommended to track progress and",
      "extractCut": true
    },
    {
      "id": "sec-081-376-clinical-outcomes-among-people-living-with-h",
      "number": "3.7.6",
      "title": "Clinical outcomes among people living with HIV enrolled in DSD ART models",
      "level": 2,
      "pageStart": 140,
      "pageEnd": 141,
      "labelStart": "110",
      "labelEnd": "111",
      "words": 230,
      "summary": {
        "text": "Explains how retention and viral suppression among people in DSD treatment models can be compared before and after implementation and assessed through adapted cohort reports. It stresses including DSD clients in cohort monitoring without double counting, and notes how treatment interruption is defined for people on longer dispensing intervals.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dsd art",
          "heading": true
        },
        {
          "term": "dsd models",
          "heading": true
        },
        {
          "term": "clinical outcomes",
          "heading": true
        },
        {
          "term": "indicator dsd",
          "heading": false
        },
        {
          "term": "art retention",
          "heading": false
        },
        {
          "term": "art cohort",
          "heading": false
        },
        {
          "term": "enrolled",
          "heading": true
        },
        {
          "term": "clinical contact",
          "heading": false
        }
      ],
      "extract": "ART models Assessment of key clinical outcomes among people receiving differentiated ART can be used to evaluate the impact of DSD models. Outcomes such as ART retention (indicator DSD.4) and viral suppression (indicator DSD.5) can be compared before and after implementation of DSD. The retention period would be defined for a relevant period (for example, 12 or 24 months after ART initiation). As various DSD models",
      "extractCut": true
    },
    {
      "id": "sec-082-377-tracing-interventions-to-identify-people-who",
      "number": "3.7.7",
      "title": "Tracing interventions to identify people who interrupt treatment and support re-engagement in care",
      "level": 2,
      "pageStart": 141,
      "pageEnd": 143,
      "labelStart": "111",
      "labelEnd": "113",
      "words": 681,
      "summary": {
        "text": "Suggests additional evaluation of DSD models, such as patient and provider satisfaction and cost-effectiveness, with indicators disaggregated by age, gender and key population. It describes tracing people who interrupt treatment, incorporating ART pick-up dates into tools to detect missed visits, and lists data to record on tracing outcomes and reasons.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tracing interventions",
          "heading": true
        },
        {
          "term": "support re-engagement",
          "heading": true
        },
        {
          "term": "dsd models",
          "heading": false
        },
        {
          "term": "receiving dsd",
          "heading": false
        },
        {
          "term": "identify people",
          "heading": true
        },
        {
          "term": "art pick-up",
          "heading": false
        },
        {
          "term": "patient recall",
          "heading": false
        },
        {
          "term": "home visits",
          "heading": false
        }
      ],
      "extract": "treatment and support their re-engagement in care. As DSD models of care aim to enhance coverage, efficiency and quality of care, additional M&E approaches may be useful – for example, surveys of patient satisfaction and provider satisfaction, assessment of providers’ patient load and productivity and cost-effectiveness evaluations of DSD models. Findings from these assessments may be used to track progress in",
      "extractCut": true
    },
    {
      "id": "sec-083-378-key-data-elements-to-monitor-for-dsd-art",
      "number": "3.7.8",
      "title": "Key data elements to monitor for DSD ART",
      "level": 2,
      "pageStart": 143,
      "pageEnd": 145,
      "labelStart": "113",
      "labelEnd": "115",
      "words": 627,
      "summary": {
        "text": "Describes how DSD elements should be built into patient cards, registers and electronic records, including ART initiation outside facilities, DSD model enrolment and community and psychosocial interventions. It highlights monitoring CD4 at presentation and on return to care to identify advanced disease, and lists key data elements for DSD clients, such as pick-up dates and reasons for exclusion from DSD.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dsd art",
          "heading": true
        },
        {
          "term": "dsd elements",
          "heading": true
        },
        {
          "term": "dsd eligibility",
          "heading": false
        },
        {
          "term": "dsd models",
          "heading": false
        },
        {
          "term": "dsd services",
          "heading": false
        },
        {
          "term": "data elements",
          "heading": true
        },
        {
          "term": "art refills",
          "heading": false
        },
        {
          "term": "key data",
          "heading": true
        }
      ],
      "extract": "DSD care elements should be integrated into existing patient monitoring tools and EMR systems in line with updates to HIV treatment and care service delivery recommendations. Updates have been made to the HIV care and treatment patient card (see Web Annex H) to capture ART initiation outside health facilities and enrolment in DSD ART models as well as delivery of community-based interventions to improve retention",
      "extractCut": true
    },
    {
      "id": "sec-084-379-monitoring-considerations-for-community-art",
      "number": "3.7.9",
      "title": "Monitoring considerations for community ART services",
      "level": 2,
      "pageStart": 145,
      "pageEnd": 150,
      "labelStart": "115",
      "labelEnd": "120",
      "words": 1771,
      "summary": {
        "text": "Sets out monitoring considerations for community-delivered ART, including developing community tools while keeping patient records at facilities, and protecting data confidentiality and security in community settings. It lists existing community ART and adherence club tools that countries can adapt. A Mozambique case study describes how its patient monitoring system, tools and DSD indicators were strengthened.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "community art",
          "heading": true
        },
        {
          "term": "art services",
          "heading": true
        },
        {
          "term": "dsd art",
          "heading": false
        },
        {
          "term": "dsd models",
          "heading": false
        },
        {
          "term": "dsd data",
          "heading": false
        },
        {
          "term": "dsd performance",
          "heading": false
        },
        {
          "term": "art dispensing",
          "heading": false
        },
        {
          "term": "dsd assess",
          "heading": false
        }
      ],
      "extract": "Key monitoring considerations related to the initiation and delivery of ART outside of health facilities and other aspects of community DSD include the following: • Development, use and storage of facility and community tools. The HIV patient card/folder, the paper or e-register should remain at the facility. Since patient monitoring tools are not available at the point of service delivery for community-based DSD",
      "extractCut": true
    },
    {
      "id": "sec-085-38-key-populations",
      "number": "3.8",
      "title": "Key populations",
      "level": 2,
      "pageStart": 150,
      "pageEnd": 150,
      "labelStart": "120",
      "labelEnd": "120",
      "words": 109,
      "summary": {
        "text": "States WHO recommendations for monitoring key populations: data protection frameworks, no key population or criminalized-behaviour information in ART registers or reports, and clinically useful information only in secure patient records.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "key populations",
          "heading": true
        },
        {
          "term": "confidential",
          "heading": false
        },
        {
          "term": "secure",
          "heading": false
        }
      ],
      "extract": "For monitoring for key populations, WHO recommends the following: All patient monitoring systems should be governed by frameworks and regulations for data protection and confidentiality. Individual-level information related to key populations and behaviours that might be criminalized or stigmatized should not be included in ART registers or reported up to subnational or national data management units. Information",
      "extractCut": true
    },
    {
      "id": "sec-086-381-background",
      "number": "3.8.1",
      "title": "Background",
      "level": 2,
      "pageStart": 150,
      "pageEnd": 151,
      "labelStart": "120",
      "labelEnd": "121",
      "words": 207,
      "summary": {
        "text": "Explains why collecting identifiable data on stigmatized or criminalized behaviours from people on ART can harm clients and providers, through law enforcement use, underreporting and discrimination. It notes that behaviours change over time, so labelling someone as a key population member may not stay meaningful.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "criminalized behaviours",
          "heading": false
        },
        {
          "term": "clients",
          "heading": false
        },
        {
          "term": "patient management",
          "heading": false
        },
        {
          "term": "programme monitoring",
          "heading": false
        },
        {
          "term": "consequences",
          "heading": false
        },
        {
          "term": "sex",
          "heading": false
        },
        {
          "term": "person",
          "heading": false
        }
      ],
      "extract": "Data relating to an individual’s behaviours can be important for patient management and programme monitoring. However, in many settings consensual same-sex sexual activity, sex work, cross-dressing or drug use are stigmatized and even criminalized. Collecting identifiable information linked to these behaviours from people receiving ART raises the potential for negative consequences both for individual clients and",
      "extractCut": true
    },
    {
      "id": "sec-087-382-considerations-for-patient-management",
      "number": "3.8.2",
      "title": "Considerations for patient management",
      "level": 2,
      "pageStart": 151,
      "pageEnd": 151,
      "labelStart": "121",
      "labelEnd": "121",
      "words": 252,
      "summary": {
        "text": "Advises that only clinically relevant information, such as drug dependence, opioid agonist therapy, hormone therapy or sexual risk, be recorded in identifiable clinical records for people on HIV treatment. Partner-related prevention interventions can be noted on the back of the patient card.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hormone therapy",
          "heading": false
        },
        {
          "term": "concomitant medications",
          "heading": false
        },
        {
          "term": "patient card",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": false
        },
        {
          "term": "clinical information",
          "heading": false
        },
        {
          "term": "oamt",
          "heading": false
        },
        {
          "term": "stigmatized",
          "heading": false
        },
        {
          "term": "behaviours",
          "heading": false
        }
      ],
      "extract": "While HIV prevention services can be provided without the need to collect personally identifying information and using anonymous UID codes to allow longitudinal monitoring, in most settings it is required that individuals receiving HIV treatment are identified. Because of the sensitivities around information that might indicate an individual’s engagement in stigmatized or criminalized behaviours or their key",
      "extractCut": true
    },
    {
      "id": "sec-088-383-considerations-for-programme-monitoring",
      "number": "3.8.3",
      "title": "Considerations for programme monitoring",
      "level": 2,
      "pageStart": 151,
      "pageEnd": 153,
      "labelStart": "121",
      "labelEnd": "123",
      "words": 683,
      "summary": {
        "text": "Explains that ART registers are not suitable for recording key population status, and that ART coverage among key populations should instead be measured through bio-behavioural and other surveys or de-identified case surveillance. It describes how key population programmes can confirm linkage to treatment while protecting identities, with an example from the EpiC programme in Malawi using triplicate referral tickets.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "epic programme",
          "heading": false
        },
        {
          "term": "referral tickets",
          "heading": false
        },
        {
          "term": "art registers",
          "heading": false
        },
        {
          "term": "key populations",
          "heading": false
        },
        {
          "term": "art coverage",
          "heading": false
        },
        {
          "term": "hiv treatment",
          "heading": false
        },
        {
          "term": "health facility",
          "heading": false
        },
        {
          "term": "populations living",
          "heading": false
        }
      ],
      "extract": "ART registers can be accessed by a variety of facility staff and other staff and so may be difficult to keep confidential. For this reason, ART registers are not appropriate for the collection of data related to key population status. Ensuring sufficient ART coverage among key populations living with HIV, however, is critical for a successful HIV response. Routine programme data reported up to subnational and",
      "extractCut": true
    },
    {
      "id": "sec-089-384-considerations-when-collecting-data-about-ge",
      "number": "3.8.4",
      "title": "Considerations when collecting data about gender",
      "level": 2,
      "pageStart": 153,
      "pageEnd": 153,
      "labelStart": "123",
      "labelEnd": "123",
      "words": 173,
      "summary": {
        "text": "Defines trans and gender diverse people and advises recording both gender identity and sex assigned at birth on clinical records, or only male and female where being trans is highly stigmatized or penalized.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gender",
          "heading": true
        },
        {
          "term": "male female",
          "heading": false
        },
        {
          "term": "gender diverse",
          "heading": false
        },
        {
          "term": "gender identity",
          "heading": false
        },
        {
          "term": "diverse people",
          "heading": false
        }
      ],
      "extract": "Trans and gender diverse people is an umbrella term for people whose gender identity and expression do not conform to the norms and expectations traditionally associated with the sex assigned to them at birth. Since gender is described differently in different countries and cultures, gender identity categories include male, female and other, where other includes trans and gender diverse people including those who",
      "extractCut": true
    },
    {
      "id": "sec-090-39-minimum-dataset-and-key-definitions-for-hiv-p",
      "number": "3.9",
      "title": "Minimum dataset and key definitions for HIV patient monitoring",
      "level": 2,
      "pageStart": 153,
      "pageEnd": 158,
      "labelStart": "123",
      "labelEnd": "128",
      "words": 2329,
      "summary": {
        "text": "Introduces the minimum dataset for HIV patient monitoring, a standardized set of demographic, clinical and laboratory data elements with defined coding, and highlights new elements in the 2022 version. It then sets out key definitions along the care cascade, such as enrolment in HIV care, ART start, transfers, loss to follow-up and treatment outcomes. It notes WHO's recommendation of rapid ART initiation within seven days of diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv patient",
          "heading": true
        },
        {
          "term": "minimum dataset",
          "heading": true
        },
        {
          "term": "patient monitoring",
          "heading": true
        },
        {
          "term": "dsd art",
          "heading": false
        },
        {
          "term": "art site",
          "heading": false
        },
        {
          "term": "started art",
          "heading": false
        },
        {
          "term": "art regimen",
          "heading": false
        },
        {
          "term": "transfer refers",
          "heading": false
        }
      ],
      "extract": "monitoring 3.9.1 Minimum dataset The minimum dataset contains core demographic, clinical and laboratory data. Each data element has a standardized definition and prescribed coding categories. The minimum dataset comprehensively assesses all people living with HIV tested and receiving HIV care. The primary purpose is to standardize patient information with a simplified and harmonized set of essential data elements",
      "extractCut": true
    },
    {
      "id": "sec-091-310-standardized-data-collection-and-reporting-t",
      "number": "3.10",
      "title": "Standardized data collection and reporting tools for HIV patient testing, treatment and care",
      "level": 2,
      "pageStart": 158,
      "pageEnd": 159,
      "labelStart": "128",
      "labelEnd": "129",
      "words": 379,
      "summary": {
        "text": "Gives WHO recommendations on standardized tools: a patient card or electronic record for every person diagnosed with HIV, ART registers wherever ART is provided, and simple standardized reporting by community ART providers. It describes the transfer and referral form and an overview figure of monitoring tools across HIV, maternal and child health and TB settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv patient",
          "heading": true
        },
        {
          "term": "art register",
          "heading": false
        },
        {
          "term": "community art",
          "heading": false
        },
        {
          "term": "hiv card",
          "heading": false
        },
        {
          "term": "tools",
          "heading": true
        },
        {
          "term": "art delivery",
          "heading": false
        },
        {
          "term": "data collection",
          "heading": true
        },
        {
          "term": "monitoring tools",
          "heading": false
        }
      ],
      "extract": "HIV patient testing, treatment and care Box 3.24 Standardized data collection and reporting tools: WHO recommendations • Health workers should create an HIV treatment and care patient card or EMR for every person who is confirmed HIV-positive and subsequently record care, regardless of the entry point (that is, HIV, MNCH, TB service). • ART registers or electronic equivalents should be kept and used at all sites",
      "extractCut": true
    },
    {
      "id": "sec-092-3101-tools-for-facility-based-monitoring-of-hiv",
      "number": "3.10.1",
      "title": "Tools for facility-based monitoring of HIV treatment and care",
      "level": 2,
      "pageStart": 159,
      "pageEnd": 161,
      "labelStart": "129",
      "labelEnd": "131",
      "words": 909,
      "summary": {
        "text": "Describes how the facility-based HIV patient monitoring system follows people from diagnosis through ART to viral suppression and should produce actionable reports. It explains the steps for starting a patient card at any entry point and in integrated settings, and lists updates to the patient card, such as TB diagnostic tests, preventive therapy codes and immunizations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv care",
          "heading": true
        },
        {
          "term": "patient card",
          "heading": false
        },
        {
          "term": "art initiation",
          "heading": false
        },
        {
          "term": "care worker",
          "heading": false
        },
        {
          "term": "patient monitoring",
          "heading": false
        },
        {
          "term": "clinical visit",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "health worker",
          "heading": false
        }
      ],
      "extract": "The HIV patient monitoring system is designed to capture and retain data on all people with a confirmed HIV diagnosis and follow them through the cascade of HIV care services, from diagnosis and ART initiation to sustained viral suppression. Patient monitoring tools should culminate in reports that are acted on. Each report should list the suggested name of who at each level should act on the outcomes of the report,",
      "extractCut": true
    },
    {
      "id": "sec-093-3102-hiv-transfer-or-referral-form",
      "number": "3.10.2",
      "title": "HIV transfer or referral form",
      "level": 2,
      "pageStart": 161,
      "pageEnd": 161,
      "labelStart": "131",
      "labelEnd": "131",
      "words": 122,
      "summary": {
        "text": "Describes the HIV transfer and referral form, which carries key patient information between facilities and community ART sites and includes a counter-referral slip confirming successful transfer.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "referral form",
          "heading": true
        },
        {
          "term": "community art",
          "heading": false
        },
        {
          "term": "transfer",
          "heading": true
        },
        {
          "term": "counter-referral",
          "heading": false
        }
      ],
      "extract": "To the extent possible, if a person is referred from or transfers from another facility or community ART site for care and treatment, key information should be recorded and sent with the patient for continuity of care, retention on ART and maintenance of viral suppression, as well as to avoid duplication in record-keeping and reporting. The generic HIV care referral form includes information taken primarily from the",
      "extractCut": true
    },
    {
      "id": "sec-094-3103-art-register",
      "number": "3.10.3",
      "title": "ART register",
      "level": 2,
      "pageStart": 161,
      "pageEnd": 163,
      "labelStart": "131",
      "labelEnd": "133",
      "words": 513,
      "summary": {
        "text": "States WHO's recommendation that everyone starting ART be entered in a longitudinal ART register organized by start cohort and used to compile cohort and cross-sectional reports. It explains benefits for integrated settings and lists updates to the register, such as DSD enrolment, weight gain as a toxicity and fluconazole prophylaxis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "art register",
          "heading": true
        },
        {
          "term": "start art",
          "heading": false
        },
        {
          "term": "generic art",
          "heading": false
        },
        {
          "term": "longitudinal follow-up",
          "heading": false
        },
        {
          "term": "patient cards",
          "heading": false
        },
        {
          "term": "follow-up status",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": false
        },
        {
          "term": "cell count",
          "heading": false
        }
      ],
      "extract": "Box 3.26 ART register: WHO recommendation All people living with HIV who initiate treatment should be entered into a longitudinal ART register or electronic equivalent when they start ART, preferably within seven days of diagnosis. The ART register: • contains a subset of key information from the HIV patient card/folder in certain settings; • is organized by the month and year (cohort) in which the patient starts",
      "extractCut": true
    },
    {
      "id": "sec-095-3104-cross-sectional-and-cohort-reports",
      "number": "3.10.4",
      "title": "Cross-sectional and cohort reports",
      "level": 2,
      "pageStart": 163,
      "pageEnd": 165,
      "labelStart": "133",
      "labelEnd": "135",
      "words": 1083,
      "summary": {
        "text": "Explains the two reports built from the ART register: a cross-sectional report of current and cumulative patients, and a cohort report of outcomes at set intervals after starting ART. It describes how indicators such as new ART patients, late initiation and people on ART are drawn from these reports. It lists updates, including viral load timing and outcomes for people in DSD models.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cohort reports",
          "heading": true
        },
        {
          "term": "dsd art",
          "heading": false
        },
        {
          "term": "cross-sectional",
          "heading": true
        },
        {
          "term": "art attrition",
          "heading": false
        },
        {
          "term": "indicator art",
          "heading": false
        },
        {
          "term": "started art",
          "heading": false
        },
        {
          "term": "art register",
          "heading": false
        },
        {
          "term": "stopped art",
          "heading": false
        }
      ],
      "extract": "Two reports aggregate data from the ART register: • The cross-sectional report tallies the cumulative and current numbers of people living with HIV in care and on ART, disaggregated by age and sex quarterly to annually. • The cohort report records outcomes of groups of people living with HIV who started ART in the same month and year at 6, 12, 24 months, etc., after ART initiation. Cross-sectional report The",
      "extractCut": true
    },
    {
      "id": "sec-096-3105-other-recommended-tools-to-facilitate-hiv-p",
      "number": "3.10.5",
      "title": "Other recommended tools to facilitate HIV patient monitoring",
      "level": 2,
      "pageStart": 165,
      "pageEnd": 166,
      "labelStart": "135",
      "labelEnd": "136",
      "words": 80,
      "summary": {
        "text": "Lists other recommended monitoring tools: appointment books to track missed visits and pharmacy data elements for monitoring adherence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "patient monitoring",
          "heading": true
        },
        {
          "term": "tools",
          "heading": true
        },
        {
          "term": "dispensed",
          "heading": false
        }
      ],
      "extract": "WHO recommends additional tools to facilitate patient monitoring, including monitoring ART adherence from pharmacy records (Box 3.29). Box 3.29 Other WHO-recommended tools for HIV patient monitoring • Appointment book in health facilities with paper reporting, for tracking patients who miss scheduled visits or drug pick-ups • List of recommended data elements for monitoring adherence in people on ART from a pharmacy",
      "extractCut": true
    },
    {
      "id": "sec-097-3106-tools-for-community---delivered-treatment-a",
      "number": "3.10.6",
      "title": "Tools for community - delivered treatment and care services",
      "level": 2,
      "pageStart": 166,
      "pageEnd": 168,
      "labelStart": "136",
      "labelEnd": "138",
      "words": 667,
      "summary": {
        "text": "Describes the role of community ART providers under WHO's 2021 DSD recommendations, including task shifting, linking clients to facilities and distributing medicines in communities. It introduces a community-based ART monitoring tool and notes links to maternal, child health and TB services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "community art",
          "heading": false
        },
        {
          "term": "art service",
          "heading": false
        },
        {
          "term": "workers community",
          "heading": false
        },
        {
          "term": "monitoring tool",
          "heading": false
        },
        {
          "term": "community health",
          "heading": false
        },
        {
          "term": "service providers",
          "heading": false
        },
        {
          "term": "delivery providers",
          "heading": false
        },
        {
          "term": "patient monitoring",
          "heading": false
        }
      ],
      "extract": "Community-based ART patient monitoring tool Under the DSD guidelines recommended by WHO in 2021, clients may initiate ART outside health facilities and clients established on ART may have less frequent clinical visits and medication pick-up, and they may access more decentralized service delivery points, including community-based services (3). To accommodate larger numbers of people enrolled in HIV care programmes,",
      "extractCut": true
    },
    {
      "id": "sec-098-311-improving-the-quality-and-use-of-individual",
      "number": "3.11",
      "title": "Improving the quality and use of individual-level data to strengthen HIV patient monitoring and care",
      "level": 2,
      "pageStart": 168,
      "pageEnd": 168,
      "labelStart": "138",
      "labelEnd": "138",
      "words": 7,
      "summary": {
        "text": "A section heading fragment on improving the quality and use of individual-level data for HIV patient monitoring.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "to strengthen HIV patient monitoring and care",
      "extractCut": false
    },
    {
      "id": "sec-099-3111-importance-of-strengthening-the-quality-of",
      "number": "3.11.1",
      "title": "Importance of strengthening the quality of individual-level HIV patient monitoring data",
      "level": 2,
      "pageStart": 168,
      "pageEnd": 173,
      "labelStart": "138",
      "labelEnd": "143",
      "words": 2060,
      "summary": {
        "text": "Stresses the importance of good-quality individual-level data for patient management and progress towards the 95–95–95 targets, with data quality work institutionalized rather than ad hoc. It sets out data quality dimensions, confidentiality principles and a systems approach to data quality improvement. It describes practical checks, such as reconciling high viral load results between laboratory systems and facility registers. It ends with district-level triangulation of data sources to improve model inputs and subnational estimates.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "data quality",
          "heading": true
        },
        {
          "term": "monitoring data",
          "heading": true
        },
        {
          "term": "patient monitoring",
          "heading": true
        },
        {
          "term": "dqi activities",
          "heading": false
        },
        {
          "term": "hiv patient",
          "heading": true
        },
        {
          "term": "dqi teams",
          "heading": false
        },
        {
          "term": "dqa tools",
          "heading": false
        },
        {
          "term": "data checks",
          "heading": false
        }
      ],
      "extract": "patient monitoring data Good-quality individual-level data are important to ensure that health care providers make well-informed decisions for improved HIV patient management. As countries move towards the UN Political Declaration 95–95–95 targets for HIV treatment and care, it is now more important than ever to collect and report accurate data in real time to understand where gaps in service delivery remain and",
      "extractCut": true
    },
    {
      "id": "sec-100-3112-data-use-for-improved-service-delivery",
      "number": "3.11.2",
      "title": "Data use for improved service delivery",
      "level": 2,
      "pageStart": 173,
      "pageEnd": 178,
      "labelStart": "143",
      "labelEnd": "148",
      "words": 1816,
      "summary": {
        "text": "Argues that data quality improvement matters only if data are used to improve services, and illustrates data use at patient, facility, district and national levels. It describes standardized information products, training, mentorship and supportive supervision, and making reports actionable with clear responsibilities. It also covers analysing loss-to-follow-up data to support tracing and lists data-use tasks for different facility staff.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "service delivery",
          "heading": true
        },
        {
          "term": "patient folders",
          "heading": false
        },
        {
          "term": "cape town",
          "heading": false
        },
        {
          "term": "data reports",
          "heading": false
        },
        {
          "term": "data visualization",
          "heading": false
        },
        {
          "term": "management reports",
          "heading": false
        },
        {
          "term": "patient monitoring",
          "heading": false
        },
        {
          "term": "clerical staff",
          "heading": false
        }
      ],
      "extract": "DQI is ultimately useful only if accompanied by enhanced data use to improve service delivery and health outcomes. Using data at the level of collection improves clinical care and management, strengthens the health service and improves the quality of the data. (See Box 3.33 for a country example of strengthening data use to improve HIV patient management and monitoring.) Enhanced data analysis and use can provide",
      "extractCut": true
    },
    {
      "id": "sec-101-312-adaption-and-implementation-of-the-hiv-patie",
      "number": "3.12",
      "title": "Adaption and implementation of the HIV patient monitoring system",
      "level": 2,
      "pageStart": 178,
      "pageEnd": 178,
      "labelStart": "148",
      "labelEnd": "148",
      "words": 2,
      "summary": {
        "text": "A section heading fragment on adapting and implementing the HIV patient monitoring system.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "monitoring system",
      "extractCut": false
    },
    {
      "id": "sec-102-3121-introduction",
      "number": "3.12.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 178,
      "pageEnd": 178,
      "labelStart": "148",
      "labelEnd": "148",
      "words": 107,
      "summary": {
        "text": "Introduces guidance on adapting and implementing the HIV patient monitoring system, from coordination across programmes to transitioning between versions, on paper or electronic platforms.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "patient monitoring",
          "heading": false
        },
        {
          "term": "monitoring system",
          "heading": false
        },
        {
          "term": "paper-to-electronic",
          "heading": false
        }
      ],
      "extract": "This section provides guidance on steps for adapting and implementing all or part of the HIV patient monitoring system outlined in this document. It includes recommendations for coordinating across programmes and services and for the transition from a previous version of the patient monitoring system to an updated one. It lays out requirements for a patient monitoring system that can be applied to any system along",
      "extractCut": true
    },
    {
      "id": "sec-103-3122-steps-for-country-adaptation-of-the-guidanc",
      "number": "3.12.2",
      "title": "Steps for country adaptation of the guidance",
      "level": 2,
      "pageStart": 178,
      "pageEnd": 182,
      "labelStart": "148",
      "labelEnd": "152",
      "words": 1424,
      "summary": {
        "text": "Explains that the generic HIV patient monitoring system supports both integrated services and linked separate sites, and lists special considerations such as the service delivery model. Table 3.11 sets out 16 adaptation steps, from forming a technical working group and inventorying tools to defining indicators, training, coordinating partners and ensuring sustainable funding. A box describes the collaboration needed across HIV and other programmes, including standard minimum datasets and unique identifiers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "revised patient",
          "heading": false
        },
        {
          "term": "revised hiv",
          "heading": false
        },
        {
          "term": "patient monitoring",
          "heading": false
        },
        {
          "term": "monitoring tools",
          "heading": false
        },
        {
          "term": "monitoring system",
          "heading": false
        },
        {
          "term": "patient card",
          "heading": false
        },
        {
          "term": "sixteen recommended",
          "heading": false
        },
        {
          "term": "integrating hiv",
          "heading": false
        }
      ],
      "extract": "The generic HIV patient monitoring system is designed to support both integrated service delivery at the facility level and facilities and community ART and testing sites where services remain separate but need to be closely linked. “Integration” refers to HIV services included in the same visit (by the same health worker or within a clinical team) along with ANC, labour and delivery, postpartum and new born care",
      "extractCut": true
    },
    {
      "id": "sec-104-3123-human-resources-and-capacity-building",
      "number": "3.12.3",
      "title": "Human resources and capacity-building",
      "level": 2,
      "pageStart": 182,
      "pageEnd": 186,
      "labelStart": "152",
      "labelEnd": "156",
      "words": 1478,
      "summary": {
        "text": "Describes staffing for HIV patient monitoring in WHO's HIV strategic information guidelines, with a table assigning roles from district teams to clinicians, data clerks and lay providers, and notes that task-shifting can extend capacity. It sets out recommendations for training, clinical mentoring and supportive supervision, including what mentoring visits should cover.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "patient record",
          "heading": false
        },
        {
          "term": "patient monitoring",
          "heading": false
        },
        {
          "term": "district supportive",
          "heading": false
        },
        {
          "term": "transcribe data",
          "heading": false
        },
        {
          "term": "clinical mentoring",
          "heading": false
        },
        {
          "term": "supportive supervision",
          "heading": false
        },
        {
          "term": "data clerk",
          "heading": false
        },
        {
          "term": "review registers",
          "heading": false
        }
      ],
      "extract": "Patient monitoring requires the participation of a wide range of staff with overlapping responsibilities. Shifting tasks to lower-level cadres and even lay providers can increase what the programme can accomplish. Table 3.12 suggests a breakdown of different roles and responsibilities among staff members. In the case of electronic systems, “EMR” may replace “patient record” and “electronic register” may replace",
      "extractCut": true
    },
    {
      "id": "sec-105-3124-transitioning-to-digital-health-systems",
      "number": "3.12.4",
      "title": "Transitioning to digital health systems",
      "level": 2,
      "pageStart": 186,
      "pageEnd": 187,
      "labelStart": "156",
      "labelEnd": "157",
      "words": 451,
      "summary": {
        "text": "Explains why many high-burden countries are moving from paper to electronic HIV patient records, such as difficulty retrieving data and the need for linkage across services, while noting that coverage is incomplete. The block also includes the end of a box on supportive supervision using checklists.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systems",
          "heading": true
        },
        {
          "term": "hiv patient",
          "heading": false
        },
        {
          "term": "health centre",
          "heading": false
        },
        {
          "term": "transitioning",
          "heading": true
        },
        {
          "term": "patient monitoring",
          "heading": false
        },
        {
          "term": "emrs",
          "heading": false
        },
        {
          "term": "mentoring",
          "heading": false
        },
        {
          "term": "paper-based",
          "heading": false
        }
      ],
      "extract": "Over time many HIV high burden countries have transitioned from paper-based systems towards the use of electronic information systems, including EMRs. This transition is driven by (a) the increasing difficulty of accurately and reliably retrieving data from a paper-based patient record system, (b) the time and effort required to maintain a paper-based system as the volume of data increases, (c) the need to support",
      "extractCut": true
    },
    {
      "id": "sec-106-references",
      "number": null,
      "title": "References",
      "level": 2,
      "pageStart": 187,
      "pageEnd": 191,
      "labelStart": "157",
      "labelEnd": "161",
      "words": 1340,
      "summary": {
        "text": "The reference list for chapter 3 of the HIV strategic information guidelines, citing mainly WHO HIV, testing and TB guidance and modelling and data-use studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "accessed december",
          "heading": false
        },
        {
          "term": "handle eng",
          "heading": false
        },
        {
          "term": "accessed september",
          "heading": false
        },
        {
          "term": "bitstream handle",
          "heading": false
        },
        {
          "term": "sequence isallowed",
          "heading": false
        },
        {
          "term": "antiretroviral therapy",
          "heading": false
        },
        {
          "term": "publications item",
          "heading": false
        }
      ],
      "extract": "1. Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Geneva: World Health Organization; 2020 (https://www.who. int/publications/i/item/9789240000735, accessed 24 June 2022). 2. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021",
      "extractCut": true
    },
    {
      "id": "sec-107-chapter-4-integrating-related-infections-into-hi",
      "number": null,
      "title": "Chapter 4 – Integrating related infections into HIV surveillance systems",
      "level": 1,
      "pageStart": 191,
      "pageEnd": 192,
      "labelStart": "161",
      "labelEnd": "162",
      "words": 97,
      "summary": {
        "text": "The opening page and contents of chapter 4, on integrating sexually transmitted infections, viral hepatitis and cervical cancer into HIV surveillance systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "integrating related",
          "heading": true
        },
        {
          "term": "surveillance systems",
          "heading": true
        },
        {
          "term": "minimum dataset",
          "heading": false
        }
      ],
      "extract": "INTEGRATING RELATED INFECTIONS INTO HIV SURVEILLANCE SYSTEMS 4 Key recommendations\b 162 4.1 Introduction\b 163 4.2 Sexually transmitted infections\b 164 4.2.1 Background and rationale\b 164 4.2.2 Minimum dataset for STIs \b 168 4.2.3 Priority indicators for STIs \b 169 4.3 Viral hepatitis\b 171 4.3.1 Background and rationale\b 171 4.3.2 Minimum dataset for viral hepatitis\b 173 4.3.3 Priority indicators for viral hepatitis",
      "extractCut": true
    },
    {
      "id": "sec-108-key-recommendations",
      "number": null,
      "title": "Key recommendations",
      "level": 2,
      "pageStart": 192,
      "pageEnd": 193,
      "labelStart": "162",
      "labelEnd": "163",
      "words": 173,
      "summary": {
        "text": "Lists five new key recommendations for chapter 4: person-centred HIV systems should monitor related infections, STI testing and treatment and recent STI history should be recorded, hepatitis B and C services should be measured for people with HIV and key populations, and cervical cancer screening should be recorded for women living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "routine hiv",
          "heading": false
        },
        {
          "term": "treatment programmes",
          "heading": false
        },
        {
          "term": "recorded",
          "heading": false
        },
        {
          "term": "men",
          "heading": false
        },
        {
          "term": "cervical",
          "heading": false
        }
      ],
      "extract": "NEW \u00071. \u0007Person-centred data should support the improved health and quality of life of people over their lifetimes, with routine HIV systems monitoring related infections such as TB, STIs, hepatitis B and C, pre-invasive cervical disease and cancer and noncommunicable diseases. NEW \u00072. \u0007STI testing and treatment should be measured as part of HIV prevention, testing and treatment programmes. NEW \u00073. \u0007A recent record",
      "extractCut": true
    },
    {
      "id": "sec-109-41-introduction",
      "number": "4.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 193,
      "pageEnd": 194,
      "labelStart": "163",
      "labelEnd": "164",
      "words": 771,
      "summary": {
        "text": "Explains that STIs and viral hepatitis share transmission routes and risk profiles with HIV and are often served through linked services, so person-centred data systems can support their monitoring and universal health coverage. It introduces a minimum dataset and indicators for STIs, hepatitis and cervical cancer, linked by unique identifiers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        },
        {
          "term": "cancer surveillance",
          "heading": false
        },
        {
          "term": "cancer screening",
          "heading": false
        },
        {
          "term": "cancer burden",
          "heading": false
        },
        {
          "term": "cervical disease",
          "heading": false
        },
        {
          "term": "hiv surveillance",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        }
      ],
      "extract": "The modes of transmission and epidemiology of a number of STIs and bloodborne infections such as viral hepatitis are similar to those of HIV, with overlapping risk profiles. Interventions to prevent, diagnose and treat these infections are often delivered through integrated or closely linked services. As countries move toward operationalizing the wider use of individual- level data, these data systems will become an",
      "extractCut": true
    },
    {
      "id": "sec-110-42-sexually-transmitted-infections",
      "number": "4.2",
      "title": "Sexually transmitted infections",
      "level": 2,
      "pageStart": 194,
      "pageEnd": 194,
      "labelStart": "164",
      "labelEnd": "164",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-111-421-background-and-rationale",
      "number": "4.2.1",
      "title": "Background and rationale",
      "level": 2,
      "pageStart": 194,
      "pageEnd": 198,
      "labelStart": "164",
      "labelEnd": "168",
      "words": 1353,
      "summary": {
        "text": "Describes the burden of STIs, with over a million curable infections a day, and the groups most vulnerable to them, with a figure of estimated 2020 cases of chlamydia, gonorrhoea, syphilis and trichomoniasis by sex. It links STIs to HIV acquisition and to the global health sector strategy for 2022–2030 and lists relevant WHO STI guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "quality-assured molecular",
          "heading": false
        },
        {
          "term": "curable stis",
          "heading": false
        },
        {
          "term": "recommends syndromic",
          "heading": false
        },
        {
          "term": "stis among",
          "heading": false
        },
        {
          "term": "sti screening",
          "heading": false
        },
        {
          "term": "syndromic treatment",
          "heading": false
        },
        {
          "term": "moderate-certainty evidence",
          "heading": false
        },
        {
          "term": "urethral discharge",
          "heading": false
        }
      ],
      "extract": "More than one million curable STIs are acquired every day worldwide, primarily caused by Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum (syphilis) and Trichomonas vaginalis (Fig. 4.1). In addition, more than one in every seven women are estimated to be infected with human papillomavirus (HPV) which causes cervical cancer, and more than 500 million people have genital herpes simplex virus (HSV)",
      "extractCut": true
    },
    {
      "id": "sec-112-422-minimum-dataset-for-stis",
      "number": "4.2.2",
      "title": "Minimum dataset for STIs",
      "level": 2,
      "pageStart": 198,
      "pageEnd": 199,
      "labelStart": "168",
      "labelEnd": "169",
      "words": 247,
      "summary": {
        "text": "Presents a recommended minimum dataset for monitoring STIs in HIV programmes, covering visit dates, syndromic or laboratory diagnoses, tests and samples, confirmatory results and treatment prescribed and dispensed, noting the need for clear case definitions where treatment is symptom-based.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "sti confirmatory",
          "heading": false
        },
        {
          "term": "date sti",
          "heading": false
        },
        {
          "term": "sti treatment",
          "heading": false
        },
        {
          "term": "sti tested",
          "heading": false
        },
        {
          "term": "sti test",
          "heading": false
        },
        {
          "term": "sti diagnosed",
          "heading": false
        },
        {
          "term": "discharge syndrome",
          "heading": false
        },
        {
          "term": "stis",
          "heading": true
        }
      ],
      "extract": "Table 4.1 presents a minimum set of data elements for monitoring STIs in individuals using HIV prevention services and people living with HIV. The data elements cover information on both clinical diagnosis and testing. The lack of low-cost reliable POC tests for STIs apart from syphilis means that in many parts of the world individuals are treated for STIs based on symptoms. For individuals treated based on",
      "extractCut": true
    },
    {
      "id": "sec-113-423-priority-indicators-for-stis",
      "number": "4.2.3",
      "title": "Priority indicators for STIs",
      "level": 2,
      "pageStart": 199,
      "pageEnd": 201,
      "labelStart": "169",
      "labelEnd": "171",
      "words": 782,
      "summary": {
        "text": "A table of priority STI indicators for HIV programmes, such as syphilis testing coverage, positivity and treatment coverage and treatment of symptomatic STIs, with numerators, denominators and notes on disaggregation and country-specific treatment rules.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "priority indicators",
          "heading": true
        },
        {
          "term": "sti syndrome",
          "heading": false
        },
        {
          "term": "gonorrhoea during",
          "heading": false
        },
        {
          "term": "attending sti",
          "heading": false
        },
        {
          "term": "reporting period",
          "heading": false
        },
        {
          "term": "syphilis during",
          "heading": false
        },
        {
          "term": "sti clinics",
          "heading": false
        },
        {
          "term": "people tested",
          "heading": false
        }
      ],
      "extract": "Ref. no. Short name Indicator definition Numerator Denominator STI.1 (NEW) Syphilis testing coverage % of people tested for syphilis during the reporting period Number of people tested for syphilis during the reporting period Number of people attending HIV treatment or prevention services during the reporting perioda STI.2 (NEW) Syphilis test positivity % of people who tested positive for syphilis during the",
      "extractCut": true
    },
    {
      "id": "sec-114-43-viral-hepatitis",
      "number": "4.3",
      "title": "Viral hepatitis",
      "level": 2,
      "pageStart": 201,
      "pageEnd": 201,
      "labelStart": "171",
      "labelEnd": "171",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-115-431-background-and-rationale",
      "number": "4.3.1",
      "title": "Background and rationale",
      "level": 2,
      "pageStart": 201,
      "pageEnd": 203,
      "labelStart": "171",
      "labelEnd": "173",
      "words": 875,
      "summary": {
        "text": "Describes the global burden of hepatitis B and C, with 296 million and 58 million people infected in 2019 and over a million deaths a year, concentrated in certain countries and populations such as people who inject drugs. It explains shared prevention approaches with HIV, elimination strategies and the need for person-centred monitoring of the hepatitis care and cure cascade.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "viral hepatitis",
          "heading": false
        },
        {
          "term": "hcv infections",
          "heading": false
        },
        {
          "term": "million people",
          "heading": false
        },
        {
          "term": "hepatitis care",
          "heading": false
        },
        {
          "term": "inject drugs",
          "heading": false
        },
        {
          "term": "hepatitis screening",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "million cases",
          "heading": false
        }
      ],
      "extract": "Viral hepatitis burden Hepatitis B and C viral infections account for a significant global disease burden and high mortality from cirrhosis and hepatocellular cancer. In 2019 WHO estimated that, worldwide, 296 million people were living with chronic HBV infection and 58 million people, with HCV infection, together causing over one million deaths annually (13). The greatest burden of viral hepatitis infection is",
      "extractCut": true
    },
    {
      "id": "sec-116-432-minimum-dataset-for-viral-hepatitis",
      "number": "4.3.2",
      "title": "Minimum dataset for viral hepatitis",
      "level": 2,
      "pageStart": 203,
      "pageEnd": 204,
      "labelStart": "173",
      "labelEnd": "174",
      "words": 161,
      "summary": {
        "text": "Presents a minimum dataset for viral hepatitis in HIV programmes, covering HBV and HCV test dates and results, treatment start and regimen and HCV cure testing, stressing disaggregation by HIV status.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "viral hepatitis",
          "heading": true
        },
        {
          "term": "hcv treatment",
          "heading": false
        },
        {
          "term": "hcv test",
          "heading": false
        },
        {
          "term": "hbv test",
          "heading": false
        },
        {
          "term": "initiation date",
          "heading": false
        },
        {
          "term": "regimen prescribed",
          "heading": false
        },
        {
          "term": "hepatitis data",
          "heading": false
        }
      ],
      "extract": "Table 4.3 presents a minimum set of data elements specifically on testing and treatment of viral hepatitis to be routinely collected and reported in HIV programmes. Viral hepatitis data may be collected and reported from different HIV programmes, that is, HIV prevention services, including community outreach programmes, HIV testing, care and treatment clinics and key population programmes. Because viral hepatitis",
      "extractCut": true
    },
    {
      "id": "sec-117-433-priority-indicators-for-viral-hepatitis",
      "number": "4.3.3",
      "title": "Priority indicators for viral hepatitis",
      "level": 2,
      "pageStart": 204,
      "pageEnd": 206,
      "labelStart": "174",
      "labelEnd": "176",
      "words": 638,
      "summary": {
        "text": "A table of priority viral hepatitis indicators for HIV programmes, including HBV and HCV testing coverage, positivity, treatment and cure, aligned with WHO's hepatitis monitoring framework and global reporting systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "viral hepatitis",
          "heading": true
        },
        {
          "term": "hcv rna",
          "heading": false
        },
        {
          "term": "hcv antibody",
          "heading": false
        },
        {
          "term": "hcv during",
          "heading": false
        },
        {
          "term": "hcv core",
          "heading": false
        },
        {
          "term": "hcv treatment",
          "heading": false
        },
        {
          "term": "completed hcv",
          "heading": false
        },
        {
          "term": "hcv infection",
          "heading": false
        }
      ],
      "extract": "Table 4.4 presents the proposed HBV and HCV indicators to be collected and reported routinely within all HIV programmes. The indicators are based on the 10 core indicators of the M&E framework for viral hepatitis (40) as well as the targets for the elimination of viral hepatitis (41). Also, data collected from these indicators complement other requirements for Member States to report to WHO. These include the Global",
      "extractCut": true
    },
    {
      "id": "sec-118-44-cervical-cancer",
      "number": "4.4",
      "title": "Cervical cancer",
      "level": 2,
      "pageStart": 206,
      "pageEnd": 206,
      "labelStart": "176",
      "labelEnd": "176",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-119-441-background-and-rationale",
      "number": "4.4.1",
      "title": "Background and rationale",
      "level": 2,
      "pageStart": 206,
      "pageEnd": 208,
      "labelStart": "176",
      "labelEnd": "178",
      "words": 706,
      "summary": {
        "text": "Explains that cervical cancer risk is six times higher in women living with HIV, with faster progression and more recurrence, and that the HIV-attributable fraction exceeds 40% in parts of southern Africa. It calls for integrated services and restates WHO's screening strategy for women living with HIV from age 25 every 3 to 5 years.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cancer screening",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "hiv prevalence",
          "heading": false
        },
        {
          "term": "fraction",
          "heading": false
        },
        {
          "term": "higher risk",
          "heading": false
        },
        {
          "term": "years",
          "heading": false
        },
        {
          "term": "hpv",
          "heading": false
        }
      ],
      "extract": "Women living with HIV have a six-fold higher risk of cervical cancer than women without HIV (6), and cervical cancer is classified as an AIDS-defining condition (42). This higher risk starts with an increased risk of acquiring HPV infection, lower chances of regression of pre- cancerous lesions, more rapid progression to cancer and higher rates of recurrence following treatment (43-45). ART has led to steep declines",
      "extractCut": true
    },
    {
      "id": "sec-120-442-minimum-dataset-for-cervical-cancer",
      "number": "4.4.2",
      "title": "Minimum dataset for cervical cancer",
      "level": 2,
      "pageStart": 208,
      "pageEnd": 210,
      "labelStart": "178",
      "labelEnd": "180",
      "words": 628,
      "summary": {
        "text": "A minimum dataset for cervical cancer screening and treatment among women living with HIV, covering HPV vaccination, primary and triage testing, pre-cancer treatment and follow-up, invasive cancer treatment and death. It notes that screening should also be offered to transgender men and other people with a cervix.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": true
        },
        {
          "term": "pre-invasive cervical",
          "heading": false
        },
        {
          "term": "invasive cervical",
          "heading": false
        },
        {
          "term": "cancer screening",
          "heading": false
        },
        {
          "term": "cervical pre-cancer",
          "heading": false
        },
        {
          "term": "minimum dataset",
          "heading": true
        },
        {
          "term": "hpv dna",
          "heading": false
        },
        {
          "term": "cervical disease",
          "heading": false
        }
      ],
      "extract": "screening and treatment among women living with HIV Area Data element Details HPV vaccination Age at last HPV vaccine dose received Number of last dose (1, 2 or 3)a Primary screening Cervical cancer screening test date Lifetime screening test number First in lifetime, second in lifetime, etc. Screening test used HPV DNA testing (including genotyping where done), visual inspection with acetic acid, cytology, other",
      "extractCut": true
    },
    {
      "id": "sec-121-443-priority-indicators-for-cervical-cancer",
      "number": "4.4.3",
      "title": "Priority indicators for cervical cancer",
      "level": 2,
      "pageStart": 210,
      "pageEnd": 212,
      "labelStart": "180",
      "labelEnd": "182",
      "words": 564,
      "summary": {
        "text": "Presents four priority indicators for cervical cancer screening and treatment among women living with HIV, aligned with WHO screening guidance and the elimination strategy, with age disaggregation from 20 and inclusive, confidential gender categories.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": true
        },
        {
          "term": "invasive cervical",
          "heading": false
        },
        {
          "term": "priority indicators",
          "heading": true
        },
        {
          "term": "pre-invasive cervical",
          "heading": false
        },
        {
          "term": "cancer screening",
          "heading": false
        },
        {
          "term": "cervical disease",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "gender diverse",
          "heading": false
        }
      ],
      "extract": "The four priority indicators in Table 4.6 were selected based on their importance for measuring programmatic progress in increasing cervical screening and treatment for women living with HIV (47). These indicators are aligned with WHO’s guideline for screening and treatment of cervical pre-cancerous lesions for cervical cancer prevention (9), the noncommunicable disease primary care facility-based patient and",
      "extractCut": true
    },
    {
      "id": "sec-122-references",
      "number": null,
      "title": "References",
      "level": 2,
      "pageStart": 212,
      "pageEnd": 217,
      "labelStart": "182",
      "labelEnd": "187",
      "words": 1413,
      "summary": {
        "text": "The reference list for chapter 4, citing mainly studies and WHO strategies on STIs, viral hepatitis, HPV and cervical cancer in people living with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "transm infect",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "lancet infect",
          "heading": false
        },
        {
          "term": "sex transm",
          "heading": false
        },
        {
          "term": "hepatitis virus",
          "heading": false
        },
        {
          "term": "viral hepatitis",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        }
      ],
      "extract": "1. Tracking universal health coverage: 2021 Global Monitoring Report (Conference edition). Geneva and Washington (DC): World Health Organization and World Bank; 2021 (https:// www.who.int/publications/i/item/9789240040618, accessed 23 June 2022). 2. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual",
      "extractCut": true
    },
    {
      "id": "sec-123-chapter-5-harnessing-the-strength-of-routine-dat",
      "number": null,
      "title": "Chapter 5 – Harnessing the strength of routine data for HIV surveillance",
      "level": 1,
      "pageStart": 217,
      "pageEnd": 218,
      "labelStart": "187",
      "labelEnd": "188",
      "words": 111,
      "summary": {
        "text": "The opening page and contents of chapter 5, on using routine data for HIV surveillance, including methods for estimating incidence and prevalence, a minimum dataset and data quality needs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "routine data",
          "heading": true
        },
        {
          "term": "hiv surveillance",
          "heading": true
        },
        {
          "term": "harnessing",
          "heading": true
        },
        {
          "term": "estimating hiv",
          "heading": false
        }
      ],
      "extract": "HARNESSING THE STRENGTH OF ROUTINE DATA FOR HIV SURVEILLANCE 5 Key recommendations\b 188 5.1 Introduction\b 189 5.1.1 Harnessing routine data to track the epidemic and guide the response \b 189 5.1.2 Using data from routine HIV surveillance systems \b 193 5.2 Methods for estimating HIV incidence and prevalence using routine data\b 194 5.2.1 CD4/AIDS back-calculation\b 194 5.2.2 Retesting\b 198 5.2.3 Recency assays\b 201",
      "extractCut": true
    },
    {
      "id": "sec-124-key-recommendations",
      "number": null,
      "title": "Key recommendations",
      "level": 2,
      "pageStart": 218,
      "pageEnd": 219,
      "labelStart": "188",
      "labelEnd": "189",
      "words": 218,
      "summary": {
        "text": "Lists five new key recommendations for chapter 5: individual-level HIV surveillance linking data over time, a minimum routine clinical dataset to support incidence measurement, CD4 testing at diagnosis, reporting mortality and causes of death, and stronger electronic case surveillance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv surveillance",
          "heading": false
        },
        {
          "term": "information systems",
          "heading": false
        },
        {
          "term": "health information",
          "heading": false
        },
        {
          "term": "recommended",
          "heading": false
        },
        {
          "term": "incidence",
          "heading": false
        },
        {
          "term": "measurement",
          "heading": false
        },
        {
          "term": "routine",
          "heading": false
        },
        {
          "term": "mortality",
          "heading": false
        }
      ],
      "extract": "NEW \u00071. \u0007It is recommended that national health information systems include and strengthen individual-level HIV surveillance that: a) \u0007routinely links individual data on HIV prevention, diagnosis and treatment over time as people move between facilities and locations b) \u0007provides granular, subnational strategic information for public health action. NEW \u00072. \u0007Collection of a minimum dataset of routine clinical health",
      "extractCut": true
    },
    {
      "id": "sec-125-51-introduction",
      "number": "5.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 219,
      "pageEnd": 219,
      "labelStart": "189",
      "labelEnd": "189",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-126-511-harnessing-routine-data-to-track-the-epidemi",
      "number": "5.1.1",
      "title": "Harnessing routine data to track the epidemic and guide the response",
      "level": 2,
      "pageStart": 219,
      "pageEnd": 223,
      "labelStart": "189",
      "labelEnd": "193",
      "words": 2135,
      "summary": {
        "text": "Explains why tracking HIV incidence, prevalence and mortality matters for guiding the response and meeting global targets, and how routine person-centred data can complement other sources. It describes common measurement methods, including population-based and bio-behavioural surveys, cohort studies and mathematical models such as Spectrum, with their strengths and limits. It also addresses mortality measurement. It ends by advising against routinely collecting key population information where safety is a concern and suggesting triangulation of programme and survey data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv incidence",
          "heading": false
        },
        {
          "term": "incidence estimation",
          "heading": false
        },
        {
          "term": "incidence among",
          "heading": false
        },
        {
          "term": "hiv prevalence",
          "heading": false
        },
        {
          "term": "deaths among",
          "heading": false
        },
        {
          "term": "key populations",
          "heading": false
        },
        {
          "term": "hiv data",
          "heading": false
        },
        {
          "term": "hiv infections",
          "heading": false
        }
      ],
      "extract": "the response Several indicators are important for tracking the course of the HIV epidemic and progress of the response. Impact indicators that measure trends in HIV incidence, all-cause and AIDS- related mortality among persons with HIV, and outcomes such as ART coverage and viral suppression have been critical in identifying service gaps and for prioritizing commitments of resources and services (1, 2). Typically,",
      "extractCut": true
    },
    {
      "id": "sec-127-512-using-data-from-routine-hiv-surveillance-sys",
      "number": "5.1.2",
      "title": "Using data from routine HIV surveillance systems",
      "level": 2,
      "pageStart": 223,
      "pageEnd": 224,
      "labelStart": "193",
      "labelEnd": "194",
      "words": 450,
      "summary": {
        "text": "Describes how countries combine individual patient-level and aggregated data, noting that manual aggregation limits flexible analysis and quality checks. It outlines what HIV case surveillance should capture and the rights-based framework, case definitions and data systems it requires.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "data",
          "heading": true
        },
        {
          "term": "individual-level data",
          "heading": false
        },
        {
          "term": "hiv",
          "heading": true
        },
        {
          "term": "data elements",
          "heading": false
        },
        {
          "term": "hiv information",
          "heading": false
        },
        {
          "term": "deduplicate",
          "heading": false
        },
        {
          "term": "systems",
          "heading": true
        },
        {
          "term": "facility level",
          "heading": false
        }
      ],
      "extract": "Most countries manage a complex system of individual patient-level data and summed aggregated information based on these data. Patient information systems typically interface (directly, via interoperability, or indirectly, via manual data transfer) with laboratory and pharmacy routine information systems to more efficiently capture essential information for use in routine cascade analyses as well as in data",
      "extractCut": true
    },
    {
      "id": "sec-128-52-methods-for-estimating-hiv-incidence-and-prev",
      "number": "5.2",
      "title": "Methods for estimating HIV incidence and prevalence using routine data",
      "level": 2,
      "pageStart": 224,
      "pageEnd": 224,
      "labelStart": "194",
      "labelEnd": "194",
      "words": 154,
      "summary": {
        "text": "Introduces methods for estimating HIV incidence and prevalence from routinely collected individual-level programme data to inform models such as Spectrum, including seroconversion rates as a proxy for incidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "methods",
          "heading": true
        },
        {
          "term": "routine",
          "heading": true
        },
        {
          "term": "estimating",
          "heading": true
        },
        {
          "term": "data",
          "heading": true
        },
        {
          "term": "hiv",
          "heading": true
        }
      ],
      "extract": "using routine data To promote sustainable and efficient surveillance platforms to guide HIV prevention, testing and treatment efforts, it is essential to strengthen the demand, supply, analysis and use of routine HIV programme or service data. To demonstrate the utility of routine programmatic surveillance data to guide the global, national and subnational response, and to inform models such as Spectrum, the methods",
      "extractCut": true
    },
    {
      "id": "sec-129-521-cd4aids-back-calculation",
      "number": "5.2.1",
      "title": "CD4/AIDS back-calculation",
      "level": 2,
      "pageStart": 224,
      "pageEnd": 228,
      "labelStart": "194",
      "labelEnd": "198",
      "words": 1329,
      "summary": {
        "text": "Lists seven methods for using routine data to estimate HIV incidence and explains the first, CD4/AIDS back-calculation, which infers time since infection from CD4 levels at diagnosis. It describes how missing CD4 values can be imputed and why the method is often the only option in concentrated epidemics. A Brazilian example shows the approach applied to national surveillance data, with a map of new HIV cases by municipality in 2019.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "back-calculation",
          "heading": true
        },
        {
          "term": "back-calculation method",
          "heading": false
        },
        {
          "term": "cell counts",
          "heading": false
        },
        {
          "term": "hiv diagnoses",
          "heading": false
        },
        {
          "term": "hiv incidence",
          "heading": false
        },
        {
          "term": "hiv infection",
          "heading": false
        },
        {
          "term": "count measurement",
          "heading": false
        },
        {
          "term": "estimating hiv",
          "heading": false
        }
      ],
      "extract": "2. retesting 3. recency testing 4. routine antenatal HIV testing 5. age-specific HIV prevalence 6. phylogenetics 7. inclusion of routine data in modelling. 5.2.1 CD4/AIDS back-calculation Background Back-calculation is a widely used method to estimate the number of newly acquired HIV infections over time, or HIV incidence, from observed longitudinal data on HIV or AIDS diagnoses (19-21, 33). The principle underlying",
      "extractCut": true
    },
    {
      "id": "sec-130-522-retesting",
      "number": "5.2.2",
      "title": "Retesting",
      "level": 2,
      "pageStart": 228,
      "pageEnd": 231,
      "labelStart": "198",
      "labelEnd": "201",
      "words": 1497,
      "summary": {
        "text": "Explains how HIV retesting supports prevention and re-linkage to care, the factors linked to retesting, and why some people who already know they are positive retest. It discusses how longitudinal testing data can identify duplicate diagnoses and support a cyclical care cascade. It describes using seroconversions in routine testing data to estimate incidence, the biases involved, and a study where behavioural and serological estimates agreed closely.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "retesting",
          "heading": true
        },
        {
          "term": "hiv seroconversion",
          "heading": false
        },
        {
          "term": "frequent retesting",
          "heading": false
        },
        {
          "term": "seroconversion rates",
          "heading": false
        },
        {
          "term": "hiv-positive test",
          "heading": false
        },
        {
          "term": "diagnosed hiv",
          "heading": false
        },
        {
          "term": "first-time testers",
          "heading": false
        },
        {
          "term": "hiv incidence",
          "heading": false
        }
      ],
      "extract": "Background Retesting for HIV can play an important part in sustaining prevention activities, particularly in high burden settings, as it provides opportunities to engage or re-engage people testing HIV-negative (39) and facilitates re-linkage to HIV care among those who are HIV-positive (40). Frequent retesting among priority groups such as key populations, for whom testing at least annually is recommended (41), can",
      "extractCut": true
    },
    {
      "id": "sec-131-523-recency-assays",
      "number": "5.2.3",
      "title": "Recency assays",
      "level": 2,
      "pageStart": 231,
      "pageEnd": 234,
      "labelStart": "201",
      "labelEnd": "204",
      "words": 1857,
      "summary": {
        "text": "Explains how recency assays can estimate incidence in population surveys, but in routine programmes are best applied to groups tested for reasons unrelated to risk, such as antenatal clients, and not used for individual clinical management. It discusses biases from non-random testing and how testing history, viral load and ART exposure improve classification of recent infections. It concludes that recency data on distribution and trends should be compared with other surveillance methods for estimating incidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "recency assays",
          "heading": true
        },
        {
          "term": "recency testing",
          "heading": false
        },
        {
          "term": "recency tests",
          "heading": false
        },
        {
          "term": "incorporating recency",
          "heading": false
        },
        {
          "term": "recency data",
          "heading": false
        },
        {
          "term": "recent infections",
          "heading": false
        },
        {
          "term": "frr",
          "heading": false
        },
        {
          "term": "hiv incidence",
          "heading": false
        }
      ],
      "extract": "A primary outcome of interest in routine surveillance is HIV status. Beyond knowing whether a person is either HIV-negative or positive, it can also be useful to ascertain, among those testing HIV-positive, whether they were likely to have been infected recently. In population- based surveys, recency assays can be used to accurately estimate HIV incidence. In routine programmatic settings the individuals who attend",
      "extractCut": true
    },
    {
      "id": "sec-132-524-routine-antenatal-hiv-testing",
      "number": "5.2.4",
      "title": "Routine antenatal HIV testing",
      "level": 2,
      "pageStart": 234,
      "pageEnd": 238,
      "labelStart": "204",
      "labelEnd": "208",
      "words": 2224,
      "summary": {
        "text": "Describes the long use of pregnant women at antenatal clinics as a sentinel population for HIV trends and the shift to near-universal routine antenatal testing. It discusses how changes in testing or reporting practices can distort trends and why antenatal prevalence differs systematically from that of the general population. It lists conditions for routine antenatal data to be reliable for surveillance, such as high attendance and testing coverage and using only the first test per pregnancy. It also considers incidence during pregnancy and the postpartum period.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv testing",
          "heading": true
        },
        {
          "term": "anc prevalence",
          "heading": false
        },
        {
          "term": "attending anc",
          "heading": false
        },
        {
          "term": "anc sentinel",
          "heading": false
        },
        {
          "term": "anc visit",
          "heading": false
        },
        {
          "term": "anc clients",
          "heading": false
        },
        {
          "term": "anc attendees",
          "heading": false
        },
        {
          "term": "among anc",
          "heading": false
        }
      ],
      "extract": "Background Early in the global HIV/AIDS pandemic, pregnant women attending ANC were identified as an ideal sentinel population through which to monitor population-wide HIV trends (77) because women become pregnant and present for health screening at ANC for reasons unrelated to HIV risk factors or disease. Therefore, measures of HIV prevalence among pregnant women were considered more representative of",
      "extractCut": true
    },
    {
      "id": "sec-133-525-age-specific-hiv-prevalence",
      "number": "5.2.5",
      "title": "Age-specific HIV prevalence",
      "level": 2,
      "pageStart": 238,
      "pageEnd": 239,
      "labelStart": "208",
      "labelEnd": "209",
      "words": 468,
      "summary": {
        "text": "Notes that methods estimating HIV incidence from age-specific prevalence rely on strong assumptions and are no longer recommended, though they may still indicate plausible limits. It explains the assumptions involved and includes a figure of people living with HIV by timing of infection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "age-specific prevalence",
          "heading": true
        },
        {
          "term": "hiv prevalence",
          "heading": true
        },
        {
          "term": "hiv incidence",
          "heading": false
        },
        {
          "term": "cumulative incidence",
          "heading": false
        },
        {
          "term": "steep rise",
          "heading": false
        },
        {
          "term": "plausible limits",
          "heading": false
        },
        {
          "term": "population ages",
          "heading": false
        },
        {
          "term": "prevalence data",
          "heading": false
        }
      ],
      "extract": "Demographic methods have been developed to use age-specific cross-sectional HIV prevalence data, and, therefore, changes in HIV prevalence by age, to better understand HIV incidence (6, 99). Methods previously used for estimating HIV incidence from age-specific prevalence data include cumulative incidence methods and survival methods (99). As several assumptions (described below) are required to draw conclusions",
      "extractCut": true
    },
    {
      "id": "sec-134-526-phylogenetics",
      "number": "5.2.6",
      "title": "Phylogenetics",
      "level": 2,
      "pageStart": 239,
      "pageEnd": 241,
      "labelStart": "209",
      "labelEnd": "211",
      "words": 737,
      "summary": {
        "text": "Describes how phylogenetic analysis of HIV sequences, for instance from drug resistance surveillance, can reveal transmission clusters and recent rapid transmission, as used in the US Ending the Epidemic programme. It notes limited feasibility in resource-limited settings and illustrates how a cluster grows between samples taken two years apart.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "phylogenetic analysis",
          "heading": false
        },
        {
          "term": "microbetrace",
          "heading": false
        },
        {
          "term": "cluster",
          "heading": false
        },
        {
          "term": "data security",
          "heading": false
        },
        {
          "term": "allows rapid",
          "heading": false
        },
        {
          "term": "hiv-trace",
          "heading": false
        },
        {
          "term": "phylogeny",
          "heading": false
        },
        {
          "term": "sequences",
          "heading": false
        }
      ],
      "extract": "In recent years the use of molecular epidemiology to reconstruct viral transmission networks has been recognized widely as a tool for successful interventions to curtail outbreaks of infection. This approach forms an explicit part of the Ending the Epidemic programme in the USA (https://www.cdc.gov/endhiv/index.html). Recent studies published by the Centers for Disease Control and Prevention (CDC) demonstrate the",
      "extractCut": true
    },
    {
      "id": "sec-135-527-inclusion-of-routine-data-in-modelling",
      "number": "5.2.7",
      "title": "Inclusion of routine data in modelling",
      "level": 2,
      "pageStart": 241,
      "pageEnd": 243,
      "labelStart": "211",
      "labelEnd": "213",
      "words": 800,
      "summary": {
        "text": "Sets out the advantages of using routine data in modelling HIV incidence and prevalence, such as low cost and easy updating, and the difficulties in key population epidemics. It stresses engaging key population organizations and describes data cleaning and imputation methods for missing values, favouring multiple imputation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "routine data",
          "heading": true
        },
        {
          "term": "undiagnosed population",
          "heading": false
        },
        {
          "term": "hiv incidence",
          "heading": false
        },
        {
          "term": "missing values",
          "heading": false
        },
        {
          "term": "missing information",
          "heading": false
        },
        {
          "term": "hiv diagnoses",
          "heading": false
        },
        {
          "term": "key population",
          "heading": false
        },
        {
          "term": "survey data",
          "heading": false
        }
      ],
      "extract": "Using routine data for estimates of HIV incidence and prevalence has several advantages. As these data are routinely collected, few extra resources are needed for measuring incidence and prevalence. Another important advantage of routine data is that estimates can easily be updated over time as additional years of data become available. In settings with HIV epidemics concentrated in key populations, use of routine",
      "extractCut": true
    },
    {
      "id": "sec-136-53-minimum-dataset-required-for-estimating-hiv-i",
      "number": "5.3",
      "title": "Minimum dataset required for estimating HIV incidence and prevalence",
      "level": 2,
      "pageStart": 243,
      "pageEnd": 246,
      "labelStart": "213",
      "labelEnd": "216",
      "words": 960,
      "summary": {
        "text": "Explains that national surveillance systems need a standardized minimum set of reportable data elements, such as diagnosis date, CD4 count and viral load, to estimate incidence and prevalence. It recommends linking case reports to laboratory data and collecting CD4 at diagnosis as a minimum. Table 5.1 lists the required elements, with notes on recency testing and use of electronic records.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "incidence prevalence",
          "heading": true
        },
        {
          "term": "hiv incidence",
          "heading": true
        },
        {
          "term": "estimating hiv",
          "heading": true
        },
        {
          "term": "art register",
          "heading": false
        },
        {
          "term": "minimum dataset",
          "heading": true
        },
        {
          "term": "anc register",
          "heading": false
        },
        {
          "term": "hiv diagnoses",
          "heading": false
        },
        {
          "term": "register data",
          "heading": false
        }
      ],
      "extract": "incidence and prevalence National routine HIV surveillance systems will need to collect a minimum standardized set of reportable data elements (Table 5.1) in order to estimate HIV incidence and prevalence using the methods described above. These data elements include HIV diagnosis date and all immunological testing results such as CD4 count and viral load for individuals newly diagnosed with HIV, as WHO clinical",
      "extractCut": true
    },
    {
      "id": "sec-137-54-data-quality-needs-for-the-use-of-routine-dat",
      "number": "5.4",
      "title": "Data quality needs for the use of routine data",
      "level": 2,
      "pageStart": 246,
      "pageEnd": 247,
      "labelStart": "216",
      "labelEnd": "217",
      "words": 516,
      "summary": {
        "text": "Notes that routine data quality depends on how well information is captured and cleaned, and that inconsistent reporting can be mistaken for real changes in coverage. It calls for a culture of data quality assessment and use so that routine facility data can sustainably monitor incidence, prevalence and the HIV response.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "data quality",
          "heading": true
        },
        {
          "term": "routine",
          "heading": true
        },
        {
          "term": "facility data",
          "heading": false
        },
        {
          "term": "hiv data",
          "heading": false
        },
        {
          "term": "art data",
          "heading": false
        },
        {
          "term": "improving data",
          "heading": false
        },
        {
          "term": "quality assessment",
          "heading": false
        },
        {
          "term": "multiple times",
          "heading": false
        }
      ],
      "extract": "While routine facility data provide a powerful tool for granular, timely analyses, in different settings integrated data systems with high coverage are at different stages of maturation. Still, in many of these same settings, some form of HIV case reporting and surveillance has been in place for years, either through paper or electronic systems. The quality of routine data (including reliability, completeness,",
      "extractCut": true
    },
    {
      "id": "sec-138-references",
      "number": null,
      "title": "References",
      "level": 2,
      "pageStart": 247,
      "pageEnd": 255,
      "labelStart": "217",
      "labelEnd": "225",
      "words": 3687,
      "summary": {
        "text": "The reference list for the chapter on routine data for HIV surveillance, citing WHO and UNAIDS guidance, population surveys, and studies on back-calculation, recency testing, antenatal surveillance, phylogenetics and modelling tools.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "defic syndr",
          "heading": false
        },
        {
          "term": "aids soc",
          "heading": false
        },
        {
          "term": "estimating hiv",
          "heading": false
        },
        {
          "term": "hiv incidence",
          "heading": false
        },
        {
          "term": "acquir immune",
          "heading": false
        },
        {
          "term": "recency assays",
          "heading": false
        },
        {
          "term": "incidence trends",
          "heading": false
        }
      ],
      "extract": "1. Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Geneva: World Health Organization; 2020 (https://www. who.int/publications/i/item/9789240000735, accessed 2 April 2022). 2. Global AIDS Update 2021. Confronting inequalities: lessons for pandemic responses from 40 years of AIDS. Geneva: United Nations Joint Programme on HIV/AIDS (UNAIDS)",
      "extractCut": true
    },
    {
      "id": "sec-139-chapter-6-digital-health-data",
      "number": null,
      "title": "Chapter 6 – Digital health data",
      "level": 1,
      "pageStart": 255,
      "pageEnd": 256,
      "labelStart": "225",
      "labelEnd": "226",
      "words": 102,
      "summary": {
        "text": "The contents listing for Chapter 6 on digital health data, covering interoperability, unique identifiers, and privacy, security and data access.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "digital health",
          "heading": true
        },
        {
          "term": "health data",
          "heading": true
        },
        {
          "term": "data access",
          "heading": false
        }
      ],
      "extract": "DIGITAL HEALTH DATA 6 Key recommendations\b 226 6.1 Introduction\b 227 6.1.1 Overview\b 227 6.2 Interoperability\b 232 6.2.1 Overview\b 232 6.2.2 Organizational interoperability (governance)\b 234 6.2.3 Legal interoperability\b 236 6.2.4 Technical interoperability\b 237 6.2.5 Data use and exchange\b 238 6.3 Unique identifiers\b 239 6.3.1 Overview\b 239 6.3.2 Development path for UIDs\b 241 6.3.3 System architecture and methods",
      "extractCut": true
    },
    {
      "id": "sec-140-key-recommendations",
      "number": null,
      "title": "Key recommendations",
      "level": 2,
      "pageStart": 256,
      "pageEnd": 257,
      "labelStart": "226",
      "labelEnd": "227",
      "words": 294,
      "summary": {
        "text": "Sets out updated and new recommendations on digital health data: building interoperability standards and transparent data governance, publishing data-use rules, and using anonymous unique identifiers to link a person's records across services. It also covers privacy, security and restricting access to personal data to authorized parties.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "unique identifiers",
          "heading": false
        },
        {
          "term": "confidential data",
          "heading": false
        },
        {
          "term": "personal data",
          "heading": false
        },
        {
          "term": "data security",
          "heading": false
        },
        {
          "term": "data elements",
          "heading": false
        },
        {
          "term": "health data",
          "heading": false
        },
        {
          "term": "data governance",
          "heading": false
        },
        {
          "term": "different data",
          "heading": false
        }
      ],
      "extract": "Interoperability UPDATE 1. \u0007Explicitly build in interoperability standards, data use rules and obligations and transparent data governance in digital health systems to allow the secure exchange and use of health data: UPDATE a) \u0007Use technical, organizational and legal interoperability standards to facilitate data governance and to smooth data exchange and use between health care sector partners. NEW b) \u0007Publish",
      "extractCut": true
    },
    {
      "id": "sec-141-61-introduction",
      "number": "6.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 257,
      "pageEnd": 257,
      "labelStart": "227",
      "labelEnd": "227",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-142-611-overview",
      "number": "6.1.1",
      "title": "Overview",
      "level": 3,
      "pageStart": 257,
      "pageEnd": 262,
      "labelStart": "227",
      "labelEnd": "232",
      "words": 2393,
      "summary": {
        "text": "Introduces the shift from paper to digital health data, describing its opportunities for better outcomes and its risks for privacy and individual rights, especially in HIV. It stresses that governance and a protective policy environment matter as much as technology, and notes that some aspects of care are hard to capture digitally. It discusses the digital divide that limits access to digital services. A case example from Malawi describes a digital platform for managing HIV programme performance that flags facilities with worrying trends.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "blantyre district",
          "heading": false
        },
        {
          "term": "digital divide",
          "heading": false
        },
        {
          "term": "ucd approach",
          "heading": false
        },
        {
          "term": "digital disruption",
          "heading": false
        },
        {
          "term": "digital data",
          "heading": false
        },
        {
          "term": "digital systems",
          "heading": false
        },
        {
          "term": "chapter digital",
          "heading": false
        },
        {
          "term": "digital booking",
          "heading": false
        }
      ],
      "extract": "The exponential growth in, and use of, health data necessitates systematic investment in digital health care systems. Capitalizing on this growth in digital data in health care is a major opportunity for a country’s health care services to work in concert to improve health outcomes of all individuals. Health care systems are complex, involving many different individuals, facilities, conditions and treatments, and",
      "extractCut": true
    },
    {
      "id": "sec-143-62-interoperability",
      "number": "6.2",
      "title": "Interoperability",
      "level": 2,
      "pageStart": 262,
      "pageEnd": 262,
      "labelStart": "232",
      "labelEnd": "232",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-144-621-overview",
      "number": "6.2.1",
      "title": "Overview",
      "level": 3,
      "pageStart": 262,
      "pageEnd": 264,
      "labelStart": "232",
      "labelEnd": "234",
      "words": 1003,
      "summary": {
        "text": "Defines interoperability as the ability of systems to access, exchange and use data across organizations and boundaries, and outlines organizational, legal and technical types. It describes benefits at the point of care, within and between facilities, such as reducing loss to follow-up and improving supply decisions, and the value of publishing standards and business processes. It notes that full interoperability is hard to achieve and needs incentives at technical and legal levels.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "interoperability initiatives",
          "heading": false
        },
        {
          "term": "data exchange",
          "heading": false
        },
        {
          "term": "data systems",
          "heading": false
        },
        {
          "term": "some interoperability",
          "heading": false
        },
        {
          "term": "care data",
          "heading": false
        },
        {
          "term": "health data",
          "heading": false
        },
        {
          "term": "data sharing",
          "heading": false
        },
        {
          "term": "real-time data",
          "heading": false
        }
      ],
      "extract": "In order for data to be used effectively, data needs to be exchanged between, and understood by, the many different stakeholders in the health care system. Interoperability enables this exchange and a common understanding of the data. This section outlines the different types of interoperability, the benefits of an interoperable health care system and considerations for progressive and sustainable adoption of",
      "extractCut": true
    },
    {
      "id": "sec-145-622-organizational-interoperability-governance",
      "number": "6.2.2",
      "title": "Organizational interoperability (governance)",
      "level": 3,
      "pageStart": 264,
      "pageEnd": 266,
      "labelStart": "234",
      "labelEnd": "236",
      "words": 756,
      "summary": {
        "text": "Explains organizational interoperability as aligning the goals and relationships of organizations so data can be exchanged, and describes supporting measures such as national strategy documents. It illustrates business process mapping with an example workflow for HIV testing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "organizational interoperability",
          "heading": true
        },
        {
          "term": "business processes",
          "heading": false
        },
        {
          "term": "business process",
          "heading": false
        },
        {
          "term": "process workflows",
          "heading": false
        },
        {
          "term": "digital systems",
          "heading": false
        },
        {
          "term": "interoperability standards",
          "heading": false
        },
        {
          "term": "sharing agreements",
          "heading": false
        },
        {
          "term": "organizations working",
          "heading": false
        }
      ],
      "extract": "To maximize the benefits from investments in digital systems, countries need to ensure that the systems follow and maintain interoperability standards. The health care system is complex, involving many stakeholders working in overlapping areas. National digitization strategies need to acknowledge this complexity and convene stakeholders to develop data systems that reflect and benefit the different participating",
      "extractCut": true
    },
    {
      "id": "sec-146-623-legal-interoperability",
      "number": "6.2.3",
      "title": "Legal interoperability",
      "level": 3,
      "pageStart": 266,
      "pageEnd": 267,
      "labelStart": "236",
      "labelEnd": "237",
      "words": 437,
      "summary": {
        "text": "Explains legal interoperability, which removes legal barriers to data sharing and sets rules on ownership, protection, privacy, individual access and storage. It continues the HIV testing business process diagram.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "legal interoperability",
          "heading": true
        },
        {
          "term": "data sharing",
          "heading": false
        },
        {
          "term": "different jurisdictions",
          "heading": false
        },
        {
          "term": "legal barriers",
          "heading": false
        },
        {
          "term": "post test",
          "heading": false
        },
        {
          "term": "serious illness",
          "heading": false
        },
        {
          "term": "retest",
          "heading": false
        },
        {
          "term": "partner services",
          "heading": false
        }
      ],
      "extract": "Legal interoperability aims to enforce organizational interoperability and to ensure that there are no legal barriers that might prevent or restrict the sharing or understanding of data between organizations working across different regions, countries or jurisdictions. It also lays out the rules and obligations for data sharing and use within the health system, including sharing a minimum data set with the health",
      "extractCut": true
    },
    {
      "id": "sec-147-624-technical-interoperability",
      "number": "6.2.4",
      "title": "Technical interoperability",
      "level": 3,
      "pageStart": 267,
      "pageEnd": 268,
      "labelStart": "237",
      "labelEnd": "238",
      "words": 465,
      "summary": {
        "text": "Explains technical interoperability, covering semantic and syntactic standards and secure exchange protocols developed by bodies such as ISO, HL7 and SNOMED International. It uses everyday product standards as an analogy and names JSON and XML as common data formats.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "technical interoperability",
          "heading": true
        },
        {
          "term": "data elements",
          "heading": false
        },
        {
          "term": "specify data",
          "heading": false
        },
        {
          "term": "technical standards",
          "heading": false
        },
        {
          "term": "standard iso",
          "heading": false
        },
        {
          "term": "standards exist",
          "heading": false
        },
        {
          "term": "clinical terminology",
          "heading": false
        },
        {
          "term": "international classification",
          "heading": false
        }
      ],
      "extract": "Technical interoperability encompasses a range of areas. Semantic interoperability covers the standards for the meaning of data elements and relationships between them. Syntactic standards specify data formats, or the “grammar” of the data to be shared. Technical interoperability also covers standards that define protocols for data exchange that ensure security and privacy. Conventions for technical interoperability",
      "extractCut": true
    },
    {
      "id": "sec-148-625-data-use-and-exchange",
      "number": "6.2.5",
      "title": "Data use and exchange",
      "level": 3,
      "pageStart": 268,
      "pageEnd": 269,
      "labelStart": "238",
      "labelEnd": "239",
      "words": 396,
      "summary": {
        "text": "Explains the need to share health data between facilities and systems and describes the HL7 FHIR specification, its resources, formats and exchange protocols and why it is popular. Box 6.5 uses WHO's digital documentation of COVID-19 certificates to illustrate technical, semantic and governance aspects of interoperability.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "data exchange",
          "heading": true
        },
        {
          "term": "digital certificates",
          "heading": false
        },
        {
          "term": "covid digital",
          "heading": false
        },
        {
          "term": "fhir",
          "heading": false
        },
        {
          "term": "technical specifications",
          "heading": false
        },
        {
          "term": "ddcc",
          "heading": false
        },
        {
          "term": "digital health",
          "heading": false
        },
        {
          "term": "vaccination status",
          "heading": false
        }
      ],
      "extract": "It is important to be able to share data between facilities and between systems to provide continuous, person-centred services when, for example, an individual moves to a different location and clinical setting. Fast Health care Interoperability Resources (FHIR, pronounced “fire”) is a popular specification for data exchange maintained by HL7 (36). The FHIR specification is composed of 1) definitions of data models",
      "extractCut": true
    },
    {
      "id": "sec-149-63-unique-identifiers",
      "number": "6.3",
      "title": "Unique identifiers",
      "level": 2,
      "pageStart": 269,
      "pageEnd": 269,
      "labelStart": "239",
      "labelEnd": "239",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-150-631-overview",
      "number": "6.3.1",
      "title": "Overview",
      "level": 3,
      "pageStart": 269,
      "pageEnd": 271,
      "labelStart": "239",
      "labelEnd": "241",
      "words": 1230,
      "summary": {
        "text": "Describes unique identifiers (UIDs) that let people be recognised across HIV and other health services, stressing that they should be content-free and hold no personal details such as birth date or location. It outlines their benefits for linking records and efficiency, and the security and confidentiality risks they pose. The section closes by stating that sensitive details such as sexual orientation should not be collected unless clinically relevant, and that relevant clinical information can be kept in secure records.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "health uids",
          "heading": false
        },
        {
          "term": "key populations",
          "heading": false
        },
        {
          "term": "iso iec",
          "heading": false
        },
        {
          "term": "uid",
          "heading": false
        },
        {
          "term": "covid digital",
          "heading": false
        },
        {
          "term": "digital certificates",
          "heading": false
        },
        {
          "term": "legal interoperability",
          "heading": false
        },
        {
          "term": "data security",
          "heading": false
        }
      ],
      "extract": "UIDs are numeric or alphanumeric codes that support individuals to identify themselves when accessing a variety of health services and support health workers in linking relevant health information when providing services.1 The UID should be anonymized and used in individual-level health data systems. A well-designed UID is free of any personally identifiable information (that is, “content-free” unique identifiers2).",
      "extractCut": true
    },
    {
      "id": "sec-151-632-development-path-for-uids",
      "number": "6.3.2",
      "title": "Development path for UIDs",
      "level": 3,
      "pageStart": 271,
      "pageEnd": 277,
      "labelStart": "241",
      "labelEnd": "247",
      "words": 2546,
      "summary": {
        "text": "Recommends a step-wise path for introducing health UIDs, moving from situation analysis through data security and data use to programme improvement and sustainability. It details what the situation analysis should cover, including existing identifiers, data systems and capacities, and privacy and security laws and policies. It also covers costing benefits, maturity stages for technical components and integrating HIV monitoring into a national UID system. The section ends by stressing planning for policies, maintenance, hardware, software, staff and analytical capacity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "uids",
          "heading": true
        },
        {
          "term": "content-free uids",
          "heading": false
        },
        {
          "term": "implementing uids",
          "heading": false
        },
        {
          "term": "uid system",
          "heading": false
        },
        {
          "term": "name-based identifiers",
          "heading": false
        },
        {
          "term": "electronic records",
          "heading": false
        },
        {
          "term": "data security",
          "heading": false
        },
        {
          "term": "maturation pathway",
          "heading": false
        }
      ],
      "extract": "Implementation of UIDs should take place in a step-wise fashion, reflecting country context. The following steps are suggested: 1. Situation analysis. Countries should conduct a situation analysis that reviews current policies, data sources and systems and identifies incremental improvements, costs, risks and benefits. This analysis should be tailored to the country context and involve the participation of people",
      "extractCut": true
    },
    {
      "id": "sec-152-633-system-architecture-and-methods-of-uid",
      "number": "6.3.3",
      "title": "System architecture and methods of UID",
      "level": 1,
      "pageStart": 277,
      "pageEnd": 282,
      "labelStart": "247",
      "labelEnd": "252",
      "words": 1994,
      "summary": {
        "text": "Outlines the system architecture for a UID system, pointing to ASTM, ISO and CEN technical standards for health identifiers. It describes three facility layers (paper only, reliable power, and network) and the equipment each needs, from data-entry workstations to central, regional or cloud registry servers, noting data-protection questions when data are stored abroad. It then covers interoperability and the technical components and attributes of a UID, ending with how registration and service data are captured and linked to commodity inventory systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "uid",
          "heading": true
        },
        {
          "term": "system architecture",
          "heading": true
        },
        {
          "term": "nai zindagi",
          "heading": false
        },
        {
          "term": "uid numbers",
          "heading": false
        },
        {
          "term": "registry servers",
          "heading": false
        },
        {
          "term": "cloud computing",
          "heading": false
        },
        {
          "term": "security measures",
          "heading": false
        },
        {
          "term": "zindagi trust",
          "heading": false
        }
      ],
      "extract": "Technical resources This section presents the basic components of system architecture and the UID. This guidance should enable programme managers to discuss the key considerations with the technical specialists who will develop UID systems. It should be used in conjunction with documents that provide more detailed technical information, including the following: • Standard guide for properties of a universal",
      "extractCut": true
    },
    {
      "id": "sec-153-64-privacy-security-data-access-and-control",
      "number": "6.4",
      "title": "Privacy, security, data access and control",
      "level": 2,
      "pageStart": 282,
      "pageEnd": 282,
      "labelStart": "252",
      "labelEnd": "252",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-154-641-overview",
      "number": "6.4.1",
      "title": "Overview",
      "level": 2,
      "pageStart": 282,
      "pageEnd": 284,
      "labelStart": "252",
      "labelEnd": "254",
      "words": 798,
      "summary": {
        "text": "Warns that growing volumes of centralised digital health data raise the risk and impact of breaches, so systems must be designed for privacy, security and confidentiality from the outset. An example describes a real-time, person-centred electronic system for services to people who use drugs, with safeguards such as access levels, encryption and de-identified dashboards. Table 6.4 then sets out five types of health data, from personally identifiable to non-personal information.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "data breaches",
          "heading": false
        },
        {
          "term": "breaches due",
          "heading": false
        },
        {
          "term": "health data",
          "heading": false
        },
        {
          "term": "personal information",
          "heading": false
        },
        {
          "term": "medical records",
          "heading": false
        },
        {
          "term": "digital health",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        },
        {
          "term": "iversen",
          "heading": false
        }
      ],
      "extract": "The increasing volume of digital data, along with the increasing use and transfer of these data and the concentration of data in centralized data warehouses, heightens both the risks and the consequences of data breaches. Digital health care systems need to be designed from the start and implemented with privacy, security and confidentiality in mind. These topics warrant serious scrutiny, not only to avoid breaches",
      "extractCut": true
    },
    {
      "id": "sec-155-642-situation-analysis-to-assess-privacy-confide",
      "number": "6.4.2",
      "title": "Situation analysis to assess privacy, confidentiality and security of a digital system",
      "level": 1,
      "pageStart": 284,
      "pageEnd": 285,
      "labelStart": "254",
      "labelEnd": "255",
      "words": 470,
      "summary": {
        "text": "Recommends a situation analysis as the first step in securing a digital health system, using the UNAIDS privacy, confidentiality and security assessment tool run through stakeholder workshops. Table 6.5 lists sample questions on governance and policy and related areas at facility, data warehouse and policy levels.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "security",
          "heading": true
        },
        {
          "term": "digital system",
          "heading": true
        },
        {
          "term": "situation analysis",
          "heading": true
        },
        {
          "term": "confidentiality",
          "heading": true
        },
        {
          "term": "identifiable data",
          "heading": false
        },
        {
          "term": "privacy",
          "heading": true
        },
        {
          "term": "data backed",
          "heading": false
        },
        {
          "term": "identifiable health",
          "heading": false
        }
      ],
      "extract": "of a digital system A situation analysis should be the first step in designing and implementing a digital system that ensures security and the maintenance of confidentiality and privacy. UNAIDS has developed a tool for this purpose, The privacy, confidentiality and security assessment tool (56). The tool assesses privacy, confidentiality and security through facilitation of a series of discussion workshops with key",
      "extractCut": true
    },
    {
      "id": "sec-156-643-data-access-and-control",
      "number": "6.4.3",
      "title": "Data access and control",
      "level": 1,
      "pageStart": 285,
      "pageEnd": 288,
      "labelStart": "255",
      "labelEnd": "258",
      "words": 1520,
      "summary": {
        "text": "Argues that patients should have legally protected access to and control over their own health data and recommends rights-based legal protections. The continuation of Table 6.5 lists questions on access control, data release, transmission security and disposal. It then lists key legal provisions for personal health data, such as portability, revoking access, data protection officers, breach notification and penalties, and cites the EU GDPR principle of data minimisation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "security assurances",
          "heading": false
        },
        {
          "term": "processing personal",
          "heading": false
        },
        {
          "term": "personal data",
          "heading": false
        },
        {
          "term": "storing personal",
          "heading": false
        },
        {
          "term": "data breaches",
          "heading": false
        },
        {
          "term": "protection act",
          "heading": false
        },
        {
          "term": "privacy act",
          "heading": false
        },
        {
          "term": "security measures",
          "heading": false
        }
      ],
      "extract": "Patients are the primary stakeholders in their own health. Accessing one’s personal health data and legal assurance of its protection can build patients’ engagement with health systems and motivate individuals to see themselves as partners in their own health. Legislation is an important mechanism for ensuring that patients have access to, and control of, their own health data. These guidelines recommend that",
      "extractCut": true
    },
    {
      "id": "sec-157-644-indirect-benefits",
      "number": "6.4.4",
      "title": "Indirect benefits",
      "level": 1,
      "pageStart": 288,
      "pageEnd": 289,
      "labelStart": "258",
      "labelEnd": "259",
      "words": 130,
      "summary": {
        "text": "Notes that legal protection of people's access to their health data brings indirect benefits, such as encouraging interoperability standards, content-free identifiers and digital platforms to hold personal records.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "interoperability standards",
          "heading": false
        },
        {
          "term": "care data",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        },
        {
          "term": "easing",
          "heading": false
        }
      ],
      "extract": "Providing legal protections for the continuity of access and maintenance of rights of access to data has many secondary benefits that may drive other areas of digitization of the health care system. As individuals move locations, maintenance of access also requires the movement of personal health care data across regions and facilities. This encourages initiatives easing that process, such as the use of",
      "extractCut": true
    },
    {
      "id": "sec-158-references",
      "number": null,
      "title": "References",
      "level": 2,
      "pageStart": 289,
      "pageEnd": 295,
      "labelStart": "259",
      "labelEnd": "265",
      "words": 1826,
      "summary": {
        "text": "The reference list for the chapter on digital health data, citing WHO digital health guidance, digital adaptation kits, COVID-19 certificate specifications, technical standards and GDPR articles.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "gdpr right",
          "heading": false
        },
        {
          "term": "accessed march",
          "heading": false
        },
        {
          "term": "privacy act",
          "heading": false
        },
        {
          "term": "protection act",
          "heading": false
        },
        {
          "term": "act data",
          "heading": false
        },
        {
          "term": "webpage",
          "heading": false
        },
        {
          "term": "privacy commission",
          "heading": false
        }
      ],
      "extract": "1. Principles for digital development [website]. 2018 (https://digitalprinciples.org/principles/, accessed 23 June 2022). 2. The State of the World’s Children 2017: children in a digital world New York: United Nations Children’s Fund (UNICEF); 2017 (https://www.unicef.org/reports/state-worlds- children-2017, accessed 23 June 2022). 3. World Development Report 2021: data for better lives. Washington (DC): World Bank;",
      "extractCut": true
    },
    {
      "id": "sec-159-chapter-7-strengthening-data-use-from-all-source",
      "number": null,
      "title": "Chapter 7 – Strengthening data use from all sources",
      "level": 1,
      "pageStart": 295,
      "pageEnd": 296,
      "labelStart": "265",
      "labelEnd": "266",
      "words": 121,
      "summary": {
        "text": "The opening page of Chapter 7 on strengthening data use from all sources, listing its sections, including quality of care, community-led monitoring, logistics systems, surveys, modelling and data quality review.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "measuring qoc",
          "heading": false
        },
        {
          "term": "strengthening data",
          "heading": true
        },
        {
          "term": "sources",
          "heading": true
        },
        {
          "term": "chapter",
          "heading": true
        }
      ],
      "extract": "STRENGTHENING DATA USE FROM ALL SOURCES 7 7.1 Introduction\b 266 7.1.1 A comprehensive data use framework\b 266 7.1.2 Sources of data on HIV and their use\b 267 7.2 Measuring and improving the quality of person-centred care\b 268 7.2.1 Background and rationale\b 268 7.2.2 Measuring QOC\b 269 7.2.3 Community engagement in measuring QOC\b 271 7.2.4 A QOC framework for selecting indicators\b 271 7.2.5 Priority indicators\b 273",
      "extractCut": true
    },
    {
      "id": "sec-160-71-introduction",
      "number": "7.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 296,
      "pageEnd": 296,
      "labelStart": "266",
      "labelEnd": "266",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-161-711-a-comprehensive-data-use-framework",
      "number": "7.1.1",
      "title": "A comprehensive data use framework",
      "level": 2,
      "pageStart": 296,
      "pageEnd": 297,
      "labelStart": "266",
      "labelEnd": "267",
      "words": 550,
      "summary": {
        "text": "Argues that a national HIV monitoring and evaluation framework should combine multiple data sources, each with strengths and limits, and map data elements to users and purposes. It lists the many ways HIV and related data can be collected and stresses simple recording and reporting. The section ends with points on community data, such as linking identifiers to avoid double counting between community and facility services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "community-led services",
          "heading": false
        },
        {
          "term": "community-based services",
          "heading": false
        },
        {
          "term": "data",
          "heading": true
        },
        {
          "term": "data systems",
          "heading": false
        },
        {
          "term": "data elements",
          "heading": false
        },
        {
          "term": "health services",
          "heading": false
        },
        {
          "term": "service providers",
          "heading": false
        },
        {
          "term": "programme monitoring",
          "heading": false
        }
      ],
      "extract": "Incorporating data from multiple sources is essential to the ability to make a comprehensive assessment of programme performance. Data systems differ, however, due to differences in local infrastructure capacity, digital health governance and planning, and the resources invested in building and maintaining systems. Therefore, as countries plan investments in their data systems, it is important to take into account",
      "extractCut": true
    },
    {
      "id": "sec-162-712-sources-of-data-on-hiv-and-their-use",
      "number": "7.1.2",
      "title": "Sources of data on HIV and their use",
      "level": 3,
      "pageStart": 297,
      "pageEnd": 298,
      "labelStart": "267",
      "labelEnd": "268",
      "words": 352,
      "summary": {
        "text": "Lists the most common sources of HIV programme data, from routine health information and case surveillance to laboratory and logistics systems, vital statistics, population surveys, special studies and community-led monitoring. It also outlines what the rest of the chapter covers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "special surveys",
          "heading": false
        },
        {
          "term": "community-led monitoring",
          "heading": false
        },
        {
          "term": "monitoring systems",
          "heading": false
        },
        {
          "term": "data",
          "heading": true
        },
        {
          "term": "routine monitoring",
          "heading": false
        },
        {
          "term": "facility assessments",
          "heading": false
        },
        {
          "term": "information systems",
          "heading": false
        },
        {
          "term": "logistics management",
          "heading": false
        }
      ],
      "extract": "In considering how best to collect key data on the HIV programme and response, efforts should be made to review current monitoring systems, to better link the monitoring of related services such as those for STIs, TB, viral hepatitis and cervical cancer, and to include an integrated set of quality of care (QOC) indicators relevant for programme management. Evaluations or special surveys can be considered when",
      "extractCut": true
    },
    {
      "id": "sec-163-72-measuring-and-improving-the-quality-of-person",
      "number": "7.2",
      "title": "Measuring and improving the quality of person-centred care",
      "level": 2,
      "pageStart": 298,
      "pageEnd": 298,
      "labelStart": "268",
      "labelEnd": "268",
      "words": 2,
      "summary": {
        "text": "A fragment of a section heading on measuring and improving the quality of person-centred care.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "person-centred care",
      "extractCut": false
    },
    {
      "id": "sec-164-721-background-and-rationale",
      "number": "7.2.1",
      "title": "Background and rationale",
      "level": 3,
      "pageStart": 298,
      "pageEnd": 299,
      "labelStart": "268",
      "labelEnd": "269",
      "words": 612,
      "summary": {
        "text": "Sets out the rationale for measuring quality of care, citing estimates that poor-quality care causes millions of deaths and huge economic losses in low- and middle-income countries. It argues that people receiving HIV services need high-quality care, that quality must be measured across health system levels, and that WHO quality definitions should be used locally.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qoc",
          "heading": false
        },
        {
          "term": "poor-quality care",
          "heading": false
        },
        {
          "term": "quality health",
          "heading": false
        },
        {
          "term": "quality improvement",
          "heading": false
        },
        {
          "term": "health services",
          "heading": false
        },
        {
          "term": "poor quality",
          "heading": false
        },
        {
          "term": "quality across",
          "heading": false
        },
        {
          "term": "data quality",
          "heading": false
        }
      ],
      "extract": "Each year poor-quality care contributes to 5.7–8.4 million deaths from all causes in low- and middle-income countries (LMICs), comprising 15% of total deaths in these countries (5). More lives are lost due to poor-quality care than to lack of access to health care (6). In addition to the tremendous loss of life, annual economic losses associated with poor quality care are enormous, exceeding US$ 6 trillion (6).",
      "extractCut": true
    },
    {
      "id": "sec-165-722-measuring-qoc",
      "number": "7.2.2",
      "title": "Measuring QOC",
      "level": 3,
      "pageStart": 299,
      "pageEnd": 301,
      "labelStart": "269",
      "labelEnd": "271",
      "words": 1219,
      "summary": {
        "text": "Describes how quality of HIV care should be measured mainly through existing information systems and routine data, with a framework that defines data sources, capacity, triangulation and use for improvement. It stresses capturing integrated, longitudinal care across service points, considering the diversity of clients and keeping data anonymised. The section also notes related services, such as palliative and psychosocial care, that should be considered when measuring quality.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "measuring qoc",
          "heading": true
        },
        {
          "term": "qoc measurement",
          "heading": false
        },
        {
          "term": "qoc data",
          "heading": false
        },
        {
          "term": "documentation journals",
          "heading": false
        },
        {
          "term": "improvement essentials",
          "heading": false
        },
        {
          "term": "patient-level data",
          "heading": false
        },
        {
          "term": "essentials toolkit",
          "heading": false
        },
        {
          "term": "pdsa",
          "heading": false
        }
      ],
      "extract": "Ideally, QOC is measured through existing strategic information systems. Thus, QOC data depend on the strength of national health management information systems. A health system’s framework for measuring QOC should: • support the national strategic direction for quality • clearly define what data should be collected from which sources • be cognizant of capacity for measurement • strategize how data will be",
      "extractCut": true
    },
    {
      "id": "sec-166-723-community-engagement-in-measuring-qoc",
      "number": "7.2.3",
      "title": "Community engagement in measuring QOC",
      "level": 1,
      "pageStart": 301,
      "pageEnd": 301,
      "labelStart": "271",
      "labelEnd": "271",
      "words": 154,
      "summary": {
        "text": "Highlights the role of communities and community-led organisations in defining and measuring quality of HIV care and holding stakeholders accountable, pointing to community-led monitoring as a complement to routine data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qoc",
          "heading": true
        },
        {
          "term": "qoc measurement",
          "heading": false
        },
        {
          "term": "community",
          "heading": true
        },
        {
          "term": "community stakeholders",
          "heading": false
        },
        {
          "term": "invaluable",
          "heading": false
        }
      ],
      "extract": "The community plays an invaluable role in measuring QOC and holding all stakeholders accountable for offering high-quality care to all people seeking and using HIV services, including subpopulations such as key populations. Community stakeholders and community-led organizations, especially those involving specific subgroups, experience QOC first-hand and so may be best equipped to identify what is important to these",
      "extractCut": true
    },
    {
      "id": "sec-167-724-a-qoc-framework-for-selecting-indicators",
      "number": "7.2.4",
      "title": "A QOC framework for selecting indicators",
      "level": 2,
      "pageStart": 301,
      "pageEnd": 303,
      "labelStart": "271",
      "labelEnd": "273",
      "words": 570,
      "summary": {
        "text": "Describes what a quality-of-care measurement framework should include, such as what matters most to service users, multiple stakeholders, validated tools, and clinical and patient-reported indicators of experience, perception, knowledge and outcomes. It introduces a person-centred indicator framework (Table 7.2) for selecting indicators.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qoc indicators",
          "heading": true
        },
        {
          "term": "indicators framework",
          "heading": true
        },
        {
          "term": "providing care",
          "heading": false
        },
        {
          "term": "integrated services",
          "heading": false
        },
        {
          "term": "related services",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        },
        {
          "term": "person-centred",
          "heading": false
        }
      ],
      "extract": "A QOC measurement framework should encompass: • factors of greatest importance and concern to people accessing HIV prevention, testing, treatment and related services at different stages of life; • multiple stakeholders engaged in the health care system, including physicians, provider organizations and patients or clients, and a review of the challenges and enablers they face in the provision of quality of care,",
      "extractCut": true
    },
    {
      "id": "sec-168-725-priority-indicators",
      "number": "7.2.5",
      "title": "Priority indicators",
      "level": 1,
      "pageStart": 303,
      "pageEnd": 305,
      "labelStart": "273",
      "labelEnd": "275",
      "words": 1053,
      "summary": {
        "text": "Presents Table 7.3, the priority indicators recommended for monitoring quality of HIV care across prevention, testing, treatment and other care stages, such as linkage to treatment, viral load suppression and coverage of differentiated service delivery models. It notes that more indicators are in a web annex and that most come from earlier chapters and the minimum dataset. It ends by urging that quality concepts be built into national strategic information frameworks and routine systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "priority indicators",
          "heading": true
        },
        {
          "term": "qoc domain",
          "heading": false
        },
        {
          "term": "dsd art",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "art models",
          "heading": false
        },
        {
          "term": "self-report receiving",
          "heading": false
        },
        {
          "term": "among people",
          "heading": false
        },
        {
          "term": "people attending",
          "heading": false
        }
      ],
      "extract": "Table 7.3 presents indicators recommended for all programmes intending to comprehensively measure and monitor QOC for people receiving HIV services. Web Annex B provides additional indicators for programmes with the capacity to adopt and sustain more indicators for more robust QOC monitoring. The majority of indicators highlighted in this subsection have been recommended in Chapters 2, 3, and 4 of these guidelines",
      "extractCut": true
    },
    {
      "id": "sec-169-73-community-led-monitoring",
      "number": "7.3",
      "title": "Community-led monitoring",
      "level": 2,
      "pageStart": 305,
      "pageEnd": 307,
      "labelStart": "275",
      "labelEnd": "277",
      "words": 1169,
      "summary": {
        "text": "Describes community-led monitoring as an accountability and advocacy strategy led by organisations of people living with HIV and key populations to improve the quality and accessibility of services. It distinguishes it from community-based service delivery and stresses that communities should set its focus free from outside influence. The section explains how its findings, combined with routine person-centred data, can reveal gaps that might otherwise be missed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "through clm",
          "heading": false
        },
        {
          "term": "community-led",
          "heading": true
        },
        {
          "term": "community-led organizations",
          "heading": false
        },
        {
          "term": "community-led networks",
          "heading": false
        },
        {
          "term": "data collection",
          "heading": false
        },
        {
          "term": "data sharing",
          "heading": false
        },
        {
          "term": "community groups",
          "heading": false
        },
        {
          "term": "hiv services",
          "heading": false
        }
      ],
      "extract": "Community engagement of people living with and affected by HIV through CLM is fundamental to using data to improve the quality of HIV and related services. Community engagement creates an enabling environment for stakeholders to work together to address health- related issues and promote well-being and, ultimately, to achieve positive health impact and outcomes (23). CLM is an accountability and advocacy strategy",
      "extractCut": true
    },
    {
      "id": "sec-170-74-logistics-management-information-systems",
      "number": "7.4",
      "title": "Logistics management information systems",
      "level": 2,
      "pageStart": 307,
      "pageEnd": 309,
      "labelStart": "277",
      "labelEnd": "279",
      "words": 651,
      "summary": {
        "text": "Explains why an uninterrupted supply of antiretroviral drugs and diagnostics is essential to HIV programmes and what a good distribution system achieves. It notes that drug dispensing data can measure multi-month dispensing under differentiated service delivery. It argues that linking logistics management information systems with deduplicated, de-identified patient-level data helps avoid wastage and stock-outs, with quarterly review recommended.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "drug wastage",
          "heading": false
        },
        {
          "term": "management information",
          "heading": true
        },
        {
          "term": "central warehouse",
          "heading": false
        },
        {
          "term": "individual-level data",
          "heading": false
        },
        {
          "term": "logistics",
          "heading": true
        },
        {
          "term": "deduplicated",
          "heading": false
        },
        {
          "term": "reduce drug",
          "heading": false
        },
        {
          "term": "hiv service",
          "heading": false
        }
      ],
      "extract": "An uninterrupted supply of ARV drugs and diagnostics commodities for HIV prevention, testing and treatment of people living with HIV is a prerequisite for all HIV programmes. An effective and sustainable supply chain system for drugs and other commodities is complex and has many stakeholders. A well-run distribution system keeps drugs in good condition, rationalizes drug storage points, uses transport as efficiently",
      "extractCut": true
    },
    {
      "id": "sec-171-75-health-facility-assessments",
      "number": "7.5",
      "title": "Health facility assessments",
      "level": 2,
      "pageStart": 309,
      "pageEnd": 310,
      "labelStart": "279",
      "labelEnd": "280",
      "words": 369,
      "summary": {
        "text": "Describes how health facility assessments monitor the availability and readiness of HIV services, including staff, equipment, medicines and diagnostics, and warns that private facilities are often under-represented in samples. It mentions tools such as the Service Availability and Readiness Assessment and includes part of a case study from Malawi on electronic medical records.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "facility assessments",
          "heading": true
        },
        {
          "term": "health facility",
          "heading": true
        },
        {
          "term": "health facilities",
          "heading": false
        },
        {
          "term": "facility survey",
          "heading": false
        },
        {
          "term": "site-level",
          "heading": false
        },
        {
          "term": "hiv services",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        },
        {
          "term": "basic",
          "heading": false
        }
      ],
      "extract": "The ready availability and good quality of health services are integral to strong primary health care and universal health coverage and contribute to achieving the Sustainable Development Goals. Data collected from health facility assessments monitor the capability and performance of health facilities and can support evidence-based decision-making in health sector reviews, planning, management and policy-making. The",
      "extractCut": true
    },
    {
      "id": "sec-172-76-civil-registration-and-vital-statistics",
      "number": "7.6",
      "title": "Civil registration and vital statistics",
      "level": 2,
      "pageStart": 310,
      "pageEnd": 310,
      "labelStart": "280",
      "labelEnd": "280",
      "words": 174,
      "summary": {
        "text": "Describes how civil registration and vital statistics provide data on births, deaths and causes of death for HIV mortality, and the conditions for these data to be usable, such as confidentiality and completeness. It notes that verbal autopsy and other special studies, and linking data systems, can fill gaps.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "crvs systems",
          "heading": false
        },
        {
          "term": "registration",
          "heading": true
        },
        {
          "term": "hiv-related mortality",
          "heading": false
        },
        {
          "term": "completeness",
          "heading": false
        },
        {
          "term": "autopsy",
          "heading": false
        },
        {
          "term": "death",
          "heading": false
        }
      ],
      "extract": "CRVS systems provide the data required on the number of births in the population as well as deaths and causes of death for the HIV-related mortality measure. The completeness and accuracy of vital registration data vary considerably among countries. The usability of CRVS data for monitoring the health sector response to HIV depends on strict compliance with reporting requirements; reporting both primary and",
      "extractCut": true
    },
    {
      "id": "sec-173-77-population-based-survey-data",
      "number": "7.7",
      "title": "Population-based survey data",
      "level": 2,
      "pageStart": 310,
      "pageEnd": 311,
      "labelStart": "280",
      "labelEnd": "281",
      "words": 598,
      "summary": {
        "text": "Explains that population-based surveys capture people not reached by health services and complement routine data, listing survey types such as DHS, AIS, PHIA, bio-behavioural surveys and the Stigma Index. It sets out considerations for using survey indicators, including their cost, infrequency, limited geographic precision and the difficulty of surveying children and adolescents.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "population-based survey",
          "heading": true
        },
        {
          "term": "survey data",
          "heading": true
        },
        {
          "term": "probability surveys",
          "heading": false
        },
        {
          "term": "hiv prevalence",
          "heading": false
        },
        {
          "term": "key populations",
          "heading": false
        },
        {
          "term": "hiv drug",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "confidence intervals",
          "heading": false
        }
      ],
      "extract": "Population-based surveys are very important for capturing the situation of people who are not engaged in health services. For example, if a country has ART treatment coverage of 70%, understanding why the remaining 30% are not engaged in care is possible only through a population-based survey that reaches a representative group of people not engaged with health services. Thus, surveys complement routine programme",
      "extractCut": true
    },
    {
      "id": "sec-174-78-mathematical-modelling",
      "number": "7.8",
      "title": "Mathematical modelling",
      "level": 2,
      "pageStart": 311,
      "pageEnd": 312,
      "labelStart": "281",
      "labelEnd": "282",
      "words": 538,
      "summary": {
        "text": "Explains why modelled estimates are needed for numbers of people living with HIV, new infections and AIDS deaths, and how models such as Spectrum AIM combine survey, surveillance and programme data. It notes that models allow comparison over time and across countries and can answer other policy questions, and recommends including model results in regular data reviews.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "optima hiv",
          "heading": false
        },
        {
          "term": "modelled estimates",
          "heading": false
        },
        {
          "term": "hiv epidemic",
          "heading": false
        },
        {
          "term": "hiv infections",
          "heading": false
        },
        {
          "term": "mathematical",
          "heading": true
        },
        {
          "term": "hiv transmission",
          "heading": false
        },
        {
          "term": "modelling",
          "heading": true
        },
        {
          "term": "people living",
          "heading": false
        }
      ],
      "extract": "Estimating the number of people newly infected with HIV or who have died of AIDS-related causes is important for understanding the potential impact and costs associated with implementing interventions and services for HIV prevention, testing and treatment. Using modelled estimates is helpful because it is impossible to directly count the numbers of people living with HIV, of people who are newly infected with HIV or",
      "extractCut": true
    },
    {
      "id": "sec-175-79-data-quality-review-triangulation-and-use",
      "number": "7.9",
      "title": "Data quality review, triangulation and use",
      "level": 2,
      "pageStart": 312,
      "pageEnd": 313,
      "labelStart": "282",
      "labelEnd": "283",
      "words": 594,
      "summary": {
        "text": "Describes the harmonized data quality review framework developed by WHO, the Global Fund and Gavi, recommended for integration into health information systems and at least annual national review. It lists the quality dimensions assessed, such as completeness, timeliness and internal and external consistency, and notes that subnational and facility managers may review data more often.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "data quality",
          "heading": true
        },
        {
          "term": "data reviews",
          "heading": false
        },
        {
          "term": "external consistency",
          "heading": false
        },
        {
          "term": "routine data",
          "heading": false
        },
        {
          "term": "reported data",
          "heading": false
        },
        {
          "term": "population data",
          "heading": false
        },
        {
          "term": "indicators based",
          "heading": false
        },
        {
          "term": "health indicator",
          "heading": false
        }
      ],
      "extract": "A systems approach to improving data quality includes establishing a data quality review (DQR) process. Such a process will help countries be more confident that their data accurately reflect the status of the populations served and the performance of their programmes. Through a collaborative effort of WHO, the Global Fund and Gavi, a harmonized, health sector-wide framework for DQR was developed (37). It is",
      "extractCut": true
    },
    {
      "id": "sec-176-710-evaluation-and-operational-research",
      "number": "7.10",
      "title": "Evaluation and operational research",
      "level": 2,
      "pageStart": 313,
      "pageEnd": 314,
      "labelStart": "283",
      "labelEnd": "284",
      "words": 208,
      "summary": {
        "text": "Stresses that HIV programmes need regular evaluation and operational research alongside routine data, with a prioritized evaluation agenda and studies managed as formal projects, noting that individual-level data are better suited to research questions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "operational research",
          "heading": true
        },
        {
          "term": "evaluation",
          "heading": true
        },
        {
          "term": "agenda",
          "heading": false
        },
        {
          "term": "regular",
          "heading": false
        },
        {
          "term": "addressing",
          "heading": false
        },
        {
          "term": "data",
          "heading": false
        },
        {
          "term": "questions",
          "heading": false
        }
      ],
      "extract": "In addition to routine programme data, programmes need regular evaluations and a system for conducting operational research to learn from implementation and answer complex questions or to test new approaches in service delivery. Evaluation, operational research and implementation science employ research methods to address such questions, which complement routine data review as a data-driven approach to continuous",
      "extractCut": true
    },
    {
      "id": "sec-177-references",
      "number": null,
      "title": "References",
      "level": 2,
      "pageStart": 314,
      "pageEnd": 317,
      "labelStart": "284",
      "labelEnd": "287",
      "words": 906,
      "summary": {
        "text": "The reference list for the chapter on HIV data sources, citing WHO guidance on surveys, quality of care and consolidated HIV guidelines, survey programmes such as DHS and AIS, and data collection tools.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "hiv aids",
          "heading": false
        },
        {
          "term": "avenir health",
          "heading": false
        },
        {
          "term": "united nations",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "joint united",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "webpage",
          "heading": false
        }
      ],
      "extract": "1. World Health Organization, Centers for Disease Control and Prevention, Joint United Nations Programme on HIV/AIDS, FHI 360. Biobehavioral survey guidelines for populations at risk for HIV. Geneva: World Health Organization; 2017 (https://www.who.int/ publications/i/item/978-92-4-151301-2, accessed 24 June 2022). 2. Justman JE, Mugurungi O, El-Sadr WM. HIV population surveys—bringing precision to the global",
      "extractCut": true
    },
    {
      "id": "sec-178-chapter-8-priority-indicators",
      "number": null,
      "title": "Chapter 8 – Priority indicators",
      "level": 1,
      "pageStart": 317,
      "pageEnd": 318,
      "labelStart": "287",
      "labelEnd": "288",
      "words": 81,
      "summary": {
        "text": "The contents page of Chapter 8 on priority indicators, listing sections by programme area from HIV prevention and testing to hepatitis, cervical cancer and stigma.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "priority indicators",
          "heading": true
        },
        {
          "term": "chapter",
          "heading": true
        },
        {
          "term": "hiv",
          "heading": false
        }
      ],
      "extract": "PRIORITY INDICATORS 8 8.1 Introduction\b 288 8.1.1 Disaggregation\b 288 8.1.2 Time periods\b 289 8.1.3 Inclusion of community-based service data\b 290 8.2 Priority indicators by programme area\b 291 8.2.1 HIV prevention\b 291 8.2.2 HIV testing services\b 313 8.2.3 HIV treatment\b 325 8.2.4 TB/HIV\b 344 8.2.5 Differentiated service delivery\b 353 8.2.6 Sexually transmitted infections \b 359 8.2.7 Viral hepatitis\b 373 8.2.8",
      "extractCut": true
    },
    {
      "id": "sec-179-81-introduction",
      "number": "8.1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 318,
      "pageEnd": 318,
      "labelStart": "288",
      "labelEnd": "288",
      "words": 87,
      "summary": {
        "text": "Introduces Chapter 8, which details priority and core indicators organized under prevention, testing and treatment, related infections, impact, and stigma and discrimination.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "indicators",
          "heading": false
        },
        {
          "term": "needle-syringe",
          "heading": false
        },
        {
          "term": "vmmc",
          "heading": false
        },
        {
          "term": "multi-month",
          "heading": false
        }
      ],
      "extract": "This chapter details the recommended priority indicators, including core indicators, organized by five programme areas: • prevention, including indicators on condom programming, PrEP, PEP, needle-syringe programmes, OAMT, VMMC; • testing and treatment, including indicators on HIV testing, HIV treatment and care, vertical transmission, TB/HIV, multi-month ARV dispensing; • related infections, including indicators on",
      "extractCut": true
    },
    {
      "id": "sec-180-811-disaggregation",
      "number": "8.1.1",
      "title": "Disaggregation",
      "level": 2,
      "pageStart": 318,
      "pageEnd": 319,
      "labelStart": "288",
      "labelEnd": "289",
      "words": 830,
      "summary": {
        "text": "Explains why data should be disaggregated by geography, age, gender, priority population and patient group to assess equity and close gaps for underserved groups. It discusses age bands and other disaggregation categories and the need for consistent categories across indicators. It ends by warning that fine-grained disaggregation in small areas can breach confidentiality where stigma or criminalization are common.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "disaggregation",
          "heading": true
        },
        {
          "term": "gender diverse",
          "heading": false
        },
        {
          "term": "age bands",
          "heading": false
        },
        {
          "term": "key populations",
          "heading": false
        },
        {
          "term": "narrower age",
          "heading": false
        },
        {
          "term": "disaggregated data",
          "heading": false
        },
        {
          "term": "diverse people",
          "heading": false
        },
        {
          "term": "population status",
          "heading": false
        }
      ],
      "extract": "8.1.1 Disaggregation Disaggregated data are needed to assess equity and performance in health service access and health outcomes among different geographic and sociodemographic subpopulations and important patient subgroups. Routine assessment of equity in service delivery and quality across groups is fundamental to honouring the commitment of the HIV response to equity. In terms of improving programme performance,",
      "extractCut": true
    },
    {
      "id": "sec-181-812-time-periods",
      "number": "8.1.2",
      "title": "Time periods",
      "level": 3,
      "pageStart": 319,
      "pageEnd": 320,
      "labelStart": "289",
      "labelEnd": "290",
      "words": 184,
      "summary": {
        "text": "Explains that most priority indicators have no fixed reporting period and can be calculated over different periods, while some track individuals' service use over time, such as follow-up viral load testing, which may need longitudinal registers or digital systems.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "periods",
          "heading": true
        },
        {
          "term": "reporting period",
          "heading": false
        },
        {
          "term": "time",
          "heading": true
        },
        {
          "term": "indicators",
          "heading": false
        },
        {
          "term": "months",
          "heading": false
        },
        {
          "term": "track",
          "heading": false
        }
      ],
      "extract": "In general, the priority indicators use an unspecified reporting period. They can be calculated over different periods of time to answer programme management questions at different levels and as required for differing reporting purposes. Some indicators have specific reporting periods (for example, “in the last 12 months”) that are important because they reflect recommended service delivery guidelines or the way",
      "extractCut": true
    },
    {
      "id": "sec-182-813-inclusion-of-community-based-service-data",
      "number": "8.1.3",
      "title": "Inclusion of community-based service data",
      "level": 3,
      "pageStart": 320,
      "pageEnd": 321,
      "labelStart": "290",
      "labelEnd": "291",
      "words": 108,
      "summary": {
        "text": "Stresses that monitoring systems should capture community-based service data and avoid double counting people referred between community and facility services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "community-based",
          "heading": true
        },
        {
          "term": "community-based services",
          "heading": false
        },
        {
          "term": "data systems",
          "heading": false
        },
        {
          "term": "facility-based",
          "heading": false
        }
      ],
      "extract": "Although a majority of routine health information systems are based at health facilities, effective programme monitoring and programme management also require data from health services delivered in community-based settings. Increasingly, data systems must be able to capture and integrate data on the delivery of community-based services, delivered via mobile or satellite clinics and often by peer or outreach workers.",
      "extractCut": true
    },
    {
      "id": "sec-183-82-priority-indicators-by-programme-area",
      "number": "8.2",
      "title": "Priority indicators by programme area",
      "level": 2,
      "pageStart": 321,
      "pageEnd": 321,
      "labelStart": "291",
      "labelEnd": "291",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-184-821-hiv-prevention",
      "number": "8.2.1",
      "title": "HIV prevention",
      "level": 3,
      "pageStart": 321,
      "pageEnd": 343,
      "labelStart": "291",
      "labelEnd": "313",
      "words": 5428,
      "summary": {
        "text": "Sets out the priority indicators for HIV prevention, each with what it measures, rationale, numerator, denominator, measurement method and disaggregation. It opens with condoms distributed and people receiving pre-exposure prophylaxis, and covers the range of prevention services. It ends with indicators on condom use at last sex for the general population and key populations, with notes on survey sources and adapting recall periods to local context.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "oamt recipients",
          "heading": false
        },
        {
          "term": "prescribed pep",
          "heading": false
        },
        {
          "term": "drop-in centres",
          "heading": false
        },
        {
          "term": "non-regular male",
          "heading": false
        },
        {
          "term": "prep prescribed",
          "heading": false
        },
        {
          "term": "oamt during",
          "heading": false
        },
        {
          "term": "inject drugs",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": true
        }
      ],
      "extract": "PRV.1 Condoms distributed Total number of condoms distributed during the reporting period What it measures This indicator measures the number of condoms distributed through different modalities. Rationale • Proactive distribution of condoms is a strategy for ensuring adequate availability. • By analysing the proportion of condoms distributed through different modalities, national programmes can optimize their",
      "extractCut": true
    },
    {
      "id": "sec-185-822-hiv-testing-services",
      "number": "8.2.2",
      "title": "HIV testing services",
      "level": 3,
      "pageStart": 343,
      "pageEnd": 355,
      "labelStart": "313",
      "labelEnd": "325",
      "words": 3604,
      "summary": {
        "text": "Sets out the priority indicators for HIV testing services, starting with the number and percentage of people living with HIV who know their status (the first 95). It explains how to estimate this from case surveillance or models and how to deduplicate records. Further indicators cover testing services and yield. It ends with a new indicator on HIV retesting coverage among key populations, measured through survey questions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv testing",
          "heading": true
        },
        {
          "term": "testing services",
          "heading": true
        },
        {
          "term": "gender diverse",
          "heading": false
        },
        {
          "term": "received hts",
          "heading": false
        },
        {
          "term": "diverse people",
          "heading": false
        },
        {
          "term": "hivst kits",
          "heading": false
        },
        {
          "term": "disaggregation gender",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        }
      ],
      "extract": "HTS.1 People living with HIV who know their HIV status (first 95) Number and % of people living with HIV who know their HIV status What it measures This measures the number and percentage of people living with HIV who have been tested and know their HIV status. Rationale • Knowledge of HIV status is the entry point for people living with HIV to treatment and the continuum of care, and for those who test HIV-negative",
      "extractCut": true
    },
    {
      "id": "sec-186-823-hiv-treatment",
      "number": "8.2.3",
      "title": "HIV treatment",
      "level": 3,
      "pageStart": 355,
      "pageEnd": 374,
      "labelStart": "325",
      "labelEnd": "344",
      "words": 5692,
      "summary": {
        "text": "Sets out the priority indicators for HIV treatment, starting with the number and percentage of people living with HIV on antiretroviral therapy, linked to the second 95 target. It explains how to calculate the numerator accounting for attrition and which denominators to use. Further indicators cover treatment outcomes and vertical transmission. It ends with HIV prevalence among antenatal clinic attendees and the conditions under which these data can be used for surveillance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "art registers",
          "heading": false
        },
        {
          "term": "anc attendees",
          "heading": false
        },
        {
          "term": "hiv-exposed infants",
          "heading": false
        },
        {
          "term": "population-based denominator",
          "heading": false
        },
        {
          "term": "art during",
          "heading": false
        },
        {
          "term": "initiated art",
          "heading": false
        },
        {
          "term": "hiv-exposed breastfeeding",
          "heading": false
        },
        {
          "term": "anc visit",
          "heading": false
        }
      ],
      "extract": "ART.1 People living with HIV on ART Number and % of people on ART among all people living with HIV at the end of the reporting period What it measures Measures progress towards providing ART to all people living with HIV, that is, treatment coverage, taking into account total attrition during the reporting period. Rationale • WHO currently recommends treatment for all people living with HIV to achieve viral",
      "extractCut": true
    },
    {
      "id": "sec-187-824-tbhiv",
      "number": "8.2.4",
      "title": "TB/HIV",
      "level": 3,
      "pageStart": 374,
      "pageEnd": 383,
      "labelStart": "344",
      "labelEnd": "353",
      "words": 2694,
      "summary": {
        "text": "Sets out the priority indicators for TB/HIV, starting with initiation of TB preventive treatment among eligible people on ART and a formula for calculating eligibility. Disaggregation by gender, age and regimen is specified. The indicators follow a screening cascade for high-burden settings. They end with the share of people newly started on ART and diagnosed with active TB who began TB treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "initiated tpt",
          "heading": false
        },
        {
          "term": "initiated art",
          "heading": false
        },
        {
          "term": "art registers",
          "heading": false
        },
        {
          "term": "tpt completion",
          "heading": false
        },
        {
          "term": "tpt during",
          "heading": false
        },
        {
          "term": "art enrolment",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "tpt regimen",
          "heading": false
        }
      ],
      "extract": "TBH.1 TPT initiation Number and % of eligible people living with HIV on ART who initiated TB preventive treatment What it measures This indicator measures the extent to which people on ART initiated treatment for latent TB infection. Rationale • TB preventive treatment (TPT) is a critical component of preventing TB-related morbidity and mortality among people living with HIV. • In the wake of recent high-level",
      "extractCut": true
    },
    {
      "id": "sec-188-825-differentiated-service-delivery",
      "number": "8.2.5",
      "title": "Differentiated service delivery",
      "level": 3,
      "pageStart": 383,
      "pageEnd": 389,
      "labelStart": "353",
      "labelEnd": "359",
      "words": 2034,
      "summary": {
        "text": "Sets out the priority indicators for differentiated service delivery, starting with a new indicator on multi-month dispensing of antiretroviral medicines and its rationale for adherence and system efficiency. It explains numerators by months of supply dispensed. It ends with viral load suppression among people enrolled in differentiated ART models, monitored where electronic systems exist.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dsd art",
          "heading": false
        },
        {
          "term": "dsd models",
          "heading": false
        },
        {
          "term": "multi-month dispensing",
          "heading": false
        },
        {
          "term": "multi-month arv",
          "heading": false
        },
        {
          "term": "receiving multi-month",
          "heading": false
        },
        {
          "term": "people enrolled",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "gender diverse",
          "heading": false
        }
      ],
      "extract": "DSD.1 Multi-month ARV dispensing (NEW) % of people living with HIV and currently on ART who are receiving multi-month dispensing of ARV medicine during the reporting period What it measures Percentage of all people living with HIV and currently on ART who received a multi-month supply of ARV medicine (as specified below) at their most recent ARV medicine pick-up. Rationale • The recommendation for people living with",
      "extractCut": true
    },
    {
      "id": "sec-189-826-sexually-transmitted-infections",
      "number": "8.2.6",
      "title": "Sexually transmitted infections",
      "level": 3,
      "pageStart": 389,
      "pageEnd": 403,
      "labelStart": "359",
      "labelEnd": "373",
      "words": 3245,
      "summary": {
        "text": "Sets out the priority indicators for sexually transmitted infections, starting with a new indicator on syphilis testing coverage among people using HIV prevention services, people living with HIV and pregnant women. Each indicator gives rationale, numerator, denominator, measurement and disaggregation. Further indicators cover STI diagnosis and treatment. The section ends with repeat diagnoses of the same STI syndrome, which may signal inadequate treatment or an untreated partner.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gonorrhoea during",
          "heading": false
        },
        {
          "term": "people attending",
          "heading": false
        },
        {
          "term": "sti syndrome",
          "heading": false
        },
        {
          "term": "gonorrhoea test",
          "heading": false
        },
        {
          "term": "discharge syndrome",
          "heading": false
        },
        {
          "term": "syphilis positivity",
          "heading": false
        },
        {
          "term": "attending hiv",
          "heading": false
        },
        {
          "term": "people tested",
          "heading": false
        }
      ],
      "extract": "STI.1. Syphilis testing coverage (NEW) % of people tested for syphilis during the reporting period What it measures A: \u0007% of people attending HIV prevention services who were tested for syphilis during the reporting period B: \u0007% of people living with HIV who were tested for syphilis during the reporting period C: % of pregnant women who were tested for syphilis during the reporting period Rationale • Measuring the",
      "extractCut": true
    },
    {
      "id": "sec-190-827-viral-hepatitis",
      "number": "8.2.7",
      "title": "Viral hepatitis",
      "level": 3,
      "pageStart": 403,
      "pageEnd": 412,
      "labelStart": "373",
      "labelEnd": "382",
      "words": 2388,
      "summary": {
        "text": "Defines new viral hepatitis indicators for HIV strategic information, starting with hepatitis B surface antigen testing coverage among people using HIV prevention services, people living with HIV and pregnant women. For each indicator it sets out what is measured, the rationale, numerator, denominator, measurement method and disaggregation. Further indicators cover hepatitis B and C treatment and outcomes, such as people with HIV cured of hepatitis C, with disaggregation by medicine type and region. Footnotes clarify gender categories and data confidentiality considerations for key populations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hcv rna",
          "heading": false
        },
        {
          "term": "hcv co-infection",
          "heading": false
        },
        {
          "term": "hcv during",
          "heading": false
        },
        {
          "term": "hcv antibody",
          "heading": false
        },
        {
          "term": "hcv test",
          "heading": false
        },
        {
          "term": "hcv treatment",
          "heading": false
        },
        {
          "term": "hcv core",
          "heading": false
        },
        {
          "term": "hcv infection",
          "heading": false
        }
      ],
      "extract": "HEP.1. HBV test coverage (NEW) % of people who were tested for hepatitis B surface antigen (HBsAg) during the reporting period (laboratory-based test or rapid test) What it measures A: \u0007% of people attending HIV prevention services who were tested for HBsAg during the reporting period (laboratory-based test or rapid test) B: \u0007% of people living with HIV who were tested for HBsAg during the reporting period",
      "extractCut": true
    },
    {
      "id": "sec-191-828-cervical-cancer",
      "number": "8.2.8",
      "title": "Cervical cancer",
      "level": 3,
      "pageStart": 412,
      "pageEnd": 416,
      "labelStart": "382",
      "labelEnd": "386",
      "words": 949,
      "summary": {
        "text": "Defines new cervical cancer indicators for women living with HIV, including the number screened with any test, with guidance on counting each woman once and using facility registers. Further indicators address follow-up and treatment of screen-positive women and survival 12 months after a cervical cancer diagnosis, disaggregated by age, stage and area. The section ends by introducing a cervical cancer survival indicator.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": true
        },
        {
          "term": "invasive cervical",
          "heading": false
        },
        {
          "term": "pre-invasive cervical",
          "heading": false
        },
        {
          "term": "cancer treatment",
          "heading": false
        },
        {
          "term": "cancer survival",
          "heading": false
        },
        {
          "term": "women living",
          "heading": false
        },
        {
          "term": "cervical disease",
          "heading": false
        },
        {
          "term": "cancer among",
          "heading": false
        }
      ],
      "extract": "CCA.1 Cervical cancer screening (NEW) Number of women living with HIV who were screened for cervical cancer using any screening test What it measures Progress towards scaling up population-based screening for the prevention of cervical cancer among women living with HIV. Rationale To measure progress towards scaling up screening for the prevention of cervical cancer among women living with HIV. Since the screening",
      "extractCut": true
    },
    {
      "id": "sec-192-829-hiv-incidence",
      "number": "8.2.9",
      "title": "HIV incidence",
      "level": 3,
      "pageStart": 416,
      "pageEnd": 417,
      "labelStart": "386",
      "labelEnd": "387",
      "words": 290,
      "summary": {
        "text": "Defines the HIV incidence indicator as new infections per 1000 uninfected people, with its rationale, measurement through programme data or modelling tools such as Spectrum, and disaggregation by gender, age and route of transmission.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv incidence",
          "heading": true
        },
        {
          "term": "uninfected population",
          "heading": false
        },
        {
          "term": "hiv aids",
          "heading": false
        },
        {
          "term": "sex",
          "heading": false
        },
        {
          "term": "men",
          "heading": false
        },
        {
          "term": "people",
          "heading": false
        },
        {
          "term": "trans",
          "heading": false
        },
        {
          "term": "infected",
          "heading": false
        }
      ],
      "extract": "INC.1 HIV incidence Estimated number of people newly infected with HIV per 1000 uninfected population What it measures This indicator measures progress towards ending the HIV/AIDS epidemic and achieving the goal of “zero new infections”. Rationale The overarching goal of the global HIV/AIDS response is to reduce the number of people newly infected to fewer than 200 000 by 2030. Numerator Number of people newly",
      "extractCut": true
    },
    {
      "id": "sec-193-8210-aids-related-mortality",
      "number": "8.2.10",
      "title": "AIDS-related mortality",
      "level": 3,
      "pageStart": 417,
      "pageEnd": 418,
      "labelStart": "387",
      "labelEnd": "388",
      "words": 229,
      "summary": {
        "text": "Defines the AIDS mortality indicator as AIDS-related deaths per 100,000 population, explaining its purpose, data sources such as vital registration or modelling, and disaggregation by gender, age and key population.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "aids-related",
          "heading": true
        },
        {
          "term": "aids-related causes",
          "heading": false
        },
        {
          "term": "diverse people",
          "heading": false
        },
        {
          "term": "gender diverse",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "trans",
          "heading": false
        },
        {
          "term": "female",
          "heading": false
        },
        {
          "term": "male",
          "heading": false
        }
      ],
      "extract": "MOR.1 AIDS mortality Total number of people who have died from AIDS-related causes per 100 000 population What it measures This indicator measures the impact of HIV prevention, care and treatment programmes. Rationale In the era of “Treat All”, effective diagnosis and treatment of people living with HIV should greatly reduce deaths due to AIDS-related causes. Numerator Estimated number of people dying from",
      "extractCut": true
    },
    {
      "id": "sec-194-8211-stigma-and-discrimination",
      "number": "8.2.11",
      "title": "Stigma and discrimination",
      "level": 3,
      "pageStart": 418,
      "pageEnd": 424,
      "labelStart": "388",
      "labelEnd": "394",
      "words": 570,
      "summary": {
        "text": "Defines indicators on avoidance of health care because of stigma and discrimination among key populations and among people living with HIV, using survey questions about avoiding testing, care or treatment. It gives numerator, denominator, data sources such as the Stigma Index, and disaggregation, and ends with WHO contact details and the ISBN.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "discrimination",
          "heading": true
        },
        {
          "term": "stigma",
          "heading": true
        },
        {
          "term": "perceived discrimination",
          "heading": false
        },
        {
          "term": "experience discrimination",
          "heading": false
        },
        {
          "term": "respondents living",
          "heading": false
        },
        {
          "term": "reduce discrimination",
          "heading": false
        },
        {
          "term": "survey respondents",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        }
      ],
      "extract": "SDC.1 Avoidance of health care due to stigma and discrimination (key populations) % of key population members who avoid health care because of stigma and discrimination. What it measures This indicator measures the extent to which perceived stigma and discrimination in health care settings results in members of key populations avoiding health care. Rationale • Health care settings are one of the most common places",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 14,
        "items": [
          "8 – Priority indicators\b",
          "9 Operational and service delivery manual for HIV prevention, care and treatment,",
          "11 EpiC decentralized drug distribution mobile application: overview and technical architecture guide (FHI360)",
          "3 Data security, confidentiality1 and policies",
          "4 Physical, human and financial resources",
          "6 Collate risks and benefits",
          "7.5 Health facility assessments",
          "7.6 Civil registration and vital statistics",
          "7.7 Population-based survey data",
          "7.8 Mathematical modelling",
          "7.9 Data quality review, triangulation and use",
          "7.10 Evaluation and operational research",
          "8 – PRIORITY INDICATORS",
          "8.2 Priority indicators by programme area"
        ]
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [
      "table 4.1",
      "table 4.2",
      "table 4.4",
      "table 4.5"
    ],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "hiv data",
      "heading": true
    },
    {
      "term": "hiv treatment",
      "heading": true
    },
    {
      "term": "hiv monitoring",
      "heading": true
    },
    {
      "term": "hiv services",
      "heading": true
    },
    {
      "term": "care hiv",
      "heading": true
    },
    {
      "term": "art data",
      "heading": true
    },
    {
      "term": "hiv health",
      "heading": true
    },
    {
      "term": "key hiv",
      "heading": true
    },
    {
      "term": "hiv patient",
      "heading": true
    },
    {
      "term": "hiv systems",
      "heading": true
    },
    {
      "term": "hiv indicators",
      "heading": true
    },
    {
      "term": "hiv testing",
      "heading": true
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "C1",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "C2",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 11,
      "label": "ix",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "x",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 13,
      "label": "xi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 14,
      "label": "xii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "xiii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 16,
      "label": "xiv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "xv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "xvi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 19,
      "label": "xvii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 20,
      "label": "xviii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "xix",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 22,
      "label": "xx",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 23,
      "label": "xxi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "xxii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 25,
      "label": "xxiii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 26,
      "label": "xxiv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "xxv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 28,
      "label": "xxvi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "xxvii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "xxviii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 31,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 32,
      "label": "2",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 33,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "4",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 36,
      "label": "6",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 37,
      "label": "7",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 38,
      "label": "8",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "10",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 41,
      "label": "11",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 42,
      "label": "12",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 43,
      "label": "13",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 44,
      "label": "14",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 45,
      "label": "15",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 46,
      "label": "16",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 47,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 48,
      "label": "18",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 49,
      "label": "19",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 50,
      "label": "20",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 51,
      "label": "21",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 52,
      "label": "22",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 53,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 54,
      "label": "24",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 55,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 56,
      "label": "26",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 57,
      "label": "27",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 58,
      "label": "28",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 59,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 60,
      "label": "30",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 61,
      "label": "31",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 62,
      "label": "32",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 63,
      "label": "33",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 64,
      "label": "34",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 65,
      "label": "35",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 66,
      "label": "36",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 67,
      "label": "37",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 68,
      "label": "38",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 69,
      "label": "39",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 70,
      "label": "40",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 71,
      "label": "41",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 72,
      "label": "42",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 73,
      "label": "43",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 74,
      "label": "44",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 75,
      "label": "45",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 76,
      "label": "46",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 77,
      "label": "47",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 78,
      "label": "48",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 79,
      "label": "49",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 80,
      "label": "50",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 81,
      "label": "51",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 82,
      "label": "52",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 83,
      "label": "53",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 84,
      "label": "54",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 85,
      "label": "55",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 86,
      "label": "56",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 87,
      "label": "57",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 88,
      "label": "58",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 89,
      "label": "59",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 90,
      "label": "60",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 91,
      "label": "61",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 92,
      "label": "62",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 93,
      "label": "63",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 94,
      "label": "64",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 95,
      "label": "65",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 96,
      "label": "66",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 97,
      "label": "67",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 98,
      "label": "68",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 99,
      "label": "69",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 100,
      "label": "70",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 101,
      "label": "71",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 102,
      "label": "72",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 103,
      "label": "73",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 104,
      "label": "74",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 105,
      "label": "75",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 106,
      "label": "76",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 107,
      "label": "77",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 108,
      "label": "78",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 109,
      "label": "79",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 110,
      "label": "80",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 111,
      "label": "81",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 112,
      "label": "82",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 113,
      "label": "83",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 114,
      "label": "84",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 115,
      "label": "85",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 116,
      "label": "86",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 117,
      "label": "87",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 118,
      "label": "88",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 119,
      "label": "89",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 120,
      "label": "90",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 121,
      "label": "91",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 122,
      "label": "92",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 123,
      "label": "93",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 124,
      "label": "94",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 125,
      "label": "95",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 126,
      "label": "96",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 127,
      "label": "97",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 128,
      "label": "98",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 129,
      "label": "99",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 130,
      "label": "100",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 131,
      "label": "101",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 132,
      "label": "102",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 133,
      "label": "103",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 134,
      "label": "104",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 135,
      "label": "105",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 136,
      "label": "106",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 137,
      "label": "107",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 138,
      "label": "108",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 139,
      "label": "109",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 140,
      "label": "110",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 141,
      "label": "111",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 142,
      "label": "112",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 143,
      "label": "113",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 144,
      "label": "114",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 145,
      "label": "115",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 146,
      "label": "116",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 147,
      "label": "117",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 148,
      "label": "118",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 149,
      "label": "119",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 150,
      "label": "120",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 151,
      "label": "121",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 152,
      "label": "122",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 153,
      "label": "123",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 154,
      "label": "124",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 155,
      "label": "125",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 156,
      "label": "126",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 157,
      "label": "127",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 158,
      "label": "128",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 159,
      "label": "129",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 160,
      "label": "130",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 161,
      "label": "131",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 162,
      "label": "132",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 163,
      "label": "133",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 164,
      "label": "134",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 165,
      "label": "135",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 166,
      "label": "136",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 167,
      "label": "137",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 168,
      "label": "138",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 169,
      "label": "139",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 170,
      "label": "140",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 171,
      "label": "141",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 172,
      "label": "142",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 173,
      "label": "143",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 174,
      "label": "144",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 175,
      "label": "145",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 176,
      "label": "146",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 177,
      "label": "147",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 178,
      "label": "148",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 179,
      "label": "149",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 180,
      "label": "150",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 181,
      "label": "151",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 182,
      "label": "152",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 183,
      "label": "153",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 184,
      "label": "154",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 185,
      "label": "155",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 186,
      "label": "156",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 187,
      "label": "157",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 188,
      "label": "158",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 189,
      "label": "159",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 190,
      "label": "160",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 191,
      "label": "161",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 192,
      "label": "162",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 193,
      "label": "163",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 194,
      "label": "164",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 195,
      "label": "165",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 196,
      "label": "166",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 197,
      "label": "167",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 198,
      "label": "168",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 199,
      "label": "169",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 200,
      "label": "170",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 201,
      "label": "171",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 202,
      "label": "172",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 203,
      "label": "173",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 204,
      "label": "174",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 205,
      "label": "175",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 206,
      "label": "176",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 207,
      "label": "177",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 208,
      "label": "178",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 209,
      "label": "179",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 210,
      "label": "180",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 211,
      "label": "181",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 212,
      "label": "182",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 213,
      "label": "183",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 214,
      "label": "184",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 215,
      "label": "185",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 216,
      "label": "186",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 217,
      "label": "187",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 218,
      "label": "188",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 219,
      "label": "189",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 220,
      "label": "190",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 221,
      "label": "191",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 222,
      "label": "192",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 223,
      "label": "193",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 224,
      "label": "194",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 225,
      "label": "195",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 226,
      "label": "196",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 227,
      "label": "197",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 228,
      "label": "198",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 229,
      "label": "199",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 230,
      "label": "200",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 231,
      "label": "201",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 232,
      "label": "202",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 233,
      "label": "203",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 234,
      "label": "204",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 235,
      "label": "205",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 236,
      "label": "206",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 237,
      "label": "207",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 238,
      "label": "208",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 239,
      "label": "209",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 240,
      "label": "210",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 241,
      "label": "211",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 242,
      "label": "212",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 243,
      "label": "213",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 244,
      "label": "214",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 245,
      "label": "215",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 246,
      "label": "216",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 247,
      "label": "217",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 248,
      "label": "218",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 249,
      "label": "219",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 250,
      "label": "220",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 251,
      "label": "221",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 252,
      "label": "222",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 253,
      "label": "223",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 254,
      "label": "224",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 255,
      "label": "225",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 256,
      "label": "226",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 257,
      "label": "227",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 258,
      "label": "228",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 259,
      "label": "229",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 260,
      "label": "230",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 261,
      "label": "231",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 262,
      "label": "232",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 263,
      "label": "233",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 264,
      "label": "234",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 265,
      "label": "235",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 266,
      "label": "236",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 267,
      "label": "237",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 268,
      "label": "238",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 269,
      "label": "239",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 270,
      "label": "240",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 271,
      "label": "241",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 272,
      "label": "242",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 273,
      "label": "243",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 274,
      "label": "244",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 275,
      "label": "245",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 276,
      "label": "246",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 277,
      "label": "247",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 278,
      "label": "248",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 279,
      "label": "249",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 280,
      "label": "250",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 281,
      "label": "251",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 282,
      "label": "252",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 283,
      "label": "253",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 284,
      "label": "254",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 285,
      "label": "255",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 286,
      "label": "256",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 287,
      "label": "257",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 288,
      "label": "258",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 289,
      "label": "259",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 290,
      "label": "260",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 291,
      "label": "261",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 292,
      "label": "262",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 293,
      "label": "263",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 294,
      "label": "264",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 295,
      "label": "265",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 296,
      "label": "266",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 297,
      "label": "267",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 298,
      "label": "268",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 299,
      "label": "269",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 300,
      "label": "270",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 301,
      "label": "271",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 302,
      "label": "272",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 303,
      "label": "273",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 304,
      "label": "274",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 305,
      "label": "275",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 306,
      "label": "276",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 307,
      "label": "277",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 308,
      "label": "278",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 309,
      "label": "279",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 310,
      "label": "280",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 311,
      "label": "281",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 312,
      "label": "282",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 313,
      "label": "283",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 314,
      "label": "284",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 315,
      "label": "285",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 316,
      "label": "286",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 317,
      "label": "287",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 318,
      "label": "288",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 319,
      "label": "289",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 320,
      "label": "290",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 321,
      "label": "291",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 322,
      "label": "292",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 323,
      "label": "293",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 324,
      "label": "294",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 325,
      "label": "295",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 326,
      "label": "296",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 327,
      "label": "297",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 328,
      "label": "298",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 329,
      "label": "299",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 330,
      "label": "300",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 331,
      "label": "301",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 332,
      "label": "302",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 333,
      "label": "303",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 334,
      "label": "304",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 335,
      "label": "305",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 336,
      "label": "306",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 337,
      "label": "307",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 338,
      "label": "308",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 339,
      "label": "309",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 340,
      "label": "310",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 341,
      "label": "311",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 342,
      "label": "312",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 343,
      "label": "313",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 344,
      "label": "314",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 345,
      "label": "315",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 346,
      "label": "316",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 347,
      "label": "317",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 348,
      "label": "318",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 349,
      "label": "319",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 350,
      "label": "320",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 351,
      "label": "321",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 352,
      "label": "322",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 353,
      "label": "323",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 354,
      "label": "324",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 355,
      "label": "325",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 356,
      "label": "326",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 357,
      "label": "327",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 358,
      "label": "328",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 359,
      "label": "329",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 360,
      "label": "330",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 361,
      "label": "331",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 362,
      "label": "332",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 363,
      "label": "333",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 364,
      "label": "334",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 365,
      "label": "335",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 366,
      "label": "336",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 367,
      "label": "337",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 368,
      "label": "338",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 369,
      "label": "339",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 370,
      "label": "340",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 371,
      "label": "341",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 372,
      "label": "342",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 373,
      "label": "343",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 374,
      "label": "344",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 375,
      "label": "345",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 376,
      "label": "346",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 377,
      "label": "347",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 378,
      "label": "348",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 379,
      "label": "349",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 380,
      "label": "350",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 381,
      "label": "351",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 382,
      "label": "352",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 383,
      "label": "353",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 384,
      "label": "354",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 385,
      "label": "355",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 386,
      "label": "356",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 387,
      "label": "357",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 388,
      "label": "358",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 389,
      "label": "359",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 390,
      "label": "360",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 391,
      "label": "361",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 392,
      "label": "362",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 393,
      "label": "363",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 394,
      "label": "364",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 395,
      "label": "365",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 396,
      "label": "366",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 397,
      "label": "367",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 398,
      "label": "368",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 399,
      "label": "369",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 400,
      "label": "370",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 401,
      "label": "371",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 402,
      "label": "372",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 403,
      "label": "373",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 404,
      "label": "374",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 405,
      "label": "375",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 406,
      "label": "376",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 407,
      "label": "377",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 408,
      "label": "378",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 409,
      "label": "379",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 410,
      "label": "380",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 411,
      "label": "381",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 412,
      "label": "382",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 413,
      "label": "383",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 414,
      "label": "384",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 415,
      "label": "385",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 416,
      "label": "386",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 417,
      "label": "387",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 418,
      "label": "388",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 419,
      "label": "389",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 420,
      "label": "390",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 421,
      "label": "391",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 422,
      "label": "392",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 423,
      "label": "393",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 424,
      "label": "394",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "table",
      "number": "4.3",
      "title": "Recommended minimum dataset for viral hepatitis",
      "page": 204,
      "pageLabel": "174",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "table",
      "number": "4.6",
      "title": "Priority indicators for cervical cancer screening and",
      "page": 211,
      "pageLabel": "181",
      "confidence": 0.7,
      "evidence": [
        "referenced"
      ]
    },
    {
      "kind": "figure",
      "number": "6.1",
      "title": "shows a PALMS dashboard presenting HIV rates among those diagnosed",
      "page": 261,
      "pageLabel": "231",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    }
  ],
  "images": [
    {
      "id": "vfig-p034",
      "file": "figures/vfig-p034.webp",
      "page": 34,
      "shows": [
        "Fig. 1.1"
      ],
      "narratives": {
        "en": "Fig. 1.1, a concentric circle diagram titled 'Harnessing person-centred data to improve HIV services and impact'. A human figure at the centre is surrounded by a ring labelled HIV prevention, HIV treatment and Related infections; the next ring lists Monitor impact, Improve quality of services, Identify HIV testing, prevention & treatment needs, Improve integration, and Ensure data privacy, confidentiality, & security. The outer ring reads 'Improved health' at the top and 'Individual-level data' at the bottom.",
        "ar": "الشكل 1.1، مخطط دوائر متحدة المركز بعنوان \"تسخير البيانات المتمحورة حول الشخص لتحسين خدمات فيروس العوز المناعي البشري وأثرها\". يحيط بشكل بشري في المركز حلقة تحمل عناوين الوقاية من فيروس العوز المناعي البشري، وعلاج فيروس العوز المناعي البشري، والعداوى ذات الصلة؛ وتضم الحلقة التالية: رصد الأثر، وتحسين جودة الخدمات، وتحديد احتياجات اختبار فيروس العوز المناعي البشري والوقاية منه وعلاجه، وتحسين التكامل، وضمان خصوصية البيانات وسريتها وأمنها. وتحمل الحلقة الخارجية عبارة \"تحسين الصحة\" في الأعلى و\"البيانات على المستوى الفردي\" في الأسفل.",
        "zh": "图1.1，题为\"利用以人为本的数据改善艾滋病毒服务和影响\"的同心圆示意图。中心为一个人形图标，周围一圈标注艾滋病毒预防、艾滋病毒治疗和相关感染；下一圈列出监测影响、提高服务质量、确定艾滋病毒检测、预防和治疗需求、改进整合，以及确保数据隐私、保密和安全。最外圈上方为\"改善健康\"，下方为\"个人层面数据\"。",
        "es": "Fig. 1.1, diagrama de círculos concéntricos titulado «Aprovechar los datos centrados en la persona para mejorar los servicios relacionados con el VIH y su impacto». Una figura humana en el centro está rodeada por un anillo con las etiquetas Prevención del VIH, Tratamiento del VIH e Infecciones relacionadas; el siguiente anillo enumera Vigilar el impacto, Mejorar la calidad de los servicios, Determinar las necesidades de pruebas, prevención y tratamiento del VIH, Mejorar la integración y Garantizar la privacidad, confidencialidad y seguridad de los datos. El anillo exterior dice «Mejora de la salud» en la parte superior y «Datos a nivel individual» en la inferior.",
        "fr": "Fig. 1.1, diagramme en cercles concentriques intitulé « Exploiter les données centrées sur la personne pour améliorer les services liés au VIH et leur impact ». Une silhouette humaine au centre est entourée d'un anneau portant les mentions Prévention du VIH, Traitement du VIH et Infections associées ; l'anneau suivant énumère Suivre l'impact, Améliorer la qualité des services, Identifier les besoins en dépistage, prévention et traitement du VIH, Améliorer l'intégration, et Garantir la confidentialité, le secret et la sécurité des données. L'anneau extérieur indique « Amélioration de la santé » en haut et « Données individuelles » en bas.",
        "ru": "Рис. 1.1 — диаграмма из концентрических кругов под названием «Использование персонализированных данных для улучшения услуг в связи с ВИЧ и их результативности». В центре — фигура человека, окружённая кольцом с надписями «Профилактика ВИЧ», «Лечение ВИЧ» и «Сопутствующие инфекции»; следующее кольцо содержит пункты «Мониторинг результатов», «Повышение качества услуг», «Выявление потребностей в тестировании, профилактике и лечении ВИЧ», «Улучшение интеграции» и «Обеспечение конфиденциальности, неприкосновенности и безопасности данных». Внешнее кольцо подписано «Улучшение здоровья» сверху и «Данные на индивидуальном уровне» снизу."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p038",
      "file": "figures/vfig-p038.webp",
      "page": 38,
      "shows": [
        "Fig. 1.2"
      ],
      "narratives": {
        "en": "Fig. 1.2, a block diagram of an integrated data system architecture. A central 'Routine health service data' box shows service sources (HIV prevention, testing, treatment services; STI, TB, hepatitis, cervical cancer services; laboratory; private sector health services; HIV case surveillance; community-based or outreach services; drug and logistics management; civil registration & vital statistics) feeding a minimum dataset, which feeds priority indicators based on individual-level data. These, together with 'Other data sources' (population-based survey statistics, modelled estimates, epidemiologic studies and research, community-led monitoring), flow to 'Data use for programme monitoring & management', which loops to 'Improved health services' and back to the routine data.",
        "ar": "الشكل 1.2، مخطط كتلي لبنية نظام بيانات متكامل. يعرض مربع مركزي بعنوان \"بيانات الخدمات الصحية الروتينية\" مصادر الخدمات (خدمات الوقاية من فيروس العوز المناعي البشري واختباره وعلاجه؛ وخدمات العداوى المنقولة جنسياً والسل والتهاب الكبد وسرطان عنق الرحم؛ والمختبر؛ والخدمات الصحية للقطاع الخاص؛ وترصد حالات فيروس العوز المناعي البشري؛ والخدمات المجتمعية أو خدمات التوعية؛ وإدارة الأدوية واللوجستيات؛ والتسجيل المدني والإحصاءات الحيوية) التي تغذي الحد الأدنى من مجموعة البيانات، والتي تغذي بدورها المؤشرات ذات الأولوية القائمة على البيانات الفردية. وتتدفق هذه، مع \"مصادر البيانات الأخرى\" (إحصاءات المسوح السكانية، والتقديرات المستندة إلى النماذج، والدراسات الوبائية والبحوث، والرصد بقيادة المجتمع)، إلى \"استخدام البيانات لرصد البرامج وإدارتها\"، الذي يؤدي إلى \"تحسين الخدمات الصحية\" ثم يعود إلى البيانات الروتينية.",
        "zh": "图1.2，综合数据系统架构框图。中央的\"常规卫生服务数据\"框列出各服务来源（艾滋病毒预防、检测和治疗服务；性传播感染、结核病、肝炎和宫颈癌服务；实验室；私营部门卫生服务；艾滋病毒病例监测；社区或外展服务；药品和物流管理；民事登记和人口动态统计），这些来源汇入最低数据集，再形成基于个人层面数据的优先指标。这些指标与\"其他数据来源\"（基于人群的调查统计、模型估计、流行病学研究和科研、社区主导的监测）一起流向\"用于规划监测和管理的数据使用\"，后者通向\"改善卫生服务\"并回到常规数据。",
        "es": "Fig. 1.2, diagrama de bloques de una arquitectura de sistema de datos integrado. Un recuadro central de «Datos de servicios de salud rutinarios» muestra las fuentes de servicios (servicios de prevención, pruebas y tratamiento del VIH; servicios de ITS, TB, hepatitis y cáncer cervicouterino; laboratorio; servicios de salud del sector privado; vigilancia de casos de VIH; servicios comunitarios o de extensión; gestión de medicamentos y logística; registro civil y estadísticas vitales) que alimentan un conjunto mínimo de datos, el cual alimenta los indicadores prioritarios basados en datos a nivel individual. Estos, junto con «Otras fuentes de datos» (estadísticas de encuestas poblacionales, estimaciones modelizadas, estudios epidemiológicos e investigación, y monitoreo dirigido por la comunidad), confluyen en «Uso de datos para el seguimiento y la gestión de programas», que conduce a «Mejores servicios de salud» y vuelve a los datos rutinarios.",
        "fr": "Fig. 1.2, schéma fonctionnel d'une architecture de système de données intégré. Un encadré central « Données de routine des services de santé » présente les sources (services de prévention, de dépistage et de traitement du VIH ; services liés aux IST, à la tuberculose, à l'hépatite et au cancer du col de l'utérus ; laboratoire ; services de santé du secteur privé ; surveillance des cas de VIH ; services communautaires ou de proximité ; gestion des médicaments et de la logistique ; enregistrement des faits d'état civil et statistiques de l'état civil) qui alimentent un ensemble minimal de données, lequel alimente les indicateurs prioritaires fondés sur des données individuelles. Ceux-ci, avec les « Autres sources de données » (statistiques d'enquêtes en population, estimations modélisées, études épidémiologiques et recherche, suivi communautaire), aboutissent à « Utilisation des données pour le suivi et la gestion des programmes », qui mène à « Amélioration des services de santé » puis revient aux données de routine.",
        "ru": "Рис. 1.2 — блок-схема архитектуры интегрированной системы данных. Центральный блок «Данные регулярной статистики медицинских услуг» включает источники (услуги по профилактике, тестированию и лечению ВИЧ; услуги в связи с ИППП, ТБ, гепатитом и раком шейки матки; лаборатория; медицинские услуги частного сектора; эпиднадзор за случаями ВИЧ; услуги на уровне сообществ или выездные услуги; управление лекарственными средствами и логистикой; регистрация актов гражданского состояния и статистика естественного движения населения), которые формируют минимальный набор данных, а он, в свою очередь, — приоритетные показатели на основе данных индивидуального уровня. Вместе с «Другими источниками данных» (статистика популяционных обследований, модельные оценки, эпидемиологические исследования и научные работы, мониторинг силами сообществ) они поступают в блок «Использование данных для мониторинга программ и управления ими», который ведёт к «Улучшению медицинских услуг» и обратно к регулярным данным."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p051",
      "file": "figures/vfig-p051.webp",
      "page": 51,
      "shows": [
        "Fig. 2.1"
      ],
      "narratives": {
        "en": "Fig. 2.1, three donut charts showing the distribution of new HIV infections by population in 2020 for Global, Sub-Saharan Africa and Rest of world. Categories are sex workers, people who inject drugs, men who have sex with men, trans and gender diverse people, clients of sex workers and sex partners of all key populations, and remaining population. The remaining population accounts for 30% globally and 49% in sub-Saharan Africa but 6% in the rest of the world, where men who have sex with men make up 41%. Source: UNAIDS special analysis and epidemiological estimates, 2022.",
        "ar": "الشكل 2.1، ثلاثة مخططات دائرية مجوّفة تبيّن توزيع حالات العدوى الجديدة بفيروس العوز المناعي البشري حسب الفئة السكانية في عام 2020 على الصعيد العالمي، وفي أفريقيا جنوب الصحراء الكبرى، وفي بقية العالم. والفئات هي: المشتغلون بالجنس، ومتعاطو المخدرات بالحقن، والرجال الذين يمارسون الجنس مع الرجال، والأشخاص مغايرو الهوية الجنسانية والمتنوعون جنسانياً، وزبائن المشتغلين بالجنس والشركاء الجنسيون لجميع الفئات السكانية الرئيسية، وبقية السكان. وتمثل بقية السكان 30% على الصعيد العالمي و49% في أفريقيا جنوب الصحراء الكبرى، ولكن 6% فقط في بقية العالم، حيث يشكل الرجال الذين يمارسون الجنس مع الرجال 41%. المصدر: تحليل خاص وتقديرات وبائية لبرنامج الأمم المتحدة المشترك المعني بفيروس العوز المناعي البشري/الإيدز، 2022.",
        "zh": "图2.1，三个环形图，显示2020年全球、撒哈拉以南非洲和世界其他地区按人群划分的新发艾滋病毒感染分布。类别包括性工作者、注射吸毒者、男男性行为者、跨性别和性别多元者、性工作者的客户及所有重点人群的性伴侣，以及其余人群。其余人群在全球占30%，在撒哈拉以南非洲占49%，在世界其他地区仅占6%，而在世界其他地区男男性行为者占41%。来源：联合国艾滋病规划署特别分析和流行病学估计，2022年。",
        "es": "Fig. 2.1, tres gráficos de anillo que muestran la distribución de las nuevas infecciones por el VIH por población en 2020 a nivel mundial, en el África subsahariana y en el resto del mundo. Las categorías son trabajadores sexuales, personas que se inyectan drogas, hombres que tienen relaciones sexuales con hombres, personas trans y de género diverso, clientes de trabajadores sexuales y parejas sexuales de todas las poblaciones clave, y resto de la población. El resto de la población representa el 30% a nivel mundial y el 49% en el África subsahariana, pero el 6% en el resto del mundo, donde los hombres que tienen relaciones sexuales con hombres suponen el 41%. Fuente: análisis especial y estimaciones epidemiológicas de ONUSIDA, 2022.",
        "fr": "Fig. 2.1, trois graphiques en anneau montrant la répartition des nouvelles infections à VIH par population en 2020 au niveau mondial, en Afrique subsaharienne et dans le reste du monde. Les catégories sont les professionnel(le)s du sexe, les personnes qui s'injectent des drogues, les hommes ayant des rapports sexuels avec des hommes, les personnes transgenres et de genre divers, les clients des professionnel(le)s du sexe et partenaires sexuels de toutes les populations clés, et le reste de la population. Le reste de la population représente 30 % au niveau mondial et 49 % en Afrique subsaharienne, mais 6 % dans le reste du monde, où les hommes ayant des rapports sexuels avec des hommes représentent 41 %. Source : analyse spéciale et estimations épidémiologiques de l'ONUSIDA, 2022.",
        "ru": "Рис. 2.1 — три кольцевые диаграммы распределения новых случаев инфицирования ВИЧ по группам населения в 2020 г.: в мире в целом, в Африке к югу от Сахары и в остальном мире. Категории: работники секс-бизнеса, люди, употребляющие инъекционные наркотики, мужчины, практикующие секс с мужчинами, трансгендерные и гендерно разнообразные люди, клиенты работников секс-бизнеса и половые партнёры представителей всех ключевых групп населения, а также остальное население. На остальное население приходится 30% в мире и 49% в Африке к югу от Сахары, но лишь 6% в остальном мире, где 41% составляют мужчины, практикующие секс с мужчинами. Источник: специальный анализ и эпидемиологические оценки ЮНЭЙДС, 2022 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p084",
      "file": "figures/vfig-p084.webp",
      "page": 84,
      "shows": [
        "Fig. 3.1"
      ],
      "narratives": {
        "en": "Fig. 3.1, a chevron diagram of the scope of HIV patient monitoring within the 2022 WHO consolidated HIV strategic information guidelines. Three arrows run in sequence: HIV testing, ART initiation and Viral suppression, above a bar spanning all three labelled 'Linkage to care, retention on ART and integrated chronic care'.",
        "ar": "الشكل 3.1، مخطط على شكل أسهم يبيّن نطاق رصد مرضى فيروس العوز المناعي البشري ضمن المبادئ التوجيهية الموحدة لمنظمة الصحة العالمية لعام 2022 بشأن المعلومات الاستراتيجية الخاصة بفيروس العوز المناعي البشري. تتوالى ثلاثة أسهم: اختبار فيروس العوز المناعي البشري، وبدء العلاج المضاد للفيروسات القهقرية، والكبت الفيروسي، فوق شريط يمتد عبرها جميعاً بعنوان \"الربط بالرعاية، والاستبقاء في العلاج المضاد للفيروسات القهقرية، والرعاية المتكاملة للأمراض المزمنة\".",
        "zh": "图3.1，箭头示意图，显示2022年世卫组织艾滋病毒战略信息综合指南中艾滋病毒患者监测的范围。三个箭头依次为：艾滋病毒检测、启动抗逆转录病毒治疗和病毒抑制，其下方有一条贯穿三者的横条，标注\"与关怀衔接、维持抗逆转录病毒治疗和综合慢性病关怀\"。",
        "es": "Fig. 3.1, diagrama de flechas sobre el alcance del seguimiento de pacientes con VIH en las directrices unificadas de la OMS de 2022 sobre información estratégica relativa al VIH. Tres flechas se suceden: Pruebas del VIH, Inicio del TAR y Supresión viral, sobre una barra que abarca las tres con el texto «Vinculación con la atención, retención en el TAR y atención integrada de enfermedades crónicas».",
        "fr": "Fig. 3.1, diagramme en chevrons du champ du suivi des patients vivant avec le VIH dans les lignes directrices unifiées de l'OMS de 2022 sur l'information stratégique relative au VIH. Trois flèches se suivent : Dépistage du VIH, Mise sous TAR et Suppression virale, au-dessus d'une barre couvrant les trois intitulée « Orientation vers les soins, maintien sous TAR et soins intégrés des maladies chroniques ».",
        "ru": "Рис. 3.1 — диаграмма из стрелок, показывающая охват мониторинга пациентов с ВИЧ в сводном руководстве ВОЗ 2022 г. по стратегической информации в области ВИЧ. Три стрелки идут последовательно: «Тестирование на ВИЧ», «Начало АРТ» и «Вирусная супрессия»; под ними — полоса, охватывающая все три этапа, с надписью «Направление на лечение, удержание на АРТ и комплексная помощь при хронических заболеваниях»."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p087",
      "file": "figures/vfig-p087.webp",
      "page": 87,
      "shows": [
        "Fig. 3.2"
      ],
      "narratives": {
        "en": "Fig. 3.2, a grid overview of the 36 priority, core and differentiated indicators from the HIV patient monitoring system, arranged along the HIV testing, treatment and care cascade (Testing, Linkage to care, ART initiation, Retention in HIV care, VL suppression). Columns list indicator codes such as HTS.1–HTS.6, TBH.1–TBH.4, VER.1–VER.7, ART.1–ART.9 and DSD.1–DSD.5, with the 1st, 2nd and 3rd 95 targets marked at HTS.1, ART.1 and ART.3. A separate lower block lists differentiated priority indicators DFT.1–DFT.5 for high TB–HIV burden countries; shading distinguishes core, priority and differentiated indicators and asterisks mark new 2022 indicators.",
        "ar": "الشكل 3.2، شبكة تعرض لمحة عامة عن المؤشرات الستة والثلاثين ذات الأولوية والأساسية والمتمايزة لنظام رصد مرضى فيروس العوز المناعي البشري، مرتبة على امتداد سلسلة اختبار فيروس العوز المناعي البشري وعلاجه ورعايته (الاختبار، والربط بالرعاية، وبدء العلاج المضاد للفيروسات القهقرية، والاستبقاء في رعاية فيروس العوز المناعي البشري، وكبت الحمل الفيروسي). وتتضمن الأعمدة رموز المؤشرات مثل HTS.1–HTS.6 وTBH.1–TBH.4 وVER.1–VER.7 وART.1–ART.9 وDSD.1–DSD.5، مع تحديد الأهداف 95 الأول والثاني والثالث عند HTS.1 وART.1 وART.3. وتسرد كتلة سفلية منفصلة المؤشرات المتمايزة ذات الأولوية DFT.1–DFT.5 للبلدان ذات العبء المرتفع من السل وفيروس العوز المناعي البشري؛ ويميّز التظليل بين المؤشرات الأساسية وذات الأولوية والمتمايزة، وتشير العلامات النجمية إلى المؤشرات الجديدة لعام 2022.",
        "zh": "图3.2，以网格形式概述艾滋病毒患者监测系统的36项优先、核心和差异化指标，按艾滋病毒检测、治疗和关怀级联（检测、与关怀衔接、启动抗逆转录病毒治疗、维持艾滋病毒关怀、病毒载量抑制）排列。各列列出指标代码，如HTS.1–HTS.6、TBH.1–TBH.4、VER.1–VER.7、ART.1–ART.9和DSD.1–DSD.5，并在HTS.1、ART.1和ART.3处标出第一、第二和第三个\"95\"目标。下方单独一块列出适用于结核病/艾滋病毒高负担国家的差异化优先指标DFT.1–DFT.5；底色区分核心、优先和差异化指标，星号标示2022年新增指标。",
        "es": "Fig. 3.2, cuadrícula que resume los 36 indicadores prioritarios, básicos y diferenciados del sistema de seguimiento de pacientes con VIH, ordenados a lo largo de la cascada de pruebas, tratamiento y atención del VIH (Pruebas, Vinculación con la atención, Inicio del TAR, Retención en la atención del VIH, Supresión de la CV). Las columnas recogen códigos de indicadores como HTS.1–HTS.6, TBH.1–TBH.4, VER.1–VER.7, ART.1–ART.9 y DSD.1–DSD.5, con los objetivos del primer, segundo y tercer 95 señalados en HTS.1, ART.1 y ART.3. Un bloque inferior aparte enumera los indicadores prioritarios diferenciados DFT.1–DFT.5 para países con alta carga de TB/VIH; el sombreado distingue los indicadores básicos, prioritarios y diferenciados, y los asteriscos señalan los indicadores nuevos de 2022.",
        "fr": "Fig. 3.2, grille présentant les 36 indicateurs prioritaires, essentiels et différenciés du système de suivi des patients vivant avec le VIH, disposés le long de la cascade du dépistage, du traitement et des soins du VIH (Dépistage, Orientation vers les soins, Mise sous TAR, Maintien dans les soins du VIH, Suppression de la charge virale). Les colonnes indiquent des codes d'indicateurs tels que HTS.1–HTS.6, TBH.1–TBH.4, VER.1–VER.7, ART.1–ART.9 et DSD.1–DSD.5, les premier, deuxième et troisième objectifs 95 étant signalés à HTS.1, ART.1 et ART.3. Un bloc inférieur distinct énumère les indicateurs prioritaires différenciés DFT.1–DFT.5 pour les pays à forte charge de tuberculose/VIH ; des teintes distinguent les indicateurs essentiels, prioritaires et différenciés, et des astérisques signalent les nouveaux indicateurs de 2022.",
        "ru": "Рис. 3.2 — сетка с обзором 36 приоритетных, основных и дифференцированных показателей системы мониторинга пациентов с ВИЧ, расположенных вдоль каскада тестирования, лечения и помощи в связи с ВИЧ («Тестирование», «Направление на лечение», «Начало АРТ», «Удержание в системе помощи», «Супрессия ВН»). В столбцах приведены коды показателей, например HTS.1–HTS.6, TBH.1–TBH.4, VER.1–VER.7, ART.1–ART.9 и DSD.1–DSD.5; первая, вторая и третья цели «95» отмечены у HTS.1, ART.1 и ART.3. Отдельный нижний блок содержит дифференцированные приоритетные показатели DFT.1–DFT.5 для стран с высоким бременем ТБ/ВИЧ; цветом различаются основные, приоритетные и дифференцированные показатели, а звёздочками отмечены новые показатели 2022 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p105",
      "file": "figures/vfig-p105.webp",
      "page": 105,
      "shows": [
        "Fig. 3.3"
      ],
      "narratives": {
        "en": "Fig. 3.3, a flowchart of the HIV treatment monitoring algorithm. Routine viral load monitoring (result by 6 months after ART initiation, at 12 months and yearly thereafter) branches into undetectable (maintain ARV drug regimen), suppressed (viral load detected and ≤1000 copies/mL) or unsuppressed (>1000 copies/mL; if on an NNRTI-based regimen, switch). Suppressed and unsuppressed results lead to enhanced adherence counselling and a repeat viral load test after 3 months, after which unsuppressed results lead to switching to an appropriate regimen. Source: WHO, 2021.",
        "ar": "الشكل 3.3، مخطط انسيابي لخوارزمية رصد علاج فيروس العوز المناعي البشري. يتفرع الرصد الروتيني للحمل الفيروسي (الحصول على النتيجة بحلول 6 أشهر من بدء العلاج المضاد للفيروسات القهقرية، وعند 12 شهراً، ثم سنوياً) إلى: غير قابل للكشف (الإبقاء على نظام الأدوية المضادة للفيروسات القهقرية)، أو مكبوت (حمل فيروسي مكتشف و≤1000 نسخة/مل)، أو غير مكبوت (>1000 نسخة/مل؛ وإذا كان المريض يتلقى نظاماً قائماً على مثبطات المنتسخة العكسية غير النظيرة للنوكليوزيدات، يُغيَّر النظام). وتؤدي النتائج المكبوتة وغير المكبوتة إلى تعزيز المشورة بشأن الالتزام بالعلاج وتكرار اختبار الحمل الفيروسي بعد 3 أشهر، وبعد ذلك تؤدي النتائج غير المكبوتة إلى التحول إلى نظام علاجي مناسب. المصدر: منظمة الصحة العالمية، 2021.",
        "zh": "图3.3，艾滋病毒治疗监测算法流程图。常规病毒载量监测（在启动抗逆转录病毒治疗后6个月内、12个月时获得结果，此后每年一次）分为：检测不到（维持抗逆转录病毒药物方案）、已抑制（检出病毒载量且≤1000拷贝/毫升）或未抑制（>1000拷贝/毫升；如正在使用基于非核苷类逆转录酶抑制剂的方案，则转换方案）。已抑制和未抑制的结果均需加强依从性咨询，并在3个月后复查病毒载量，此后仍未抑制者转换为适当方案。来源：世卫组织，2021年。",
        "es": "Fig. 3.3, diagrama de flujo del algoritmo de seguimiento del tratamiento del VIH. El monitoreo rutinario de la carga viral (resultado a los 6 meses del inicio del TAR, a los 12 meses y luego anualmente) se divide en indetectable (mantener la pauta de ARV), suprimida (carga viral detectada y ≤1000 copias/ml) o no suprimida (>1000 copias/ml; si recibe una pauta basada en INNTI, cambiar). Los resultados suprimidos y no suprimidos conducen a un refuerzo del asesoramiento sobre la adherencia y a repetir la prueba de carga viral a los 3 meses, tras lo cual los resultados no suprimidos llevan a cambiar a una pauta adecuada. Fuente: OMS, 2021.",
        "fr": "Fig. 3.3, logigramme de l'algorithme de suivi du traitement du VIH. La mesure systématique de la charge virale (résultat à 6 mois après la mise sous TAR, à 12 mois puis chaque année) aboutit à : indétectable (maintenir le schéma ARV), supprimée (charge virale détectée et ≤1000 copies/ml) ou non supprimée (>1000 copies/ml ; en cas de schéma à base d'INNTI, changer). Les résultats supprimés et non supprimés mènent à un soutien renforcé à l'observance et à une nouvelle mesure de la charge virale après 3 mois, après quoi un résultat non supprimé entraîne le passage à un schéma approprié. Source : OMS, 2021.",
        "ru": "Рис. 3.3 — блок-схема алгоритма мониторинга лечения ВИЧ. Плановое определение вирусной нагрузки (результат через 6 месяцев после начала АРТ, через 12 месяцев и далее ежегодно) даёт три варианта: неопределяемая (сохранить схему АРВ-препаратов), подавленная (вирусная нагрузка определяется и ≤1000 копий/мл) или неподавленная (>1000 копий/мл; при схеме на основе ННИОТ — сменить схему). При подавленной и неподавленной нагрузке проводится усиленное консультирование по приверженности и повторный тест на вирусную нагрузку через 3 месяца, после чего при неподавленной нагрузке назначается соответствующая схема. Источник: ВОЗ, 2021 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p107",
      "file": "figures/vfig-p107.webp",
      "page": 107,
      "shows": [
        "Fig. 3.4"
      ],
      "narratives": {
        "en": "Fig. 3.4, a staircase diagram of the cyclical cascade of HIV care. Four stages rise in steps: Stage 1 HIV+ diagnosis / HIV+ re-diagnosis, Stage 2 linked / relinked to HIV care, Stage 3 initiated / reinitiated on ART, Stage 4 early retention (<6 months), leading to long-term retention (>6 months). At each step a dashed arrow marks disengagement (after positive test, after linkage, within 6 months of ART, after 6 months of ART), and a dotted 're-engagement in care' path loops back to the start. Source: Ehrenkranz et al., 2021.",
        "ar": "الشكل 3.4، مخطط على شكل درج يبيّن السلسلة الدورية لرعاية فيروس العوز المناعي البشري. ترتفع أربع مراحل على شكل درجات: المرحلة 1 تشخيص الإصابة بالفيروس/إعادة التشخيص، والمرحلة 2 الربط/إعادة الربط برعاية فيروس العوز المناعي البشري، والمرحلة 3 بدء/إعادة بدء العلاج المضاد للفيروسات القهقرية، والمرحلة 4 الاستبقاء المبكر (<6 أشهر)، وصولاً إلى الاستبقاء الطويل الأمد (>6 أشهر). وعند كل درجة يشير سهم متقطع إلى الانقطاع عن الرعاية (بعد الاختبار الإيجابي، وبعد الربط، وخلال 6 أشهر من العلاج، وبعد 6 أشهر من العلاج)، ويعود مسار منقط بعنوان \"العودة إلى الرعاية\" إلى البداية. المصدر: Ehrenkranz وآخرون، 2021.",
        "zh": "图3.4，阶梯图，显示艾滋病毒关怀的循环级联。四个阶段逐级上升：阶段1艾滋病毒阳性诊断/再诊断，阶段2衔接/重新衔接艾滋病毒关怀，阶段3启动/重新启动抗逆转录病毒治疗，阶段4早期维持（<6个月），最终达到长期维持（>6个月）。每一级都有虚线箭头标示脱离关怀（检测阳性后、衔接后、抗逆转录病毒治疗6个月内、6个月后），一条点线\"重新参与关怀\"路径回到起点。来源：Ehrenkranz等，2021年。",
        "es": "Fig. 3.4, diagrama escalonado de la cascada cíclica de la atención del VIH. Cuatro etapas ascienden en escalones: etapa 1 diagnóstico/nuevo diagnóstico de VIH+, etapa 2 vinculación/revinculación con la atención del VIH, etapa 3 inicio/reinicio del TAR, etapa 4 retención temprana (<6 meses), que conduce a la retención a largo plazo (>6 meses). En cada escalón una flecha discontinua señala la desvinculación (tras la prueba positiva, tras la vinculación, en los 6 primeros meses de TAR, tras 6 meses de TAR) y una trayectoria punteada de «reincorporación a la atención» regresa al inicio. Fuente: Ehrenkranz et al., 2021.",
        "fr": "Fig. 3.4, diagramme en escalier de la cascade cyclique des soins du VIH. Quatre étapes montent par paliers : étape 1 diagnostic/nouveau diagnostic VIH+, étape 2 orientation/réorientation vers les soins du VIH, étape 3 mise/remise sous TAR, étape 4 maintien précoce (<6 mois), menant au maintien à long terme (>6 mois). À chaque palier, une flèche en pointillés indique le désengagement (après un test positif, après l'orientation, dans les 6 mois suivant la mise sous TAR, après 6 mois de TAR), et un trajet pointillé « réengagement dans les soins » revient au point de départ. Source : Ehrenkranz et al., 2021.",
        "ru": "Рис. 3.4 — ступенчатая диаграмма циклического каскада помощи в связи с ВИЧ. Четыре этапа поднимаются ступенями: этап 1 — диагностика/повторная диагностика ВИЧ+, этап 2 — направление/повторное направление на лечение ВИЧ, этап 3 — начало/возобновление АРТ, этап 4 — раннее удержание (<6 месяцев), ведущее к долгосрочному удержанию (>6 месяцев). На каждой ступени пунктирная стрелка обозначает выбывание (после положительного теста, после направления на лечение, в течение 6 месяцев АРТ, после 6 месяцев АРТ), а пунктирный путь «повторное вовлечение в лечение» возвращается к началу. Источник: Ehrenkranz et al., 2021 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p113",
      "file": "figures/vfig-p113.webp",
      "page": 113,
      "shows": [
        "Fig. 3.5"
      ],
      "narratives": {
        "en": "Fig. 3.5, a diagram of longitudinal monitoring of adverse drug reactions and clinical characteristics among people receiving ARV drugs, based on data extraction from electronic medical records. A timeline shows extraction points: first clinical encounter (DTG or new antiretroviral drug initiated), periodic intervals such as 6 months, 12 months, 18 months, and continue periodically. Below, data to be extracted are grouped as weight gain, patient demographic characteristics, medical history and clinical characteristics, comorbidities, risk factors associated with weight gain, and drug exposure. Source: WHO, 2020.",
        "ar": "الشكل 3.5، مخطط للرصد الطولي للتفاعلات الدوائية الضارة والخصائص السريرية لدى الأشخاص الذين يتلقون الأدوية المضادة للفيروسات القهقرية، استناداً إلى استخراج البيانات من السجلات الطبية الإلكترونية. يعرض خط زمني نقاط الاستخراج: أول لقاء سريري (بدء دواء DTG أو دواء جديد مضاد للفيروسات القهقرية)، وفترات دورية مثل 6 أشهر، و12 شهراً، و18 شهراً، والاستمرار دورياً. وفي الأسفل، تُجمَّع البيانات المطلوب استخراجها تحت: زيادة الوزن، والخصائص الديمغرافية للمريض، والتاريخ الطبي والخصائص السريرية، والأمراض المصاحبة، وعوامل الخطر المرتبطة بزيادة الوزن، والتعرض للأدوية. المصدر: منظمة الصحة العالمية، 2020.",
        "zh": "图3.5，示意图，显示基于电子病历数据提取，对接受抗逆转录病毒药物者的药物不良反应和临床特征进行纵向监测。时间轴标出提取时点：首次临床接触（开始使用DTG或新的抗逆转录病毒药物）、定期间隔如6个月、12个月、18个月，以及此后定期持续。下方将需提取的数据分为体重增加、患者人口学特征、病史和临床特征、合并症、与体重增加相关的风险因素以及药物暴露。来源：世卫组织，2020年。",
        "es": "Fig. 3.5, diagrama del seguimiento longitudinal de las reacciones adversas a medicamentos y las características clínicas de las personas que reciben ARV, a partir de la extracción de datos de historias clínicas electrónicas. Una línea temporal muestra los puntos de extracción: primer contacto clínico (inicio de DTG o de un nuevo antirretroviral), intervalos periódicos como 6 meses, 12 meses, 18 meses, y continuar periódicamente. Debajo, los datos que deben extraerse se agrupan en aumento de peso, características demográficas del paciente, antecedentes médicos y características clínicas, comorbilidades, factores de riesgo asociados al aumento de peso y exposición a medicamentos. Fuente: OMS, 2020.",
        "fr": "Fig. 3.5, schéma du suivi longitudinal des effets indésirables des médicaments et des caractéristiques cliniques des personnes recevant des ARV, à partir de l'extraction de données des dossiers médicaux électroniques. Une frise chronologique indique les points d'extraction : première consultation clinique (début du DTG ou d'un nouvel antirétroviral), intervalles périodiques tels que 6 mois, 12 mois, 18 mois, puis de façon périodique. En dessous, les données à extraire sont regroupées en prise de poids, caractéristiques démographiques du patient, antécédents médicaux et caractéristiques cliniques, comorbidités, facteurs de risque associés à la prise de poids et exposition aux médicaments. Source : OMS, 2020.",
        "ru": "Рис. 3.5 — схема продольного мониторинга нежелательных лекарственных реакций и клинических характеристик у людей, получающих АРВ-препараты, на основе извлечения данных из электронных медицинских карт. Временная шкала показывает точки извлечения данных: первый клинический контакт (начало приёма DTG или нового антиретровирусного препарата), периодические интервалы, например 6 месяцев, 12 месяцев, 18 месяцев, и далее периодически. Ниже извлекаемые данные сгруппированы по разделам: прибавка массы тела, демографические характеристики пациента, анамнез и клинические характеристики, сопутствующие заболевания, факторы риска, связанные с прибавкой массы тела, и воздействие лекарственных средств. Источник: ВОЗ, 2020 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p124",
      "file": "figures/vfig-p124.webp",
      "page": 124,
      "shows": [
        "Fig. 3.6"
      ],
      "narratives": {
        "en": "Fig. 3.6, a diagram summarizing key patient monitoring tools for the PMTCT cascade across service delivery settings. Along a 'Timing of diagnosis' arrow are four columns, Preconception, Pregnancy, Labour & delivery and Postnatal, each listing tools such as the HIV care & treatment card, maternal health card, ANC register, labour record, L&D register, child health card, HEI card and register, PNC register and MIP register. Service delivery points shown include family planning, HIV prevention services, other outpatient services, antenatal care, labour & delivery and MNCH, with referral and linkage to MNCH/PMTCT services.",
        "ar": "الشكل 3.6، مخطط يلخص الأدوات الرئيسية لرصد المرضى في سلسلة الوقاية من انتقال العدوى من الأم إلى الطفل عبر مختلف أماكن تقديم الخدمات. على امتداد سهم \"توقيت التشخيص\" توجد أربعة أعمدة: ما قبل الحمل، والحمل، والمخاض والولادة، وما بعد الولادة، ويسرد كل منها أدوات مثل بطاقة رعاية وعلاج فيروس العوز المناعي البشري، وبطاقة صحة الأم، وسجل الرعاية السابقة للولادة، وسجل المخاض، وسجل المخاض والولادة، وبطاقة صحة الطفل، وبطاقة وسجل الرضع المعرضين للفيروس، وسجل الرعاية اللاحقة للولادة، وسجل ثنائي الأم والرضيع. وتشمل نقاط تقديم الخدمات المعروضة تنظيم الأسرة، وخدمات الوقاية من فيروس العوز المناعي البشري، وخدمات العيادات الخارجية الأخرى، والرعاية السابقة للولادة، والمخاض والولادة، وصحة الأم والوليد والطفل، مع الإحالة والربط بخدمات صحة الأم والوليد والطفل/الوقاية من انتقال العدوى من الأم إلى الطفل.",
        "zh": "图3.6，示意图，概述在不同服务提供场所监测预防母婴传播级联的主要患者监测工具。沿\"诊断时间\"箭头分为四栏：孕前、妊娠、分娩和产后，每栏列出相应工具，如艾滋病毒关怀和治疗卡、孕产妇保健卡、产前保健登记册、分娩记录、分娩登记册、儿童保健卡、艾滋病毒暴露婴儿卡和登记册、产后保健登记册以及母婴对登记册。所示服务提供点包括计划生育、艾滋病毒预防服务、其他门诊服务、产前保健、分娩以及孕产妇、新生儿和儿童健康服务，并有转诊和衔接至孕产妇、新生儿和儿童健康/预防母婴传播服务。",
        "es": "Fig. 3.6, diagrama que resume las principales herramientas de seguimiento de pacientes para la cascada de PTMI en distintos entornos de prestación de servicios. A lo largo de una flecha de «Momento del diagnóstico» hay cuatro columnas, Preconcepción, Embarazo, Parto y Posnatal, cada una con herramientas como la tarjeta de atención y tratamiento del VIH, la tarjeta de salud materna, el registro de atención prenatal, el registro del parto, el registro de parto, la tarjeta de salud infantil, la tarjeta y el registro de lactantes expuestos al VIH, el registro de atención posnatal y el registro de la díada madre-lactante. Los puntos de prestación de servicios incluyen planificación familiar, servicios de prevención del VIH, otros servicios ambulatorios, atención prenatal, parto y SMNI, con derivación y vinculación a los servicios de SMNI/PTMI.",
        "fr": "Fig. 3.6, schéma résumant les principaux outils de suivi des patients pour la cascade de PTME dans divers lieux de prestation de services. Le long d'une flèche « Moment du diagnostic » figurent quatre colonnes, Préconception, Grossesse, Travail et accouchement, et Post-natal, chacune énumérant des outils tels que la fiche de soins et de traitement du VIH, la carte de santé maternelle, le registre des CPN, le dossier d'accouchement, le registre travail et accouchement, la carte de santé de l'enfant, la fiche et le registre des nourrissons exposés au VIH, le registre des soins post-natals et le registre du couple mère-enfant. Les points de prestation de services comprennent la planification familiale, les services de prévention du VIH, d'autres services ambulatoires, les soins prénatals, le travail et l'accouchement et la SMNI, avec orientation et liaison vers les services de SMNI/PTME.",
        "ru": "Рис. 3.6 — схема основных инструментов мониторинга пациентов для каскада ППМР в различных условиях оказания услуг. Вдоль стрелки «Время постановки диагноза» расположены четыре столбца — «До зачатия», «Беременность», «Роды» и «Послеродовой период», — в каждом из которых перечислены инструменты, например карта помощи и лечения при ВИЧ, карта здоровья матери, журнал дородового наблюдения, протокол родов, журнал родов, карта здоровья ребёнка, карта и журнал детей, подвергшихся воздействию ВИЧ, журнал послеродового наблюдения и журнал пар «мать–ребёнок». Показаны пункты оказания услуг: планирование семьи, услуги по профилактике ВИЧ, другие амбулаторные услуги, дородовое наблюдение, роды и ОЗМНД, с направлением и связью со службами ОЗМНД/ППМР."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p149",
      "file": "figures/vfig-p149.webp",
      "page": 149,
      "shows": [
        "Fig. 3.7"
      ],
      "narratives": {
        "en": "Fig. 3.7, an icon-based flow diagram of data flow from the health facility to the Ministry of Health in Mozambique. Data move from the health facility to the master card and then to the EMR, which feeds three implementing partners; their data flow (shown with a chart icon) to CDC/USAID, which passes them to the MOH. Source: Ministry of Health of Mozambique.",
        "ar": "الشكل 3.7، مخطط انسيابي بالأيقونات يبيّن تدفق البيانات من المرفق الصحي إلى وزارة الصحة في موزمبيق. تنتقل البيانات من المرفق الصحي إلى البطاقة الرئيسية ثم إلى السجل الطبي الإلكتروني، الذي يغذي ثلاثة شركاء منفذين؛ وتتدفق بياناتهم (المبيّنة بأيقونة رسم بياني) إلى المراكز الأمريكية لمكافحة الأمراض والوقاية منها/الوكالة الأمريكية للتنمية الدولية، التي تنقلها إلى وزارة الصحة. المصدر: وزارة الصحة في موزمبيق.",
        "zh": "图3.7，以图标表示的流程图，显示莫桑比克从卫生机构到卫生部的数据流。数据从卫生机构流向主卡，再进入电子病历，电子病历向三个实施伙伴提供数据；这些数据（以图表图标表示）流向美国疾病控制和预防中心/美国国际开发署，再转至卫生部。来源：莫桑比克卫生部。",
        "es": "Fig. 3.7, diagrama de flujo con iconos sobre el flujo de datos desde el establecimiento de salud hasta el Ministerio de Salud de Mozambique. Los datos pasan del establecimiento de salud a la tarjeta maestra y luego a la HCE, que alimenta a tres asociados en la ejecución; sus datos (representados con un icono de gráfico) llegan a los CDC/USAID, que los transmiten al Ministerio de Salud. Fuente: Ministerio de Salud de Mozambique.",
        "fr": "Fig. 3.7, diagramme de flux à icônes du flux de données de l'établissement de santé au ministère de la Santé au Mozambique. Les données passent de l'établissement de santé à la fiche principale puis au DME, qui alimente trois partenaires de mise en œuvre ; leurs données (représentées par une icône de graphique) parviennent aux CDC/USAID, qui les transmettent au ministère de la Santé. Source : ministère de la Santé du Mozambique.",
        "ru": "Рис. 3.7 — схема потока данных с иконками, показывающая передачу данных от медицинского учреждения в Министерство здравоохранения Мозамбика. Данные поступают из медицинского учреждения в основную карту, а затем в ЭМК, которая передаёт их трём партнёрам-исполнителям; их данные (обозначенные значком диаграммы) поступают в CDC/USAID, которые передают их в Минздрав. Источник: Министерство здравоохранения Мозамбика."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p158",
      "file": "figures/vfig-p158.webp",
      "page": 158,
      "shows": [
        "Table 3.9"
      ],
      "narratives": {
        "en": "A page render showing the continuation of Table 3.9, 'Key terms and definitions used in this guidance for HIV patient monitoring', with two rows: 'Net current cohort (cohort analysis report)' and 'Final outcome status of PMTCT' with their definitions. Below it, Box 3.24 lists WHO recommendations on standardized data collection and reporting tools (patient card or EMR for every person confirmed HIV-positive, ART registers at all ART sites, and routine minimum reporting by community ART providers).",
        "ar": "صورة لصفحة تعرض تتمة الجدول 3.9، \"المصطلحات والتعاريف الرئيسية المستخدمة في هذه الإرشادات لرصد مرضى فيروس العوز المناعي البشري\"، ويتضمن صفين: \"الفوج الحالي الصافي (تقرير تحليل الأفواج)\" و\"حالة النتيجة النهائية للوقاية من انتقال العدوى من الأم إلى الطفل\" مع تعريفيهما. وتحته، يسرد الإطار 3.24 توصيات منظمة الصحة العالمية بشأن الأدوات الموحدة لجمع البيانات والإبلاغ (بطاقة مريض أو سجل طبي إلكتروني لكل شخص تأكدت إصابته بفيروس العوز المناعي البشري، وسجلات العلاج المضاد للفيروسات القهقرية في جميع مواقع تقديمه، والإبلاغ الروتيني عن الحد الأدنى من البيانات من جانب مقدمي العلاج المجتمعيين).",
        "zh": "页面渲染图，显示表3.9\"本指南中用于艾滋病毒患者监测的关键术语和定义\"的续表，包括\"净现有队列（队列分析报告）\"和\"预防母婴传播的最终结局状态\"两行及其定义。其下方的框3.24列出世卫组织关于标准化数据收集和报告工具的建议（为每位确诊艾滋病毒阳性者建立患者卡或电子病历，在所有提供抗逆转录病毒治疗的地点保存治疗登记册，社区抗逆转录病毒治疗提供者常规报告最低限度数据）。",
        "es": "Representación de una página con la continuación del Cuadro 3.9, «Términos clave y definiciones utilizados en esta orientación para el seguimiento de pacientes con VIH», con dos filas: «Cohorte actual neta (informe de análisis de cohortes)» y «Situación del resultado final de la PTMI», con sus definiciones. Debajo, el Recuadro 3.24 enumera recomendaciones de la OMS sobre herramientas normalizadas de recopilación y notificación de datos (tarjeta de paciente o HCE para toda persona con VIH confirmado, registros de TAR en todos los centros que lo ofrecen y notificación rutinaria mínima por parte de los proveedores comunitarios de TAR).",
        "fr": "Rendu d'une page montrant la suite du Tableau 3.9, « Principaux termes et définitions utilisés dans ces orientations pour le suivi des patients vivant avec le VIH », avec deux lignes : « Cohorte actuelle nette (rapport d'analyse de cohorte) » et « Statut du résultat final de la PTME », accompagnées de leurs définitions. En dessous, l'Encadré 3.24 énumère des recommandations de l'OMS sur les outils normalisés de collecte et de notification des données (fiche patient ou DME pour toute personne dont la séropositivité est confirmée, registres de TAR sur tous les sites qui le dispensent et notification systématique minimale par les prestataires communautaires de TAR).",
        "ru": "Изображение страницы с продолжением таблицы 3.9 «Основные термины и определения, используемые в настоящем руководстве по мониторингу пациентов с ВИЧ», включающей две строки: «Чистая текущая когорта (отчёт о когортном анализе)» и «Окончательный исход ППМР» с их определениями. Ниже во вставке 3.24 перечислены рекомендации ВОЗ по стандартизированным инструментам сбора данных и отчётности (карта пациента или ЭМК для каждого человека с подтверждённым ВИЧ, журналы АРТ во всех учреждениях, предоставляющих АРТ, и регулярная отчётность по минимальному набору данных со стороны поставщиков АРТ на уровне сообществ)."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p159",
      "file": "figures/vfig-p159.webp",
      "page": 159,
      "shows": [
        "Fig. 3.8"
      ],
      "narratives": {
        "en": "Fig. 3.8, a diagram of the standardized HIV patient monitoring system and linkages by service delivery area and level. Three facility columns, MNCH, HIV and TB, show patient records (e.g. HIV card, maternal/child health cards, TB treatment card), registers (ART, HTS, ANC/L&D/HEI/MIP, TB laboratory registers) and reports, linked by UID, ANC number and TB register number. Community tools (community health worker tools, community ART tool, DSD tools, community testing tools) feed upward, and facility data flow to the HIV cross-sectional report and ART cohort report, which inform indicators for patient management, programme monitoring and management at subnational and national level.",
        "ar": "الشكل 3.8، مخطط للنظام الموحد لرصد مرضى فيروس العوز المناعي البشري والروابط حسب مجال تقديم الخدمات ومستواها. تعرض ثلاثة أعمدة على مستوى المرفق، هي صحة الأم والوليد والطفل، وفيروس العوز المناعي البشري، والسل، سجلات المرضى (مثل بطاقة فيروس العوز المناعي البشري، وبطاقات صحة الأم/الطفل، وبطاقة علاج السل)، والسجلات (سجل العلاج المضاد للفيروسات القهقرية، وسجل خدمات الاختبار، وسجلات الرعاية السابقة للولادة/المخاض والولادة/الرضع المعرضين/ثنائي الأم والرضيع، وسجلات مختبر السل)، والتقارير، وهي مرتبطة بواسطة المعرّف الفريد ورقم الرعاية السابقة للولادة ورقم سجل السل. وتغذي الأدوات المجتمعية (أدوات العاملين الصحيين المجتمعيين، وأداة العلاج المجتمعي، وأدوات تقديم الخدمات المتمايزة، وأدوات الاختبار المجتمعي) المستويات الأعلى، وتتدفق بيانات المرافق إلى التقرير المقطعي لفيروس العوز المناعي البشري وتقرير أفواج العلاج المضاد للفيروسات القهقرية، اللذين يستند إليهما في مؤشرات إدارة المرضى ورصد البرامج وإدارتها على المستويين دون الوطني والوطني.",
        "zh": "图3.8，示意图，显示按服务领域和层级划分的标准化艾滋病毒患者监测系统及其联系。机构层面的三栏——孕产妇、新生儿和儿童健康、艾滋病毒和结核病——分别列出患者记录（如艾滋病毒卡、孕产妇/儿童保健卡、结核病治疗卡）、登记册（抗逆转录病毒治疗、艾滋病毒检测服务、产前保健/分娩/艾滋病毒暴露婴儿/母婴对登记册、结核病实验室登记册）和报告，并通过唯一标识符、产前保健编号和结核病登记号相互关联。社区工具（社区卫生工作者工具、社区抗逆转录病毒治疗工具、差异化服务提供工具、社区检测工具）向上汇入，机构数据流向艾滋病毒横断面报告和抗逆转录病毒治疗队列报告，为国家以下和国家层面的患者管理、规划监测和管理指标提供信息。",
        "es": "Fig. 3.8, diagrama del sistema normalizado de seguimiento de pacientes con VIH y sus vínculos por ámbito y nivel de prestación de servicios. Tres columnas del establecimiento, SMNI, VIH y TB, muestran registros de pacientes (p. ej., tarjeta de VIH, tarjetas de salud materna/infantil, tarjeta de tratamiento de la TB), registros (TAR, SPV, APN/parto/lactantes expuestos/díada madre-lactante, registros de laboratorio de TB) e informes, vinculados mediante el IU, el número de APN y el número de registro de TB. Las herramientas comunitarias (de agentes de salud comunitarios, de TAR comunitario, de PDS y de pruebas comunitarias) alimentan los niveles superiores, y los datos de los establecimientos llegan al informe transversal de VIH y al informe de cohortes de TAR, que nutren los indicadores para la gestión de pacientes y el seguimiento y la gestión de programas a nivel subnacional y nacional.",
        "fr": "Fig. 3.8, schéma du système normalisé de suivi des patients vivant avec le VIH et de ses liens par domaine et niveau de prestation de services. Trois colonnes au niveau de l'établissement, SMNI, VIH et tuberculose, présentent les dossiers patients (p. ex. fiche VIH, carnets de santé de la mère et de l'enfant, fiche de traitement de la tuberculose), les registres (TAR, services de dépistage du VIH, CPN/accouchement/nourrissons exposés/couple mère-enfant, registres de laboratoire tuberculose) et les rapports, reliés par l'IU, le numéro de CPN et le numéro de registre tuberculose. Les outils communautaires (outils des agents de santé communautaires, outil de TAR communautaire, outils de PSD, outils de dépistage communautaire) alimentent les niveaux supérieurs, et les données des établissements aboutissent au rapport transversal VIH et au rapport de cohorte TAR, qui alimentent les indicateurs de prise en charge des patients et de suivi et gestion des programmes aux niveaux infranational et national.",
        "ru": "Рис. 3.8 — схема стандартизированной системы мониторинга пациентов с ВИЧ и связей по областям и уровням оказания услуг. Три столбца уровня учреждения — ОЗМНД, ВИЧ и ТБ — показывают медицинскую документацию пациентов (например, карта ВИЧ, карты здоровья матери/ребёнка, карта лечения ТБ), журналы (АРТ, ТВИЧ, дородового наблюдения/родов/детей, подвергшихся воздействию ВИЧ/пар «мать–ребёнок», лабораторные журналы ТБ) и отчёты, связанные через УИК, номер дородового наблюдения и регистрационный номер ТБ. Инструменты уровня сообществ (инструменты общинных медработников, инструмент АРТ на уровне сообществ, инструменты ДПУ, инструменты тестирования в сообществах) передают данные наверх, а данные учреждений поступают в поперечный отчёт по ВИЧ и когортный отчёт по АРТ, на основе которых формируются показатели для ведения пациентов, мониторинга программ и управления ими на субнациональном и национальном уровнях."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p171",
      "file": "figures/vfig-p171.webp",
      "page": 171,
      "shows": [
        "Fig. 3.9"
      ],
      "narratives": {
        "en": "Fig. 3.9, an example data quality improvement and use framework in three columns: focus areas, major activities and resources. The focus areas are DQI, DQA and Data use, each with a list of activities such as training of health care workers and data clerks, routine DQA and remedial action plans, and data review meetings at facilities and districts. Resources include DQI teams at all levels, infrastructure and hardware, standardized HIV patient monitoring tools, SOPs/job aids, DQA tools and EMR systems. Source: adapted from PEPFAR Ethiopia data improvement and use initiative campaign, 2019.",
        "ar": "الشكل 3.9، مثال على إطار لتحسين جودة البيانات واستخدامها في ثلاثة أعمدة: مجالات التركيز، والأنشطة الرئيسية، والموارد. ومجالات التركيز هي تحسين جودة البيانات، وتقييم جودة البيانات، واستخدام البيانات، ولكل منها قائمة أنشطة مثل تدريب العاملين في مجال الرعاية الصحية وكتبة البيانات، والتقييم الروتيني لجودة البيانات وخطط الإجراءات التصحيحية، واجتماعات مراجعة البيانات في المرافق والمناطق. وتشمل الموارد فرق تحسين جودة البيانات على جميع المستويات، والبنية التحتية والأجهزة، والأدوات الموحدة لرصد مرضى فيروس العوز المناعي البشري، وإجراءات التشغيل الموحدة/أدوات العمل المساعدة، وأدوات تقييم جودة البيانات، وأنظمة السجلات الطبية الإلكترونية. المصدر: مقتبس من حملة مبادرة تحسين البيانات واستخدامها لخطة الرئيس الأمريكي الطارئة للإغاثة من الإيدز في إثيوبيا، 2019.",
        "zh": "图3.9，数据质量改进和使用框架示例，分为三栏：重点领域、主要活动和资源。重点领域为数据质量改进、数据质量评估和数据使用，每项列出相应活动，如培训卫生保健工作者和数据录入员、常规数据质量评估和补救行动计划，以及在机构和地区召开数据审查会议。资源包括各级数据质量改进团队、基础设施和硬件、标准化艾滋病毒患者监测工具、标准操作程序/工作辅助工具、数据质量评估工具和电子病历系统。来源：改编自美国总统艾滋病紧急救援计划埃塞俄比亚数据改进和使用倡议运动，2019年。",
        "es": "Fig. 3.9, ejemplo de marco de mejora de la calidad y uso de los datos en tres columnas: áreas de interés, actividades principales y recursos. Las áreas de interés son MCD, ECD y Uso de los datos, cada una con una lista de actividades como la capacitación de trabajadores de salud y auxiliares de datos, la ECD rutinaria y los planes de medidas correctivas, y las reuniones de examen de datos en establecimientos y distritos. Los recursos incluyen equipos de MCD en todos los niveles, infraestructura y equipos informáticos, herramientas normalizadas de seguimiento de pacientes con VIH, POE/ayudas de trabajo, herramientas de ECD y sistemas de HCE. Fuente: adaptado de la campaña de la iniciativa de mejora y uso de datos de PEPFAR en Etiopía, 2019.",
        "fr": "Fig. 3.9, exemple de cadre d'amélioration de la qualité et d'utilisation des données en trois colonnes : domaines prioritaires, activités principales et ressources. Les domaines prioritaires sont l'AQD, l'EQD et l'utilisation des données, chacun accompagné d'une liste d'activités telles que la formation des agents de santé et des agents de saisie, l'EQD systématique et les plans de mesures correctives, et les réunions d'examen des données dans les établissements et les districts. Les ressources comprennent des équipes d'AQD à tous les niveaux, les infrastructures et le matériel, des outils normalisés de suivi des patients vivant avec le VIH, des modes opératoires normalisés/aide-mémoire, des outils d'EQD et des systèmes de DME. Source : adapté de la campagne de l'initiative d'amélioration et d'utilisation des données du PEPFAR en Éthiopie, 2019.",
        "ru": "Рис. 3.9 — пример рамочной структуры повышения качества и использования данных в трёх столбцах: направления работы, основные мероприятия и ресурсы. Направления — ПКД, ОКД и использование данных, для каждого из которых перечислены мероприятия, например обучение медицинских работников и операторов данных, регулярная ОКД и планы корректирующих мер, совещания по анализу данных в учреждениях и районах. Ресурсы включают группы ПКД на всех уровнях, инфраструктуру и оборудование, стандартизированные инструменты мониторинга пациентов с ВИЧ, СОП/памятки, инструменты ОКД и системы ЭМК. Источник: адаптировано по материалам кампании PEPFAR в Эфиопии по совершенствованию и использованию данных, 2019 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p173",
      "file": "figures/vfig-p173.webp",
      "page": 173,
      "shows": [
        "Fig. 3.10"
      ],
      "narratives": {
        "en": "Fig. 3.10, a six-step process diagram with icons showing steps for implementing routine HIV data quality assurance activities at health facilities: Determine the purpose; Select levels and sites to be included; Identify indicators, data sources and reporting period; Conduct site visits; Review outputs and findings; Develop a system strengthening plan, including follow-up actions. Source: WHO, 2020.",
        "ar": "الشكل 3.10، مخطط عملية من ست خطوات بالأيقونات يبيّن خطوات تنفيذ الأنشطة الروتينية لضمان جودة بيانات فيروس العوز المناعي البشري في المرافق الصحية: تحديد الغرض؛ واختيار المستويات والمواقع المشمولة؛ وتحديد المؤشرات ومصادر البيانات وفترة الإبلاغ؛ وإجراء الزيارات الميدانية؛ ومراجعة المخرجات والنتائج؛ ووضع خطة لتعزيز النظام تتضمن إجراءات المتابعة. المصدر: منظمة الصحة العالمية، 2020.",
        "zh": "图3.10，带图标的六步流程图，显示在卫生机构实施常规艾滋病毒数据质量保证活动的步骤：确定目的；选择纳入的层级和地点；确定指标、数据来源和报告期；开展现场访问；审查产出和结果；制定系统加强计划，包括后续行动。来源：世卫组织，2020年。",
        "es": "Fig. 3.10, diagrama de proceso de seis pasos con iconos que muestra los pasos para aplicar actividades rutinarias de garantía de la calidad de los datos sobre el VIH en los establecimientos de salud: Determinar el propósito; Seleccionar los niveles y centros que se incluirán; Identificar los indicadores, las fuentes de datos y el período de notificación; Realizar visitas a los centros; Examinar los productos y resultados; Elaborar un plan de fortalecimiento del sistema, con medidas de seguimiento. Fuente: OMS, 2020.",
        "fr": "Fig. 3.10, schéma de processus en six étapes avec icônes présentant les étapes de mise en œuvre des activités systématiques d'assurance de la qualité des données sur le VIH dans les établissements de santé : Déterminer l'objectif ; Sélectionner les niveaux et les sites à inclure ; Identifier les indicateurs, les sources de données et la période de notification ; Effectuer des visites sur site ; Examiner les résultats et constatations ; Élaborer un plan de renforcement du système, y compris les mesures de suivi. Source : OMS, 2020.",
        "ru": "Рис. 3.10 — схема процесса из шести шагов с иконками, показывающая этапы проведения регулярных мероприятий по обеспечению качества данных о ВИЧ в медицинских учреждениях: определить цель; выбрать охватываемые уровни и учреждения; определить показатели, источники данных и отчётный период; провести выезды на места; проанализировать результаты и выводы; разработать план укрепления системы, включая последующие действия. Источник: ВОЗ, 2020 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p174",
      "file": "figures/vfig-p174.webp",
      "page": 174,
      "shows": [
        "Fig. 3.11"
      ],
      "narratives": {
        "en": "Fig. 3.11, a tiered diagram of examples of data use at different levels. At facility level (facility computers and paper register): patient management, facility management, nationally required and staff accountability reports. At district level: service delivery quality and comparisons, district outcomes and burden, and informing intervention discussions. At subnational level: epidemiological and temporal trends, business plans, projections for unmet need and data triangulation. At national level: impact of HIV and TB services, informing policy change and reporting on international obligations. Source: University of Cape Town, 2021.",
        "ar": "الشكل 3.11، مخطط متدرج يعرض أمثلة على استخدام البيانات على مستويات مختلفة. على مستوى المرفق (حواسيب المرفق والسجل الورقي): تقارير إدارة المرضى، وتقارير إدارة المرفق، والتقارير المطلوبة وطنياً، وتقارير مساءلة الموظفين. وعلى مستوى المنطقة: جودة تقديم الخدمات والمقارنات بينها، ونتائج المنطقة وعبئها، والاستناد إليها في مناقشات التدخلات. وعلى المستوى دون الوطني: الاتجاهات الوبائية والزمنية، وخطط العمل، وإسقاطات الاحتياجات غير الملباة، والتثليث بين البيانات. وعلى المستوى الوطني: أثر خدمات فيروس العوز المناعي البشري والسل، والمساعدة في توجيه تغيير السياسات، والإبلاغ عن الالتزامات الدولية. المصدر: جامعة كيب تاون، 2021.",
        "zh": "图3.11，分层示意图，举例说明不同层级的数据使用。机构层面（机构计算机和纸质登记册）：患者管理报告、机构管理报告、国家要求的报告和员工问责报告。地区层面：服务提供质量和比较、地区结果和负担，以及为干预讨论提供信息。国家以下层面：流行病学和时间趋势、业务计划、未满足需求预测和数据三角互证。国家层面：艾滋病毒和结核病服务的影响、为政策变革提供信息，以及履行国际义务的报告。来源：开普敦大学，2021年。",
        "es": "Fig. 3.11, diagrama por niveles con ejemplos de uso de los datos en distintos niveles. En el establecimiento (computadoras del establecimiento y registro en papel): informes de gestión de pacientes, de gestión del establecimiento, informes exigidos a nivel nacional y de rendición de cuentas del personal. En el distrito: calidad y comparación de la prestación de servicios, resultados y carga del distrito, y aportes a los debates sobre intervenciones. En el nivel subnacional: tendencias epidemiológicas y temporales, planes de actividades, proyecciones de necesidades no cubiertas y triangulación de datos. En el nivel nacional: impacto de los servicios de VIH y TB, apoyo a cambios de políticas y notificación de obligaciones internacionales. Fuente: Universidad de Ciudad del Cabo, 2021.",
        "fr": "Fig. 3.11, schéma par niveaux présentant des exemples d'utilisation des données à différents niveaux. Au niveau de l'établissement (ordinateurs de l'établissement et registre papier) : rapports de prise en charge des patients, de gestion de l'établissement, rapports exigés au niveau national et rapports de redevabilité du personnel. Au niveau du district : qualité et comparaisons de la prestation de services, résultats et charge de morbidité du district, et contribution aux discussions sur les interventions. Au niveau infranational : tendances épidémiologiques et temporelles, plans d'activité, projections des besoins non satisfaits et triangulation des données. Au niveau national : impact des services de lutte contre le VIH et la tuberculose, contribution à l'évolution des politiques et notification au titre des obligations internationales. Source : Université du Cap, 2021.",
        "ru": "Рис. 3.11 — многоуровневая схема с примерами использования данных на разных уровнях. На уровне учреждения (компьютеры учреждения и бумажный журнал): отчёты по ведению пациентов, управлению учреждением, отчёты, требуемые на национальном уровне, и отчёты о подотчётности персонала. На уровне района: качество и сравнение оказания услуг, результаты и бремя болезней в районе, информационная поддержка обсуждения мер. На субнациональном уровне: эпидемиологические и временные тенденции, бизнес-планы, прогнозы неудовлетворённых потребностей и триангуляция данных. На национальном уровне: результативность услуг в связи с ВИЧ и ТБ, содействие изменению политики и отчётность по международным обязательствам. Источник: Кейптаунский университет, 2021 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p176",
      "file": "figures/vfig-p176.webp",
      "page": 176,
      "shows": [
        "Fig. 3.12",
        "Box 3.33"
      ],
      "narratives": {
        "en": "Fig. 3.12, within Box 3.33, a grouped bar chart of completion of the first viral load test (3–6 months) after ART initiation by clinic in Subdistrict X, comparing quarter 4 2020 and quarter 1 2021 for Clinics A–F on a 0–100% axis. Clinics D, E and F are at about 80–90%, Clinics A and B at about 60–70%, and Clinic C, circled, is lowest at about 40% falling to under 40%. Source: University of Cape Town, 2021.",
        "ar": "الشكل 3.12، ضمن الإطار 3.33، مخطط أعمدة مجمّعة يبيّن نسبة استكمال أول اختبار للحمل الفيروسي (3–6 أشهر) بعد بدء العلاج المضاد للفيروسات القهقرية حسب العيادة في المنطقة الفرعية X، مقارناً الربع الرابع من 2020 والربع الأول من 2021 للعيادات من A إلى F على محور من 0 إلى 100%. وتبلغ العيادات D وE وF نحو 80–90%، والعيادتان A وB نحو 60–70%، بينما العيادة C، المحاطة بدائرة، هي الأدنى بنحو 40% وتنخفض إلى أقل من 40%. المصدر: جامعة كيب تاون، 2021.",
        "zh": "图3.12（位于框3.33内），分组柱状图，显示X分区各诊所启动抗逆转录病毒治疗后首次病毒载量检测（3–6个月）的完成率，比较A至F诊所2020年第4季度和2021年第1季度的情况，纵轴为0–100%。D、E、F诊所约为80–90%，A、B诊所约为60–70%，被圈出的C诊所最低，约为40%，随后降至40%以下。来源：开普敦大学，2021年。",
        "es": "Fig. 3.12, dentro del Recuadro 3.33, gráfico de barras agrupadas sobre la realización de la primera prueba de carga viral (3–6 meses) tras el inicio del TAR por clínica en el Subdistrito X, que compara el cuarto trimestre de 2020 y el primer trimestre de 2021 para las clínicas A a F en un eje de 0 a 100%. Las clínicas D, E y F se sitúan en torno al 80–90%, las clínicas A y B en torno al 60–70%, y la clínica C, marcada con un círculo, es la más baja, en torno al 40% y luego por debajo del 40%. Fuente: Universidad de Ciudad del Cabo, 2021.",
        "fr": "Fig. 3.12, dans l'Encadré 3.33, graphique à barres groupées de la réalisation du premier test de charge virale (3–6 mois) après la mise sous TAR, par clinique, dans le sous-district X, comparant le 4e trimestre 2020 et le 1er trimestre 2021 pour les cliniques A à F sur un axe de 0 à 100 %. Les cliniques D, E et F se situent autour de 80–90 %, les cliniques A et B autour de 60–70 %, et la clinique C, entourée, est la plus basse, autour de 40 % puis sous les 40 %. Source : Université du Cap, 2021.",
        "ru": "Рис. 3.12 во вставке 3.33 — сгруппированная столбчатая диаграмма выполнения первого теста на вирусную нагрузку (через 3–6 месяцев) после начала АРТ по клиникам субрайона X; сравниваются 4-й квартал 2020 г. и 1-й квартал 2021 г. для клиник A–F по шкале 0–100%. Клиники D, E и F находятся на уровне примерно 80–90%, клиники A и B — около 60–70%, а обведённая кружком клиника C имеет самый низкий показатель — около 40% со снижением до уровня ниже 40%. Источник: Кейптаунский университет, 2021 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p194",
      "file": "figures/vfig-p194.webp",
      "page": 194,
      "shows": [
        "Fig. 4.1"
      ],
      "narratives": {
        "en": "Fig. 4.1, a grouped bar chart with error bars of estimated new cases of four curable STIs among adults aged 15–49 years, by sex, in 2020. Totals are trichomoniasis 156.3 million (female 73.7m, male 82.6m), chlamydia 128.5 million (69.9m, 58.6m), gonorrhoea 82.4 million (35.9m, 46.4m) and syphilis 7.1 million (3.5m, 3.6m), with uncertainty ranges shown above each total. Source: WHO, 2021.",
        "ar": "الشكل 4.1، مخطط أعمدة مجمّعة مع أشرطة خطأ يبيّن العدد التقديري للحالات الجديدة من أربع عداوى منقولة جنسياً قابلة للشفاء بين البالغين في الفئة العمرية 15–49 سنة، حسب الجنس، في عام 2020. والمجاميع هي: داء المشعرات 156.3 مليون (الإناث 73.7 مليون، الذكور 82.6 مليون)، والمتدثرة 128.5 مليون (69.9 مليون، 58.6 مليون)، والسيلان 82.4 مليون (35.9 مليون، 46.4 مليون)، والزهري 7.1 ملايين (3.5 ملايين، 3.6 ملايين)، مع عرض نطاقات عدم اليقين فوق كل مجموع. المصدر: منظمة الصحة العالمية، 2021.",
        "zh": "图4.1，带误差线的分组柱状图，显示2020年15–49岁成人中四种可治愈性传播感染的估计新发病例数（按性别）。总数分别为：滴虫病1.563亿（女性7370万，男性8260万），衣原体感染1.285亿（6990万，5860万），淋病8240万（3590万，4640万），梅毒710万（350万，360万），每个总数上方标有不确定性范围。来源：世卫组织，2021年。",
        "es": "Fig. 4.1, gráfico de barras agrupadas con barras de error de los casos nuevos estimados de cuatro ITS curables en adultos de 15 a 49 años, por sexo, en 2020. Los totales son tricomoniasis 156,3 millones (mujeres 73,7 m, hombres 82,6 m), clamidiasis 128,5 millones (69,9 m, 58,6 m), gonorrea 82,4 millones (35,9 m, 46,4 m) y sífilis 7,1 millones (3,5 m, 3,6 m), con los intervalos de incertidumbre indicados sobre cada total. Fuente: OMS, 2021.",
        "fr": "Fig. 4.1, graphique à barres groupées avec barres d'erreur du nombre estimé de nouveaux cas de quatre IST curables chez les adultes de 15 à 49 ans, par sexe, en 2020. Les totaux sont : trichomonase 156,3 millions (femmes 73,7 M, hommes 82,6 M), chlamydiose 128,5 millions (69,9 M, 58,6 M), gonorrhée 82,4 millions (35,9 M, 46,4 M) et syphilis 7,1 millions (3,5 M, 3,6 M), les intervalles d'incertitude figurant au-dessus de chaque total. Source : OMS, 2021.",
        "ru": "Рис. 4.1 — сгруппированная столбчатая диаграмма с планками погрешностей, показывающая расчётное число новых случаев четырёх излечимых ИППП среди взрослых в возрасте 15–49 лет по полу в 2020 г. Итоговые значения: трихомониаз — 156,3 млн (женщины 73,7 млн, мужчины 82,6 млн), хламидиоз — 128,5 млн (69,9 млн, 58,6 млн), гонорея — 82,4 млн (35,9 млн, 46,4 млн) и сифилис — 7,1 млн (3,5 млн, 3,6 млн); над каждым итогом указаны интервалы неопределённости. Источник: ВОЗ, 2021 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p202",
      "file": "figures/vfig-p202.webp",
      "page": 202,
      "shows": [
        "Fig. 4.2"
      ],
      "narratives": {
        "en": "Fig. 4.2, four world choropleth maps of the prevalence of hepatitis B surface antigen (HBsAg) among people living with HIV in (A) the general population, (B) people who inject drugs, (C) men who have sex with men and (D) other populations at elevated risk of HIV. Countries are shaded by prevalence category (<5%, 5 to <15%, 15 to <50%, ≥50%) or marked as missing; most countries have missing data in each map, with data mainly from parts of Africa, Asia and the Americas. Source: Platt et al., 2020.",
        "ar": "الشكل 4.2، أربع خرائط عالمية ملوّنة حسب القيم تبيّن معدل انتشار المستضد السطحي لالتهاب الكبد B بين المتعايشين مع فيروس العوز المناعي البشري في: (A) عموم السكان، و(B) متعاطي المخدرات بالحقن، و(C) الرجال الذين يمارسون الجنس مع الرجال، و(D) الفئات السكانية الأخرى المعرضة لخطر مرتفع للإصابة بفيروس العوز المناعي البشري. وتُظلَّل البلدان حسب فئة معدل الانتشار (<5%، و5 إلى <15%، و15 إلى <50%، و≥50%) أو تُعلَّم بأن بياناتها مفقودة؛ ومعظم البلدان بلا بيانات في كل خريطة، وتأتي البيانات أساساً من أجزاء من أفريقيا وآسيا والأمريكتين. المصدر: Platt وآخرون، 2020.",
        "zh": "图4.2，四幅世界分级统计地图，显示艾滋病毒感染者中乙型肝炎表面抗原（HBsAg）的流行率，分别针对（A）一般人群、（B）注射吸毒者、（C）男男性行为者和（D）其他艾滋病毒高风险人群。各国按流行率类别着色（<5%、5至<15%、15至<50%、≥50%）或标为数据缺失；每幅地图中大多数国家数据缺失，数据主要来自非洲、亚洲和美洲的部分地区。来源：Platt等，2020年。",
        "es": "Fig. 4.2, cuatro mapas mundiales coropléticos de la prevalencia del antígeno de superficie del virus de la hepatitis B (HBsAg) en personas con el VIH en (A) la población general, (B) personas que se inyectan drogas, (C) hombres que tienen relaciones sexuales con hombres y (D) otras poblaciones con riesgo elevado de VIH. Los países están sombreados por categoría de prevalencia (<5%, 5 a <15%, 15 a <50%, ≥50%) o marcados como sin datos; en cada mapa la mayoría de los países carecen de datos, que proceden principalmente de partes de África, Asia y las Américas. Fuente: Platt et al., 2020.",
        "fr": "Fig. 4.2, quatre cartes choroplèthes du monde montrant la prévalence de l'antigène de surface du virus de l'hépatite B (AgHBs) chez les personnes vivant avec le VIH dans (A) la population générale, (B) les personnes qui s'injectent des drogues, (C) les hommes ayant des rapports sexuels avec des hommes et (D) d'autres populations à risque élevé de VIH. Les pays sont colorés par catégorie de prévalence (<5 %, 5 à <15 %, 15 à <50 %, ≥50 %) ou signalés comme données manquantes ; sur chaque carte, la plupart des pays n'ont pas de données, celles-ci provenant surtout de régions d'Afrique, d'Asie et des Amériques. Source : Platt et al., 2020.",
        "ru": "Рис. 4.2 — четыре картограммы мира, показывающие распространённость поверхностного антигена вируса гепатита B (HBsAg) среди людей, живущих с ВИЧ: (A) в общей популяции, (B) среди людей, употребляющих инъекционные наркотики, (C) среди мужчин, практикующих секс с мужчинами, и (D) в других группах населения с повышенным риском ВИЧ. Страны окрашены по категориям распространённости (<5%, от 5 до <15%, от 15 до <50%, ≥50%) или отмечены как не имеющие данных; на каждой карте у большинства стран данные отсутствуют, а имеющиеся данные относятся главным образом к частям Африки, Азии и Америки. Источник: Platt et al., 2020 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p206",
      "file": "figures/vfig-p206.webp",
      "page": 206,
      "shows": [
        "Fig. 4.3"
      ],
      "narratives": {
        "en": "Fig. 4.3, four world choropleth maps of the HIV-attributable fraction in cervical cancer in 2020 for age groups ≤34, 35–44, 45–54 and ≥55 years. Countries are shaded by population attributable fraction (0 to <10, 10 to <20, 20 to <40, 40 to <80, ≥80%, or no data). Most of the world is in the lowest category; the highest fractions are concentrated in southern and eastern Africa, and the areas with higher fractions shrink with increasing age. Source: Ibrahim Khalil et al., 2022.",
        "ar": "الشكل 4.3، أربع خرائط عالمية ملوّنة حسب القيم تبيّن الجزء المنسوب إلى فيروس العوز المناعي البشري من سرطان عنق الرحم في عام 2020 للفئات العمرية ≤34 و35–44 و45–54 و≥55 سنة. وتُظلَّل البلدان حسب الجزء المنسوب على مستوى السكان (0 إلى <10، و10 إلى <20، و20 إلى <40، و40 إلى <80، و≥80%، أو لا توجد بيانات). ويقع معظم العالم في الفئة الدنيا، وتتركز أعلى النسب في الجنوب الأفريقي وشرق أفريقيا، وتتقلص المناطق ذات النسب الأعلى مع تقدم العمر. المصدر: Ibrahim Khalil وآخرون، 2022.",
        "zh": "图4.3，四幅世界分级统计地图，显示2020年≤34岁、35–44岁、45–54岁和≥55岁各年龄组宫颈癌中可归因于艾滋病毒的比例。各国按人群归因分值着色（0至<10、10至<20、20至<40、40至<80、≥80%，或无数据）。世界大部分地区处于最低类别；最高比例集中在非洲南部和东部，且随年龄增长，较高比例的地区范围缩小。来源：Ibrahim Khalil等，2022年。",
        "es": "Fig. 4.3, cuatro mapas mundiales coropléticos de la fracción del cáncer cervicouterino atribuible al VIH en 2020 para los grupos de edad ≤34, 35–44, 45–54 y ≥55 años. Los países están sombreados según la fracción atribuible poblacional (0 a <10, 10 a <20, 20 a <40, 40 a <80, ≥80% o sin datos). La mayor parte del mundo está en la categoría más baja; las fracciones más altas se concentran en África meridional y oriental, y las zonas con fracciones más altas se reducen al aumentar la edad. Fuente: Ibrahim Khalil et al., 2022.",
        "fr": "Fig. 4.3, quatre cartes choroplèthes du monde montrant la fraction du cancer du col de l'utérus attribuable au VIH en 2020 pour les tranches d'âge ≤34, 35–44, 45–54 et ≥55 ans. Les pays sont colorés selon la fraction attribuable dans la population (0 à <10, 10 à <20, 20 à <40, 40 à <80, ≥80 %, ou pas de données). La majeure partie du monde se situe dans la catégorie la plus basse ; les fractions les plus élevées se concentrent en Afrique australe et orientale, et les zones à fraction élevée se réduisent avec l'âge. Source : Ibrahim Khalil et al., 2022.",
        "ru": "Рис. 4.3 — четыре картограммы мира, показывающие долю рака шейки матки, обусловленную ВИЧ, в 2020 г. для возрастных групп ≤34, 35–44, 45–54 и ≥55 лет. Страны окрашены по величине популяционной атрибутивной доли (от 0 до <10, от 10 до <20, от 20 до <40, от 40 до <80, ≥80% или нет данных). Бо́льшая часть мира относится к самой низкой категории; наибольшие доли сосредоточены на юге и востоке Африки, а площадь районов с высокими долями сокращается с возрастом. Источник: Ibrahim Khalil et al., 2022 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p227",
      "file": "figures/vfig-p227.webp",
      "page": 227,
      "shows": [
        "Fig. 5.1",
        "Box 5.1"
      ],
      "narratives": {
        "en": "Fig. 5.1, within Box 5.1, a proportional-symbol map of Brazil showing the number of new HIV cases by municipality in 2019, with dot sizes for categories from 0–0 up to 1000–2081 cases. The largest clusters of dots are along the south-eastern and southern coast and in the north-east, with a large dot in the Amazon region and sparse dots in the interior. Source: Ministry of Health, Brazil.",
        "ar": "الشكل 5.1، ضمن الإطار 5.1، خريطة بالرموز التناسبية للبرازيل تبيّن عدد حالات الإصابة الجديدة بفيروس العوز المناعي البشري حسب البلدية في عام 2019، مع أحجام نقاط لفئات تتراوح من 0–0 إلى 1000–2081 حالة. وتوجد أكبر تجمعات النقاط على امتداد الساحل الجنوبي الشرقي والجنوبي وفي الشمال الشرقي، مع نقطة كبيرة في منطقة الأمازون ونقاط متناثرة في الداخل. المصدر: وزارة الصحة، البرازيل.",
        "zh": "图5.1（位于框5.1内），巴西比例符号地图，显示2019年按市划分的新发艾滋病毒病例数，圆点大小代表从0–0到1000–2081例的类别。圆点最密集处位于东南和南部沿海以及东北部，亚马孙地区有一个大圆点，内陆地区圆点稀疏。来源：巴西卫生部。",
        "es": "Fig. 5.1, dentro del Recuadro 5.1, mapa de símbolos proporcionales del Brasil con el número de casos nuevos de VIH por municipio en 2019, con tamaños de punto para categorías de 0–0 hasta 1000–2081 casos. Las mayores concentraciones de puntos están a lo largo de la costa sudeste y sur y en el nordeste, con un punto grande en la región amazónica y puntos dispersos en el interior. Fuente: Ministerio de Salud del Brasil.",
        "fr": "Fig. 5.1, dans l'Encadré 5.1, carte à symboles proportionnels du Brésil indiquant le nombre de nouveaux cas de VIH par municipalité en 2019, la taille des points correspondant à des catégories allant de 0–0 à 1000–2081 cas. Les plus fortes concentrations de points se situent le long des côtes du sud-est et du sud et dans le nord-est, avec un gros point dans la région amazonienne et des points épars à l'intérieur. Source : ministère de la Santé du Brésil.",
        "ru": "Рис. 5.1 во вставке 5.1 — карта Бразилии с пропорциональными символами, показывающая число новых случаев ВИЧ по муниципалитетам в 2019 г.; размер точек соответствует категориям от 0–0 до 1000–2081 случая. Наибольшие скопления точек находятся вдоль юго-восточного и южного побережья и на северо-востоке, в районе Амазонии есть крупная точка, а во внутренних районах точки редки. Источник: Министерство здравоохранения Бразилии."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p228",
      "file": "figures/vfig-p228.webp",
      "page": 228,
      "shows": [
        "Fig. 5.2"
      ],
      "narratives": {
        "en": "Fig. 5.2, three linked 100% stacked bars showing HIV test positivity by prior testing status in Western Cape Province, South Africa. Of those presenting for testing, 8938 (78.8%) were HIV-negative and 2399 (21.2%) HIV-positive from all sources. Of all positives, 1184 (49.4%) self-reported HIV-positive and were not retested, 623 (24.4%) were retested HIV-positive and 592 (24.7%) were newly diagnosed. Of those testing positive, 592 (48.7%) were newly diagnosed, 308 (25.3%) retested in spite of self-reporting prior HIV and 315 (25.9%) were retested without self-reporting prior knowledge of status. Source: Jacob et al., 2020.",
        "ar": "الشكل 5.2، ثلاثة أعمدة مكدسة مترابطة بنسبة 100% تبيّن إيجابية اختبار فيروس العوز المناعي البشري حسب حالة الاختبار السابقة في مقاطعة ويسترن كيب، جنوب أفريقيا. فمن بين من تقدموا للاختبار، كان 8938 (78.8%) سلبيين للفيروس و2399 (21.2%) إيجابيين من جميع المصادر. ومن بين جميع الحالات الإيجابية، أفاد 1184 (49.4%) ذاتياً بأنهم إيجابيون ولم يُعَد اختبارهم، وأُعيد اختبار 623 (24.4%) وكانوا إيجابيين، وشُخّص 592 (24.7%) حديثاً. ومن بين من كانت نتيجة اختبارهم إيجابية، شُخّص 592 (48.7%) حديثاً، وأعاد 308 (25.3%) الاختبار رغم إفادتهم الذاتية بإصابة سابقة، وأعاد 315 (25.9%) الاختبار دون الإفادة الذاتية بمعرفة سابقة بحالتهم. المصدر: Jacob وآخرون، 2020.",
        "zh": "图5.2，三根相互关联的100%堆积柱，显示南非西开普省按既往检测状况划分的艾滋病毒检测阳性率。在前来检测者中，8938人（78.8%）为艾滋病毒阴性，2399人（21.2%）为各来源的艾滋病毒阳性。在所有阳性者中，1184人（49.4%）自报阳性且未复检，623人（24.4%）复检为阳性，592人（24.7%）为新诊断。在检测阳性者中，592人（48.7%）为新诊断，308人（25.3%）虽自报既往感染仍复检，315人（25.9%）复检但未自报既往知晓感染状况。来源：Jacob等，2020年。",
        "es": "Fig. 5.2, tres barras apiladas al 100% vinculadas que muestran la positividad de las pruebas del VIH según el antecedente de pruebas en la provincia del Cabo Occidental (Sudáfrica). De quienes acudieron a hacerse la prueba, 8938 (78,8%) fueron negativos y 2399 (21,2%) positivos de todas las fuentes. De todos los positivos, 1184 (49,4%) declararon ser VIH-positivos y no se volvieron a hacer la prueba, 623 (24,4%) se volvieron a hacer la prueba con resultado positivo y 592 (24,7%) fueron diagnósticos nuevos. De quienes dieron positivo en la prueba, 592 (48,7%) eran diagnósticos nuevos, 308 (25,3%) repitieron la prueba pese a declarar un VIH previo y 315 (25,9%) la repitieron sin declarar conocimiento previo de su estado. Fuente: Jacob et al., 2020.",
        "fr": "Fig. 5.2, trois barres empilées à 100 % reliées montrant la positivité des tests VIH selon les antécédents de dépistage dans la province du Cap-Occidental (Afrique du Sud). Parmi les personnes venues se faire dépister, 8938 (78,8 %) étaient séronégatives et 2399 (21,2 %) séropositives toutes sources confondues. Parmi l'ensemble des personnes séropositives, 1184 (49,4 %) ont déclaré être séropositives et n'ont pas été retestées, 623 (24,4 %) ont été retestées positives et 592 (24,7 %) ont été nouvellement diagnostiquées. Parmi les personnes testées positives, 592 (48,7 %) étaient nouvellement diagnostiquées, 308 (25,3 %) ont été retestées bien qu'elles aient déclaré un VIH antérieur et 315 (25,9 %) ont été retestées sans avoir déclaré connaître leur statut. Source : Jacob et al., 2020.",
        "ru": "Рис. 5.2 — три связанных столбца с накоплением до 100%, показывающие долю положительных результатов тестирования на ВИЧ в зависимости от предшествующего тестирования в провинции Западный Кейп (Южная Африка). Из обратившихся за тестированием 8938 человек (78,8%) были ВИЧ-отрицательными и 2399 (21,2%) — ВИЧ-положительными по всем источникам. Из всех ВИЧ-положительных 1184 (49,4%) сами сообщили о своём статусе и не тестировались повторно, 623 (24,4%) прошли повторное тестирование с положительным результатом и 592 (24,7%) были диагностированы впервые. Из получивших положительный результат теста 592 (48,7%) были диагностированы впервые, 308 (25,3%) прошли повторное тестирование, несмотря на то что сообщили о ранее выявленном ВИЧ, и 315 (25,9%) прошли повторное тестирование, не сообщив о том, что знали свой статус. Источник: Jacob et al., 2020 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p239",
      "file": "figures/vfig-p239.webp",
      "page": 239,
      "shows": [
        "Fig. 5.3"
      ],
      "narratives": {
        "en": "Fig. 5.3, a stacked bar chart of the number of adolescents aged 15–19 living with HIV globally, 2000–2021, by timing of infection (perinatally infected vs. infected after age 15). Totals stay around 1.0–1.15 million throughout. The perinatally infected share rises steadily from under 50 000 in 2000 to about 650 000 by 2018–2021, while the number infected after age 15 falls correspondingly. Source: UNAIDS epidemiological estimates, 2022.",
        "ar": "الشكل 5.3، مخطط أعمدة مكدسة يبيّن عدد المراهقين في الفئة العمرية 15–19 سنة المتعايشين مع فيروس العوز المناعي البشري على الصعيد العالمي، 2000–2021، حسب توقيت العدوى (العدوى في الفترة المحيطة بالولادة مقابل العدوى بعد سن 15). وتبقى المجاميع بين نحو 1.0 و1.15 مليون طوال الفترة. وترتفع حصة المصابين في الفترة المحيطة بالولادة باطراد من أقل من 50000 في عام 2000 إلى نحو 650000 في الفترة 2018–2021، بينما ينخفض عدد المصابين بعد سن 15 بما يقابل ذلك. المصدر: التقديرات الوبائية لبرنامج الأمم المتحدة المشترك المعني بفيروس العوز المناعي البشري/الإيدز، 2022.",
        "zh": "图5.3，堆积柱状图，显示2000–2021年全球15–19岁青少年艾滋病毒感染者人数，按感染时间划分（围产期感染与15岁后感染）。各年总数始终约为100万至115万。围产期感染者人数从2000年不足5万稳步上升至2018–2021年的约65万，而15岁后感染者人数相应下降。来源：联合国艾滋病规划署流行病学估计，2022年。",
        "es": "Fig. 5.3, gráfico de barras apiladas del número de adolescentes de 15 a 19 años con el VIH en el mundo, 2000–2021, según el momento de la infección (infección perinatal frente a infección después de los 15 años). Los totales se mantienen en torno a 1,0–1,15 millones durante todo el periodo. La parte con infección perinatal aumenta de forma constante, de menos de 50 000 en 2000 a unos 650 000 en 2018–2021, mientras que el número infectado después de los 15 años disminuye en consecuencia. Fuente: estimaciones epidemiológicas de ONUSIDA, 2022.",
        "fr": "Fig. 5.3, graphique à barres empilées du nombre d'adolescents de 15 à 19 ans vivant avec le VIH dans le monde, 2000–2021, selon le moment de l'infection (infection périnatale ou infection après l'âge de 15 ans). Les totaux restent autour de 1,0 à 1,15 million sur toute la période. La part des infections périnatales augmente régulièrement, de moins de 50 000 en 2000 à environ 650 000 en 2018–2021, tandis que le nombre de personnes infectées après 15 ans diminue en conséquence. Source : estimations épidémiologiques de l'ONUSIDA, 2022.",
        "ru": "Рис. 5.3 — столбчатая диаграмма с накоплением, показывающая число подростков в возрасте 15–19 лет, живущих с ВИЧ, в мире в 2000–2021 гг. по времени инфицирования (перинатальное инфицирование и инфицирование после 15 лет). Общее число на протяжении всего периода остаётся на уровне около 1,0–1,15 млн. Число инфицированных перинатально неуклонно растёт — с менее чем 50 000 в 2000 г. до примерно 650 000 в 2018–2021 гг., тогда как число инфицированных после 15 лет соответственно снижается. Источник: эпидемиологические оценки ЮНЭЙДС, 2022 г."
      },
      "state": "draft"
    },
    {
      "id": "img-p262-1",
      "file": "images/img-p262-1.webp",
      "page": 262,
      "narratives": {
        "en": "Screenshot of the PALMS 'Sexually Transmitted Infections' dashboard for Blantyre district (Fig. 6.1). A map shows facilities as circles coloured by % new HIV positive (0–10%) in 2021 Q4, with circle size indicating total tested for HIV; a line chart of % new HIV positive by quarter, 2018 Q1 to 2022 Q2, stays around 4–6% except a spike to about 16% in 2019 Q4; and a table lists facilities by total clients (total 267 new HIV positive, 3.7%, of 7257 tested), with red flags against Ndirande Health Centre and Makhetha Clinic.",
        "ar": "لقطة شاشة للوحة متابعة PALMS بعنوان \"العداوى المنقولة جنسياً\" لمنطقة بلانتاير (الشكل 6.1). تعرض خريطة المرافق على هيئة دوائر ملوّنة حسب النسبة المئوية للإصابات الجديدة الإيجابية بفيروس العوز المناعي البشري (0–10%) في الربع الرابع من 2021، ويشير حجم الدائرة إلى العدد الإجمالي لمن خضعوا لاختبار الفيروس؛ ويبقى مخطط خطي للنسبة المئوية للإصابات الجديدة حسب الربع، من الربع الأول 2018 إلى الربع الثاني 2022، عند نحو 4–6% باستثناء ارتفاع حاد إلى نحو 16% في الربع الرابع من 2019؛ ويسرد جدول المرافق حسب العدد الإجمالي للمترددين (المجموع 267 حالة إيجابية جديدة، 3.7%، من أصل 7257 شخصاً خضعوا للاختبار)، مع أعلام حمراء بجانب مركز Ndirande الصحي وعيادة Makhetha.",
        "zh": "布兰太尔区PALMS\"性传播感染\"仪表板截图（图6.1）。地图以圆点表示各机构，按2021年第4季度新发艾滋病毒阳性百分比（0–10%）着色，圆点大小表示接受艾滋病毒检测的总人数；按季度的新发艾滋病毒阳性百分比折线图（2018年第1季度至2022年第2季度）除2019年第4季度骤升至约16%外，基本保持在4–6%左右；表格按就诊者总数列出各机构（合计7257人接受检测，新发阳性267人，占3.7%），Ndirande卫生中心和Makhetha诊所旁标有红旗。",
        "es": "Captura de pantalla del tablero «Sexually Transmitted Infections» de PALMS para el distrito de Blantyre (Fig. 6.1). Un mapa muestra los establecimientos como círculos coloreados según el % de nuevos positivos al VIH (0–10%) en el 4.º trimestre de 2021, con el tamaño del círculo según el total de personas sometidas a la prueba del VIH; un gráfico de líneas del % de nuevos positivos por trimestre, del 1.er trimestre de 2018 al 2.º trimestre de 2022, se mantiene en torno al 4–6% salvo un pico de alrededor del 16% en el 4.º trimestre de 2019; y una tabla enumera los establecimientos por número total de usuarios (total de 267 nuevos positivos, 3,7%, de 7257 personas sometidas a la prueba), con banderas rojas junto al Ndirande Health Centre y la Makhetha Clinic.",
        "fr": "Capture d'écran du tableau de bord PALMS « Sexually Transmitted Infections » pour le district de Blantyre (Fig. 6.1). Une carte représente les établissements par des cercles colorés selon le pourcentage de nouveaux positifs au VIH (0–10 %) au 4e trimestre 2021, la taille du cercle indiquant le nombre total de personnes dépistées ; un graphique linéaire du pourcentage de nouveaux positifs par trimestre, du 1er trimestre 2018 au 2e trimestre 2022, reste autour de 4–6 % hormis un pic à environ 16 % au 4e trimestre 2019 ; et un tableau liste les établissements par nombre total d'usagers (au total 267 nouveaux positifs, 3,7 %, sur 7257 personnes dépistées), avec des drapeaux rouges en regard du Ndirande Health Centre et de la Makhetha Clinic.",
        "ru": "Снимок экрана панели PALMS «Sexually Transmitted Infections» для округа Блантайр (рис. 6.1). На карте учреждения показаны кружками, окрашенными по доле новых ВИЧ-положительных результатов (0–10%) в 4-м квартале 2021 г.; размер кружка соответствует общему числу протестированных на ВИЧ. Линейный график доли новых ВИЧ-положительных результатов по кварталам с 1-го квартала 2018 г. по 2-й квартал 2022 г. держится на уровне около 4–6%, за исключением скачка примерно до 16% в 4-м квартале 2019 г. В таблице учреждения перечислены по общему числу клиентов (всего 267 новых ВИЧ-положительных, 3,7%, из 7257 протестированных); у Ndirande Health Centre и Makhetha Clinic стоят красные флажки."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p262",
      "file": "figures/vfig-p262.webp",
      "page": 262,
      "shows": [
        "Fig. 6.1",
        "Box 6.3"
      ],
      "narratives": {
        "en": "Fig. 6.1, within Box 6.3, a screenshot of the PALMS 'Sexually Transmitted Infections' dashboard showing HIV rates among STI clients in Blantyre district, Malawi. It combines a map of facilities with circles coloured by % new HIV positive (0–10%) in 2021 Q4, a line chart of % new HIV positive by quarter from 2018 Q1 to 2022 Q2 that stays around 4–6% apart from a spike to about 16% in 2019 Q4, and a table of facilities by total clients (total 267 new HIV positive, 3.7%, of 7257 tested), with red flags against two facilities. Developed by Cooper/Smith with Georgetown University through the Blantyre Prevention Strategy.",
        "ar": "الشكل 6.1، ضمن الإطار 6.3، لقطة شاشة للوحة متابعة PALMS بعنوان \"العداوى المنقولة جنسياً\" تبيّن معدلات فيروس العوز المناعي البشري بين المترددين على خدمات العداوى المنقولة جنسياً في منطقة بلانتاير، ملاوي. وتجمع بين خريطة للمرافق بدوائر ملوّنة حسب النسبة المئوية للإصابات الجديدة الإيجابية بالفيروس (0–10%) في الربع الرابع من 2021، ومخطط خطي للنسبة المئوية للإصابات الجديدة حسب الربع من الربع الأول 2018 إلى الربع الثاني 2022 يبقى عند نحو 4–6% باستثناء ارتفاع حاد إلى نحو 16% في الربع الرابع من 2019، وجدول للمرافق حسب العدد الإجمالي للمترددين (المجموع 267 حالة إيجابية جديدة، 3.7%، من أصل 7257 شخصاً خضعوا للاختبار)، مع أعلام حمراء بجانب مرفقين. طوّرتها Cooper/Smith بالتعاون مع جامعة جورجتاون في إطار استراتيجية الوقاية في بلانتاير.",
        "zh": "图6.1（位于框6.3内），PALMS\"性传播感染\"仪表板截图，显示马拉维布兰太尔区性传播感染就诊者中的艾滋病毒感染率。截图包括：一幅机构地图，圆点按2021年第4季度新发艾滋病毒阳性百分比（0–10%）着色；一幅2018年第1季度至2022年第2季度按季度的新发艾滋病毒阳性百分比折线图，除2019年第4季度骤升至约16%外，基本保持在4–6%左右；以及一张按就诊者总数排列的机构表（合计7257人接受检测，新发阳性267人，占3.7%），其中两个机构旁标有红旗。由Cooper/Smith与乔治敦大学通过布兰太尔预防战略合作开发。",
        "es": "Fig. 6.1, dentro del Recuadro 6.3, captura de pantalla del tablero «Sexually Transmitted Infections» de PALMS que muestra las tasas de VIH entre los usuarios de servicios de ITS en el distrito de Blantyre (Malawi). Combina un mapa de establecimientos con círculos coloreados según el % de nuevos positivos al VIH (0–10%) en el 4.º trimestre de 2021, un gráfico de líneas del % de nuevos positivos por trimestre del 1.er trimestre de 2018 al 2.º trimestre de 2022 que se mantiene en torno al 4–6% salvo un pico de alrededor del 16% en el 4.º trimestre de 2019, y una tabla de establecimientos por número total de usuarios (total de 267 nuevos positivos, 3,7%, de 7257 personas sometidas a la prueba), con banderas rojas junto a dos establecimientos. Desarrollado por Cooper/Smith con la Universidad de Georgetown en el marco de la Estrategia de Prevención de Blantyre.",
        "fr": "Fig. 6.1, dans l'Encadré 6.3, capture d'écran du tableau de bord PALMS « Sexually Transmitted Infections » montrant les taux de VIH parmi les usagers des services IST dans le district de Blantyre (Malawi). Il associe une carte des établissements avec des cercles colorés selon le pourcentage de nouveaux cas positifs au VIH (0–10 %) au 4e trimestre 2021, un graphique linéaire du pourcentage de nouveaux positifs par trimestre du 1er trimestre 2018 au 2e trimestre 2022, qui reste autour de 4–6 % hormis un pic à environ 16 % au 4e trimestre 2019, et un tableau des établissements par nombre total d'usagers (au total 267 nouveaux positifs, 3,7 %, sur 7257 personnes dépistées), avec des drapeaux rouges en regard de deux établissements. Développé par Cooper/Smith avec l'Université de Georgetown dans le cadre de la Blantyre Prevention Strategy.",
        "ru": "Рис. 6.1 во вставке 6.3 — снимок экрана панели PALMS «Sexually Transmitted Infections», показывающей частоту ВИЧ среди клиентов служб ИППП в округе Блантайр (Малави). Он включает карту учреждений с кружками, окрашенными по доле новых ВИЧ-положительных результатов (0–10%) в 4-м квартале 2021 г.; линейный график доли новых ВИЧ-положительных результатов по кварталам с 1-го квартала 2018 г. по 2-й квартал 2022 г., которая держится на уровне около 4–6%, за исключением скачка примерно до 16% в 4-м квартале 2019 г.; и таблицу учреждений по общему числу клиентов (всего 267 новых ВИЧ-положительных, 3,7%, из 7257 протестированных), где у двух учреждений стоят красные флажки. Разработано Cooper/Smith совместно с Джорджтаунским университетом в рамках Стратегии профилактики Блантайра."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p266",
      "file": "figures/vfig-p266.webp",
      "page": 266,
      "shows": [
        "Fig. 6.2",
        "Box 6.4"
      ],
      "narratives": {
        "en": "Fig. 6.2, within Box 6.4, an abridged swimlane business process diagram for HIV testing, with lanes for the client and the trained lay provider at the health facility/community. After registration, the provider determines the reason for visit and checks for signs of serious illness (referral if yes), then within a post-test package collects client details, takes vital signs, provides pre-test information, tests for HIV using the testing algorithm, provides post-test counselling and determines recommended services. Depending on the HIV test result, positive leads to counselling on ART and disclosure and partner services, while negative or inconclusive leads to a retest decision and scheduling a retest; the client makes an informed decision on care. Source: WHO, 2022.",
        "ar": "الشكل 6.2، ضمن الإطار 6.4، مخطط مختصر لعملية العمل الخاصة باختبار فيروس العوز المناعي البشري بمسارات منفصلة للعميل ولمقدم الخدمة غير المتخصص المدرَّب في المرفق الصحي/المجتمع. بعد التسجيل، يحدد مقدم الخدمة سبب الزيارة ويتحقق من علامات المرض الخطير (مع الإحالة في حال وجودها)، ثم ضمن حزمة ما بعد الاختبار يجمع بيانات العميل، ويقيس العلامات الحيوية، ويقدم معلومات ما قبل الاختبار، ويُجري اختبار فيروس العوز المناعي البشري باستخدام خوارزمية الاختبار، ويقدم المشورة بعد الاختبار ويحدد الخدمات الموصى بها. وبحسب نتيجة الاختبار، تؤدي النتيجة الإيجابية إلى المشورة بشأن العلاج المضاد للفيروسات القهقرية والإفصاح وخدمات الشركاء، بينما تؤدي النتيجة السلبية أو غير الحاسمة إلى قرار بإعادة الاختبار وتحديد موعد له؛ ويتخذ العميل قراراً مستنيراً بشأن الرعاية. المصدر: منظمة الصحة العالمية، 2022.",
        "zh": "图6.2（位于框6.4内），艾滋病毒检测业务流程泳道图（节选），泳道分为服务对象以及卫生机构/社区中经过培训的非专业服务提供者。登记后，服务提供者确定就诊原因并检查严重疾病体征（如有则转诊），随后在检测后服务包中收集服务对象信息、测量生命体征、提供检测前信息、按检测算法进行艾滋病毒检测、提供检测后咨询并确定推荐服务。根据检测结果，阳性者接受关于抗逆转录病毒治疗益处、告知和性伴服务的咨询，阴性或不确定者则决定是否复检并安排复检；服务对象就关怀作出知情决定。来源：世卫组织，2022年。",
        "es": "Fig. 6.2, dentro del Recuadro 6.4, diagrama de proceso operativo por carriles (abreviado) para las pruebas del VIH, con carriles para el usuario y el proveedor lego capacitado del establecimiento de salud/comunidad. Tras el registro, el proveedor determina el motivo de la visita y comprueba si hay signos de enfermedad grave (derivación en caso afirmativo); luego, dentro de un paquete posprueba, recoge los datos del usuario, toma las constantes vitales, proporciona información previa a la prueba, realiza la prueba del VIH según el algoritmo, ofrece asesoramiento posprueba y determina los servicios recomendados. Según el resultado, un positivo conduce a asesoramiento sobre el TAR, la revelación y los servicios para la pareja, mientras que un negativo o no concluyente conduce a decidir y programar una nueva prueba; el usuario toma una decisión informada sobre la atención. Fuente: OMS, 2022.",
        "fr": "Fig. 6.2, dans l'Encadré 6.4, diagramme de processus métier en couloirs (abrégé) pour le dépistage du VIH, avec des couloirs pour le client et pour le prestataire non professionnel formé de l'établissement de santé/la communauté. Après l'enregistrement, le prestataire détermine le motif de la visite et recherche des signes de maladie grave (orientation si oui), puis, dans un ensemble de services post-test, recueille les informations du client, prend les signes vitaux, fournit les informations pré-test, réalise le test VIH selon l'algorithme de dépistage, assure le conseil post-test et détermine les services recommandés. Selon le résultat, un résultat positif mène au conseil sur le TAR, la divulgation et les services aux partenaires, tandis qu'un résultat négatif ou non concluant mène à une décision de nouveau test et à sa programmation ; le client prend une décision éclairée sur les soins. Source : OMS, 2022.",
        "ru": "Рис. 6.2 во вставке 6.4 — сокращённая диаграмма бизнес-процесса тестирования на ВИЧ с дорожками для клиента и для обученного немедицинского работника в медицинском учреждении/сообществе. После регистрации работник определяет причину обращения и проверяет признаки тяжёлого заболевания (при их наличии — направление), затем в рамках пакета послетестовых услуг собирает данные клиента, измеряет жизненные показатели, предоставляет дотестовую информацию, проводит тест на ВИЧ по алгоритму тестирования, проводит послетестовое консультирование и определяет рекомендуемые услуги. В зависимости от результата положительный результат ведёт к консультированию о пользе АРТ, раскрытии статуса и услугах для партнёров, а отрицательный или неопределённый — к решению о повторном тестировании и его планированию; клиент принимает информированное решение о лечении. Источник: ВОЗ, 2022 г."
      },
      "state": "draft"
    },
    {
      "id": "vfig-p273",
      "file": "figures/vfig-p273.webp",
      "page": 273,
      "shows": [
        "Fig. 6.3"
      ],
      "narratives": {
        "en": "Fig. 6.3, a flow diagram of the broad stages and transitions of the maturation pathway for UIDs: name-based identifiers, then unique identifiers at select facilities (early transition), then unique identifiers widespread (middle), then data linked by UID across services, facilities and locations (advanced).",
        "ar": "الشكل 6.3، مخطط انسيابي للمراحل والتحولات العامة لمسار نضج المعرّفات الفريدة: المعرّفات القائمة على الأسماء، ثم المعرّفات الفريدة في مرافق مختارة (تحول مبكر)، ثم انتشار المعرّفات الفريدة على نطاق واسع (مرحلة متوسطة)، ثم ربط البيانات بالمعرّف الفريد عبر الخدمات والمرافق والمواقع (مرحلة متقدمة).",
        "zh": "图6.3，流程图，显示唯一标识符成熟路径的主要阶段和过渡：基于姓名的标识符，然后在部分机构使用唯一标识符（早期过渡），然后广泛使用唯一标识符（中期），最后通过唯一标识符在不同服务、机构和地点之间关联数据（高级）。",
        "es": "Fig. 6.3, diagrama de flujo de las grandes etapas y transiciones de la trayectoria de maduración de los IU: identificadores basados en el nombre, luego identificadores únicos en determinados establecimientos (transición temprana), luego identificadores únicos generalizados (intermedia) y, por último, datos vinculados mediante IU entre servicios, establecimientos y ubicaciones (avanzada).",
        "fr": "Fig. 6.3, diagramme de flux des grandes étapes et transitions du parcours de maturation des IU : identifiants fondés sur le nom, puis identifiants uniques dans certains établissements (transition précoce), puis identifiants uniques généralisés (intermédiaire), puis données reliées par IU entre services, établissements et lieux (avancée).",
        "ru": "Рис. 6.3 — схема основных этапов и переходов на пути развития УИК: идентификаторы на основе имени, затем уникальные идентификаторы в отдельных учреждениях (ранний переход), затем повсеместное использование уникальных идентификаторов (средний этап) и, наконец, связывание данных по УИК между услугами, учреждениями и местами (продвинутый этап)."
      },
      "state": "draft"
    },
    {
      "id": "img-p424-1",
      "file": "images/img-p424-1.webp",
      "page": 424,
      "narratives": {
        "en": "ISBN barcode with the number 9789240055315.",
        "ar": "رمز شريطي للرقم الدولي المعياري للكتاب يحمل الرقم 9789240055315.",
        "zh": "国际标准书号条形码，编号9789240055315。",
        "es": "Código de barras del ISBN con el número 9789240055315.",
        "fr": "Code-barres ISBN portant le numéro 9789240055315.",
        "ru": "Штрихкод ISBN с номером 9789240055315."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 4.3",
      "caption": "Table 4.3. Recommended minimum dataset for viral hepatitis",
      "pages": [
        204
      ],
      "columns": [
        {
          "titles": "Topic area"
        },
        {
          "titles": "Data element"
        }
      ],
      "rows": [
        [
          "Testing and diagnosis",
          "HBV test date"
        ],
        [
          "",
          "HBV test result (HBsAg)"
        ],
        [
          "",
          "HCV test date"
        ],
        [
          "",
          "HCV test result (HCV antibody, HCV RNA or HCV core antigen)"
        ],
        [
          "Treatment initiation and continuation",
          "HBV treatment initiation date"
        ],
        [
          "",
          "HBV regimen prescribed"
        ],
        [
          "",
          "HCV treatment initiation date"
        ],
        [
          "",
          "HCV treatment regimen prescribed"
        ],
        [
          "Monitoring of treatment effectiveness",
          "HCV viral suppression test date"
        ],
        [
          "",
          "HCV suppression test result"
        ]
      ],
      "narratives": {
        "en": "The table lists the minimum data elements recommended for recording viral hepatitis (HBV and HCV) information in HIV programmes, grouped by topic area: testing and diagnosis, treatment initiation and continuation, and monitoring of treatment effectiveness.",
        "ar": "يسرد الجدول الحد الأدنى من عناصر البيانات الموصى بتسجيلها بشأن التهاب الكبد الفيروسي (فيروس التهاب الكبد B وفيروس التهاب الكبد C) في برامج فيروس العوز المناعي البشري، مصنفة حسب المجال: الاختبار والتشخيص، وبدء العلاج ومواصلته، ورصد فعالية العلاج.",
        "zh": "该表列出了艾滋病毒规划中建议记录的病毒性肝炎（乙肝病毒和丙肝病毒）最低数据要素，按主题领域分组：检测和诊断、治疗启动和持续、以及治疗效果监测。",
        "es": "La tabla enumera los elementos de datos mínimos recomendados para registrar información sobre las hepatitis víricas (VHB y VHC) en los programas de VIH, agrupados por área temática: pruebas y diagnóstico, inicio y continuación del tratamiento, y seguimiento de la eficacia del tratamiento.",
        "fr": "Le tableau énumère les éléments de données minimaux recommandés pour enregistrer les informations sur l'hépatite virale (VHB et VHC) dans les programmes de lutte contre le VIH, regroupés par domaine : dépistage et diagnostic, mise en route et poursuite du traitement, et suivi de l'efficacité du traitement.",
        "ru": "В таблице перечислены рекомендуемые минимальные элементы данных о вирусном гепатите (ВГВ и ВГС) для программ по ВИЧ, сгруппированные по тематическим областям: тестирование и диагностика, начало и продолжение лечения, мониторинг эффективности лечения."
      },
      "csv": "tables/table-4-3.csv"
    },
    {
      "label": "Table 4.6",
      "caption": "Table 4.6. Priority indicators for cervical cancer screening and treatment among womenᵃ living with HIV",
      "pages": [
        211
      ],
      "columns": [
        {
          "titles": "Ref. no."
        },
        {
          "titles": "Short name"
        },
        {
          "titles": "Indicator definition"
        },
        {
          "titles": "Numerator"
        },
        {
          "titles": "Denominator"
        }
      ],
      "rows": [
        [
          "CCA.1 (NEW) ●",
          "Cervical cancer screening",
          "Number of women living with HIV who were screened for cervical cancer using any screening test",
          "Number of women living with HIV who were screened for cervical cancer using any screening test (HPV DNA test, visual inspection with acetic acid, cytology, other)",
          "NA"
        ],
        [
          "CCA.2 (NEW) ●",
          "Pre-invasive cervical disease treatment",
          "% of women living with HIV who screened positive for pre-invasive cervical disease and received treatment for it",
          "Number of women living with HIV who received treatment after screening positive for pre-invasive cervical disease and were deemed eligible for treatment",
          "Number of women living with HIV who screened positive for pre-invasive cervical disease"
        ],
        [
          "CCA.3 (NEW)",
          "Invasive cervical cancer treatment",
          "% of women living with HIV diagnosed with invasive cancer who were treated",
          "Number of women living with HIV who received treatment after being diagnosed with invasive cervical cancer",
          "Number of women living with HIV who were diagnosed with invasive cervical cancer"
        ],
        [
          "CCA.4 (NEW)",
          "Cervical cancer survival",
          "Crude probability of surviving 1 year after a diagnosis of cervical cancer",
          "Number of women living with HIV still alive 12 months after receiving a diagnosis of invasive cervical cancer",
          "Number of women living with HIV who received a diagnosis of invasive cervical cancer within a 12-month cohort observation period"
        ]
      ],
      "notes": "● (blue dot printed under the reference number) = Core indicator. Abbreviations: DNA = deoxyribonucleic acid; HIV = human immunodeficiency virus; HPV = human papilloma virus; NA = Not Applicable. a To be concise and facilitate readability, the term “women” is used, noting that that all gender diverse people with a female reproductive system are at risk for cervical cancer and should receive screening and treatment services. Most of the available evidence on cervical cancer is based on study populations of cisgender women. All individuals have the right to equality and non-discrimination in sexual and reproductive health care.",
      "narratives": {
        "en": "The table defines four priority indicators (CCA.1–CCA.4) for cervical cancer screening and treatment among women living with HIV, giving for each its reference number, short name, definition, numerator and denominator. CCA.1 and CCA.2 are marked as core indicators.",
        "ar": "يعرّف الجدول أربعة مؤشرات ذات أولوية (CCA.1–CCA.4) لفحص سرطان عنق الرحم وعلاجه لدى النساء المصابات بفيروس العوز المناعي البشري، مع بيان الرقم المرجعي والاسم المختصر والتعريف والبسط والمقام لكل منها. ويُشار إلى CCA.1 وCCA.2 بوصفهما مؤشرين أساسيين.",
        "zh": "该表界定了感染艾滋病毒妇女宫颈癌筛查和治疗的四项优先指标（CCA.1–CCA.4），列出每项指标的编号、简称、定义、分子和分母。CCA.1和CCA.2被标为核心指标。",
        "es": "La tabla define cuatro indicadores prioritarios (CCA.1–CCA.4) para el tamizaje y el tratamiento del cáncer cervicouterino en mujeres con VIH, con su número de referencia, nombre abreviado, definición, numerador y denominador. CCA.1 y CCA.2 están marcados como indicadores básicos.",
        "fr": "Le tableau définit quatre indicateurs prioritaires (CCA.1–CCA.4) pour le dépistage et le traitement du cancer du col de l'utérus chez les femmes vivant avec le VIH, avec pour chacun son numéro de référence, son nom abrégé, sa définition, son numérateur et son dénominateur. CCA.1 et CCA.2 sont signalés comme indicateurs de base.",
        "ru": "В таблице определены четыре приоритетных показателя (CCA.1–CCA.4) скрининга и лечения рака шейки матки у женщин, живущих с ВИЧ, с указанием для каждого номера, краткого названия, определения, числителя и знаменателя. CCA.1 и CCA.2 отмечены как основные показатели."
      },
      "csv": "tables/table-4-6.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 254,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 196,
      "note": "3 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 27
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 2
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p45); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p12); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 180,
      "note": "180 of 196 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-360948"
  }
}
